FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Matos, CO
   Passos, YM
   do Amaral, MJ
   Macedo, B
   Tempone, MH
   Bezerra, OCL
   Moraes, MO
   Almeida, MS
   Weber, G
   Missailidis, S
   Silva, JL
   Uversky, VN
   Pinheiro, AS
   Cordeiro, Y
AF Matos, Carolina O.
   Passos, Yulli M.
   do Amaral, Mariana J.
   Macedo, Bruno
   Tempone, Matheus H.
   Bezerra, Ohanna C. L.
   Moraes, Milton O.
   Almeida, Marcius S.
   Weber, Gerald
   Missailidis, Sotiris
   Silva, Jerson L.
   Uversky, Vladimir N.
   Pinheiro, Anderson S.
   Cordeiro, Yraima
TI Liquid-liquid phase separation and fibrillation of the prion protein
   modulated by a high-affinity DNA aptamer
SO FASEB JOURNAL
LA English
DT Article
DE neurodegenerative diseases; nucleic acid; phase transitions; prions;
   SELEX
ID NUCLEIC-ACID; SECONDARY STRUCTURE; CONFORMATION; TRANSITION; BINDING;
   PRP; DROPLETS; SEQUENCE; COMPLEXITY; PREDICTION
AB Structural conversion of cellular prion protein (PrP (c)) into scrapie PrP (PrPSc) and subsequent aggregation are key events associated with the onset of transmissible spongiform encephalopathies (TSEs). Experimental evidence supports the role of nucleic acids (NAs) in assisting this conversion. Here, we asked whether PrP undergoes liquid-liquid phase separation (LLPS) and if this process is modulated by NAs. To this end, two 25-mer DNA aptamers, A1 and A2, were selected against the globular domain of recombinant murine PrP (rPrP(90-231)) using SELEX methodology. Multiparametric structural analysis of these aptamers revealed that A1 adopts a hairpin conformation. Aptamer binding caused partial unfolding of rPrP(90-231) and modulated its ability to undergo LLPS and fibrillate. In fact, although free rPrP(90-231) phase separated into large droplets, aptamer binding increased the number of droplets but noticeably reduced their size. Strikingly, a modified A1 aptamer that does not adopt a hairpin structure induced formation of amyloid fibrils on the surface of the droplets. We show here that PrP undergoes LLPS, and that the PrP interaction with NAs modulates phase separation and promotes PrP fibrillation in a NA structure and concentration-dependent manner. These results shed new light on the roles of NAs in PrP misfolding and TSEs.
C1 [Matos, Carolina O.; Pinheiro, Anderson S.] Univ Fed Rio de Janeiro, Inst Chem, Dept Biochem, Rio De Janeiro, Brazil.
   [Passos, Yulli M.; Macedo, Bruno; Tempone, Matheus H.; Cordeiro, Yraima] Univ Fed Rio de Janeiro, Fac Pharm, Av Carlos Chagas Filho 373,Bl BSs 17, BR-21941902 Rio De Janeiro, Brazil.
   [do Amaral, Mariana J.; Almeida, Marcius S.; Silva, Jerson L.] Univ Fed Rio de Janeiro, Natl Ctr Struct Biol & Bioimaging CENABIO, Inst Med Biochem Leopoldo de Meis, Rio De Janeiro, Brazil.
   [Bezerra, Ohanna C. L.; Moraes, Milton O.] Oswaldo Cruz Fdn FIOCRUZ, Inst Oswaldo Cruz, Leprosy Lab, Rio De Janeiro, Brazil.
   [Weber, Gerald] Univ Fed Minas Gerais, Dept Phys, Belo Horizonte, MG, Brazil.
   [Missailidis, Sotiris] Oswaldo Cruz Fdn FIOCRUZ, Inst Technol Immunobiol Biomanguinhos, Rio De Janeiro, Brazil.
   [Uversky, Vladimir N.] Univ S Florida, USF Hlth Byrd Alzheimers Res Inst, Morsani Coll Med, Dept Mol Med, Tampa, FL 33620 USA.
   [Uversky, Vladimir N.] Russian Acad Sci, Inst Biol Instrumentat, Lab New Methods Biol, Pushchino, Russia.
RP Cordeiro, Y (corresponding author), Univ Fed Rio de Janeiro, Fac Pharm, Av Carlos Chagas Filho 373,Bl BSs 17, BR-21941902 Rio De Janeiro, Brazil.; Pinheiro, AS (corresponding author), Univ Fed Rio de Janeiro, Inst Chem, Av Athos da Silveira Ramos 149,Bl A,536-B, BR-21941909 Rio De Janeiro, RJ, Brazil.
EM pinheiro@iq.ufrj.br; yraima@pharma.ufrj.br
RI Weber, Gerald/A-8669-2010; Uversky, Vladimir N./F-4515-2011; Moraes,
   Milton Ozorio/G-9753-2011; Silva, Jerson/J-8984-2014; Pinheiro, Anderson
   S/B-6350-2014
OI Weber, Gerald/0000-0002-2935-1571; Uversky, Vladimir
   N./0000-0002-4037-5857; Moraes, Milton Ozorio/0000-0003-2653-0037;
   Silva, Jerson/0000-0001-9523-9441; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [01]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio
   de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ); Brown University (Brown),
   Brazil Initiative Collaboration Grant
FX Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Grant/Award Number: Finance Code 01; Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); Brown University
   (Brown), Grant/Award Number: Brazil Initiative Collaboration Grant
CR Abid K, 2010, FEBS LETT, V584, P2409, DOI 10.1016/j.febslet.2010.04.040
   Balzani E, 2016, CELL REP, V16, P615, DOI 10.1016/j.celrep.2016.06.017
   Banerjee A, 2017, ADV PURE APPL MATH, V8, P1, DOI 10.1515/apam-2016-0032
   Banjade S, 2014, ELIFE, V3, DOI 10.7554/eLife.04123
   Beaudoin S, 2009, BBA-MOL CELL RES, V1793, P335, DOI 10.1016/j.bbamcr.2008.10.009
   Biasini E, 2019, NAT BIOMED ENG, V3, P167, DOI 10.1038/s41551-019-0367-6
   BRAM S, 1971, J MOL BIOL, V58, P277, DOI 10.1016/0022-2836(71)90246-4
   Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046
   Cavaliere P, 2013, NUCLEIC ACIDS RES, V41, P1
   Chan FTS, 2013, ANALYST, V138, P2156, DOI 10.1039/c3an36798c
   Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793
   Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200
   Cordeiro Y, 2019, BBA-PROTEINS PROTEOM, V1867, P933, DOI 10.1016/j.bbapap.2019.02.006
   Dard R, 2017, EUR J MED GENET, V60, P639, DOI 10.1016/j.ejmg.2017.08.015
   Darling AL, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11060990
   de Oliveira GAP, 2016, SCI REP-UK, V6, DOI 10.1038/srep37990
   Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104
   Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979
   Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k
   Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541
   Dragich JM, 2016, ELIFE, V5, DOI 10.7554/eLife.14810
   Elbaum-Garfinkle S, 2019, J BIOL CHEM, V294, P7160, DOI 10.1074/jbc.REV118.001188
   Fang XJ, 2017, CHINESE MED J-PEKING, V130, P242, DOI 10.4103/0366-6999.198019
   Gasset-Rosa F, 2019, NEURON, V102, P339, DOI 10.1016/j.neuron.2019.02.038
   Gomes MPB, 2008, J BIOL CHEM, V283, P19616, DOI 10.1074/jbc.M802102200
   Groveman BR, 2014, J BIOL CHEM, V289, P24129, DOI 10.1074/jbc.M114.578344
   Hamilton MJ, 2018, J MED GENET, V55, P28, DOI 10.1136/jmedgenet-2017-104620
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109
   Kostylev MA, 2018, MOL CELL, V72, P426, DOI 10.1016/j.molcel.2018.10.009
   Kovachev PS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48883-x
   Kroschwald S, 2017, CELL, V168, P947, DOI 10.1016/j.cell.2017.02.029
   Kypr J, 2009, NUCLEIC ACIDS RES, V37, P1713, DOI 10.1093/nar/gkp026
   Langdon EM, 2018, SCIENCE, V7432, P1
   Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761
   Lin Y, 2015, MOL CELL, V60, P208, DOI 10.1016/j.molcel.2015.08.018
   Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619
   Macedo B, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051023
   Macedo B, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0361-y
   Macedo B, 2012, BIOCHEMISTRY-US, V51, P5402, DOI 10.1021/bi300440e
   Maharana S, 2018, SCIENCE, V360, P918, DOI 10.1126/science.aar7366
   Mange A, 2004, J CELL SCI, V117, P2411, DOI 10.1242/jcs.01094
   Meszaros B, 2018, NUCLEIC ACIDS RES, V46, pW329, DOI 10.1093/nar/gky384
   Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7
   Molliex A, 2015, CELL, V163, P123, DOI 10.1016/j.cell.2015.09.015
   Murakami T, 2015, NEURON, V88, P678, DOI 10.1016/j.neuron.2015.10.030
   Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7
   Nott TJ, 2015, MOL CELL, V57, P936, DOI 10.1016/j.molcel.2015.01.013
   Obradovic Z, 2003, PROTEINS, V53, P566, DOI 10.1002/prot.10532
   Obradovic Z, 2005, PROTEINS, V61, P176, DOI 10.1002/prot.20735
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P1989, DOI 10.1021/bi047993o
   Patel A, 2015, CELL, V162, P1066, DOI 10.1016/j.cell.2015.07.047
   Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
   Rajagopalan K, 2011, J CELL BIOCHEM, V112, P3256, DOI 10.1002/jcb.23252
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X
   Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
   Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200
   Schmidt HB, 2016, CELL REP, V16, P1228, DOI 10.1016/j.celrep.2016.06.088
   Sebollela A, 2014, ACS CHEM NEUROSCI, V5, P1238, DOI 10.1021/cn500156r
   Silva JL, 2008, TRENDS BIOCHEM SCI, V33, P132, DOI 10.1016/j.tibs.2007.11.003
   Silva JL, 2016, J BIOL CHEM, V291, P15482, DOI 10.1074/jbc.R116.733428
   Steinberg TH, 1996, ANAL BIOCHEM, V239, P223, DOI 10.1006/abio.1996.0319
   Takemura K, 2006, EXP BIOL MED, V231, P204
   Tataurov AV, 2008, BIOPHYS CHEM, V133, P66, DOI 10.1016/j.bpc.2007.12.004
   Lima LMTR, 2006, BIOCHEMISTRY-US, V45, P9180, DOI 10.1021/bi060532d
   Turoverov KK, 2019, TRENDS BIOCHEM SCI, V44, P716, DOI 10.1016/j.tibs.2019.03.005
   Uversky VN, 2017, CURR OPIN STRUC BIOL, V44, P18, DOI 10.1016/j.sbi.2016.10.015
   VOORHEES PW, 1992, ANNU REV MATER SCI, V22, P197, DOI 10.1146/annurev.ms.22.080192.001213
   Warwicker J, 2000, BIOCHEM BIOPH RES CO, V278, P646, DOI 10.1006/bbrc.2000.3829
   Wegmann S, 2018, EMBO J, V37, DOI 10.15252/embj.201798049
   Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997
   Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011
   Yin S, 2008, J BIOL CHEM, V283, P25446, DOI 10.1074/jbc.M800814200
   Yu L, 2015, JAMA NEUROL, V72, P15, DOI 10.1001/jamaneurol.2014.3049
   Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396
   Zeng ML, 2016, CELL, V166, P1163, DOI 10.1016/j.cell.2016.07.008
   Zhang J, 2019, BRIEF BIOINFORM, V20, P1250, DOI 10.1093/bib/bbx168
   Zhang XM, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002183
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 79
TC 2
Z9 2
U1 4
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2020
VL 34
IS 1
BP 365
EP 385
DI 10.1096/fj.201901897R
PG 21
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA KC6TY
UT WOS:000507308900026
PM 31914616
DA 2020-12-17
ER

PT J
AU Bom, APDA
   Neves, PCD
   de Almeida, CEB
   Silva, D
   Missailidis, S
AF Dinis Ano Bom, Ana Paula
   da Costa Neves, Patricia Cristina
   Bonacossa de Almeida, Carlos Eduardo
   Silva, Dilson
   Missailidis, Sotiris
TI Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the
   Treatment of Cancer
SO PHARMACEUTICS
LA English
DT Review
DE siRNA; aptamers; cancer; nanoparticles
ID BCL-XL SHRNA; TARGETED DELIVERY; CO-DELIVERY; AS1411 APTAMER;
   DOXORUBICIN; GENE; NANOPARTICLES; COMPLEX; SYSTEM; RNA
AB Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in combination with siRNAs, in the form of specific delivery agents. This combination offers the potential to explore the high affinity and specificity of aptamers, the silencing power of siRNA, and, at times, the cytotoxicity of chemotherapy molecules in powerful combinations that promise to delivery new and potent therapies. In this review, we report new developments in the field, following up from our previous work, more specifically on the use of aptamers as delivery agents of siRNA in nanoparticle formulations, alone or in combination with chemotherapy, for the treatment of cancer.
C1 [Dinis Ano Bom, Ana Paula; da Costa Neves, Patricia Cristina; Silva, Dilson; Missailidis, Sotiris] Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol Biomanguinhos, Av Brasil, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Bonacossa de Almeida, Carlos Eduardo] Comissao Nacl Energia Nucl, Lab Radiobiol, Inst Radioprotecao & Dosimetria, Divisao Fis Med, Av Salvador Allende S-N, BR-22783127 Rio De Janeiro, RJ, Brazil.
RP Missailidis, S (corresponding author), Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol Biomanguinhos, Av Brasil, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM adinis@bio.fiocruz.br; Pcristina@bio.fiocruz.br; ce.bonacossa@gmail.com;
   dilson.silva@bio.fiocruz.br; sotiris.missailidis@bio.fiocruz.br
RI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/M-7511-2013
OI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/0000-0003-0108-3998; Silva,
   Dilson/0000-0001-9726-2442
FU Instituto de Tecnologia em Imunobiologicos (Bio-Manguinhos)
FX This work was supported by Instituto de Tecnologia em Imunobiologicos
   (Bio-Manguinhos).
CR Afonin KA, 2014, NANO LETT, V14, P5662, DOI 10.1021/nl502385k
   Alshaer W, 2018, J CONTROL RELEASE, V271, P98, DOI 10.1016/j.jconrel.2017.12.022
   AlShamaileh H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05859-z
   Ayatollahi S, 2017, INT J BIOCHEM CELL B, V92, P210, DOI 10.1016/j.biocel.2017.10.005
   Bagalkot V, 2011, ACS NANO, V5, P8131, DOI 10.1021/nn202772p
   Balasubramanyam J., 2019, EPCAM APTAMER SIRNA, DOI [10.1101/656199, DOI 10.1101/656199]
   Bayrac AT, 2018, J BIOSCIENCES, V43, P97, DOI 10.1007/s12038-018-9733-x
   Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164
   Bhushan B., 2017, SPRINGER HDB NANOTEC
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   de Almeida CEB, 2017, INT J PHARMACEUT, V525, P334, DOI 10.1016/j.ijpharm.2017.03.086
   Diao YJ, 2016, CANCER BIOL THER, V17, P498, DOI 10.1080/15384047.2016.1156266
   Dong JH, 2018, BIOMED PHARMACOTHER, V107, P849, DOI 10.1016/j.biopha.2018.08.042
   Dou XQ, 2018, INT J NANOMED, V13, P763, DOI 10.2147/IJN.S149887
   Eloy JO, 2018, CURR PHARM DESIGN, V24, P2664, DOI 10.2174/1381612824666180807121935
   Esposito CL, 2018, MOL THER-NUCL ACIDS, V10, P398, DOI 10.1016/j.omtn.2017.12.021
   Faraji AH, 2009, BIOORGAN MED CHEM, V17, P2950, DOI 10.1016/j.bmc.2009.02.043
   Goldberg MS, 2019, NAT REV CANCER, V19, P587, DOI 10.1038/s41568-019-0186-9
   Guaragna A, 2012, BIOCONJUGATE CHEM, V23, P84, DOI 10.1021/bc200410d
   Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0
   Hu J, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.60
   Jafari Reza, 2019, Iranian Biomedical Journal, V23, P21, DOI 10.29252/.23.1.21
   Jeelani S, 2014, J PHARM BIOALLIED SC, V6, P6, DOI 10.4103/0975-7406.137249
   Jeong H, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600343
   Keefe AD, 2008, CURR OPIN CHEM BIOL, V12, P448, DOI 10.1016/j.cbpa.2008.06.028
   Kim E, 2010, BIOMATERIALS, V31, P4592, DOI 10.1016/j.biomaterials.2010.02.030
   Kim MW, 2019, THERANOSTICS, V9, P837, DOI 10.7150/thno.30228
   Kim MW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09555-w
   Kratschmer C, 2018, MOL THER-NUCL ACIDS, V10, P227, DOI 10.1016/j.omtn.2017.11.013
   Kruspe S, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030045
   Lachelt U, 2015, CHEM REV, V115, P11043, DOI 10.1021/cr5006793
   Li H, 2017, THERANOSTICS, V7, P1204, DOI 10.7150/thno.17069
   Li L, 2017, MOL THER-NUCL ACIDS, V8, P169, DOI 10.1016/j.omtn.2017.06.014
   Li N, 2009, J PROTEOME RES, V8, P2438, DOI 10.1021/pr801048z
   Liu Q, 2019, CHEMBIOCHEM, V20, P1139, DOI 10.1002/cbic.201800761
   Luo ZM, 2017, J COLLOID INTERF SCI, V490, P783, DOI 10.1016/j.jcis.2016.12.004
   Lv TT, 2018, ACTA BIOMATER, V76, P257, DOI 10.1016/j.actbio.2018.06.034
   Soldevilla MM, 2015, BIOMATERIALS, V67, P274, DOI 10.1016/j.biomaterials.2015.07.020
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Mishra DK, 2017, DRUG DELIV TRANSL RE, V7, P346, DOI 10.1007/s13346-016-0352-5
   Mohamed M, 2019, SCI TECHNOL ADV MAT, V20, P710, DOI 10.1080/14686996.2019.1627174
   Nanjwade BK, 2019, MICRO NANO TECHNOL, P337, DOI 10.1016/B978-0-12-814031-4.00012-X
   Nozari A, 2017, MOL THER-NUCL ACIDS, V6, P29, DOI 10.1016/j.omtn.2016.12.002
   Panigaj M., 2016, DNA RNA NANOTECHNOLO, V2, P42, DOI DOI 10.1515/rnan-2015-0005
   Pastor F, 2018, NAT REV DRUG DISCOV, V17, P751, DOI 10.1038/nrd.2018.132
   Powell D, 2017, EUR J PHARM BIOPHARM, V114, P108, DOI 10.1016/j.ejpb.2017.01.011
   Pratico ED, 2013, NUCLEIC ACID THER, V23, P35, DOI 10.1089/nat.2012.0388
   Prusty DK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02929-2
   Puplampu-Dove Y, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1349588
   Rajagopalan A, 2017, MOL THER, V25, P54, DOI 10.1016/j.ymthe.2016.10.021
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Singh A, 2018, ARTIF CELL NANOMED B, V46, P274, DOI 10.1080/21691401.2017.1307210
   Sivakumar P, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1543
   Song PF, 2014, BIOCHEM BIOPH RES CO, V452, P1040, DOI 10.1016/j.bbrc.2014.09.037
   Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394
   Subramanian N, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0108-9
   Taghavi S, 2017, INT J PHARMACEUT, V516, P301, DOI 10.1016/j.ijpharm.2016.11.027
   Tseng YC, 2009, ADV DRUG DELIVER REV, V61, P721, DOI 10.1016/j.addr.2009.03.003
   Wang XX, 2011, BIOMATERIALS, V32, P5673, DOI 10.1016/j.biomaterials.2011.04.029
   Wilner SE, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.14
   Wu M, 2018, DRUG DELIV, V25, P226, DOI 10.1080/10717544.2017.1422300
   Wu X, 2011, INT J NANOMED, V6, P1747, DOI 10.2147/IJN.S23747
   Xiang DX, 2017, THERANOSTICS, V7, P4071, DOI 10.7150/thno.20168
   Xu XD, 2017, ACS NANO, V11, P2618, DOI 10.1021/acsnano.6b07195
   Xu Y, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101085
   Xue L, 2018, MOL PHARMACEUT, V15, P4801, DOI 10.1021/acs.molpharmaceut.8b00388
   Yan W, 2018, CELL PHYSIOL BIOCHEM, V50, P79, DOI 10.1159/000493960
   Yao VJ, 2016, J CONTROL RELEASE, V240, P267, DOI 10.1016/j.jconrel.2016.01.002
   Yu XL, 2018, MOL THER-NUCL ACIDS, V10, P317, DOI 10.1016/j.omtn.2017.12.015
   Zhao NX, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-2
   Zolbanin NM, 2018, ADV PHARM BULL, V8, P383, DOI 10.15171/apb.2018.045
NR 71
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD DEC
PY 2019
VL 11
IS 12
AR 684
DI 10.3390/pharmaceutics11120684
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KC0JU
UT WOS:000506874300057
PM 31888119
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Alves, LN
   Missailidis, S
   Lage, CAS
   De Almeida, CEB
AF Alves, Lais N.
   Missailidis, Sotiris
   Lage, Claudia A. S.
   De Almeida, Carlos Eduardo B.
TI Anti-MUC1 Aptamer as Carrier Tool of the Potential Radiosensitizer
   Phenanthroline in MCF-7 Breast Cancer 1,10 Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Aptamer; breast cancer; 1,10-phenanthroline; radiosensitizers; MUC1
ID MUC1 TUMOR-MARKER; DELIVERY-SYSTEMS; DNA APTAMERS; 1,10-PHENANTHROLINE;
   CHEMOTHERAPY; SIRNA; RADIOTHERAPY; COMPLEX; DESIGN; RADIOCHEMOTHERAPY
AB Background: Proteins overexpressed in malignant tissues form important targets in the development of targeted therapeutics, and aptamers comprise an important affinity agent for therapy and drug delivery. In this study, aberrantly expressed mucin 1 glycoprotein was investigated as a therapeutic target in a breast cancer model. Materials and Methods: In order to determine the feasibility of using an aptamer against mucin 1 (aptA) as carrier of the cytotoxic compound 1,10-phenanthroline to MCF-7 cells, as a potential radiosensitizer, was studied in experiments using circular dichroism and rhodamine labelling by fluorescent microscopy and flow cytometry. Results: 1,10-Phenanthroline can be intercalated within aptA when complexed with Fe(II) ions, with dissociation constant (Kd) of 30 mu M. The complex was subsequently capable of binding to and being internalised in MCF-7 breast cancer cells. Conclusion: aptA can carry 1,10-phenanthroline to cancer cells specifically and this complex represents a potential target-directed anticancer therapy.
C1 [Alves, Lais N.; De Almeida, Carlos Eduardo B.] Brazilian Nucl Energy Commiss, Inst Radioprotect & Dosimetry, Lab Radiobiol, Div Med Phys, Rio De Janeiro, Brazil.
   [Alves, Lais N.; Missailidis, Sotiris] Fundacao Oswaldo Cruz, Inst Technol Immunobiol Biomanguinhos, Rio De Janeiro, Brazil.
   [Lage, Claudia A. S.] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, Rio De Janeiro, Brazil.
RP De Almeida, CEB (corresponding author), Comissao Nacl Energia Nucl, Inst Radioprotecao & Dosimetria, Div Fis Med, Lab Radiobiol, Av Salvador Allende S-N, BR-22783127 Rio De Janeiro, RJ, Brazil.
EM cbonacos@ird.gov.br
OI Bonacossa de Almeida, Carlos Eduardo/0000-0003-0108-3998
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); IRD/CNEN; Bio-Manguinhos/FIOCRUZ; CAPESCAPES
FX The Authors are grateful to Dr. Januario Bispo Cabral-Neto for their
   help in the early part of this work. This work was supported by CNPq,
   IRD/CNEN, Bio-Manguinhos/FIOCRUZ and CAPES.
CR Babu A, 2014, AAPS PHARMSCITECH, V15, P709, DOI 10.1208/s12249-014-0089-8
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Bahreyni A, 2017, INT J PHARMACEUT, V526, P391, DOI 10.1016/j.ijpharm.2017.05.014
   Baouendi M, 2012, FEBS J, V279, P479, DOI 10.1111/j.1742-4658.2011.08440.x
   Bollet MA, 2012, RADIOTHER ONCOL, V102, P82, DOI 10.1016/j.radonc.2011.08.017
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   BYRNES RW, 1992, FREE RADICAL BIO MED, V12, P457, DOI 10.1016/0891-5849(92)90099-3
   Chen AY, 2004, CRIT REV ONCOL HEMAT, V50, P111, DOI 10.1016/j.critrevonc.2003.09.005
   Da Pieve C, 2012, BIOCONJUGATE CHEM, V23, P1377, DOI 10.1021/bc300128r
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   de Almeida CEB, 2017, INT J PHARMACEUT, V525, P334, DOI 10.1016/j.ijpharm.2017.03.086
   de Avelar IGJ, 2004, BBA-GEN SUBJECTS, V1675, P46, DOI 10.1016/j.bbagen.2004.08.006
   Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Formenti SC, 2009, LANCET ONCOL, V10, P718, DOI 10.1016/S1470-2045(09)70082-8
   Furtado FAC, 1997, MUTAT RES-DNA REPAIR, V385, P251, DOI 10.1016/S0921-8777(97)00055-4
   Hassan MSU, 2010, ONCOL REP, V24, P1121, DOI 10.3892/or_00000963
   Hu YC, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0043558, 10.1371/journal.pone.0031970]
   Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761
   Liu CM, 2002, INORG CHEM, V41, P140, DOI 10.1021/ic010735k
   Liu Z, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-148
   Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007
   LYNG R, 1992, BIOPOLYMERS, V32, P1201, DOI 10.1002/bip.360320910
   Ma G, 2002, EUR J INORG CHEM, P1307
   Mardas M, 2017, WSPOLCZESNA ONKOL, V21, P162, DOI 10.5114/wo.2017.66896
   Matuschek C, 2012, STRAHLENTHER ONKOL, V188, P777, DOI 10.1007/s00066-012-0162-8
   Matuschek C, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0796-x
   McCann Malachy, 2000, Metal-Based Drugs, V7, P185, DOI 10.1155/MBD.2000.185
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Miecznikowski JC, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-573
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Mudasir, 2003, J INORG BIOCHEM, V94, P263, DOI 10.1016/S0162-0134(03)00007-2
   Nishimura Yasumasa, 2004, Int J Clin Oncol, V9, P414, DOI 10.1007/s10147-004-0443-z
   Pearce A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184360
   Periasamy U, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0680-2
   Powell D, 2017, EUR J PHARM BIOPHARM, V114, P108, DOI 10.1016/j.ejpb.2017.01.011
   Riccardi C, 2017, ACS APPL MATER INTER, V9, P35574, DOI 10.1021/acsami.7b11195
   Schutze T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029604
   SENTER PD, 1995, BIOCONJUGATE CHEM, V6, P389, DOI 10.1021/bc00034a008
   Sharma S, 2009, INDIAN J MED PAEDIAT, V30, P1, DOI 10.4103/0971-5851.56328
   Subramanian N, 2012, MOL VIS, V18, P2783
   Tatiparti K, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040077
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230-973X.96920
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Wesselinova D, 2009, EUR J MED CHEM, V44, P2720, DOI 10.1016/j.ejmech.2009.01.036
   Xie XD, 2016, EUR J PHARM SCI, V83, P28, DOI 10.1016/j.ejps.2015.12.014
   Yan AC, 2009, RNA BIOL, V6, P316, DOI 10.4161/rna.6.3.8808
   Yu G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147674
   Zeng LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep19449
   Zhang RH, 2009, INORG CHEM COMMUN, V12, P583, DOI 10.1016/j.inoche.2009.04.028
   Zhang Z, 2012, J BIOL INORG CHEM, V17, P1257, DOI 10.1007/s00775-012-0940-x
NR 58
TC 1
Z9 1
U1 3
U2 16
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR
PY 2019
VL 39
IS 4
BP 1859
EP 1867
DI 10.21873/anticanres.13293
PG 9
WC Oncology
SC Oncology
GA HS1JZ
UT WOS:000463619600025
PM 30952726
DA 2020-12-17
ER

PT J
AU Vayrynen, O
   Piippo, M
   Jamsa, H
   Vaisanen, T
   de Almeida, CEB
   Salo, T
   Missailidis, S
   Risteli, M
AF Vayrynen, Otto
   Piippo, Markku
   Jamsa, Hannaleena
   Vaisanen, Tuomas
   de Almeida, Carlos E. B.
   Salo, Tuula
   Missailidis, Sotiris
   Risteli, Maija
TI Effects of ionizing radiation and HPSE1 inhibition on the invasion of
   oral tongue carcinoma cells on human extracellular matrices in vitro
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Oral tongue cancer; Ionizing radiation; Aptamer; Myogel; HPSE1
ID METASTATIC NICHE; PROMOTES MIGRATION; CANCER INVASION; GLIOMA-CELLS;
   HEPARANASE; HEAD; MECHANISMS; INVASIVENESS; ENVIRONMENT; PROGRESSION
AB Chemoradiation is an established approach in the treatment of advanced oral tongue squamous cell carcinoma (OTSCC), but therapy may cause severe side-effects due to signal interchanges between carcinoma and the tumour microenvironment (TME). In this study, we examined the potential use of our human 3D myoma disc and Myogel models in in vitro chemoradiation studies by analysing the effects of ionizing radiation (IR) and the combined effect of heparanase 1 (HPSE1) inhibitors and IR on OTSCC cell proliferation, invasion and MMP-2 and - 9 production. Finally, we analysed the long-term effects of IR by studying clones of previously irradiated and invaded HSC-3 cells. We found that in both human uterine leiomyoma-based extracellular matrix models IR inhibited the invasion of HSC-3 cells, but blocking HPSE1 activity combined with IR induced their invasion. Low doses of IR increased MMP expression and initiated epithelial-mesenchymal transition in cells cultured on myoma discs. We conclude that myoma models offer consistent methods for testing human carcinoma cell invasion and phenotypic changes during chemoradiation treatment. In addition, we showed that IR had long-term effects on MMP-2 and - 9, which might elicit different HSC-3 invasion responses when cells were under the challenge of HPSE1 inhibitors and IR.
C1 [Vayrynen, Otto; Piippo, Markku; Jamsa, Hannaleena; Vaisanen, Tuomas; Salo, Tuula; Risteli, Maija] Univ Oulu, Canc Res & Translat Med Res Unit, Fac Med, POB 8000, FI-90014 Oulu, Finland.
   [Vayrynen, Otto; Piippo, Markku; Jamsa, Hannaleena; Vaisanen, Tuomas; Salo, Tuula; Risteli, Maija] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [de Almeida, Carlos E. B.] Comissao Nacl Energia Nucl, Lab Radiobiol, Inst Radioprotecao & Dosimetria, Rio De Janeiro, Brazil.
   [Salo, Tuula] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland.
   [Salo, Tuula] Univ Helsinki, Cent Hosp, HUSLAB, Dept Pathol, Helsinki, Finland.
   [Missailidis, Sotiris] Fiocruz MS, Biomanguinhos Inst Technol Immunobiol, Rio De Janeiro, Brazil.
RP Risteli, M (corresponding author), Univ Oulu, Canc Res & Translat Med Res Unit, Fac Med, POB 8000, FI-90014 Oulu, Finland.
EM maija.risteli@oulu.fi
RI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/M-7511-2013
OI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/0000-0003-0108-3998; Salo,
   Tuula/0000-0001-6039-0088
FU Sigrid Juselius FoundationSigrid Juselius Foundation; Cancer Foundation
   of Finland; Medical Research Center Oulu; Finnish Dental Society
   Apollonia; Orion Research Foundation; Ida Montin Foundation; Medical
   Faculty of the University of Oulu; Medical Faculty of the Oulu
   University Hospital
FX We gratefully acknowledge Maija-Leena Lehtonen, Tanja Kuusisto,
   Eeva-Maija Kiljander, Piia Makela and the staff of the Radiotherapy Unit
   of Oulu University Hospital for expert technical assistance. Paula
   Pesonen and Jari Jokelainen are thanked for assistance with statistical
   analyses. The work was supported by research grants from Sigrid Juselius
   Foundation, Cancer Foundation of Finland, Medical Research Center Oulu,
   Finnish Dental Society Apollonia, Orion Research Foundation, Ida Montin
   Foundation and research funds from the Medical Faculty of the University
   of Oulu and Oulu University Hospital special state support for research.
CR Argiris A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00072
   Astrom P, 2018, METHODS MOL BIOL, V1731, P213, DOI 10.1007/978-1-4939-7595-2_19
   Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706
   Chin AR, 2016, CLIN CANCER RES, V22, P3725, DOI 10.1158/1078-0432.CCR-16-0028
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   He XT, 2004, CANCER RES, V64, P3928, DOI 10.1158/0008-5472.CAN-03-2718
   Hillbertz NS, 2012, ANTICANCER RES, V32, P4201
   Ikuta M., ORAL ONCOL, V37
   Kaliski A, 2005, MOL CANCER THER, V4, P1717, DOI 10.1158/1535-7163.MCT-05-0179
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kargiotis O, 2010, J NEURO-ONCOL, V100, P323, DOI 10.1007/s11060-010-0199-4
   Kundu SK, 2012, TUMOR BIOL, V33, P707, DOI 10.1007/s13277-012-0350-2
   Kurokawa H, 2003, CANCER SCI, V94, P277, DOI 10.1111/j.1349-7006.2003.tb01433.x
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4
   Madani I, 2008, B CANCER, V95, P292, DOI 10.1684/bdc.2008.0598
   MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807
   McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015
   Meirovitz A, 2011, CANCER RES, V71, P2772, DOI 10.1158/0008-5472.CAN-10-3402
   MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x
   Moncharmont C, 2014, CRIT REV ONCOL HEMAT, V92, P133, DOI 10.1016/j.critrevonc.2014.05.006
   Mroueh R, 2017, HEAD NECK-J SCI SPEC, V39, P1306, DOI 10.1002/hed.24744
   Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110
   Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200
   Okumura K, 1996, J CANCER RES CLIN, V122, P243, DOI 10.1007/BF01209653
   Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340
   Piazza C, 2014, CURR OPIN OTOLARYNGO, V22, P81, DOI 10.1097/MOO.0000000000000038
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200
   Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007
   Ramos DM, 1997, INT J CANCER, V72, P369, DOI 10.1002/(SICI)1097-0215(19970717)72:2<369::AID-IJC28>3.3.CO;2-7
   Regezi J.A., 2017, ORAL PATHOLOGY CLIN, P176
   Sacco AG, 2016, ONCOTARGETS THER, V9, P1927, DOI 10.2147/OTT.S93720
   Sacco AG, 2015, J CLIN ONCOL, V33, P3305, DOI 10.1200/JCO.2015.62.0963
   Salo T, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0482
   Salo T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1944-z
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1
   Simmons SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096846
   Simmons SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037938
   Sleeman JP, 2012, CANCER METAST REV, V31, P429, DOI 10.1007/s10555-012-9373-9
   Sundquist E, 2016, EXP CELL RES, V344, P229, DOI 10.1016/j.yexcr.2016.04.003
   Szturz P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0879-4
   Teppo S, 2013, EXP CELL RES, V319, P376, DOI 10.1016/j.yexcr.2012.12.010
   Toulany M., RADIOTHER ONCOL, V97
   Vermorken JB, 2010, ANN ONCOL, V21, P252, DOI 10.1093/annonc/mdq453
   Wild-Bode C, 2001, CANCER RES, V61, P2744
   Yang Y, 2015, ONCOGENE, V34, P5832, DOI 10.1038/onc.2015.40
   Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181
NR 51
TC 2
Z9 2
U1 1
U2 11
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 1
PY 2018
VL 371
IS 1
BP 151
EP 161
DI 10.1016/j.yexcr.2018.08.005
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA GT6WI
UT WOS:000444661200014
PM 30086306
OA Green Published, Green Accepted
DA 2020-12-17
ER

PT S
AU Alves, LN
   Abalo, AA
   Argondizzo, APC
   Rocha, HF
   Silva, D
   Cortez, CM
   Missailidis, S
AF Alves, L. N.
   Abalo, A. A.
   Argondizzo, A. P. C.
   Rocha, H. F.
   Silva, D.
   Cortez, C. M.
   Missailidis, S.
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI Selection and Evaluation of the Binding of Aptamers Against NS5 Zika
   Virus Using Fluorescence Spectroscopy
SO INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND
   ENGINEERING 2018 (ICCMSE-2018)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering (ICCMSE)
CY MAR 14-18, 2018
CL Thessaloniki, GREECE
SP European Soc Computat Methods Sci & Engn
AB The Zika virus (ZIKV) is an Arbovirus belonging to the family Flaviviridae, genus Flavivirus, whose transmission occurs mainly by bites of mosquitoes of the genus Aedes. Although clinical manifestations of the disease are usually mild, increasing evidence is associated with ZIKV infection with increased congenital neurological abnormalities and neuropathic disorders. The laboratory diagnosis of the infection is based on molecular tests and viral isolation since serological tests usually present cross - reaction with other Flaviviruses. A promising solution for rapid and early diagnosis of infection is the development of nucleic acid aptamers capable of specifically interacting, recognizing infectious agents or detecting antibodies. Following this premise, this study aims to identify specific aptamers for NS5 protein of ZIKV, in order to use them in serological tests.
C1 [Alves, L. N.; Abalo, A. A.; Rocha, H. F.] Biomanguinhos FIOCRUZ, Lab Tecnol Anticorpos Monoclonais, Ave Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Argondizzo, A. P. C.] Biomanguinhos FIOCRUZ, Lab Tecnol Recombinante, Ave Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Silva, D.; Cortez, C. M.] Univ Estado Rio De Janeiro, Dept Matemat Aplicada, 524,Maracana, BR-20550900 Rio De Janeiro, RJ, Brazil.
   [Missailidis, S.] Fiocruz MS, Biomanguinhos, Desenvolvimento Tecnol, Edificio Rocha Lima,Ave Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Missailidis, S (corresponding author), Fiocruz MS, Biomanguinhos, Desenvolvimento Tecnol, Edificio Rocha Lima,Ave Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM sotiris.missailidis@bio.fiocruz.br
RI Argondizzo, Ana Paula C/D-5880-2017; CORTEZ, CELIA MARTINS/X-3247-2018
OI CORTEZ, CELIA MARTINS/0000-0002-7857-1167; Silva,
   Dilson/0000-0001-9726-2442
CR Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Franco LD, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0395-z
   Klema VJ, 2015, VIRUSES-BASEL, V7, P4640, DOI 10.3390/v7082837
   Missailidis Sotiris, 2004, Methods Mol Biol, V248, P431
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Simmons SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037938
   Wang W, 2018, NATURE COMMUNICATION, V106, P1
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
   2017, GENE, V628, P117, DOI DOI 10.1016/J.GENE.2017.07.049
   2016, CELL HOST MICROBE, V19, P882, DOI DOI 10.1016/J.CHOM.2016.05.009
   2016, EMERG INFECT DIS, V22, P1185, DOI DOI 10.3201/EID2207.151990
   2016, VIRUS DIS, V27, P111, DOI DOI 10.1007/S13337-016-0307-Y
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1766-3
J9 AIP CONF PROC
PY 2018
VL 2040
AR 100005
DI 10.1063/1.5079160
PG 4
WC Computer Science, Interdisciplinary Applications; Engineering,
   Multidisciplinary; Multidisciplinary Sciences
SC Computer Science; Engineering; Science & Technology - Other Topics
GA BM7JO
UT WOS:000467966400109
DA 2020-12-17
ER

PT S
AU Morais, LM
   Alves, LN
   Argondizzo, APC
   Rocha, HF
   Silva, D
   Valdez, ECN
   Filippis, AMB
   Missailidis, S
AF Morais, L. M.
   Alves, L. N.
   Argondizzo, A. P. C.
   Rocha, H. F.
   Silva, D.
   Valdez, E. C. N.
   Filippis, A. M. B.
   Missailidis, S.
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI DNA Aptamer as Molecular Tool for ZIKV NS1 Protein Detection
SO INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND
   ENGINEERING 2018 (ICCMSE-2018)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering (ICCMSE)
CY MAR 14-18, 2018
CL Thessaloniki, GREECE
SP European Soc Computat Methods Sci & Engn
AB The Zika virus (ZIKV) is an Arbovirus belonging to the family Flaviviridae, genus Flavivirus, whose transmission occurs mainly by bites of of Aedes aegypti mosquitoes. Although clinical manifestations of the disease are usually mild, increasing evidence is associated with ZIKV infection with increased congenital neurological abnormalities and neuropathic disorders. The laboratory diagnosis of the infection is based on molecular tests and viral isolation since serological tests usually present cross-reaction with other Flaviviruses. A promising solution for rapid and early diagnosis of infection is the development of nucleic acid aptamers capable of specifically interacting, recognizing infectious agents or detecting antibodies. Following this premise, this study aims to identify specific aptamers for NS1 protein of ZIKV, in order to use them in serological tests.
C1 [Morais, L. M.] Biomanguinhos Fiocruz, Lab Tecnol Virol, Edificio Rocha Lima,Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Alves, L. N.; Rocha, H. F.] Biomanguinhos Fiocruz, Lab Tecnol Anticorpos Monoclonais, Pavilhao Rockfeller,Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Argondizzo, A. P. C.] Biomanguinhos Fiocruz, Lab Tecnol Recombinante, Pavilhao Rockfeller,Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Silva, D.; Valdez, E. C. N.] Univ Estado Rio De Janeiro, Dept Matemat Aplicada, R Sao Francisco Xavier,524, BR-20550900 Rio De Janeiro, RJ, Brazil.
   [Filippis, A. M. B.] Fiocruz MS, Inst Oswaldo Cruz, Lab Flavivirus, Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Missailidis, S.] Fiocruz MS, Biomanguinhos, Desenvolvimento Tecnol, Edificio Rocha Lima,Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Missailidis, S (corresponding author), Fiocruz MS, Biomanguinhos, Desenvolvimento Tecnol, Edificio Rocha Lima,Ave Brasil,4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM sotiris.missailidis@bio.fiocruz.br
RI Argondizzo, Ana Paula C/D-5880-2017
OI Silva, Dilson/0000-0001-9726-2442
CR Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Haddow AD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001477
   Li X-F, 2016, SCI CHINA LIFE SCI, V59, P2012
   Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7
   Saiz JC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00496
   Zhou J, 2016, NAT REV D D
   2011, P NATL ACAD SCI USA, V108, P8003, DOI DOI 10.1073/PNAS.1017338108
   2016, ANTIVIR RES, V130, P7, DOI DOI 10.1016/J.ANTIVIRAL.2016.02.014
   2014, SCIENCE, V343, P881, DOI DOI 10.1126/SCIENCE.1247749
   2017, INT J PHARMACEUT, V525, P334, DOI DOI 10.1016/J.IJPHARM.2017.03.086
   1990, J VIROL, V64, P4356
   2016, VIRUSDISEASE, V27, P111, DOI DOI 10.1007/S13337-016-0307-Y
   2015, REV MED VIROL, V25, P205, DOI DOI 10.1002/RMV.1835
   2016, ONCOTARGET, V7, P1344
   2016, A LITERATURE REVIEW, V22, P1185, DOI DOI 10.3201/EID2207.151990
   2013, ANTIVIR RES, V98, P192, DOI DOI 10.1016/J.ANTIVIRAL.2013.03.008
NR 17
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1766-3
J9 AIP CONF PROC
PY 2018
VL 2040
AR 100007
DI 10.1063/1.5079162
PG 4
WC Computer Science, Interdisciplinary Applications; Engineering,
   Multidisciplinary; Multidisciplinary Sciences
SC Computer Science; Engineering; Science & Technology - Other Topics
GA BM7JO
UT WOS:000467966400111
DA 2020-12-17
ER

PT J
AU Pascual, L
   Cerqueira-Coutinho, C
   Garcia-Fernandez, A
   de Luis, B
   Bernardes, ES
   Albernaz, MS
   Missailidis, S
   Martinez-Manez, R
   Santos-Oliveira, R
   Orzaez, M
   Sancenon, F
AF Pascual, Lluis
   Cerqueira-Coutinho, Cristal
   Garcia-Fernandez, Alba
   de Luis, Beatriz
   Bernardes, Emerson Soares
   Albernaz, Marta Souza
   Missailidis, Sotiris
   Martinez-Manez, Ramon
   Santos-Oliveira, Ralph
   Orzaez, Mar
   Sancenon, Felix
TI MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug
   delivery and radio-imaging applications
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Radiopharmaceuticals; Nanotechnology; Oncology; Mesoporous silica
   nanoparticles
ID CONTROLLED-RELEASE; BIODISTRIBUTION; SUPPORTS; TC-99M; CELLS; PARTICLES;
   DESIGN
AB Mucin 1 (MUC1) is a cell surface protein overexpressed in breast cancer. Mesoporous silica nanoparticles (MSNs) loaded with safranin O, functionalized with aminopropyl groups and gated with the negatively charged MUC1 aptamer have been prepared (S1-apMUC1) for specific targeting and cargo release in tumoral versus non-tumoral cells. Confocal microscopy studies showed that the S1-apMUC1 nanoparticles were internalized in MDA-MB-231 breast cancer cells that overexpress MUC1 receptor with subsequent pore opening and cargo release. Interestingly, the MCF-10-A non-tumorigenic breast epithelial cell line that do not overexpress MUC1, showed reduced (S1-apMUC1) internalization. Negligible internalization was also found for S1-ap nanoparticles that contained a scrambled DNA sequence as gatekeeper. S2-apMUC1 nanoparticles (similar to S1-apMUC1 but loaded with doxorubicin) internalized in MDA-MB-231 cells and induced a remarkable reduction in cell viability. Moreover, S1-apMUC1 nanoparticles radio-labeled with Tc-99m (S1-apMUC1-Tc) showed a remarkable tumor targeting in in vivo studies with MDA-MB-231 tumor-bearing Balb/c mice. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Pascual, Lluis; Garcia-Fernandez, Alba; de Luis, Beatriz; Martinez-Manez, Ramon; Sancenon, Felix] Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Recon Reconocimiento Mol &, Valencia, Spain.
   [Pascual, Lluis; Garcia-Fernandez, Alba; de Luis, Beatriz; Martinez-Manez, Ramon; Sancenon, Felix] Univ Politecn Valencia, Dept Quim, Camino Vera S-N, E-46022 Valencia, Spain.
   [Pascual, Lluis; Garcia-Fernandez, Alba; de Luis, Beatriz; Martinez-Manez, Ramon; Sancenon, Felix] CIBER BBN, Valencia, Spain.
   [Pascual, Lluis; Garcia-Fernandez, Alba; de Luis, Beatriz; Martinez-Manez, Ramon; Orzaez, Mar; Sancenon, Felix] Univ Politecn Valencia, Ctr Invest Principe Felipe, Unidad Mixta UPV CIPF Invest Mecanismos Enfermeda, Valencia, Spain.
   [Cerqueira-Coutinho, Cristal] Univ Fed Rio de Janeiro, Fac Pharm, Rio De Janeiro, Brazil.
   [Bernardes, Emerson Soares] Inst Pesquisas Energet & Nucl, Ctr Radiofarm, Sao Paulo, Brazil.
   [Albernaz, Marta Souza; Santos-Oliveira, Ralph] Brazilian Nucl Energy Commiss, Nucl Engn Inst, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Fundacao Oswaldo Cruz, Biomanguinhos, Rio De Janeiro, Brazil.
   [Orzaez, Mar] Ctr Invest Principe Felipe, Eduardo Primo Yufera 3, Valencia 46012, Spain.
RP Martinez-Manez, R (corresponding author), Univ Valencia, Univ Politecn Valencia, Inst Interuniv Invest Recon Reconocimiento Mol &, Valencia, Spain.; Martinez-Manez, R (corresponding author), Univ Politecn Valencia, Dept Quim, Camino Vera S-N, E-46022 Valencia, Spain.; Martinez-Manez, R (corresponding author), CIBER BBN, Valencia, Spain.; Martinez-Manez, R (corresponding author), Univ Politecn Valencia, Ctr Invest Principe Felipe, Unidad Mixta UPV CIPF Invest Mecanismos Enfermeda, Valencia, Spain.; Santos-Oliveira, R (corresponding author), Brazilian Nucl Energy Commiss, Nucl Engn Inst, Rio De Janeiro, Brazil.
EM rmaez@qim.upv.es
RI Martinez-Manez, Ramon/O-8915-2014; de Luis, Beatriz/E-8434-2016; Orzaez,
   Mar/B-4992-2014; Sancenon, Felix/AAD-3203-2020
OI Martinez-Manez, Ramon/0000-0001-5873-9674; de Luis,
   Beatriz/0000-0001-9353-8632; Orzaez, Mar/0000-0003-3231-5835; 
FU Spanish GovernmentSpanish Government; FEDEREuropean Union (EU)
   [MAT2015-64139-C4-1]; Generalitat ValencianaGeneralitat Valenciana
   [PROMETEOII/2014/047]
FX Financial support from the Spanish Government and FEDER funds (Project
   MAT2015-64139-C4-1) and the Generalitat Valenciana (Project
   PROMETEOII/2014/047) is gratefully acknowledged.
CR Agostini A, 2012, LANGMUIR, V28, P14766, DOI 10.1021/la303161e
   Agostini A, 2012, ANGEW CHEM INT EDIT, V51, P10556, DOI 10.1002/anie.201204663
   Apostolopoulos V, 2015, CELL MOL LIFE SCI, V72, P4475, DOI 10.1007/s00018-015-2014-z
   Arias JL., 2016, NANOTECHNOLOGY DRUG
   Aznar E, 2016, CHEM REV, V116, P561, DOI 10.1021/acs.chemrev.5b00456
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   de Barros ALB, 2015, MAT SCI ENG C-MATER, V56, P181, DOI 10.1016/j.msec.2015.06.030
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Carmo FS, 2016, LAT AM J PHARM, V35, P2056
   Chen F, 2015, ACS NANO, V9, P7950, DOI 10.1021/acsnano.5b00526
   Chen F, 2015, ACS NANO, V9, P3926, DOI 10.1021/nn507241v
   Chen F, 2014, SCI REP-UK, V4, DOI 10.1038/srep05080
   Chen F, 2013, ACS NANO, V7, P9027, DOI [10.1021/nn403617j, 10.1021/nn403617J]
   Cheng SH, 2016, J NUCL MED, V57, P279, DOI 10.2967/jnumed.115.163006
   Chrastina A, 2010, INT J NANOMED, V5, P653, DOI 10.2147/IJN.S11677
   Coll C, 2013, ACCOUNTS CHEM RES, V46, P339, DOI 10.1021/ar3001469
   Coll C, 2011, ANGEW CHEM INT EDIT, V50, P2138, DOI 10.1002/anie.201004133
   Da Pieve C, 2008, EJC SUPPL, V6, P30, DOI 10.1016/S1359-6349(08)71292-8
   Da Pieve C, 2012, BIOCONJUGATE CHEM, V23, P1377, DOI 10.1021/bc300128r
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   de la Torre C, 2014, CHEM-EUR J, V20, P15309, DOI 10.1002/chem.201404382
   de Sousa Azevedo RC, 2012, J BIOMATER NANOTECHN, V3, P163
   Denk C, 2016, BIOCONJUGATE CHEM, V27, P1707, DOI 10.1021/acs.bioconjchem.6b00234
   Du JZ, 2015, J CONTROL RELEASE, V219, P205, DOI 10.1016/j.jconrel.2015.08.050
   Ferreira CSM, 2007, BRAZ ARCH BIOL TECHN, V50, P63, DOI 10.1590/S1516-89132007000600008
   FORNARI FA, 1994, MOL PHARMACOL, V45, P649
   Guo ZD, 2016, SCI REP-UK, V6, DOI 10.1038/srep28812
   Hernandez FJ, 2013, CHEM COMMUN, V49, P1285, DOI 10.1039/c2cc37370j
   Jacobson O, 2015, J NUCL MED, V56, P616, DOI 10.2967/jnumed.114.149484
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jo H, 2015, BIOSENS BIOELECTRON, V71, P129, DOI 10.1016/j.bios.2015.04.030
   Kita K, 2011, EXPERT OPIN DRUG DEL, V8, P329, DOI 10.1517/17425247.2011.553216
   Kobayashi Y, 2016, CURR TOP MED CHEM, V16, P2694, DOI 10.2174/1568026616666160413134922
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Li ZH, 2012, BIOMACROMOLECULES, V13, P4257, DOI 10.1021/bm301563q
   Ligiero TB, 2016, BIOMED PHYS ENG EXPR, V2, DOI 10.1088/2057-1976/2/4/045017
   Lu CH, 2013, ACS NANO, V7, P8320, DOI 10.1021/nn404613v
   Mas N, 2013, CHEM-EUR J, V19, P1346, DOI 10.1002/chem.201202740
   Oroval M, 2013, CHEM COMMUN, V49, P5480, DOI 10.1039/c3cc42157k
   Patel K, 2008, J AM CHEM SOC, V130, P2382, DOI 10.1021/ja0772086
   Rani V, 2015, J CHEM PHARM RES, V7, P216
   Rurack K., 2010, SUPRAMOLECULAR CHEM
   Sancenon F, 2015, CHEMISTRYOPEN, V4, P418, DOI 10.1002/open.201500053
   Sandhya G, 2015, ADV NANOMATER, P251
   Sarcinelli MA, 2016, ONCOTARGETS THER, V9, P5847, DOI 10.2147/OTT.S110787
   Schlossbauer A, 2009, ANGEW CHEM INT EDIT, V48, P3092, DOI 10.1002/anie.200805818
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Stroopinsky D, 2016, LEUKEMIA LYMPHOMA, V57, P2489, DOI 10.1080/10428194.2016.1195500
   Thornton PD, 2010, J AM CHEM SOC, V132, P2024, DOI 10.1021/ja9094439
   Varmira K, 2013, NUCL MED BIOL, V40, P980, DOI 10.1016/j.nucmedbio.2013.07.004
   Walker JM, 2012, METHODS MOL BIOL, V842
   Wang F, 2015, ANGEW CHEM INT EDIT, V54, P1098, DOI 10.1002/anie.201404652
   Wilson M, 2002, NANOTECHNOLOGY BASIC
   Wuillemin MA, 2014, DALTON T, V43, P4260, DOI 10.1039/c3dt53019a
   Yang YW, 2011, MEDCHEMCOMM, V2, P1033, DOI 10.1039/c1md00158b
   Zhang XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085007
   Zhu YF, 2011, DALTON T, V40, P10203, DOI 10.1039/c1dt11114k
NR 57
TC 32
Z9 34
U1 6
U2 73
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD NOV
PY 2017
VL 13
IS 8
BP 2495
EP 2505
DI 10.1016/j.nano.2017.08.006
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA FL5QU
UT WOS:000414301400011
PM 28842375
OA Green Published
DA 2020-12-17
ER

PT J
AU de Almeida, CEB
   Alves, LN
   Rocha, HF
   Cabral-Neto, JB
   Missailidis, S
AF de Almeida, Carlos E. B.
   Alves, Lais Nascimento
   Rocha, Henrique F.
   Cabral-Neto, Januario Bispo
   Missailidis, Sotiris
TI Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in
   cancer
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Aptaniers; siRNA; RadiopharmaceuticS; Chemotherapy; Cancer
ID TARGETED DRUG-DELIVERY; DNA APTAMER; CHIMERAS; NANOPARTICLES;
   THERAPEUTICS; DOXORUBICIN; MOLECULE; THERAPY; LIGANDS; CONJUGATE
AB Aptamers are oligonucleotide reagents with high affinity and specificity, which among other therapeutic and diagnostic applications have the capability of acting as delivery agents. Thus, aptamers are capable of carrying small molecules, nanoparticles, radiopharmaceuticals or fluorescent agents as well as nucleic acid therapeutics specifically to their target cells. In most cases, the molecules may possess interesting therapeutic properties, but their lack of specificity for a particular cell type, or ability to internalise in such a cell, hinders their clinical development, or cause unwanted side effects. Thus, chemotherapy or radiotherapy agents, famous for their side effects, can be coupled to aptamers for specific delivery. Equally, siRNA have great therapeutic potential and specificity, but one of their shortcomings remain the delivery and internalisation into cells. Various methodologies have been proposed to date, including aptamers, to resolve this problem. Therapeutic or imaging reagents benefit from the adaptability and ease of chemical manipulation of aptamers, their high affinity for the specific marker of a cell type, and their internalisation ability via cell mediated endocytosis. In this review paper, we explore the potential of the aptamers as delivery agents and offer an update on current status and latest advancements. (C) 2017 Elsevier B.V. All rights reserved.
C1 [de Almeida, Carlos E. B.; Alves, Lais Nascimento; Cabral-Neto, Januario Bispo] Comissao Nacl Energia Nucl, Inst Radioprotecao & Dosimetria, Div Fis Med, Lab Radiobiol, Av Salvador Allende S-N, BR-22783127 Rio De Janeiro, RJ, Brazil.
   [Rocha, Henrique F.; Missailidis, Sotiris] Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol Biomanguinhos, Lab Anticorpos Monoclonais, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Cabral-Neto, Januario Bispo] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Av Brg Trompowski, BR-21044020 Rio De Janeiro, RJ, Brazil.
RP Missailidis, S (corresponding author), Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol Biomanguinhos, Lab Anticorpos Monoclonais, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM sotiris.missailidis@bio.fiocruz.br
RI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/M-7511-2013
OI DE ALMEIDA, CARLOS EDUARDO BONACOSSA/0000-0003-0108-3998
CR Aaldering LJ, 2015, RNA BIOL, V12, P412, DOI 10.1080/15476286.2015.1017234
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Bagalkot V, 2011, ACS NANO, V5, P8131, DOI 10.1021/nn202772p
   Bandekar A, 2014, J NUCL MED, V55, P107, DOI 10.2967/jnumed.113.125476
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Boyacioglu O, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.37
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Correa CR, 2014, BIOORG MED CHEM LETT, V24, P1998, DOI 10.1016/j.bmcl.2014.02.048
   Da Pieve C, 2012, BIOCONJUGATE CHEM, V23, P1377, DOI 10.1021/bc300128r
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Davydova AS, 2011, ACTA NATURAE, V3, P12, DOI 10.32607/20758251-2011-3-4-12-29
   Dougherty CA, 2015, CURR TOP MED CHEM, V15, P1138, DOI 10.2174/1568026615666150413153400
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Esposito Carla Lucia, 2014, J RNAi Gene Silencing, V10, P500
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Gilboa-Geffen A, 2015, MOL CANCER THER, V14, P2279, DOI 10.1158/1535-7163.MCT-15-0201-T
   Gomes SD, 2012, BIOCONJUGATE CHEM, V23, P2192, DOI 10.1021/bc300146c
   Gomes Sonia Da Rocha, 2010, Expert Opin Med Diagn, V4, P511, DOI 10.1517/17530059.2010.516248
   Herrmann A, 2014, J CLIN INVEST, V124, P2977, DOI 10.1172/JCI73174
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hu MD, 2013, FUTURE ONCOL, V9, P369, DOI [10.2217/fon.12.201, 10.2217/FON.12.201]
   Hu YC, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0043558, 10.1371/journal.pone.0031970]
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Jacobson O, 2015, J NUCL MED, V56, P1780, DOI 10.2967/jnumed.115.160960
   Jacobson O, 2015, J NUCL MED, V56, P616, DOI 10.2967/jnumed.114.149484
   Kanwar JR, 2011, CRIT REV BIOCHEM MOL, V46, P459, DOI 10.3109/10409238.2011.614592
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kryza D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149387
   Li JL, 2014, ANAL BIOCHEM, V456, P1, DOI 10.1016/j.ab.2014.03.013
   Li X, 2013, J CONTROL RELEASE, V171, P152, DOI 10.1016/j.jconrel.2013.06.006
   Liu HY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30346
   Liu Z, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-148
   Luo YL, 2011, ACS NANO, V5, P7796, DOI 10.1021/nn201592s
   Mai JH, 2014, J CONTROL RELEASE, V187, P22, DOI 10.1016/j.jconrel.2014.04.057
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033434
   Namgung R, 2012, SMALL, V8, P3209, DOI 10.1002/smll.201200496
   Ni XH, 2015, MOL CANCER THER, V14, P2797, DOI 10.1158/1535-7163.MCT-15-0291-T
   Porciani D, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.9
   Prakash JS, 2015, BIOMEDICINES, V3, P248, DOI 10.3390/biomedicines3030248
   Singh Y, 2010, CHEM SOC REV, V39, P2054, DOI 10.1039/b911431a
   Subramanian N, 2015, NUCLEIC ACID THER, V25, P317, DOI 10.1089/nat.2015.0550
   Subramanian N, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0108-9
   Subramanian N, 2012, MOL VIS, V18, P2783
   Sullenger BA, 2016, NUCLEIC ACID THER, V26, P119, DOI 10.1089/nat.2016.29001.sul
   Sun HG, 2016, ANALYST, V141, P403, DOI 10.1039/c5an01995h
   Taghdisi SM, 2010, J DRUG TARGET, V18, P277, DOI 10.3109/10611860903434050
   Thiel KW, 2012, NUCLEIC ACIDS RES, V40, P6319, DOI 10.1093/nar/gks294
   Thiel KW, 2010, THER DELIV, V1, P849, DOI [10.4155/tde.10.61, 10.4155/TDE.10.61]
   Trinh T. L., 2015, PLOS ONE, V10
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Varmira K, 2014, J DRUG TARGET, V22, P116, DOI 10.3109/1061186X.2013.839688
   Varmira K, 2013, NUCL MED BIOL, V40, P980, DOI 10.1016/j.nucmedbio.2013.07.004
   Wang AZ, 2008, CHEMMEDCHEM, V3, P1311, DOI 10.1002/cmdc.200800091
   Wilner SE, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.6
   Wu XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090752
   Wu X, 2015, THERANOSTICS, V5, P322, DOI 10.7150/thno.10257
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Xiang DX, 2015, CURR GENE THER, V15, P109, DOI 10.2174/1566523214666141224095105
   Yang J, 2012, NANOMEDICINE-UK, V7, P1297, DOI 10.2217/NNM.12.14
   You XG, 2014, CONTRAST MEDIA MOL I, V9, P349, DOI 10.1002/cmmi.1584
   Yu MK, 2011, SMALL, V7, P2241, DOI 10.1002/smll.201100472
   Zhang KC, 2015, BIOMACROMOLECULES, V16, P2618, DOI 10.1021/acs.biomac.5b00250
   Zhou JH, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.21
   Zhou Jiehua, 2012, Frontiers in Genetics, V3, P234, DOI 10.3389/fgene.2012.00234
NR 68
TC 20
Z9 20
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUN 20
PY 2017
VL 525
IS 2
SI SI
BP 334
EP 342
DI 10.1016/j.ijpharm.2017.03.086
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EX2AZ
UT WOS:000403029200004
PM 28373101
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Cerqueira-Coutinho, C
   Missailidis, S
   Alessandra-Perini, J
   Machado, DE
   Perini, JA
   Santos-Oliveira, R
AF Cerqueira-Coutinho, Cristal
   Missailidis, Sotiris
   Alessandra-Perini, Jessica
   Machado, Daniel Escorsim
   Perini, Jamila Alessandra
   Santos-Oliveira, Ralph
TI Comparison of biodistribution profile of monoclonal antibodies
   nanoparticles and aptamers in rats with breast cancer
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Aptamers; nanoparticles; nano-radiopharmaceuticals; radiopharmaceuticals
ID MESOPOROUS SILICA NANOPARTICLES; CELL LUNG-CANCER; SUBCLASSES; THERAPY
AB The use of monoclonal antibodies and aptamers is growing every single day, as the use of nanoparticle systems. Although most of the products are under investigation, there are a few commercialized products available at the market, for human consume. In this study, we have compared three formulations (aptamer anti-MUC1, monoclonal antibody -Trastuzumab and monoclonal antibodies nanoparticles -PLA/PVA/MMT trastuzumab) to identify their profile as also to understand their behavior into an alive biological system. In this direction the radiolabeling of the products were done and they were all tested in animals (in vivo) in two conditions: healthy rats and breast cancer induced animals. The results showed that the nanoparticle has the better biodistribution profile, followed by the aptamer. We conclude that more studies and a global effort to elucidate the biological behavior of drugs and especially nano-drugs are necessary.
C1 [Cerqueira-Coutinho, Cristal] Univ Fed Rio de Janeiro, Eloisa Mano Macromol Inst, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris; Alessandra-Perini, Jessica; Machado, Daniel Escorsim; Perini, Jamila Alessandra] Zona Oeste State Univ, Lab Res Pharmaceut Sci, Rio De Janeiro, Brazil.
   [Alessandra-Perini, Jessica; Perini, Jamila Alessandra] Fundacao Oswaldo Cruz, Grad Program Publ Hlth, Rio De Janeiro, Brazil.
   [Alessandra-Perini, Jessica; Perini, Jamila Alessandra] Fundacao Oswaldo Cruz, Environm Natl Sch Publ Hlth, Rio De Janeiro, Brazil.
   [Perini, Jamila Alessandra] Natl Inst Traumatol & Orthoped, Rio De Janeiro, Brazil.
   [Santos-Oliveira, Ralph] Zona Oeste State Univ, Lab Radiopharm & Nanoradiopharmaceut, Rua Helio de Almeida 75, BR-21941906 Rio De Janeiro, Brazil.
RP Santos-Oliveira, R (corresponding author), Zona Oeste State Univ, Lab Radiopharm & Nanoradiopharmaceut, Rua Helio de Almeida 75, BR-21941906 Rio De Janeiro, Brazil.
EM ralph.uezo@gmail.com
FU National Scientific and Technological Research Council (CNPQ)National
   Council for Scientific and Technological Development (CNPq); Rio de
   Janeiro State Research Foundation (FAPERJ)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX The authors would like to thank the National Scientific and
   Technological Research Council (CNPQ) and the Rio de Janeiro State
   Research Foundation (FAPERJ) for funding.
CR Albernaz MD, 2014, ARTIF CELL NANOMED B, V42, P88, DOI 10.3109/21691401.2013.785954
   Cerqueira-Coutinho C, 2015, ENG LIFE SCI, V1, P1
   Di Pasqua AJ, 2013, J NUCL MED, V54, P111, DOI 10.2967/jnumed.112.106609
   Di Pasqua AJ, 2012, INORG CHIM ACTA, V393, P334, DOI 10.1016/j.ica.2012.06.016
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Goldhirsch A, 2001, J Natl Cancer Inst Monogr, P44
   Guiu S, 2012, ANN ONCOL, V23, P2997, DOI 10.1093/annonc/mds586
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Huober J, 2010, BREAST CANCER RES TR, V124, P133, DOI 10.1007/s10549-010-1103-9
   Iliuk AB, 2011, ANAL CHEM, V83, P4440, DOI 10.1021/ac201057w
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Diniz CL, 2010, EJC SUPPL, V8, P59
   Liang Z, 2015, INT J PHARMACEUT, V494, P337, DOI 10.1016/j.ijpharm.2015.08.042
   Nahta R, 2003, CLIN CANCER RES, V9, P5078
   Patricio B, 2015, CONSID SITE INJECT, V10, P323
   Patricio B F de Carvalho, 2013, World J Nucl Med, V12, P24, DOI 10.4103/1450-1147.113946
   Pinto SR, 2014, NUCL MED BIOL, V41, P772, DOI 10.1016/j.nucmedbio.2014.05.141
   Rodriguez FJ, 2012, ONCOTARGET, V3, P98
   Soerjomataram I, 2008, BREAST CANCER RES TR, V107, P309, DOI 10.1007/s10549-007-9556-1
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Thiviyanathan V, 2012, PROTEOM CLIN APPL, V6, P563, DOI 10.1002/prca.201200042
   Wang T, 2010, MOL PHARMACEUT, V7, P1007, DOI 10.1021/mp1001125
   Wasserman MAV, 2014, RECENT PAT NANOMED, V4, P1
NR 23
TC 6
Z9 6
U1 0
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2017
VL 45
IS 3
BP 598
EP 601
DI 10.3109/21691401.2016.1163717
PG 4
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA EL4NQ
UT WOS:000394598300026
PM 28211299
OA Bronze
DA 2020-12-17
ER

PT J
AU do Carmo, FS
   Ricci, E
   Cerqueira-Coutinho, C
   Albernaz, MD
   Bernardes, ES
   Missailidis, S
   Santos-Oliveira, R
AF do Carmo, Fagner Santos
   Ricci-Junior, Eduardo
   Cerqueira-Coutinho, Cristal
   Albernaz, Marta de Souza
   Bernardes, Emerson Soares
   Missailidis, Sotiris
   Santos-Oliveira, Ralph
TI Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by
   single-photon emission computed tomography in inducted animals: initial
   considerations
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE aptamer; cancer control; imaging; nuclear medicine; radiopharmacy
ID PRIMARY CARCINOMAS; MUC1; EXPRESSION; BIODISTRIBUTION; NANOPARTICLES;
   DESIGN; MUCINS; CELLS; RADIOPHARMACEUTICALS; RADIOTHERAPY
AB The early and specific detection of tumors remains a barrier in oncology, especially in cases such as the triple-negative breast cancer (TNBC). To address this gap, aptamers have found an important application in the recognition of tumor biomarkers such as mucin 1 (MUC1). However, there are still some difficulties in the use of aptamer, as their rapid biological clearance makes their use as drugs limited. In this study, the anti-MUC1 aptamer was used as a drug delivery system (DDS) for a radioactive polymeric nanoparticle (NP) in the imaging of TNBCs. Thus, poly(lactic-co-glycolic acid) NPs loaded with the anti-MUC1 aptamer and labeled with technetium-99m were used for a biodistribution study and imaging of TNBC. The results confirmed that the NP was successfully obtained, with a mean size of 262 nm, according to the dynamic light scattering data. The biodistribution assay in induced animal models with TNBC showed that although there was a high capture by intestine (>30%), the DDS developed had a high tumor uptake (5%) and with great in vivo imaging properties, corroborating the possibility of use of this DDS as an imaging drug for TNBC.
C1 [do Carmo, Fagner Santos; Albernaz, Marta de Souza] Univ Estado Rio De Janeiro, Biol Inst Roberto Alcantara Gomes, Rio De Janeiro, Brazil.
   [do Carmo, Fagner Santos; Santos-Oliveira, Ralph] Brazilian Nucl Energy Commiss, Nucl Engn Inst, R Helio de Almeida,75 Ilha Fundao, Rio De Janeiro, Brazil.
   [Ricci-Junior, Eduardo] Univ Fed Rio de Janeiro, Fac Pharm, Rio De Janeiro, Brazil.
   [Cerqueira-Coutinho, Cristal] Univ Fed Rio de Janeiro, Inst Macromol Eloisa Mano, Rio De Janeiro, Brazil.
   [Albernaz, Marta de Souza] Univ Fed Rio de Janeiro, Univ Hosp Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Bernardes, Emerson Soares] Inst Pesquisas Energet & Nucl, Ctr Radiofarm, Sao Paulo, Brazil.
   [Missailidis, Sotiris] Oswaldo Cruz Fdn Fiocruz, Inst Technol Immunobiol Biomanguinhos, Rio De Janeiro, Brazil.
RP Santos-Oliveira, R (corresponding author), Brazilian Nucl Energy Commiss, Nucl Engn Inst, R Helio de Almeida,75 Ilha Fundao, Rio De Janeiro, Brazil.
EM presidenciaradiofarmacia@gmail.com
RI Santos-Oliveira, Ralph/J-3429-2016; Bernardes, Emerson
   Soares/D-3711-2017
OI Bernardes, Emerson Soares/0000-0002-0029-7313
CR Albernaz MD, 2014, ARTIF CELL NANOMED B, V42, P88, DOI 10.3109/21691401.2013.785954
   Anselmo AC, 2013, ACS NANO, V7, P11129, DOI 10.1021/nn404853z
   Baek JS, 2015, INT J NANOMED, V10, P5397, DOI 10.2147/IJN.S86474
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726
   Chappuis PO, 1999, ANN ONCOL, V10, P1163, DOI 10.1023/A:1008301314812
   Chopra A, 2014, APTAMERS SYN ANTIBOD, V1, P1
   Corfield AP, 2000, GUT, V47, P589, DOI 10.1136/gut.47.4.589
   Da Pieve C, 2012, BIOCONJUGATE CHEM, V23, P1377, DOI 10.1021/bc300128r
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135
   GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620
   GLOBOCAN, 2012, GLOBOCAN 2012 CANC I
   Gouyer V, 2015, SCI REP-UK, V5, DOI 10.1038/srep09577
   Hamoudeh M, 2008, ADV DRUG DELIVER REV, V60, P1329, DOI 10.1016/j.addr.2008.04.013
   HO SB, 1993, CANCER RES, V53, P641
   Hu Y, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/728342
   Jeffrey Stefanie S, 2002, Mol Interv, V2, P101, DOI 10.1124/mi.2.2.101
   Jemal Ahmedin, 2009, V471, P3, DOI 10.1007/978-1-59745-416-2_1
   Kim GE, 2002, GASTROENTEROLOGY, V123, P1052, DOI 10.1053/gast.2002.36018
   Lee MJ, 2003, MODERN PATHOL, V16, P403, DOI 10.1097/01.MP.0000067683.84284.66
   Sa LTM, 2013, J DRUG TARGET, V21, P427, DOI 10.3109/1061186X.2012.761222
   Pinto SR, 2014, NUCL MED BIOL, V41, P772, DOI 10.1016/j.nucmedbio.2014.05.141
   Reis JS, 2006, J CLIN PATHOL, V59, P225, DOI 10.1136/jcp.2005.028324
   RobilottaCecil C, 2006, VER PANAM SALUD PUBL, V20
   Santos-Oliveira R, 2011, CURR RADIOPHARM, V4, P140, DOI 10.2174/1874471011104020140
   Sarcinelli MA, 2014, THESIS
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   Tonin RS, 2011, CINTILOGRAFIA PET CT
   Vlad AM, 2006, IMMUNOL RES, V36, P229, DOI 10.1385/IR:36:1:229
   Xu F, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002286
   Yu CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024077
   Zhang YM, 2000, EUR J NUCL MED, V27, P1700, DOI 10.1007/s002590000343
   Zhou JH, 2015, CHEM BIOL, V22, P379, DOI 10.1016/j.chembiol.2015.01.005
NR 43
TC 24
Z9 24
U1 0
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2017
VL 12
BP 53
EP 60
DI 10.2147/IJN.S118482
PG 8
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA EF6TT
UT WOS:000390464500001
PM 28053523
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Carmo, FS
   Missailidis, S
   Al-Malki, Y
   Al-Qahtani, M
   Santos-Oliveira, R
AF Carmo, Fagner S.
   Missailidis, Sotiris
   Al-Malki, Yousif
   Al-Qahtani, Mohammed
   Santos-Oliveira, Ralph
TI Development of Aptamer Anti-MUC1 Labelled with Na-22 and Ga-68 as a
   Positron Emission Tomography Radiopharmaceutical
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE aptamer; imaging; PET radiopharmaceutical; radiopharmacy
ID MUC1; EXPRESSION; ANTIGENS
AB The development of radiopharmaceuticals based on biological molecules has been increasing in the last few years. The high specificity associated with high affinity, especially in tumours site has emerged this class of radiopharmaceuticals as a whole new perspective, for both: therapy and imaging. In this study we develop and evaluate the aptamer anti-MUC1 labelled with Ga-68 and Na-22 as PET radio pharmaceutical for prostate cancer. The results showed that the methodology developed for labelling the aptamer with Ga-68 and Na-22 (separately) was quite efficient and support as a methodology that could be used for cold kit in nuclear medicine daily routine.
C1 [Carmo, Fagner S.; Santos-Oliveira, Ralph] Zona Oeste State Univ, Lab Radiopharm & Nanoradiopharmaceut, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Oswaldo Cruz Fdn FIOCRUZ, Inst Technol Immunobiol Biomanguinhos, Rio De Janeiro, Brazil.
   [Al-Malki, Yousif; Al-Qahtani, Mohammed] King Faisal Specialist Hosp & Res Ctr, Cyclotron & Radiopharmaceut Dept, Riyadh, Saudi Arabia.
RP Carmo, FS (corresponding author), Zona Oeste State Univ, Lab Radiopharm & Nanoradiopharmaceut, Rio De Janeiro, Brazil.
EM presidenciaradiofarmacia@gmail.com
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-
   Brazil)National Council for Scientific and Technological Development
   (CNPq); FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX We would like to thank to CNPq (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico- Brazil) and FAPERJ (Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro) for financial support of this
   study.
CR Adams J, 1853, LANCET, V1, P393
   Breeman WAP, 2011, SEMIN NUCL MED, V41, P314, DOI 10.1053/j.semnuclmed.2011.02.001
   Cascio S, 2015, CANCERS, V7, P342, DOI 10.3390/cancers7010342
   Chiu TC, 2009, SENSORS-BASEL, V9, P10356, DOI 10.3390/s91210356
   Delacroix D., 2002, RAD PROTECTION DOSIM
   Deng M, 2013, ASIAN PAC J CANCER P, V14, P127, DOI 10.7314/APJCP.2013.14.1.127
   Feng H, 2002, JPN J CLIN ONCOL, V32, P525, DOI 10.1093/jjco/hyf111
   Feng LY, 2011, BIOMATERIALS, V32, P2930, DOI 10.1016/j.biomaterials.2011.01.002
   Han K, 2010, SENSORS-BASEL, V10, P4541, DOI 10.3390/s100504541
   Hasegawa H, 2008, SENSORS-BASEL, V8, P1090, DOI 10.3390/s8021090
   HO SB, 1993, CANCER RES, V53, P641
   Hofman MS, 2012, J MED IMAG RADIAT ON, V56, P40, DOI 10.1111/j.1754-9485.2011.02327.x
   Hua M, 2010, ANAL SCI, V26, P1265, DOI 10.2116/analsci.26.1265
   Instituto Nacional de Cancer (BR), 2014, EST 2014 INC CANC BR
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Diniz CL, 2010, EJC SUPPL, V8, P59
   Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292
   Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050
   Roberta S.S., 2014, AVALIACAO APTAMEROS
   Belluzo MS, 2008, SENSORS-BASEL, V8, P1366
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   Togami S, 2010, J OBSTET GYNAECOL RE, V36, P588, DOI 10.1111/j.1447-0756.2010.01221.x
   UNB-University of Nebraska Lincoln, 2014, SAF PROT NA 22 ENV H, P472
   Viad A.M., 2006, IMMUNOL RES, V36, P229
   Wang AZ, 2014, J NUCL MED, V55, P353, DOI 10.2967/jnumed.113.126144
   Zhang SL, 1998, CLIN CANCER RES, V4, P295
   Zhernosekov K. P., 2006, THESIS
   Zhu GZ, 2012, CHEM COMMUN, V48, P10472, DOI 10.1039/c2cc35042d
NR 28
TC 1
Z9 1
U1 0
U2 3
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326-2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PD NOV
PY 2016
VL 35
IS 9
BP 2056
EP 2063
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EF9GB
UT WOS:000390637600020
DA 2020-12-17
ER

PT S
AU Soares, MAG
   Azevedo, A
   Missailidis, S
   Silva, D
AF Gomes Soares, Marilia Amavel
   Azevedo, Alexandre
   Missailidis, Sotiris
   Silva, Dilson
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI A Computational Solution to Analyze Hydrophobic Characteristics in
   Protein Chains
SO PROCEEDINGS OF THE INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN
   SCIENCES AND ENGINEERING 2016 (ICCMSE-2016)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering (ICCMSE)
CY MAR 17-20, 2016
CL Athens, GREECE
DE computational solution; hydrophobicity analysis; protein chains
AB This paper presents a program developed to facilitate calculations of the total or partial hidrophobicity value of polypeptides and proteins chains. It was built using the Fortran 77 language and performs additional functions, determining the total free energy and the electromotive force of an amino acid in a protein. These values were then used to estimate the average hydrophobicity of the protein or fragment sequence.
C1 [Gomes Soares, Marilia Amavel] Educ Ctr David Pinto, Rio De Janeiro, Brazil.
   [Azevedo, Alexandre] Univ Fed Rural Rio de Janeiro, Dept Phys, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Inst Technol Immunobiol Biomanguinhos, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Inst Vital Brasil, Niteroi, RJ, Brazil.
   [Silva, Dilson] Univ Estado Rio De Janeiro, Postgraduat Program Computat Sci, Rio De Janeiro, RJ, Brazil.
RP Soares, MAG (corresponding author), Educ Ctr David Pinto, Rio De Janeiro, Brazil.
EM dilsons@uerj.br
OI Gomes Soares, Marilia Amavel/0000-0003-2390-8428; Silva,
   Dilson/0000-0001-9726-2442
CR Backus J, 1998, IEEE ANN HIST COMPUT, V20, P68, DOI 10.1109/85.728232
   Damodaran S., 2010, FENNEMAS FOOD CHEM
   Hagen JB, 2000, NAT REV GENET, V1, P231, DOI 10.1038/35042090
   Kubinyi H, 1979, Prog Drug Res, V23, P97
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Murphy K.P., SERIES METHODS MOL B, V168
   Nelson DL, 2008, LEHNINGER PRINCIPLES
   Oliveira LC, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2335638
   Silva LB, 2007, J MOL STRUC-THEOCHEM, V806, P23, DOI 10.1016/j.theochem.2006.10.014
   Wang S., 2015, CHINESE PHYS B, V25
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1454-9
J9 AIP CONF PROC
PY 2016
VL 1790
AR 100015
DI 10.1063/1.4968707
PG 4
WC Computer Science, Interdisciplinary Applications; Physics, Applied
SC Computer Science; Physics
GA BG5ER
UT WOS:000389449900072
DA 2020-12-17
ER

PT S
AU Missailidis, S
   de Oliveira, RC
   Silva, D
   Cortez, CM
   Guterres, A
   Vicente, LHB
   de Godoy, DT
   Lemos, E
AF Missailidis, Sotiris
   de Oliveira, Renata Carvalho
   Silva, Dilson
   Cortez, Celia Martins
   Guterres, Alexandro
   Bassan Vicente, Luciana Helena
   de Godoy, Daniela Tupy
   Lemos, Elba
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI Preliminary Selection and Evaluation of the Binding of Aptamers against
   a Hantavirus Antigen using Fluorescence Spectroscopy and Modeling
SO INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND
   ENGINEERING 2015 (ICCMSE 2015)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering (ICCMSE)
CY MAR 20-23, 2015
CL Athens, GREECE
DE Aptamers; Hantavirus; Fluorescence Spectroscopy; Diagnosis
AB In this study we have aimed to develop novel aptamers against the Hantavirus nucleoprotein N, a valid antigen already used in the Hantavirus reference laboratory of the Institute Oswaldo Cruz in Rio de Janeiro, Brazil. Such aptamers, if they are found to bind with high affinity and specificity for the selected hantavirus antigen, they could be translated into novel diagnostic assays with the ability to provide early detection for hantaviroses and their related disease syndromes. In a preliminary screening, we have managed to identify three aptamer species. We have analyzed a short and a long version of these aptamer using fluorescence spectroscopy and modelled their binding. We have identified Stern-Volmer constants for the selected aptamers, which have shown affinity for their target, with a different binding between the short and the long versions of them. Short aptamers have shown to have a higher Stern-Volmer constant and the ability to potentially bind to more than one binding site on the antigen. The information provided by the spectroscopic screening has been invaluable in allowing us to define candidates for further development into diagnostic assays.
C1 [Missailidis, Sotiris] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Fiho, BR-21941 Rio De Janeiro, Brazil.
   [de Oliveira, Renata Carvalho; Guterres, Alexandro; Bassan Vicente, Luciana Helena; de Godoy, Daniela Tupy; Lemos, Elba] Fiocruz MS, Inst Oswaldo Cruz, Lab Hantaviroses & Ricketssioses, Rio De Janeiro, Brazil.
   [Silva, Dilson; Cortez, Celia Martins] Univ Estado Rio De Janeiro, Inst Math & Stat, Rio De Janeiro, Brazil.
RP Missailidis, S (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Fiho, BR-21941 Rio De Janeiro, Brazil.
EM sotirismissailidis@gmail.com
RI CORTEZ, CELIA MARTINS/X-3247-2018; Guterres, Alexandro/AAS-2174-2020;
   Guterres, Alexandro/B-4881-2014
OI CORTEZ, CELIA MARTINS/0000-0002-7857-1167; Guterres,
   Alexandro/0000-0001-8323-1477; Guterres, Alexandro/0000-0001-8323-1477;
   Silva, Dilson/0000-0001-9726-2442; Lemos, Elba/0000-0003-3761-0200
CR [Anonymous], 2014, J CLIN VIROLOGY
   [Anonymous], 2008, AVALIACAO HISTOPATOL
   Arnold S, 2012, BIOL CHEM, V393, P343, DOI 10.1515/hsz-2011-0253
   Cortez CM, 2012, SPECTROCHIM ACTA A, V95, P270, DOI 10.1016/j.saa.2012.04.053
   Figueiredo LTM, 2009, EMERG INFECT DIS, V15, P561, DOI 10.3201/eid1504.080289
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE
   Silva D, 2013, J PHOTOCH PHOTOBIO B, V127, P68, DOI 10.1016/j.jphotobiol.2013.06.015
   Simmons SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037938
NR 8
TC 0
Z9 0
U1 0
U2 1
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1349-8
J9 AIP CONF PROC
PY 2015
VL 1702
AR 120005
DI 10.1063/1.4938904
PG 4
WC Physics, Applied
SC Physics
GA BE4JR
UT WOS:000371804300131
DA 2020-12-17
ER

PT S
AU Silva, D
   Missailidis, S
AF Silva, Dilson
   Missailidis, Sotiris
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI Drug Bind to Proteins - Why Modeling?
SO INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND
   ENGINEERING 2015 (ICCMSE 2015)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering (ICCMSE)
CY MAR 20-23, 2015
CL Athens, GREECE
DE modeling; theoretical biology; drug bind; protein
AB We have been thinking along these past ten years about the real challenges for the use of models and the theoretical biology approach on living matter. It is quite clear for all, nowadays, that we can not only consider processing the huge library of data generated by an ever increasing volume of experiments, through traditional methods or analytical solutions. We must do more, since we now have new tools available. The difficulties we face when dealing with models related to living matter, with its unique characteristics, are well documented. Here we discuss those singularities and how to propose solutions to bypass their main questions.
C1 [Silva, Dilson] Univ Estado Rio De Janeiro, Dept Appl Math, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
RP Silva, D (corresponding author), Univ Estado Rio De Janeiro, Dept Appl Math, Rio De Janeiro, Brazil.
EM dilsons@uerj.br
OI Silva, Dilson/0000-0001-9726-2442
CR Brauer MJ, 2002, MOL BIOL EVOL, V19, P1717, DOI 10.1093/oxfordjournals.molbev.a003994
   Buddelmeijer N., 2015, FEMS MICROBIOL REV
   Evrard AE, 1999, P NATL ACAD SCI USA, V96, P4228, DOI 10.1073/pnas.96.8.4228
   Harold FM, 2005, MICROBIOL MOL BIOL R, V69, P544, DOI 10.1128/MMBR.69.4.544-564.2005
   Hjorth JJJ, 2015, DEV NEUROBIOL, V75, P641, DOI 10.1002/dneu.22241
   Islam S.M., 2015, J PHYS CHEM B, V18
   Krakauer DC, 2011, J THEOR BIOL, V276, P269, DOI 10.1016/j.jtbi.2011.01.051
   Kritz MV, 2010, J THEOR BIOL, V265, P250, DOI 10.1016/j.jtbi.2010.04.026
   Matvienko S, 2015, J BIOINF COMPUT BIOL, V13, DOI 10.1142/S0219720015400041
   Want E, 2009, BIOANALYSIS, V1, P805, DOI 10.4155/BIO.09.64
   Yip C, 2014, PROTEOM CLIN APPL, V8, P807, DOI 10.1002/prca.201400048
NR 11
TC 0
Z9 0
U1 0
U2 1
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1349-8
J9 AIP CONF PROC
PY 2015
VL 1702
AR 120002
DI 10.1063/1.4938901
PG 3
WC Physics, Applied
SC Physics
GA BE4JR
UT WOS:000371804300128
DA 2020-12-17
ER

PT S
AU Silva, D
   Missailidis, S
AF Silva, Dilson
   Missailidis, Sotiris
BE Simos, TE
   Kalogiratou, Z
   Monovasilis, T
TI Analyzing Models for Interactions of Aptamers to Proteins
SO INTERNATIONAL CONFERENCE OF COMPUTATIONAL METHODS IN SCIENCES AND
   ENGINEERING 2014 (ICCMSE 2014)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference of Computational Methods in Sciences and
   Engineering 2014 (ICCMSE)
CY APR 04-07, 2014
CL Athens, GREECE
SP European Soc Computat Methods Sci Engn & Technol
DE Aptamers; interaction to protein; serum albumin
ID LASER-DESORPTION/IONIZATION; MASS-SPECTROMETRY; LIGANDS
AB We have devised an experimental and theoretical model, based on fluorescent spectroscopy and molecular modelling, to describe the interaction of aptamer (selected against various protein targets) with proteins and albumins in particular. This model, described in this work, has allowed us to decipher the nature of the interactions between aptamers and albumins, the binding site of the aptamers to albumins, the potential role of primer binding to the albumin and expand to the ability of albumin to carry aptamers in the bloodstream, providing data to better understand the level of free aptamer for target binding. We are presenting the study of a variety of aptamers, including those against the MUC1 tumour marker, heparanase and human kallikrein 6 with bovine and human serum albumins and the effect these interactions may have on the bioavailability of the aptamer for target-specific binding and therapeutic activity.
C1 [Silva, Dilson] Univ Estado Rio De Janeiro, Dept Appl Math, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
RP Silva, D (corresponding author), Univ Estado Rio De Janeiro, Dept Appl Math, Rio De Janeiro, Brazil.
OI Silva, Dilson/0000-0001-9726-2442
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX Professor Missailid's and Professor Silva would like to thank CNPq for
   the financial support to the project.
CR Aberem MB, 2006, ADV MATER, V18, P2703, DOI 10.1002/adma.200601651
   Arnold S, 2012, BIOL CHEM, V393, P343, DOI 10.1515/hsz-2011-0253
   Cole JR, 2007, ANAL CHEM, V79, P273, DOI 10.1021/ac061256b
   Cortez CM, 2012, SPECTROCHIM ACTA A, V95, P270, DOI 10.1016/j.saa.2012.04.053
   Dick LW, 2004, ANAL CHEM, V76, P3037, DOI 10.1021/ac049860e
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Kawde AN, 2005, ELECTROCHEM COMMUN, V7, P537, DOI 10.1016/j.elecom.2005.03.008
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE
   Makwana V., ANTICANCER THERAPEUT
   Missailidis S, 2009, EXPERT OPIN THER PAT, V19, P1073, DOI 10.1517/13543770903042337
   Silva D, 2013, J PHOTOCH PHOTOBIO B, V127, P68, DOI 10.1016/j.jphotobiol.2013.06.015
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Velasco-Garcia MN, 2009, GENE THER MOL BIOL, V13, P1
   Vivekananda J, 2006, LAB INVEST, V86, P610, DOI 10.1038/labinvest.3700417
   Wang YH, 2011, BIOSENS BIOELECTRON, V26, P3536, DOI 10.1016/j.bios.2011.01.041
NR 17
TC 0
Z9 1
U1 0
U2 6
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1255-2
J9 AIP CONF PROC
PY 2014
VL 1618
BP 594
EP 597
DI 10.1063/1.4897808
PG 4
WC Physics, Applied
SC Physics
GA BB7UI
UT WOS:000346015200128
DA 2020-12-17
ER

PT J
AU Silva, D
   Cortez, CM
   Silva, CMC
   Missailidis, S
AF Silva, Dilson
   Cortez, Celia Martins
   Silva, Camila M. C.
   Missailidis, Sotiris
TI A fluorescent spectroscopy and modelling analysis of anti-heparanase
   aptamers-serum protein interactions
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Modelling; Aptamers; Heparanase; Albumin; Quenching of fluorescence
ID CANCER METASTASIS; SULFATE PROTEOGLYCANS; METHYL-PARATHION;
   LIGAND-BINDING; CELL-MIGRATION; DNA APTAMERS; KEY ENZYME; IN-VITRO;
   ALBUMIN; TUMOR
AB Aptamers are short, single stranded oligonucleotide or peptide molecules that bind a specific target molecule and can be used for the delivery of therapeutic agents and/or for imaging and clinical diagnosis. Several works have been developed aiming at the production of aptamers and the study of their applications, but few results have been reported on plasmatic dynamics of such products. Aptamers against the heparanase enzyme have been previously described. In this work, the interactions of two constructs of the most promising anti-heparanase aptamer (molecular weights about 9200 Da and 22000 Da) to human and bovine serum albumins were studied by fluorescence quenching technique. Stern-Volmer graphs were plotted and quenching constants were estimated. Stern-Volmer plots obtained from experiments carried out at 25 degrees C and 37 degrees C showed that the quenching of fluorescence of HSA and BSA by the low molecular weight aptamer was a collisional phenomenon (estimated Stern-Volmer constant: 3.22 (+/- 0.01) x 10(5) M-1 for HSA at 37 degrees C and 2.47 (+/- 0.01) x 10(5) M-1 for HSA at 25 degrees C), while the high molecular weight aptamer quenched albumins by static process (estimated Stern-Volmer constant: 4.05 (+/- 0.01) x 10(5) M-1 for HSA at 37 degrees C and 6.20 (+/- 0.01) x 10(5) M-1 for HSA at 25 degrees C), interacting with those proteins constituting complexes. Linear Stern-Volmer plot from HSA titrated with the low MW aptamer suggested the existence of a single binding site for the quencher in this albumin. Differently, for aptamer 2, the slightly downward curvature of the Stern-Volmer plot of the titration for that albumin suggested a possible conformational change that led to the exposition of lower affinity binding sites in HSA at 25 degrees C. Similarly, although short aptamer does not appear to form a stable complex (collisional interaction), the longer aptamer is found to form a stable complex with HSA. In addition, the behaviour of quenching curves for HSA and BSA and values estimated for ratio R-1/R-2 from model developed by Silva et al. suggest that the primary binding site in both aptamers is located closer to the tryptophan residue in sub domain IIA. It is likely that both aptamers are competing for the same primary site in albumin. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Silva, Dilson; Cortez, Celia Martins; Silva, Camila M. C.] Open Univ, Dept Chem & Analyt Sci, London, England.
   [Silva, Dilson; Cortez, Celia Martins] Univ Estado Rio De Janeiro, Inst Math & Stat, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Fiocruz MS, Inst Oswaldo Cruz, Lab Hantaviroses & Rickettsioses, Rio De Janeiro, Brazil.
RP Silva, D (corresponding author), Univ Estado Rio De Janeiro, Inst Math & Stat, Dept Appl Math, Rio De Janeiro, Brazil.
EM sildilson@gmail.com
RI CORTEZ, CELIA MARTINS/X-3247-2018
OI CORTEZ, CELIA MARTINS/0000-0002-7857-1167; Silva,
   Dilson/0000-0001-9726-2442
FU Brazilian Foundation MEC/CAPES
FX Brazilian Foundation MEC/CAPES supported this work.
CR Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466
   Arnold S, 2012, BIOL CHEM, V393, P343, DOI 10.1515/hsz-2011-0253
   Bai HX, 2009, J CHIN CHEM SOC-TAIP, V56, P696, DOI 10.1002/jccs.200900104
   BARNER M, 1987, BLOOD, V70, P551
   Belatik A, 2012, EUR J MED CHEM, V48, P114, DOI 10.1016/j.ejmech.2011.12.002
   Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x
   Bertucci C, 2002, CURR MED CHEM, V9, P1463, DOI 10.2174/0929867023369673
   Bhattacharyya J, 2001, BIOCHEM PHARMACOL, V62, P1293, DOI 10.1016/S0006-2952(01)00786-9
   BHATTACHARYYA M, 1990, BIOCHEM BIOPH RES CO, V167, P1146, DOI 10.1016/0006-291X(90)90643-2
   Bi SY, 2004, J MOL STRUCT, V703, P37, DOI 10.1016/j.molstruc.2004.05.026
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Cortez C.M., 2013, SPECTROCHIM AC UNPUB
   Cortez CM, 2012, SPECTROCHIM ACTA A, V95, P270, DOI 10.1016/j.saa.2012.04.053
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   Edovitsky E, 2006, BLOOD, V107, P3609, DOI 10.1182/blood-2005-08-3301
   Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230
   Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje
   Ferro V, 2004, MINI-REV MED CHEM, V4, P693, DOI 10.2174/1389557043403729
   Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341
   Froehlich E, 2009, J PHYS CHEM B, V113, P6986, DOI 10.1021/jp9011119
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200
   Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200
   Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554
   HE XM, 1993, NATURE, V364, P362, DOI 10.1038/364362b0
   He XT, 2004, CANCER RES, V64, P3928, DOI 10.1158/0008-5472.CAN-03-2718
   Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004
   Jiang M, 2004, J MOL STRUCT, V692, P71, DOI 10.1016/j.molstruc.2004.01.003
   KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57
   KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17
   Kram V, 2006, J CELL PHYSIOL, V207, P784, DOI 10.1002/jcp.20625
   Kratochwil NA, 2002, BIOCHEM PHARMACOL, V64, P1355, DOI 10.1016/S0006-2952(02)01074-2
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE
   Levidiotis V, 2005, NEPHROLOGY, V10, P167, DOI 10.1111/j.1440-1797.2005.00388.x
   Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x
   Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200
   Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182
   Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230
   Myler HA, 2006, J BIOCHEM, V139, P339, DOI 10.1093/jb/mvj061
   NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Peters Jr T., 1996, ALL ALBUMIN BIOCH GE
   Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208
   PUCHALSKI MM, 1991, FRESEN J ANAL CHEM, V340, P341, DOI 10.1007/BF00321578
   ROMER J, 1979, J PHARM PHARMACOL, V31, P7, DOI 10.1111/j.2042-7158.1979.tb13411.x
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saijo M, 2003, HISTOCHEM CELL BIOL, V120, P493, DOI 10.1007/s00418-003-0589-1
   Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602
   Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004
   Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048
   Shaikh SMT, 2007, INT J BIOL MACROMOL, V41, P81, DOI 10.1016/j.ijbiomac.2007.01.004
   Silva D, 2004, BRAZ J MED BIOL RES, V37, P963, DOI 10.1590/S0100-879X2004000700004
   Silva D, 2004, TOXICOL LETT, V147, P53, DOI 10.1016/j.toxlet.2003.10.014
   Silva D, 2010, FISH PHYSIOL BIOCHEM, V36, P427, DOI 10.1007/s10695-009-9312-z
   Silva D, 2010, ECOTOX ENVIRON SAFE, V73, P32, DOI 10.1016/j.ecoenv.2009.09.003
   Simmons SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037938
   Sulkowska A, 2002, J MOL STRUCT, V614, P227, DOI 10.1016/S0022-2860(02)00256-9
   VERBEECK RK, 1983, BIOCHEM PHARMACOL, V32, P2565, DOI 10.1016/0006-2952(83)90019-9
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI13662
   Vlodavsky I., 1999, PROTOCOLS CELL BIOL, V1
   Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553
   Waterman M, 2007, MODERN PATHOL, V20, P8, DOI 10.1038/modpathol.3800710
   Wilson R, 2013, NUCLEIC ACID THER, V23, P88, DOI 10.1089/nat.2012.0386
   Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com
   Zcharia E, 2004, FASEB J, V18, P252, DOI 10.1096/fj.03-0572com
   Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811
   Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068
   Zetser A, 2003, CANCER RES, V63, P7733
   Zhao HW, 2006, SPECTROCHIM ACTA A, V65, P811, DOI 10.1016/j.saa.2005.12.038
NR 71
TC 18
Z9 18
U1 1
U2 41
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD OCT 5
PY 2013
VL 127
BP 68
EP 77
DI 10.1016/j.jphotobiol.2013.06.015
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 249GZ
UT WOS:000326767000008
PM 23968994
DA 2020-12-17
ER

PT J
AU Sa, LTM
   Simmons, S
   Missailidis, S
   da Silva, MIP
   Santos-Oliveira, R
AF Miranda Sa, Lucas Torres
   Simmons, Suzanne
   Missailidis, Sotiris
   Pais da Silva, Maria Isabel
   Santos-Oliveira, Ralph
TI Aptamer-based nanoparticles for cancer targeting
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Biodistribution; cancer; cancer targeting; controlled drug delivery;
   controlled release; radio labeling
ID MESOPOROUS SILICA NANOPARTICLES; ANTI-MUC1 APTAMERS; DELIVERY-SYSTEM;
   RADIOPHARMACEUTICALS; BIODISTRIBUTION; DIAGNOSIS; DESIGN
AB Background: The use of mesoporous silica for cancer targeting is increasing rapidly. The association between rigid model of nanoparticles such as mesoporous silica and biological compounds with affinity for oncological diseases is a very promising drug targeting system nowadays.
   Methods: In this study, we used the mesoporous silica (SBA-15) associated with aptamer (functionalized for the tumor marker MUC-1).
   Results: The results obtained in the characterization were quite interesting and demonstrated that the silica produced were very uniform and with a size range of 50-100 nm. Thus, the results of cytotoxicity demonstrated that there is no cytotoxicity related to the nanoparticle.
   Conclusion: We conclude that although further studies are required, the nanoparticle mesoporous silica model loaded with aptamer is very functional and its use can be widespread for other application especially in nuclear medicine.
C1 [Miranda Sa, Lucas Torres; Pais da Silva, Maria Isabel] Pontificia Univ Catolica Rio de Janeiro, Dept Quim, Rio De Janeiro, Brazil.
   [Simmons, Suzanne] Open Univ, Dept Hlth Life & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Missailidis, Sotiris] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz IOC, Lab Hantaviroses & Rickettsioses, Rio De Janeiro, Brazil.
   [Santos-Oliveira, Ralph] Nucl Engn Inst, Lab Nanoradiopharmaceut, BR-21941906 Rio De Janeiro, Brazil.
RP Santos-Oliveira, R (corresponding author), Nucl Engn Inst, Lab Nanoradiopharmaceut, Rua Helio de Almeida 75,Cidade Univ, BR-21941906 Rio De Janeiro, Brazil.
EM roliveira@ien.gov.br
RI Santos-Oliveira, Ralph/J-3429-2016; Santos-Oliveira, Ralph/J-8363-2013
OI Santos-Oliveira, Ralph/0000-0002-0905-481X
CR Ambrogio MW, 2011, ACCOUNTS CHEM RES, V44, P903, DOI 10.1021/ar200018x
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Ozalp VC, 2011, PHARMACEUTICALS, V4, P1137, DOI 10.3390/ph4081137
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Kim D, 2010, ACS NANO, V4, P3689, DOI 10.1021/nn901877h
   Diniz CL, 2010, EJC SUPPL, V8, P59
   Lu J, 2007, SMALL, V3, P1341, DOI 10.1002/smll.200700005
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Min K, 2011, BIOMATERIALS, V32, P2124, DOI 10.1016/j.biomaterials.2010.11.035
   Sa LTM, 2012, J PHARMACEUT BIOMED, V70, P602, DOI 10.1016/j.jpba.2012.06.008
   Missailidis S, 2007, CANCER BIOTHER RADIO, V22, P453, DOI 10.1089/cbr.2007.357
   Morelli C, 2011, NANOSCALE, V3, P3198, DOI 10.1039/c1nr10253b
   Perkins AC, 2007, Q J NUCL MED MOL IM, V51, P292
   Zhu J, 2011, CHEM-ASIAN J, V6, P2332, DOI 10.1002/asia.201100064
NR 16
TC 12
Z9 12
U1 4
U2 57
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PD MAY
PY 2013
VL 21
IS 5
BP 427
EP 434
DI 10.3109/1061186X.2012.761222
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 156LT
UT WOS:000319824300002
PM 23350808
DA 2020-12-17
ER

PT J
AU Wilson, R
   Cossins, A
   Nicolau, DV
   Missailidis, S
AF Wilson, Robert
   Cossins, Andrew
   Nicolau, Dan V.
   Missailidis, Sotiris
TI The Selection of DNA Aptamers for Two Different Epitopes of Thrombin Was
   Not Due to Different Partitioning Methods
SO NUCLEIC ACID THERAPEUTICS
LA English
DT Article
ID SINGLE-STRANDED-DNA; MULTIPLEXED DETECTION; MAGNETIC BEADS;
   HIGH-AFFINITY; BIOSENSOR; BINDS
AB Nearly all aptamers identified so far for any given target molecule have been specific for the same binding site (epitope). The most notable exception to the 1 aptamer per target molecule rule is the pair of DNA aptamers that bind to different epitopes of thrombin. This communication refutes the suggestion that these aptamers exist because different partitioning methods were used when they were selected. The possibility that selection of these aptamers was biased by conflicting secondary structures was also investigated and found not to contribute. The preparation of protein-coated magnetic beads for systematic evolution of ligands by exponential enrichment (SELEX) and the different specificities of the thrombin aptamers for the alpha and beta forms of thrombin are also reported.
C1 [Wilson, Robert; Cossins, Andrew] Univ Liverpool, Inst Integrat Biol, Liverpool L69 7ZB, Merseyside, England.
   [Nicolau, Dan V.] Univ Liverpool, Dept Elect Engn & Elect, Liverpool L69 7ZB, Merseyside, England.
   [Missailidis, Sotiris] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
RP Wilson, R (corresponding author), Univ Liverpool, Inst Integrat Biol, Crown St, Liverpool L69 7ZB, Merseyside, England.
EM r.wilson@liv.ac.uk
OI Cossins, Andrew/0000-0002-0813-5212; Nicolau, Dan V/0000-0002-9956-0600
FU United Kingdom's Biotechnology and Biological Sciences Research Council
   [BB/1013245/1]; Biotechnology and Biological Sciences Research
   CouncilBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/I012729/2, BB/I013245/1] Funding Source: researchfish
FX Financial support for this work was provided by the United Kingdom's
   Biotechnology and Biological Sciences Research Council Grant Number
   BB/1013245/1. We are grateful to Nils von Sicard of Enzyme Research
   Laboratories for information and advice about thrombin.
CR BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Cho EJ, 2009, ANNU REV ANAL CHEM, V2, P241, DOI 10.1146/annurev.anchem.1.031207.112851
   Diculescu VC, 2011, J ELECTROANAL CHEM, V656, P159, DOI 10.1016/j.jelechem.2010.11.037
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Fitter S, 2005, J BIOL CHEM, V280, P34193, DOI 10.1074/jbc.M504772200
   Hoon S, 2011, BIOTECHNIQUES, V51, P413, DOI 10.2144/000113786
   Kretz CA, 2006, J BIOL CHEM, V281, P37477, DOI 10.1074/jbc.M607359200
   Lee JA, 2008, SENSOR ACTUAT B-CHEM, V129, P372, DOI 10.1016/j.snb.2007.08.034
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Mayer G, 2009, ANGEW CHEM INT EDIT, V48, P2672, DOI 10.1002/anie.200804643
   Miyachi Y, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1101
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275
   Wang CM, 2010, BIOSENS BIOELECTRON, V26, P437, DOI 10.1016/j.bios.2010.07.097
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003
   Wilson R, 2003, ANAL CHEM, V75, P4244, DOI 10.1021/ac034163s
   Wilson R, 2007, ACS NANO, V1, P487, DOI 10.1021/nn700289m
   Wilson R, 2007, J MATER CHEM, V17, P4400, DOI 10.1039/b708174j
   Wilson R, 2011, NUCLEIC ACID THER, V21, P437, DOI 10.1089/nat.2011.0322
   Wilson R, 2009, CHEM COMMUN, P2487, DOI 10.1039/b822688a
   Yang H, 2009, ELECTROCHEM COMMUN, V11, P38, DOI 10.1016/j.elecom.2008.10.024
NR 21
TC 7
Z9 7
U1 1
U2 32
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2159-3337
J9 NUCLEIC ACID THER
JI Nucl. Acid Ther.
PD FEB
PY 2013
VL 23
IS 1
BP 88
EP 92
DI 10.1089/nat.2012.0386
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine,
   Research & Experimental
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research &
   Experimental Medicine
GA 088FJ
UT WOS:000314818900012
PM 23216233
OA Green Published
DA 2020-12-17
ER

PT J
AU Szwed, M
   Kania, KD
   Rogalska, A
   Santos-Oliveira, R
   Missailidis, S
   Marczak, A
AF Szwed, Marzena
   Kania, Katarzyna Dominika
   Rogalska, Aneta
   Santos-Oliveira, Ralph
   Missailidis, Sotiris
   Marczak, Agnieszka
TI APTAMERS AND THEIR CONJUGATES AS A NEW WAY TO DELIVER THERAPEUTIC AGENTS
   TO THE TUMOR CELLS
SO POSTEPY BIOLOGII KOMORKI
LA Polish
DT Article
DE aptamers; quantum dots; siRNA; doxorubicin
AB The improvement of the cytotoxic drug delivery system and its therapeutic index are the key challenges of the researches are faced with. Passive delivery of the drug conjugates using the vascular permeability process is only effective when a local injection is carried out directly into the solid tumor environment. The selective action, defined as specific activity only against tumor cells, is instead highly recommended. Therefore the aptamers seem to be the ideal solution for all the above conditions. This article mainly aims to present the short oligonucleotide fragments of nucleic acids used as the drug carriers due to their ability to improve the effectiveness of the thus far administered drugs during specifically directed actions. It is worth noting that whilst designing the new aptamers, cancer cells which the conjugate is targeting, must be characterized by the presence of "specific tumor receptors", such as av beta 3, VEGF, tie-2 or c-Met. Due to a well-defined molecular goal, aptamers allow for a subw stance with high toxicity index to be delivered precisely to a tumor's environment. In this article the special attention was given to the combination of diagnostic and therapeutic capabilities the aptamers offer. As a result, the real breakthrough of drug delivery research is the ability to attach fluorescent labels at the same time to the aptamers and anti-cancer drugs as this allows for their biodistribution monitoring at a cellular level.
C1 [Szwed, Marzena; Rogalska, Aneta; Marczak, Agnieszka] Uniwersytet Lodzki, Katedra Termobiol, Inst Biofizyki, Ul Pomorska 141-143, PL-90236 Lodz, Poland.
   [Kania, Katarzyna Dominika] Instytut Biol Med PAN, Pracownia Regulacji Transkrypcyjnej, Lodz, Poland.
   [Santos-Oliveira, Ralph; Missailidis, Sotiris] Zona Oeste Estadual Univ, Lab Nanoradiopharmaceut, Rio De Janeiro, RJ, Brazil.
RP Marczak, A (corresponding author), Uniwersytet Lodzki, Katedra Termobiol, Inst Biofizyki, Ul Pomorska 141-143, PL-90236 Lodz, Poland.
EM aszwar@biol.uni.lodz.pl
CR Alemdaroglu FE, 2008, ANGEW CHEM INT EDIT, V47, P974, DOI 10.1002/anie.200703466
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Berezovski MV, 2008, J AM CHEM SOC, V130, P9137, DOI 10.1021/ja801951p
   Bhagat M, 2012, CURR PHARM BIOTECHNO, V13, P1306, DOI 10.2174/138920112800624256
   Cao ZH, 2009, ANGEW CHEM INT EDIT, V48, P6494, DOI 10.1002/anie.200901452
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Di Primo C, 2011, METHODS MOL BIOL, V764, P279, DOI 10.1007/978-1-61779-188-8_19
   Dwivedi HP, 2010, APPL MICROBIOL BIOT, V87, P2323, DOI 10.1007/s00253-010-2728-7
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Friedman AD, 2013, CURR PHARM DES, DOI CPD-EPUB-20130304-8
   Germer Katherine, 2013, Int J Biochem Mol Biol, V4, P27
   Gilboa E, 2013, CLIN CANCER RES, V19, P1054, DOI 10.1158/1078-0432.CCR-12-2067
   Hong H, 2009, NANO TODAY, V4, P399, DOI 10.1016/j.nantod.2009.07.001
   Hu Y, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/728342
   Huang YF, 2008, ANAL CHEM, V80, P567, DOI 10.1021/ac702322j
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Huang Z, 2010, PROTEIN CELL, V1, P752, DOI 10.1007/s13238-010-0096-9
   Jiang HC, 2010, CANCER INVEST, V28, P74, DOI 10.3109/07357900902744510
   Kang HZ, 2010, CHEM COMMUN, V46, P249, DOI 10.1039/b916911c
   Kang WJ, 2009, SMALL, V5, P2519, DOI 10.1002/smll.200900848
   Kanwar JR, 2011, DRUG DISCOV TODAY, V16, P188, DOI 10.1016/j.drudis.2011.01.007
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kim D, 2010, ACS NANO, V4, P3689, DOI 10.1021/nn901877h
   Kohl E, 2013, HAUTARZT, V64, P363, DOI 10.1007/s00105-012-2513-x
   Lee JH, 2010, ADV DRUG DELIVER REV, V62, P592, DOI 10.1016/j.addr.2010.03.003
   Little MP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745-6150-5-19
   Mallikaratchy P, 2008, CHEMMEDCHEM, V3, P425, DOI 10.1002/cmdc.200700260
   Menna P, 2012, EXPERT OPIN DRUG SAF, V11, pS21, DOI 10.1517/14740338.2011.589834
   Min K, 2011, BIOMATERIALS, V32, P2124, DOI 10.1016/j.biomaterials.2010.11.035
   Phillips JA, 2009, ANAL CHEM, V81, P1033, DOI 10.1021/ac802092j
   Rajendran L, 2010, NAT REV DRUG DISCOV, V9, P29, DOI 10.1038/nrd2897
   Sefah K, 2009, LEUKEMIA, V23, P235, DOI 10.1038/leu.2008.335
   SHAN L., 2004, INDOTRICARBOCYANINE
   Sin M, 2012, Cesk Slov Oftalmol, V68, P57
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   SOOK B G, 2013, BIOSENS BIOELECTRON, V39, P44
   St Denis TG, 2013, BIOANALYSIS, V5, P1099, DOI [10.4155/BIO.13.37, 10.4155/bio.13.37]
   STATKIEWICZ M, 2008, NOWOTWORY, V58, P221
   Taghdisi SM, 2010, J DRUG TARGET, V18, P277, DOI 10.3109/10611860903434050
   Ulrich Henning, 2013, Methods Mol Biol, V986, P17, DOI 10.1007/978-1-62703-311-4_2
   Visani G, 2011, NANOMEDICINE-UK, V6, P303, DOI 10.2217/NNM.10.152
   Wang FB, 2013, BIOMATERIALS, V34, P3816, DOI 10.1016/j.biomaterials.2013.02.018
   Wu YR, 2008, ACS NANO, V2, P2023, DOI 10.1021/nn800325a
   Wu YR, 2010, P NATL ACAD SCI USA, V107, P5, DOI 10.1073/pnas.0909611107
   Yang J, 2012, NANOMEDICINE-UK, V7, P1297, DOI 10.2217/NNM.12.14
   Zhang H, 2004, MOL IMAGING CONTRAST
   Zhang Y, 2011, CURR MED CHEM, V18, P4185, DOI 10.2174/092986711797189547
   Zhang YM, 2010, J NUCL MED, V51, DOI 10.2967/jnumed.109.066878
   Zhang YF, 2010, BIOANALYSIS, V2, P907, DOI 10.4155/BIO.10.46
NR 50
TC 1
Z9 1
U1 0
U2 2
PU POLSKIE TOWARZYSTWO ANATOMICZNE
PI WARSAW
PA CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UL. MARYMONCKA 99, WARSAW,
   POLAND
SN 0324-833X
EI 2080-2218
J9 POSTEPY BIOL KOMORKI
JI Postepy Biol. Komorki
PY 2013
VL 40
IS 3
BP 509
EP 528
PG 20
WC Biology; Cell Biology
SC Life Sciences & Biomedicine - Other Topics; Cell Biology
GA V45PN
UT WOS:000209828600009
DA 2020-12-17
ER

PT J
AU Cortez, CM
   Silva, D
   Silva, CMC
   Missailidis, S
AF Cortez, Celia Martins
   Silva, Dilson
   Silva, Camila M. C.
   Missailidis, Sotiris
TI Interactions of aptamers with sera albumins
SO SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
LA English
DT Article
DE Aptamers; Fluorescence; Albumins; Spectroscopy; Aptamer-protein
   interactions
ID ANTI-MUC1 APTAMERS; CRYSTAL-STRUCTURE; METHYL-PARATHION; LIGAND-BINDING;
   CHLORPROMAZINE; BOVINE; FLUORESCENCE; INVITRO; DESIGN; PLASMA
AB The interactions of two short aptamers to human and bovine serum albumins were studied by fluorescence spectroscopic techniques. Intrinsic fluorescence of BSA and HSA were measured by selectively exciting their tryptophan residues. Gradual quenching was observed by titration of both proteins with aptamers. Aptamers are oligonucleic acid or peptide molecules that bind a specific target and can be used for both biotechnological and clinical purposes, since they present molecular recognition properties like that commonly found in antibodies. Two aptamers previously selected against the MUC1 tumour marker were used in this study, one selected for the protein core and one for the glycosylated MUC1. Stern-Volmer graphs were plotted and quenching constants were estimated. Plots obtained from experiments carried out at 25 degrees C and 37 degrees C showed the quenching of fluorescence of by aptamers to be a collisional phenomenon. Stern-Volmer constants estimated for HSA quenched by aptamer A were 1.68 x 10(5) (+/- 5 x 10(3)) M-1 at 37 degrees C, and 1.37 x 10(5) (+/- 10(3)) M-1 at 25 degrees C; and quenched by aptamer B were 1.67 x 10(5) (+/- 5 x 10(3)) M-1 at 37 degrees C, and 1.32 x 10(5) (+/- 10(3)) M-1 at 25 degrees C. Results suggest that the primary binding site for aptamers on albumin is close to tryptophan residues in sub domain IIA. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Cortez, Celia Martins; Silva, Dilson; Silva, Camila M. C.; Missailidis, Sotiris] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK5 7AS, Bucks, England.
   [Cortez, Celia Martins] Univ Estado Rio De Janeiro, Inst Math & Stat, Rio De Janeiro, Brazil.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK5 7AS, Bucks, England.
EM s.missailidis@open.ac.uk
RI CORTEZ, CELIA MARTINS/X-3247-2018
OI CORTEZ, CELIA MARTINS/0000-0002-7857-1167; Silva,
   Dilson/0000-0001-9726-2442
FU CAPESCAPES; Open University
FX The authors would like to acknowledge the financial support of CAPES and
   The Open University.
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Bertucci C, 2002, CURR MED CHEM, V9, P1463, DOI 10.2174/0929867023369673
   BHATTACHARYYA M, 1990, BIOCHEM BIOPH RES CO, V167, P1146, DOI 10.1016/0006-291X(90)90643-2
   BICKEL MH, 1975, J PHARM PHARMACOL, V27, P733, DOI 10.1111/j.2042-7158.1975.tb09392.x
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   Da Pieve C, 2010, BIOCONJUGATE CHEM, V21, P169, DOI 10.1021/bc900397s
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   HE XM, 1993, NATURE, V364, P362, DOI 10.1038/364362b0
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hushcha TO, 2000, TALANTA, V53, P29, DOI 10.1016/S0039-9140(00)00454-9
   KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57
   KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17
   Lakowicz J.R., 2001, PRINCIPLES FLUORESCE
   OTAGIRI M, 1987, J PHARM PHARMACOL, V39, P416, DOI 10.1111/j.2042-7158.1987.tb03412.x
   PETERS T, 1977, CLIN CHEM, V23, P5
   Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208
   PUCHALSKI MM, 1991, FRESEN J ANAL CHEM, V340, P341, DOI 10.1007/BF00321578
   ROMER J, 1979, J PHARM PHARMACOL, V31, P7, DOI 10.1111/j.2042-7158.1979.tb13411.x
   Silva D, 2004, BRAZ J MED BIOL RES, V37, P963, DOI 10.1590/S0100-879X2004000700004
   Silva D, 2004, TOXICOL LETT, V147, P53, DOI 10.1016/j.toxlet.2003.10.014
   Silva D, 2010, FISH PHYSIOL BIOCHEM, V36, P427, DOI 10.1007/s10695-009-9312-z
   Silva D, 2010, ECOTOX ENVIRON SAFE, V73, P32, DOI 10.1016/j.ecoenv.2009.09.003
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439
   Sulkowska A, 2002, J MOL STRUCT, V614, P227, DOI 10.1016/S0022-2860(02)00256-9
   TAMURA A, 1990, J PHARM PHARMACOL, V42, P577, DOI 10.1111/j.2042-7158.1990.tb07062.x
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   VERBEECK RK, 1983, BIOCHEM PHARMACOL, V32, P2565, DOI 10.1016/0006-2952(83)90019-9
NR 33
TC 17
Z9 17
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1386-1425
J9 SPECTROCHIM ACTA A
JI Spectroc. Acta Pt. A-Molec. Biomolec. Spectr.
PD SEP
PY 2012
VL 95
BP 270
EP 275
DI 10.1016/j.saa.2012.04.053
PG 6
WC Spectroscopy
SC Spectroscopy
GA 972UA
UT WOS:000306304800039
PM 22647400
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Blackshaw, E
   Missailidis, S
   Perkins, AC
AF Da Pieve, Chiara
   Blackshaw, Elaine
   Missailidis, Sotiris
   Perkins, Alan C.
TI PEGylation and Biodistribution of an anti-MUC1 Aptamer in MCF-7
   Tumor-Bearing Mice
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID DNA APTAMERS; DESIGN; CONJUGATION; TC-99M; MARKER
AB Aptamers are characterized by a rapid renal clearance leading to a short in vivo circulating half-life. In order to use aptamers as anticancer therapeutic agents, their exposure time to the tumor has to be enhanced via increasing residency in the bloodstream. A way to achieve this goal is by conjugating the aptamer to poly(ethylene glycol) (PEG). Herein, we present the conjugation of a bifunctionalized anti-MUC1 aptamer (NH2-AptA-SR) with the Tc-99m coordinating moiety MAG2 and either a conventional branched PEG or the comb-shaped PolyPEG via a two-step synthesis. The isolated products were radiolabeled with Tc-99m and their biodistribution and tumor-targeting properties in MCF-7 tumor bearing mice were analyzed and compared.
C1 [Da Pieve, Chiara; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Blackshaw, Elaine; Perkins, Alan C.] Univ Nottingham, Sch Clin Sci, Acad Med Phys, Nottingham NG7 2UH, England.
RP Da Pieve, C (corresponding author), Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
EM c.dapieve@open.ac.uk
OI Perkins, Alan/0000-0002-1054-8200
CR Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8
   Baouendi M, 2012, FEBS J, V279, P479, DOI 10.1111/j.1742-4658.2011.08440.x
   Boomer RM, 2005, OLIGONUCLEOTIDES, V15, P183, DOI 10.1089/oli.2005.15.183
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Cerchia L, 2002, FEBS LETT, V528, P12, DOI 10.1016/S0014-5793(02)03275-1
   Cosmi B, 2009, CURR OPIN MOL THER, V11, P322
   Da Pieve C, 2010, BIOCONJUGATE CHEM, V21, P169, DOI 10.1021/bc900397s
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hjelstuen OK, 1999, J LABELLED COMPD RAD, V42, P737, DOI 10.1002/(SICI)1099-1344(199908)42:8<737::AID-JLCR233>3.0.CO;2-Y
   Mayer G, 2004, BIODRUGS, V18, P351, DOI 10.2165/00063030-200418060-00002
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909
   Ryan SM, 2008, EXPERT OPIN DRUG DEL, V5, P371, DOI 10.1517/17425247.5.4.371 
   Tavitian B, 2003, GUT, V52, P40
   Zhang YM, 2000, EUR J NUCL MED, V27, P1700, DOI 10.1007/s002590000343
NR 20
TC 39
Z9 39
U1 1
U2 53
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
EI 1520-4812
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL
PY 2012
VL 23
IS 7
BP 1377
EP 1381
DI 10.1021/bc300128r
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 974QX
UT WOS:000306452500003
PM 22708500
DA 2020-12-17
ER

PT J
AU Simmons, SC
   McKenzie, EA
   Harris, LK
   Aplin, JD
   Brenchley, PE
   Velasco-Garcia, MN
   Missailidis, S
AF Simmons, Suzanne C.
   McKenzie, Edward A.
   Harris, Lynda K.
   Aplin, John D.
   Brenchley, Paul E.
   Velasco-Garcia, Maria N.
   Missailidis, Sotiris
TI Development of Novel Single-Stranded Nucleic Acid Aptamers against the
   Pro-Angiogenic and Metastatic Enzyme Heparanase (HPSE1)
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR; MAMMALIAN HEPARANASE; EXPRESSION; HEPARIN; BINDING;
   INHIBITION; RAS; INVASION; CELLS; SPECIFICITY
AB Heparanase is an enzyme involved in extracellular matrix remodelling and heparan sulphate proteoglycan catabolism. It is secreted by metastatic tumour cells, allowing them to penetrate the endothelial cell layer and basement membrane to invade target organs. The release of growth factors at the site of cleaved heparan sulphate chains further enhance the potential of the tumour by encouraging the process of angiogenesis. This leads to increased survival and further proliferation of the tumour. Aptamers are single or double stranded oligonucleotides that recognise specific small molecules, peptides, proteins, or even cells or tissues and have shown great potential over the years as diagnostic and therapeutic agents in anticancer treatment. For the first time, single stranded DNA aptamers were successfully generated against the active heterodimer form of heparanase using a modified SELEX protocol, and eluted based on increasing affinity for the target. Sandwich ELISA assays showed recognition of heparanase by the aptamers at a site distinct from that of a polyclonal HPSE1 antibody. The binding affinities of aptamer to immobilised enzyme were high (7x10(7) to 8x10(7) M-1) as measured by fluorescence spectroscopy. Immunohistochemistry and immunofluorescence studies demonstrated that the aptamers were able to recognise heparanase with staining comparable or in some cases superior to that of the HPSE1 antibody control. Finally, matrigel assay demonstrated that aptamers were able to inhibit heparanase. This study provides clear proof of principle concept that nucleic acid aptamers can be generated against heparanase. These reagents may serve as useful tools to explore the functional role of the enzyme and in the future development of diagnostic assays or therapeutic reagents.
C1 [Simmons, Suzanne C.; Velasco-Garcia, Maria N.; Missailidis, Sotiris] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
   [McKenzie, Edward A.] Univ Manchester, Manchester Interdisciplinary Bioctr, Manchester, Greater Manches, England.
   [Harris, Lynda K.; Aplin, John D.] Univ Manchester, Maternal & Fetal Hlth Res Ctr, Manchester, Greater Manches, England.
   [Brenchley, Paul E.] Univ Manchester, Renal Res Grp, Manchester, Greater Manches, England.
RP Simmons, SC (corresponding author), Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
RI Harris, Lynda K/I-2628-2019
OI Harris, Lynda K/0000-0001-7709-5202; Aplin, John/0000-0001-8777-9261;
   Brenchley, Paul/0000-0003-1290-9919
FU Open University
FX This project was funded by The Open University. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200
   ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X
   BARNER M, 1987, BLOOD, V70, P551
   Berezovski M, 2006, J AM CHEM SOC, V128, P1410, DOI 10.1021/ja056943j
   BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890
   Cao ZH, 2009, ANGEW CHEM INT EDIT, V48, P6494, DOI 10.1002/anie.200901452
   CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318
   Chuang WL, 2000, BIOCHEMISTRY-US, V39, P3542, DOI 10.1021/bi9926025
   Courtney SM, 2005, BIOORG MED CHEM LETT, V15, P2295, DOI 10.1016/j.bmcl.2005.03.014
   Da Pieve C, BIOCONJUG CHEM, V21, P169
   ELDOR A, 1987, SEMIN THROMB HEMOST, V13, P475, DOI 10.1055/s-2007-1003524
   Famulok M, 1999, CURR TOP MICROBIOL, V243, P123
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7
   Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9
   GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929
   Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A
   GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555
   He XT, 2004, CANCER RES, V64, P3928, DOI 10.1158/0008-5472.CAN-03-2718
   HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525
   Ikuta M, 2001, ORAL ONCOL, V37, P177, DOI 10.1016/S1368-8375(00)00077-4
   Ishida K, 2004, MOL CANCER THER, V3, P1069
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Kimoto M, 2002, EUR J BIOCHEM, V269, P697, DOI 10.1046/j.0014-2956.2001.02703.x
   Koliopanos A, 2001, CANCER RES, V61, P4655
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724
   Li JP, 2009, THROMB HAEMOSTASIS, V102, P823, DOI 10.1160/TH09-02-0091
   Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Marchetti D, 2001, ADV ENZYME REGUL, V41, P343, DOI 10.1016/S0065-2571(00)00016-9
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700
   Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719
   McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318
   Mikami S, 2001, JPN J CANCER RES, V92, P1062, DOI 10.1111/j.1349-7006.2001.tb01061.x
   Missailidis S, 2005, J IMMUNOL METHODS, V296, P45, DOI 10.1016/j.jim.2004.10.011
   Missailidis Sotiris, 2004, Methods Mol Biol, V248, P547
   Missailidis Sotiris, 2004, Methods Mol Biol, V248, P431
   Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0
   Parish CR, 1999, CANCER RES, V59, P3433
   Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770
   Rose Mark J., 2004, Current Drug Targets - Inflammation and Allergy, V3, P221, DOI 10.2174/1568010043343589
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460
   Tang WH, 2002, MODERN PATHOL, V15, P593, DOI 10.1038/modpathol.3880571
   VLODAVSKY I, 1992, INVAS METAST, V12, P112
   Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420
   Vlodavsky I., 2011, CANC MICROENVIRON
   Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057
   VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
   ZUKER M, 1999, RNA BIOCH BIOTECHNOL
NR 56
TC 15
Z9 15
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 15
PY 2012
VL 7
IS 6
AR e37938
DI 10.1371/journal.pone.0037938
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WX
UT WOS:000305350000009
PM 22719856
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Arnold, S
   Pampalakis, G
   Kantiotou, K
   Silva, D
   Cortez, C
   Missailidis, S
   Sotiropoulou, G
AF Arnold, Steve
   Pampalakis, Georgios
   Kantiotou, Kalliopi
   Silva, Dilson
   Cortez, Celia
   Missailidis, Sotiris
   Sotiropoulou, Georgia
TI One round of SELEX for the generation of DNA aptamers directed against
   KLK6
SO BIOLOGICAL CHEMISTRY
LA English
DT Article
DE DNA aptamers; kallikrein-related peptidase 6; SELEX
ID PROTEASE M/NEUROSIN; ANTI-MUC1 APTAMERS; KALLIKREIN-6; EXPRESSION;
   MECHANISM; DIAGNOSIS; DESIGN; BREAST; BIND
AB Kallikrein-related peptidase 6 (KLK6) is an active serine protease that has been implicated in common pathologies, including neurodegenerative disorders such as Parkinson and Alzheimer disease and certain types of cancer. Antibodies, either polyclonal or monoclonal, that exhibit specificity for distinct members of the extended kallikrein family, including KLK6, were developed. With the exception of KLK3/PSA, the identification and generation of aptamers, as potential new tools with improved characteristics demanded for therapeutic and diagnostic applications, has not been explored for KLKs. Here, we report for the first time the identification of novel DNA aptamers against KLK6 that were isolated using a modified systemic evolution of ligands by exponential enrichment technique. The identified aptamers were characterized using fluorescence spectroscopy, competition ELISA, and quartz crystal microbalance, and two aptamers (008 and 022) were found to exhibit high affinity (K-d in the low nanomolar range) for KLK6. Aptamers were tested for their ability to bind to serum albumin, to demonstrate their specificity for their target, and the possible involvement of such proteins in the transport of aptamers into the bloodstream. The developed aptamers are expected to assist the development of novel diagnostic, biosensing, and therapeutic strategies.
C1 [Arnold, Steve; Missailidis, Sotiris] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Pampalakis, Georgios; Kantiotou, Kalliopi; Sotiropoulou, Georgia] Univ Patras, Dept Pharm, GR-26500 Rion, Greece.
   [Silva, Dilson; Cortez, Celia] Univ Estado Rio de Janeiro, BR-20550170 Rio De Janeiro, Brazil.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk; gdsotiro@upatras.gr
RI CORTEZ, CELIA MARTINS/X-3247-2018
OI CORTEZ, CELIA MARTINS/0000-0002-7857-1167; Silva,
   Dilson/0000-0001-9726-2442
FU European Association for Cancer Research (EACR); ECCO-European Cancer
   Organization; Open University; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We acknowledge funding provided by the European Association for Cancer
   Research (EACR) and ECCO-European Cancer Organization through a Mike
   Price Fellowship (2008) awarded to Dr. Sotiris Missailidis. Drs. Sotiris
   Missailidis and Steve Arnold received financial support from the Open
   University. Dr. Dilson Silva and Prof. Celia Cortez received financial
   support from CNPq.
CR Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646
   Bando Y, 2006, NEUROSCI LETT, V405, P175, DOI 10.1016/j.neulet.2006.06.030
   Bayani J., 2012, CLIN CHEM L IN PRESS
   Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061
   Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Diamandis EP, 2000, CLIN BIOCHEM, V33, P663, DOI 10.1016/S0009-9120(00)00185-5
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P27273, DOI 10.1074/jbc.M201534200
   Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200
   Hein KL, 2010, J STRUCT BIOL, V171, P353, DOI 10.1016/j.jsb.2010.03.014
   Iwata A, 2003, HUM MOL GENET, V12, P2625, DOI 10.1093/hmg/ddg283
   James William, 2001, Current Opinion in Pharmacology, V1, P540, DOI 10.1016/S1471-4892(01)00093-5
   Jeong S, 2010, BIOTECHNOL LETT, V32, P379, DOI 10.1007/s10529-009-0168-1
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Menendez-Gonzalez M, 2008, J ALZHEIMERS DIS, V14, P59
   Missailidis S., 2003, ANTIBODY ENG CHARACT, P431
   Missailidis S, 2007, CANCER BIOTHER RADIO, V22, P453, DOI 10.1089/cbr.2007.357
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Pampalakis G, 2009, CANCER RES, V69, P3779, DOI 10.1158/0008-5472.CAN-08-1976
   Perez-Jimenez R, 2004, BIOPHYS J, V86, P2414, DOI 10.1016/S0006-3495(04)74298-8
   PUCHALSKI MM, 1991, FRESEN J ANAL CHEM, V340, P341, DOI 10.1007/BF00321578
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   Samanta D, 2011, CHEM SOC REV, V40, P2567, DOI 10.1039/c0cs00056f
   Savory N, 2010, BIOSENS BIOELECTRON, V26, P1386, DOI 10.1016/j.bios.2010.07.057
   Scarisbrick IA, 2006, EUR J NEUROSCI, V24, P1457, DOI 10.1111/j.1460-9568.2006.05021.x
   Scarisbrick IA, 2008, BIOL CHEM, V389, P739, DOI 10.1515/BC.2008.085
   Scarisbrick IA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018376
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747
   Silva D, 2004, SPECTROCHIM ACTA A, V60, P1215, DOI 10.1016/j.saa.2003.08.003
   Silva D, 2010, ECOTOX ENVIRON SAFE, V73, P32, DOI 10.1016/j.ecoenv.2009.09.003
   Sotiropoulou G, 2009, J BIOL CHEM, V284, P32989, DOI 10.1074/jbc.R109.027946
   Steffen P, 2006, BIOINFORMATICS, V22, P500, DOI 10.1093/bioinformatics/btk010
   Stojanovic MN, 2002, J AM CHEM SOC, V124, P9678, DOI 10.1021/ja0259483
   Terayama R, 2004, GLIA, V48, P91, DOI 10.1002/glia.20058
   Velasco-Garcia MN, 2009, GENE THER MOL BIOL, V13, P1
   Wilson C, 2006, CURR OPIN CHEM BIOL, V10, P607, DOI 10.1016/j.cbpa.2006.10.001
   Yousef GM, 2003, CANCER RES, V63, P2223
NR 44
TC 24
Z9 24
U1 0
U2 36
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
EI 1437-4315
J9 BIOL CHEM
JI Biol. Chem.
PD MAY
PY 2012
VL 393
IS 5
BP 343
EP 353
DI 10.1515/hsz-2011-0253
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 946EK
UT WOS:000304334100005
PM 22505517
DA 2020-12-17
ER

PT J
AU Baouendi, M
   Cognet, JAH
   Ferreira, CSM
   Missailidis, S
   Coutant, J
   Piotto, M
   Hantz, E
   du Penhoat, CH
AF Baouendi, Meriem
   Cognet, Jean A. H.
   Ferreira, Catia S. M.
   Missailidis, Sotiris
   Coutant, Jerome
   Piotto, Martial
   Hantz, Edith
   du Penhoat, Catherine Herve
TI Solution structure of a truncated anti-MUC1 DNA aptamer determined by
   mesoscale modeling and NMR
SO FEBS JOURNAL
LA English
DT Article
DE anti-MUC1 aptamer; biopolymer chain elasticity; DNA structure; molecular
   dynamics; NMR solution structure
ID CENTER-DOT-T; BASE-PAIR; MOLECULAR-DYNAMICS; NUCLEIC-ACIDS;
   TUMOR-MARKER; BACKBONE; THERMODYNAMICS; MISMATCHES; HAIRPINS; LIGANDS
AB Mucin 1 is a well-established target for the early diagnosis of epithelial cancers. The nucleotides of the S1.3/S2.2 DNA aptamer involved in binding to variable number tandem repeat mucin 1 peptides have been identified using footprinting experiments. The majority of these binding nucleotides are located in the 25-nucleotide variable region of the total aptamer. Imino proton and 2D NMR spectra of truncated and total aptamers in supercooled water reveal common hydrogen-bonding networks and point to a similar secondary structure for this 25-mer sequence alone or embedded within the total aptamer. NMR titration experiments confirm that the TTT triloop structure is the primary binding site and show that the initial structure of the truncated aptamers is conserved upon interaction with variable number tandem repeat peptides. The thermal dependence of the NMR chemical shift data shows that the base-paired nucleotides melt cooperatively at 47 +/- 4 degrees C. The structure of the 25-mer oligonucleotide was determined using a new combined mesoscale molecular modeling, molecular dynamics and NMR spectroscopy investigation. It contains three WatsonCrick pairs, three consecutive mispairs and four WatsonCrick pairs capped by a TTT triloop motif. The 3D model structures (PDB ) and biopolymer chain elasticity molecular models are consistent with both NMR and long unconstrained molecular dynamics (10 ns) in explicit water, respectively.
C1 [du Penhoat, Catherine Herve] Univ Paris 13, Lab Chim Struct & Proprietes Biomat & Agents Ther, CNRS, UFR SMBH,UMR 7244, F-93017 Bobigny, France.
   [Baouendi, Meriem; Cognet, Jean A. H.] Univ Paris 06, Lab Acides Nucl & Biophoton, Paris, France.
   [Ferreira, Catia S. M.; Missailidis, Sotiris] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada.
   [Ferreira, Catia S. M.; Missailidis, Sotiris] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Coutant, Jerome; Piotto, Martial] Strasbourg Univ, Inst Chim, Bruker Biospin, Wissembourg, France.
RP du Penhoat, CH (corresponding author), Univ Paris 13, Lab Chim Struct & Proprietes Biomat & Agents Ther, CNRS, UFR SMBH,UMR 7244, 74 Rue Marcel Cachin, F-93017 Bobigny, France.
EM penhoat8@aol.com
FU Paris 13 University; Open University
FX EH and CH du P acknowledge access to NMR spectrometers at Paris 5
   University and funding from Paris 13 University. Professor Jean Gariepy
   is kindly acknowledged for the provision of materials and facilities for
   the footprinting work. SM acknowledges financial support from the Open
   University.
CR Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P2694, DOI 10.1093/nar/26.11.2694
   BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Boulard Y, 1997, J MOL BIOL, V268, P331, DOI 10.1006/jmbi.1997.0975
   Cheng AKH, 2009, ANAL CHEM, V81, P6130, DOI 10.1021/ac901223q
   Chin KH, 2003, NUCLEIC ACIDS RES, V31, P2622, DOI 10.1093/nar/gkg353
   Chou SH, 2000, J BIOMOL NMR, V17, P1, DOI 10.1023/A:1008380031690
   Chou SH, 1990, NUCLEIC ACIDS RES, V31, P2461
   COGNET JAH, 1995, J MOL BIOL, V246, P209, DOI 10.1006/jmbi.1994.0077
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   GABARROARPA J, 1992, J MOL GRAPHICS, V10, P166, DOI 10.1016/0263-7855(92)80051-E
   Gueron M, 1995, METHOD ENZYMOL, V261, P383
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850
   Heddi B, 2006, J AM CHEM SOC, V128, P9170, DOI 10.1021/ja061686j
   Hobartner C, 2003, J MOL BIOL, V325, P421, DOI 10.1016/S0022-2836(02)01243-3
   KAPLAN JI, 1980, NMR CHEM EXCHANGING
   KIM SG, 1992, BIOCHEMISTRY-US, V31, P3564, DOI 10.1021/bi00129a003
   Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200
   MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911
   Nagaswamy U, 2000, NUCLEIC ACIDS RES, V28, P375, DOI 10.1093/nar/28.1.375
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Olson WK, 2001, J MOL BIOL, V313, P229, DOI 10.1006/jmbi.2001.4987
   Pakleza C, 2003, NUCLEIC ACIDS RES, V31, P1075, DOI 10.1093/nar/gkg194
   Proctor DJ, 2004, BIOCHEMISTRY-US, V43, P14004, DOI 10.1021/bi048213e
   PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304
   Saenger W., 1984, PRINCIPLES NUCL ACID
   SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800
   Santini GPH, 2003, NUCLEIC ACIDS RES, V31, P1086, DOI 10.1093/nar/gkg196
   Santini GPH, 2009, J PHYS CHEM B, V113, P6881, DOI 10.1021/jp8100656
   SARMA RH, 1973, J AM CHEM SOC, V95, P6457, DOI 10.1021/ja00800a055
   Schneider B, 1997, BIOPOLYMERS, V42, P113, DOI 10.1002/(SICI)1097-0282(199707)42:1<113::AID-BIP10>3.3.CO;2-F
   Skalicky JJ, 2000, J AM CHEM SOC, V122, P3230, DOI 10.1021/ja9938884
   Szyperski T, 1999, J BIOMOL NMR, V13, P343, DOI 10.1023/A:1008350604637
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Umezawa Y, 2002, NUCLEIC ACIDS RES, V30, P2183, DOI 10.1093/nar/30.10.2183
   Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X
   Wijmenga SS, 1997, J BIOMOL NMR, V10, P337, DOI 10.1023/A:1018348123074
   WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P203
NR 44
TC 22
Z9 22
U1 0
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD FEB
PY 2012
VL 279
IS 3
BP 479
EP 490
DI 10.1111/j.1742-4658.2011.08440.x
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 878KJ
UT WOS:000299255500010
PM 22129448
OA Bronze
DA 2020-12-17
ER

PT J
AU Sa, LTM
   Pessoa, C
   Meira, AS
   da Silva, MIP
   Missailidis, S
   Santos-Oliveira, R
AF Miranda Sa, Lucas Torres
   Pessoa, Claudia
   Meira, Assuero Silva
   Pais da Silva, Maria Isabel
   Missailidis, Sotiris
   Santos-Oliveira, Ralph
TI Development of Nanoaptamers Using a Mesoporous Silica Model Labeled with
   Tc-99m for Cancer Targeting
SO ONCOLOGY
LA English
DT Article
DE Aptamer; Nuclear medicine; Radiopharmaceuticals; Mesoporous silica
ID ANTI-MUC1 APTAMERS; DELIVERY-SYSTEM; NANOPARTICLES;
   RADIOPHARMACEUTICALS; BIODISTRIBUTION; RADIOTHERAPY; DIAGNOSIS; DESIGN
AB The use of mesoporous silica in targeted cancer therapy is increasing daily. The combination of a rigid model of nanoparticles like mesoporous silica and biological compounds with an affinity for oncological diseases is the most promising drug-targeting system nowadays. In this study, we used the mesoporous silica SBA-15 combined with aptamer (functionalized for tumor with MUC1). The results obtained were of interest and showed the formation of the silica mesoporous structure. The impregnation methodology of mesoporous silica with the aptamer was also confirmed. Cytotoxicity results demonstrated that the particle associated with the aptamer has no cytotoxicity. We conclude that although further studies are required, the mesoporous silica nanoparticle model loaded with aptamer is very functional and can be used for other applications, especially in nuclear medicine. Copyright (C) 2012 S. Karger AG, Basel
C1 [Santos-Oliveira, Ralph] Univ Hosp Clementino Fraga Filho, Nucl Engn Inst, BR-21941906 Rio De Janeiro, Brazil.
   [Santos-Oliveira, Ralph] Univ Hosp Clementino Fraga Filho, Lab Nanoradiopharmaceut, BR-21941906 Rio De Janeiro, Brazil.
   [Miranda Sa, Lucas Torres; Pais da Silva, Maria Isabel] Pontificia Univ Catolica Rio de Janeiro, Dept Quim, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Open Univ, Dept Hlth Life & Chem Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Santos-Oliveira, R (corresponding author), Univ Hosp Clementino Fraga Filho, Nucl Engn Inst, Rua Helio de Almeida 75,Cidade Univ, BR-21941906 Rio De Janeiro, Brazil.
EM roliveira@ien.gov.br
RI Santos-Oliveira, Ralph/J-8363-2013; Santos-Oliveira, Ralph/J-3429-2016
OI Santos-Oliveira, Ralph/0000-0002-0905-481X; 
CR Ambrogio MW, 2011, ACCOUNTS CHEM RES, V44, P903, DOI 10.1021/ar200018x
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967
   Diniz CL, 2010, EJC SUPPL, V8, P59
   Lu J, 2007, SMALL, V3, P1341, DOI 10.1002/smll.200700005
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Missailidis S, 2007, CANCER BIOTHER RADIO, V22, P453, DOI 10.1089/cbr.2007.357
   Morelli C, 2011, NANOSCALE, V3, P3198, DOI 10.1039/c1nr10253b
   Perkins AC, 2007, Q J NUCL MED MOL IM, V51, P292
   Zhu J, 2011, CHEM-ASIAN J, V6, P2332, DOI 10.1002/asia.201100064
NR 12
TC 11
Z9 12
U1 1
U2 30
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2012
VL 82
IS 4
BP 213
EP 217
DI 10.1159/000337226
PG 5
WC Oncology
SC Oncology
GA 931TU
UT WOS:000303243000004
PM 22508189
DA 2020-12-17
ER

PT J
AU Gould, A
   Missailidis, S
AF Gould, A.
   Missailidis, S.
TI Targeting the Hedgehog Pathway: The development of Cyclopamine and the
   Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Hedgehog pathway; cancer stem cells; cyclopamine; patched receptor;
   smoothened protein; cyclopamine analogues
ID SMALL-MOLECULE; SIGNAL-TRANSDUCTION; STEM-CELLS; CANCER; INHIBITION;
   GROWTH; SUPPRESSOR; BINDING; POTENT; TRANSCRIPTION
AB The Hedgehog signalling pathway plays a critical role in controlling growth, especially during development, but is often over-activated in tumourigenesis. It has recently emerged as an important target for anticancer drugs, with several compounds in clinical trials. This review initially describes the Hedgehog pathway, focussing on the Patched receptor, and the Smoothened GPCR-like protein, as well as discussing the role of Cancer Stem Cells. It subsequently presents the discovery and development of drugs targeting this pathway. The initial focus is on cyclopamine - the first compound discovered that could inhibit the Hedgehog pathway - and selected cyclopamine analogues, including a review of the development of IPI-926. In addition, a number of other compounds are briefly discussed, to give an overview of current therapies in clinical development, and to indicate the possibilities for targeting different parts of the Hedgehog pathway in future. Finally, combination chemotherapy - incorporating a Hedgehog pathway inhibitor as well as another drug is discussed from the perspective of drug resistance and effects on cancer stem cells.
C1 [Gould, A.; Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
FU Open University
FX Dr Missailidis would like to acknowledge the Open University for
   financial support.. This review article was produced based on work
   submitted for the Open University's S807 Master's Degree course,
   Molecules in Medicine. Mr Gould would like to acknowledge the teaching
   staff involved in S807, in particular his tutor Liz Andrews, together
   with Yao Xu, Dick Challand, and Simone Pitman.
CR Adams JM, 2007, SCIENCE, V318, DOI 10.1126/science.1149672
   Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733
   Bhatia S, 2002, NAT REV CANCER, V2, P124, DOI 10.1038/nrc722
   Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232
   Bishop B, 2009, NAT STRUCT MOL BIOL, V16, P698, DOI 10.1038/nsmb.1607
   Bosanac I, 2009, NAT STRUCT MOL BIOL, V16, P691, DOI 10.1038/nsmb.1632
   *CANC RES UK, WAYS HAV CHEM
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899
   Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033
   Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603
   Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200
   Feldmann G, 2008, MOL CANCER THER, V7, P2725, DOI 10.1158/1535-7163.MCT-08-0573
   Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775
   Incardona JP, 1998, DEVELOPMENT, V125, P3553
   *INF PHARM, DISC IPI 926 SEM CLI
   *INF PHARM, PROD CAND IPI 926
   KAPOOR N, 2006, P NATL ACAD SCI USA, V33, P12607
   KEELER RF, 1978, LIPIDS, V13, P708, DOI 10.1007/BF02533750
   KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Kennedy JA, 2007, SCIENCE, V318, DOI 10.1126/science.1149590
   Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027
   Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027
   Kumar SK, 2008, BIOORGAN MED CHEM, V16, P2764, DOI 10.1016/j.bmc.2008.01.012
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501
   Lipinski RJ, 2008, TOXICOL SCI, V104, P189, DOI 10.1093/toxsci/kfn076
   Mahindroo N, 2009, J MED CHEM, V52, P3829, DOI 10.1021/jm801420y
   Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0
   McLellan JS, 2008, NATURE, V455, P979, DOI 10.1038/nature07358
   Merchant M, 2004, MOL CELL BIOL, V24, P8627, DOI 10.1128/MCB.24.19.8627-8641.2004
   Nakamura M, 2007, ANTICANCER RES, V27, P3743
   PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770
   Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104
   Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435
   Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106
   Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007
   SHELTON CA, 2009, DRUG DISCOV TODAY TH, V6, P63, DOI DOI 10.1016/J.DDSTR.2009.07.001
   Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356
   Stanton BZ, 2009, NAT CHEM BIOL, V5, P154, DOI 10.1038/nchembio.142
   Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0
   Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013
   Taipale J, 2000, NATURE, V406, P1005
   Tas S, 2004, EUR J DERMATOL, V14, P96
   Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004
   Tremblay MR, 2008, J MED CHEM, V51, P6646, DOI 10.1021/jm8008508
   Tremblay MR, 2009, J MED CHEM, V52, P4400, DOI 10.1021/jm900305z
   *U OXF, MOL MECH HEDG SIGN P
   vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Verweij J, 2000, EUR J CANCER, V36, P1479, DOI 10.1016/S0959-8049(00)00133-7
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Weinberg RA, 2007, BIOL CANC, P725
   WEINBERG RA, 2007, BIOL CANC, P399
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Zhang YM, 2009, NEOPLASIA, V11, P96, DOI 10.1593/neo.81264
   Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737
NR 61
TC 35
Z9 38
U1 0
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD MAR
PY 2011
VL 11
IS 3
BP 200
EP 213
DI 10.2174/138955711795049871
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 743AA
UT WOS:000288985900002
PM 21222574
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Arnold, S
   Simmons, SC
   Velasco-Garcia, M
   McKenzie, EA
   Kantiotou, K
   Sotiropoulou, G
AF Missailidis, S.
   Arnold, S.
   Simmons, S. C.
   Velasco-Garcia, M.
   McKenzie, E. A.
   Kantiotou, K.
   Sotiropoulou, G.
TI Development of diagnostic and therapeutic aptamers against enzymes
   crucial for tumour development and metastasis
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 21st Meeting of the European-Association-for-Cancer-Research
CY JUN 26-29, 2010
CL Oslo, NORWAY
SP European Assoc Canc Res
C1 [Missailidis, S.; Arnold, S.; Simmons, S. C.; Velasco-Garcia, M.] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   [McKenzie, E. A.] Univ Manchester, Manchester, Lancs, England.
   [Kantiotou, K.; Sotiropoulou, G.] Univ Patras, Patras, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUN
PY 2010
VL 8
IS 5
MA 44
BP 11
EP 12
DI 10.1016/S1359-6349(10)70853-3
PG 3
WC Oncology
SC Oncology
GA 737XF
UT WOS:000288603100042
DA 2020-12-17
ER

PT J
AU Diniz, CL
   Da Pieve, C
   Perkins, A
   Haddleton, DM
   Bernardo, M
   Santos-Oliveira, R
   Missailidis, S
AF Leite Diniz, C.
   Da Pieve, C.
   Perkins, A.
   Haddleton, D. M.
   Bernardo-Filho, M.
   Santos-Oliveira, R.
   Missailidis, S.
TI Pharmacokinetic and biodistribution studies of anti MUC1 PEGylated
   aptamers with potential in the targeted radiotherapy of breast cancer
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 21st Meeting of the European-Association-for-Cancer-Research
CY JUN 26-29, 2010
CL Oslo, NORWAY
SP European Assoc Canc Res
C1 [Da Pieve, C.; Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, A.] Univ Nottingham, Sch Med, Dept Med Phys, Nottingham, England.
   [Santos-Oliveira, R.] Nucl Engn Inst, Rio De Janeiro, Brazil.
   [Leite Diniz, C.; Bernardo-Filho, M.] Univ Estado Rio de Janeiro, Dept Biofis & Biometria, BR-20550011 Rio De Janeiro, Brazil.
   [Leite Diniz, C.; Bernardo-Filho, M.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
RI Haddleton, David M/A-6233-2009; Santos-Oliveira, Ralph/J-8363-2013
OI Santos-Oliveira, Ralph/0000-0002-0905-481X
NR 0
TC 5
Z9 5
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUN
PY 2010
VL 8
IS 5
MA 227
BP 59
EP 60
PG 3
WC Oncology
SC Oncology
GA 737XF
UT WOS:000288603100223
DA 2020-12-17
ER

PT J
AU Alcaro, S
   Artese, A
   Iley, JN
   Missailidis, S
   Ortuso, F
   Parrotta, L
   Pasceri, R
   Paduano, F
   Sissi, C
   Trapasso, F
   Vigorita, MG
AF Alcaro, Stefano
   Artese, Anna
   Iley, James N.
   Missailidis, Sotiris
   Ortuso, Francesco
   Parrotta, Lucia
   Pasceri, Raffaele
   Paduano, Francesco
   Sissi, Claudia
   Trapasso, Francesco
   Vigorita, Maria Gabriella
TI Rational Design, Synthesis, Biophysical and Antiproliferative Evaluation
   of Fluorenone Derivatives with DNA G-Quadruplex Binding Properties
SO CHEMMEDCHEM
LA English
DT Article
DE docking; fluorenones; G-quadruplex binders; morpholine; telomeres
ID TELOMERIC G-QUADRUPLEX; STEREOSELECTIVE RECOGNITION MECHANISMS;
   STABILIZING LIGANDS; INHIBITORS; CYTOTOXICITY; ACRIDINES; SERIES
AB Molecular modeling studies carried out with experimental DNA models with the sequence d[AG(3)(T(2)AG(3))(3)] suggest that the introduction of a net positive charge onto the side chain of a series of fluorenone carboxamides can improve G-quadruplex binding. The terminal morpholino moiety was replaced with a novel N-methylmorpholinium cation starting from two 4-carboxamide compounds. A different substitution on the fluorenone ring was also investigated and submitted to the same quaternarization process. All compounds were analyzed for their DNA binding properties by competition dialysis methods. In vitro antiproliferative tests were carried out against two different tumor cell lines. Docking experiments were conducted by including all four known human repeat unit G-quadruplex DNA sequences (27 experimentally determined conformations) against the most active fluorenone derivatives. The results of theoretical, biophysical, and in vitro experiments indicate two novel derivatives as lead compounds for the development of a new generation of G-quadruplex ligands with greater potency and selectivity.
C1 [Alcaro, Stefano; Artese, Anna; Ortuso, Francesco; Parrotta, Lucia; Pasceri, Raffaele] Univ Magna Graecia di Catanzaro, Dipartimento Sci Farmacobiol, I-88021 Roccelletta Di Borgia, CZ, Italy.
   [Iley, James N.; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Paduano, Francesco; Trapasso, Francesco] Univ Magna Graecia di Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy.
   [Sissi, Claudia] Univ Padua, Dipartimento Sci Farmaceut, I-35131 Padua, Italy.
   [Vigorita, Maria Gabriella] Univ Messina, Fac Farm, Dipartimento Farmacochim, I-98168 Messina, Italy.
RP Alcaro, S (corresponding author), Univ Magna Graecia di Catanzaro, Dipartimento Sci Farmacobiol, Complesso Nini Barbieri, I-88021 Roccelletta Di Borgia, CZ, Italy.
EM alcaro@unicz.it
RI Paduano, Francesco/A-2548-2015; PADUANO, FRANCESCO/E-2106-2011
OI Paduano, Francesco/0000-0003-0916-8101; ALCARO,
   Stefano/0000-0002-0437-358X; Iley, Jim/0000-0002-2513-8159; ORTUSO,
   Francesco/0000-0001-6235-8161
FU Italian Ministry of University MIURMinistry of Education, Universities
   and Research (MIUR) [FIRB RBID082ATK_002]; AIRC, Associazione Italiana
   per la Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro
   (AIRC)
FX This research was supported by a grant from the Italian Ministry of
   University MIUR (FIRB RBID082ATK_002) and AIRC, Associazione Italiana
   per la Ricerca sul Cancro (CS).
CR Alcaro S, 2007, J COMPUT CHEM, V28, P1119, DOI 10.1002/jcc.20655
   Alcaro S, 2004, ARKIVOC, P334, DOI 10.3998/ark.5550190.0005.529
   Alcaro S, 2000, J COMPUT CHEM, V21, P515, DOI 10.1002/(SICI)1096-987X(200005)21:7<515::AID-JCC2>3.0.CO;2-5
   Alcaro S, 2007, BIOORG MED CHEM LETT, V17, P2509, DOI 10.1016/j.bmcl.2007.02.022
   Alcaro S, 2008, ANTICANCER THERAPEUTICS, P29, DOI 10.1002/9780470697047.ch3
   Bugelski PJ, 2000, PHARMACEUT RES, V17, P1265, DOI 10.1023/A:1026495503939
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   Cairns D, 2002, BIOORGAN MED CHEM, V10, P803, DOI 10.1016/S0968-0896(01)00337-6
   Colone M, 2008, J INVEST DERMATOL, V128, P957, DOI 10.1038/sj.jid.5701082
   CRUCIANI G, 1994, J MOL GRAPHICS, V12, P116, DOI 10.1016/0263-7855(94)80076-6
   Dai JX, 2007, NUCLEIC ACIDS RES, V35, P4927, DOI 10.1093/nar/gkm522
   Dai JX, 2007, NUCLEIC ACIDS RES, V35, P2440, DOI 10.1093/nar/gkm009
   De Cian A, 2008, BIOCHIMIE, V90, P131, DOI 10.1016/j.biochi.2007.07.011
   DeLano W. L, 2002, PYMOL MOL GRAPHICS S
   Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n
   Franceschin M, 2006, BIOORG MED CHEM LETT, V16, P1707, DOI 10.1016/j.bmcl.2005.12.001
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Gowan SM, 2001, MOL PHARMACOL, V60, P981
   Guyen B, 2004, ORG BIOMOL CHEM, V2, P981, DOI 10.1039/b316055f
   Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q
   Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024
   Kerwin SM, 2001, BIOORG MED CHEM LETT, V11, P2411, DOI 10.1016/S0960-894X(01)00490-5
   Lu YJ, 2008, J MED CHEM, V51, P6381, DOI 10.1021/jm800497p
   Martins C, 2007, BIOORG MED CHEM LETT, V17, P2293, DOI 10.1016/j.bmcl.2007.01.056
   McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   *MOL DISC LTD, GRID V 22A
   Molinari A., 2005, Italian Journal of Anatomy and Embryology, V110, P135
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Neidle S, 2009, CURR OPIN STRUC BIOL, V19, P239, DOI 10.1016/j.sbi.2009.04.001
   Olaussen KA, 2006, CRIT REV ONCOL HEMAT, V57, P191, DOI 10.1016/j.critrevonc.2005.08.007
   ORTUSO F, 2006, PHARMACOPHORES PHARM, V32, P151
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Perry PJ, 1999, ANTI-CANCER DRUG DES, V14, P373
   Perry PJ, 1998, J MED CHEM, V41, P3253, DOI 10.1021/jm9801105
   Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q
   Petraccone L, 2008, J AM CHEM SOC, V130, P16530, DOI 10.1021/ja8075567
   Phan AT, 2007, NUCLEIC ACIDS RES, V35, P6517, DOI 10.1093/nar/gkm706
   Pivetta C, 2008, BIOORGAN MED CHEM, V16, P9331, DOI 10.1016/j.bmc.2008.08.068
   Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598
   Ren JS, 2001, METHOD ENZYMOL, V340, P99
   Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099
   Rosu F, 2003, BIOCHEMISTRY-US, V42, P10361, DOI 10.1021/bi034531m
   *SCHROD INC, 1998, MAESTR V 4 1
   Shi DF, 2001, J MED CHEM, V44, P4509, DOI 10.1021/jm010246u
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
NR 48
TC 29
Z9 29
U1 0
U2 26
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD APR
PY 2010
VL 5
IS 4
BP 575
EP 583
DI 10.1002/cmdc.200900541
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 582ZX
UT WOS:000276641500012
PM 20135671
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Williams, P
   Haddleton, DM
   Palmer, RMJ
   Missailidis, S
AF Da Pieve, Chiara
   Williams, Paul
   Haddleton, David M.
   Palmer, Richard M. J.
   Missailidis, Sotiris
TI Modification of Thiol Functionalized Aptamers by Conjugation of
   Synthetic Polymers
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID LIVING RADICAL POLYMERIZATION; ATOM-TRANSFER POLYMERIZATION;
   POLYETHYLENE-GLYCOL; PEGYLATION; PROTEINS; THERAPY; DNA; PEGAPTANIB;
   DELIVERY; BIODISTRIBUTION
AB Aptamers are known for their short in vivo circulating half-life and rapid renal clearance. Their conjugation to poly(ethylene glycol) (PEG) is a way to improve their residence in the body. Two Aptamers (AptD and AptF), having a disulfide protected thiol modification oil the 3' end, have been conjugated to maleimide activated PEGs of various molecular weights and structures (linear PEG20; branched PEG20 and 40 PolyPEG17, 40, and 60 kDa). The high yield Coupling (70-80% in most of the cases) could be achieved using immobilized Iris[2-carboxyethyl]phosphine, hydrochloride (TCEP) as reducing agent at pH 4, The affinity of PEGylated AptD for its target was reduced by Conjugation to linear PEG20 and branched PEG40, but not to branched PEG20 and PolyPEGs. This work demonstrates an alternative approach to PEGylation of Aptamers, and that the effect of PEG oil the affinity for the target varies according to the structure and conformation of the synthetic polymer.
C1 [Da Pieve, Chiara; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK6 7AA, Bucks, England.
   [Williams, Paul; Palmer, Richard M. J.] Warwick Effect Polymers Ltd, Coventry CV4 7EZ, W Midlands, England.
   [Haddleton, David M.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
RP Da Pieve, C (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK6 7AA, Bucks, England.
EM c.dapieve@open.ac.uk; s.missailidis@open.ac.uk
RI Haddleton, David M/A-6233-2009
OI Haddleton, David/0000-0002-4965-0827
FU Breast Cancer Campaign
FX The work was supported by the Breast Cancer Campaign [2005May 11]. The
   authors thank Warwick Effect Polymers Ltd, Graham Jeffs, Huma Kahn,
   Sergey Bylikin, and Dave Lambert for their help and assistance.
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Bailon P, 1998, PHARM SCI TECHNOL TO, V1, P352, DOI 10.1016/S1461-5347(98)00086-8
   Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1093/toxsci/42.2.152
   BRODY EN, 2000, MOL BIOTECHNOL, V74, P5
   Conover CD, 1997, ARTIF ORGANS, V21, P1066
   Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   DELEAN A, 1978, AM J PHYSIOL, V235, pE97
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7
   FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052
   Gariepy J., 2007, WIPO patent, Patent No. [W02007129114, 2007129114]
   Haddleton DM, 1997, MACROMOLECULES, V30, P2190, DOI 10.1021/ma961074r
   Haddleton DM, 1998, MACROMOLECULES, V31, P5201, DOI 10.1021/ma980437f
   Haddleton DM, 1999, MACROMOLECULES, V32, P2110, DOI 10.1021/ma981670g
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Heredia KL, 2008, CHEM COMMUN, P3245, DOI 10.1039/b804812f
   Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324
   Hicke BJ, 2006, J NUCL MED, V47, P668
   HIORT C, 1993, J AM CHEM SOC, V115, P3448, DOI 10.1021/ja00062a007
   INADA Y, 1995, TRENDS BIOTECHNOL, V13, P86, DOI 10.1016/S0167-7799(00)88912-X
   Inoue Y, 1996, CLIN DIAGN LAB IMMUN, V3, P663, DOI 10.1128/CDLI.3.6.663-668.1996
   Kamigaito M, 2001, CHEM REV, V101, P3689, DOI 10.1021/cr9901182
   KELLER RN, 1946, INORG SYN, V2, P1, DOI 10.1002/9780470132333.ch1
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   Lecolley F, 2005, CHIM OGGI, V23, P45
   Lecolley F, 2004, CHEM COMMUN, P2026, DOI 10.1039/b407712a
   Mantovani G, 2005, J AM CHEM SOC, V127, P2966, DOI 10.1021/ja0430999
   Mayer G, 2004, BIODRUGS, V18, P351, DOI 10.2165/00063030-200418060-00002
   Moon SJ, 2005, J INORG BIOCHEM, V99, P994, DOI 10.1016/j.jinorgbio.2005.01.003
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nicolas J, 2007, MACROMOL RAPID COMM, V28, P1083, DOI 10.1002/marc.200700112
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ryan SM, 2008, EXPERT OPIN DRUG DEL, V5, P371, DOI 10.1517/17425247.5.4.371 
   Ryan SM, 2009, J CONTROL RELEASE, V135, P51, DOI 10.1016/j.jconrel.2008.12.014
   Tan YY, 1998, PROTEIN EXPRES PURIF, V12, P45, DOI 10.1006/prep.1997.0805
   Tao L, 2004, J AM CHEM SOC, V126, P13220, DOI 10.1021/ja0456454
   TSUSUMI Y, 1995, J CONTROL RELEASE, V33, P447
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
NR 42
TC 37
Z9 38
U1 1
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JAN
PY 2010
VL 21
IS 1
BP 169
EP 174
DI 10.1021/bc900397s
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 544KB
UT WOS:000273654400019
PM 20000459
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Patel, P
   Missailidis, S
AF Da Pieve, Chiara
   Patel, Pravin
   Missailidis, Sotiris
TI SYNTHETIC ROUTE TO A BENZOOXAZOLE DERIVATIVE WITH HEPARANASE INHIBITORY
   ACTIVITY
SO SYNTHETIC COMMUNICATIONS
LA English
DT Article
DE Angiogenesis; benzooxazole; heparanase; inhibitor; metastasis
ID ACID-DERIVATIVES; METASTASIS; DISCOVERY; CANCER
AB The synthesis of a benzooxazol-5-yl acetic acid derivative (9) with strong heparanase and angiogenesis inhibitory activity, and thus possible commercial interest, is described in detail.
C1 [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
CR Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R
   Courtney SM, 2005, BIOORG MED CHEM LETT, V15, P2295, DOI 10.1016/j.bmcl.2005.03.014
   Courtney SM, 2004, BIOORG MED CHEM LETT, V14, P3269, DOI 10.1016/j.bmcl.2004.03.086
   McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182
   Mikroyannidis JA, 2003, MACROMOLECULES, V36, P9295, DOI 10.1021/ma034793w
   NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207
   Parish CR, 1999, CANCER RES, V59, P3433
   SHRIDHAR DR, 1981, INDIAN J CHEM B, V20, P311
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI13662
   Wang BW, 2004, BIOORGAN MED CHEM, V12, P17, DOI 10.1016/j.bmc.2003.10.021
NR 10
TC 1
Z9 1
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0039-7911
EI 1532-2432
J9 SYNTHETIC COMMUN
JI Synth. Commun.
PY 2010
VL 40
IS 4
BP 518
EP 522
AR PII 919054726
DI 10.1080/00397910902994186
PG 5
WC Chemistry, Organic
SC Chemistry
GA 551NJ
UT WOS:000274216000007
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Hardy, A
AF Missailidis, S.
   Hardy, A.
TI Aptamers as inhibitors of target proteins
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE aptamers; patents; SELEX; therapeutics
ID HUMAN NEUTROPHIL ELASTASE; G-RICH OLIGONUCLEOTIDES; IN-VIVO;
   IRREVERSIBLE INHIBITORS; MACULAR DEGENERATION; TUMOR-CELLS; PEGAPTANIB;
   SELECTION; NEOVASCULARIZATION; CHEMOTHERAPY
AB Background: Aptamers as inhibitors of proteins in therapeutic applications offer great advantages over their antibody counterparts and the promise to be developed into the next generation therapeutic agents. However, the control of aptamer intellectual property (IP) by two major players has made aptamers an area difficult to operate and often off-putting for academic and commercial organisations. Yet, their great potential is keeping aptamers at the research forefront, with one aptamer in the clinic and various at different stages of clinical trials. Objective: To provide a comprehensive review of the aptamer IP landscape and the issues associated with aptamer therapeutics against protein targets. Methods: Extensive review of the scientific and patent literature. Conclusions: Following our experience in developing, patenting and commercialising our aptamers against MUC1 and an extensive review of the literature, we have identified a variety of issues pertaining to the development of aptamers against protein targets for therapeutic applications, their patenting and granting of patents, the original IP holders and their policy, as well as the current market and traits. Despite a slow start, aptamers have been developed against various therapeutic proteins and offer the promise of providing a novel generation of therapeutic entities with a variety of applications.
C1 [Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Hardy, A.] Open Univ, Res Sch, Innovat & Enterprise Off, Milton Keynes MK7 6AA, Bucks, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ALLEN P, 1996, Patent No. 5587468
   ALLEN PN, 1997, Patent No. 5654151
   Avci-Adali M, 2008, BIOMATERIALS, V29, P3936, DOI 10.1016/j.biomaterials.2008.07.002
   Barry P, 1996, US Patent No, Patent No. [5, 580,737, 5580737]
   BATCS PJ, 2008, Patent No. 20080318888
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369
   Bates PJ, 2005, A method for the treatment of maligant diseases by inhibiting nucleolin, Patent No. [WO2005035579, 2005035579]
   Bates PJ, 2008, Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin, Patent No. [US20080318889, 20080318889]
   BENSELER F, 1999, Patent No. 5861501
   BIESECKER G, 1997, Patent No. 5683867
   BLATT L, 2002, Patent No. 2002081494
   BOWSER MT, 2003, Patent No. 2003102212
   BRACHT F, 1998, Patent No. 5780449
   BRUCE JI, 2004, Patent No. 2004081574
   BURKE D, 1996, Patent No. 199604403
   Charlton J, 1997, BIOCHEMISTRY-US, V36, P3018, DOI 10.1021/bi962669h
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   Chu TC, 2006, BIOSENS BIOELECTRON, V21, P1859, DOI 10.1016/j.bios.2005.12.015
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   DAMHA M, 2007, Patent No. 2007038869
   DIENER JL, 2007, Patent No. 2007035922
   DIENER JL, 2006, Patent No. 2006033854
   DIENER JL, 2006, Patent No. 20060183702
   DOUGAN AH, 2004, Patent No. 6780850
   Dua Pooja, 2008, Recent Pat DNA Gene Seq, V2, P172, DOI 10.2174/187221508786241710
   DYNAN W, 1999, Patent No. 1999033971
   DZAU VJ, 2004, Patent No. 6774118
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Epstein D., 2007, Patent No. [W02007/103549, 2007103549]
   EPSTEIN D, 2004, Patent No. 2004011680
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Friebe M, 2008, World Intellectual Property Organisation, Patent No. [WO 2008028534, 2008028534]
   FURSTE JP, 1998, Patent No. 1998008856
   Gariepy J., 2007, WIPO patent, Patent No. [W02007129114, 2007129114]
   GOLD L, 2000, Patent No. 6110900
   GOLD L, 2000, Patent No. 6124449
   GOLD L, 1996, Patent No. 5567588
   GOLD L, 1999, Patent No. 6001577
   GOLD L, 2002, Patent No. 2002024954
   GOLD L, 1995, Patent No. 5475096
   GOLD L, 1998, Patent No. 5843653
   GOLD L, 1997, Patent No. 5696249
   Gold L., 1998, Flow Cell Selex. International Patent, Patent No. [W01998033941 Al, 1998033941]
   GOLD L, 1996, Patent No. 5496938
   GOLD L, 1996, Patent No. 1996027604
   GOLD L, 1998, Patent No. 5763595
   GOLD L, 1996, Patent No. 5527894
   Gold L, 1993, Methods for identifying nucleic acid ligands, Patent No. [US5270163, 5270163]
   Gold L, 2002, USA Patent 2002, Patent No. [6,387,620, 6387620]
   Gold L., 1997, U.S. Patent, Patent No. [5,670,637, 5670637]
   GORENSTEIN DG, 2000, Patent No. 2000024404
   HEILIQ JS, 2002, Patent No. 6376474
   HICKE B, 2001, Patent No. 6232071
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   JANJIC N, 1999, Patent No. 5859228
   JANJIC N, 1997, Patent No. 5668264
   JANJIC N, 1997, Patent No. 6051698
   JANJIC N, 2000, Patent No. 6051698
   JANJIC N, 1995, Patent No. 1995021853
   JAYASENA S, 2001, Patent No. 6183967
   JAYASENA SD, 1998, Patent No. 5734034
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   KLEINJUNG F, 2004, Patent No. 1386972
   KORMAN AJ, 2001, Patent No. 6171795
   LEE SW, 2008, Patent No. 2008066231
   Li N, 2009, J PROTEOME RES, V8, P2438, DOI 10.1021/pr801048z
   LIN A, 1997, Patent No. 1997042317
   LOCHRIE MA, 1998, Patent No. 5726017
   LUPOLD SE, 2005, Patent No. 6933114
   Makwana V., ANTICANCER THERAPEUT
   Missailidis S, 2008, BRAZ ARCH BIOL TECHN, V51, P77, DOI 10.1590/S1516-89132008000700013
   MORRISSEY D, 2003, Patent No. 2003106476
   NADEAU JG, 1997, Patent No. 5668265
   NIEUWLANDT DT, 1997, Patent No. 5648214
   NISHIKAWA S, 2005, Patent No. 2005151890
   PAGRATIS N, 2000, Patent No. 2000056930
   PAGRATIS N, 1998, Patent No. 5846713
   Pagratis N., 2001, U.S. Patent, Patent No. [6261774, 6,261,774]
   PARMA DH, 1998, Patent No. 5780228
   Pietras K, 2002, CANCER RES, V62, P5476
   Pietras K, 2001, CANCER RES, V61, P2929
   PIETRAS K, 2004, Patent No. 6699843
   PURSCHKE W, 2008, Patent No. 2008009437
   PURSCHKE W, 2007, Patent No. 2007093409
   RABIN R, 2003, Patent No. 20030049644
   Ruckman J., 2001, US patent, Patent No. [US7094535 B2, 7094535]
   RUCKMAN J, 2001, Patent No. 2001009159
   RUSCONI C, 2005, Patent No. 2005106042
   SCHNEIDER DJ, 1996, Patent No. 5503978
   SMITH D, 1995, CHEM BIOL, V2, P741, DOI 10.1016/1074-5521(95)90102-7
   STEPHENS A, 2000, Patent No. 6127119
   SULLENGER BA, 2007, Patent No. 2007035532
   SULLENGER BA, 2007, Patent No. 7312325
   SULLENGER BA, 2003, Patent No. 20030175703
   TRENT J, 2008, Patent No. 20080318887
   TRENT JO, 2008, Patent No. 20080318890
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Velasco-Garcia MN, 2009, GENE THER MOL BIOL, V13, P1
   Vivekananda J., 2003, US Patent, Patent No. [6569630, US 6569630 B1]
   WANG JF, 1997, Patent No. 1997020072
   WEST JAA, 2008, Patent No. 20080182759
   WILSON C, 2004, Patent No. 2004047742
   WILSON C, 2004, Patent No. 2004026260
   Wolfgang P, 1997, US Patent No, Patent No. [5,660,985, 5660985]
   Xu XH, 2001, J BIOL CHEM, V276, P43221, DOI 10.1074/jbc.M104446200
   YOKOYAMA S, 2006, Patent No. 6995249
   YOKOYAMA S, 2000, Patent No. 2000009684
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
NR 113
TC 41
Z9 44
U1 0
U2 20
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3776
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD AUG
PY 2009
VL 19
IS 8
BP 1073
EP 1082
DI 10.1517/13543770903042337
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 483TZ
UT WOS:000268992400003
PM 19514954
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Perkins, AC
   Missailidis, S
AF Da Pieve, Chiara
   Perkins, Alan C.
   Missailidis, Sotiris
TI Anti-MUC1 aptamers: radiolabelling with Tc-99m and biodistribution in
   MCF-7 tumour-bearing mice
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE Aptamers; Glycosylated MUC1; Tc-99m; MAG2; MCF7 tumour; FID binding
   assay; Biodistribution studies
ID MUC1; DNA; TARGET; PHOSPHODIESTER; ANTIBODIES; MOLECULE; DESIGN; ASSAY
AB Introduction: Aptamers previously selected against the protein core (AptA) or the tumour glycosylated (AptB) MUC1 glycoprotein have been conjugated to MAG2 and labelled with Tc-99m, for the potential use as radiopharmaceuticals for diagnostic imaging of breast cancer.
   Methods: The conjugation was achieved in high yield using standard peptide coupling reactions between an amino modification oil the aptamer and the activated carboxylic group oil the ligands. The retention of the affinity of the MAG2 modified AptA for the MUC1 protein core was confirmed using a fluorescent intercalator displacement binding assay. The labelled aptamers were separated from free Tc-99m using Ultrafiltration and monitored by high-performance liquid chromatography at all stages, to ensure that only radiolabelled aptamers were produced, The biodistribution properties of the two aptamer-radionuclide conjugates were analysed in MCF-7 tumour bearing mice and compared.
   Results: Efficient and convenient labelling of the two aptamers with Tc-99m was achieved as the last step of the synthesis (post-conjugation labelling). Both the aptamer-chelator conjugates bad strong Tc-99m binding properties and the resulting complexes were stable in vivo, both in terms of nuclease degradation and leaking of the metal. The radiolabelled aptamers showed a high renal clearance and a high uptake in the intestine.
   Conclusions: AptA and AptB have been successfully conjugated in high yield to the ligand MAG2 and labelled with Tc-99m. The radiolabelled aptamers showed different tumour uptake and clearance, but will require further development prior to diagnostic use. (C) 2009 Elsevier Inc. All lights reserved.
C1 [Da Pieve, Chiara; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, Alan C.] Univ Nottingham, Sch Clin Sci, Nottingham NG7 2UH, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
OI Perkins, Alan/0000-0002-1054-8200
FU Breast Cancer Campaign
FX This study was conducted with financial Support from the Breast Cancer
   Campaign. We thank Graham Jeffs, David Lambert, and Dr. Huma Kahn for
   assistance with HPLC and the FID assay, Elaine Blackshaw, and Andrew
   McKenzie from the Nottingham University Hospital and Clinical Science,
   University of Nottingham, for providing MCF7 tumour xenografts and their
   expertise in biodistribution Studies.
CR Apostolopoulos V, 1999, CURR OPIN MOL THER, V1, P98
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Brigui I, 2003, BIOCHEM PHARMACOL, V65, P747, DOI 10.1016/S0006-2952(02)01558-7
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Buchegger F, 2008, ONCOLOGIST, V13, P657, DOI 10.1634/theoncologist.2008-0020
   Burke John M, 2002, Cancer Control, V9, P106
   Cerchia L, 2002, FEBS LETT, V528, P12, DOI 10.1016/S0014-5793(02)03275-1
   DELEAN A, 1978, AM J PHYSIOL, V235, pE97
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Ferreira CSM, 2007, BRAZ ARCH BIOL TECHN, V50, P63, DOI 10.1590/S1516-89132007000600008
   FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052
   Gariepy J., 2007, WIPO patent, Patent No. [W02007129114, 2007129114]
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   Hagenbeek A, 2003, LEUKEMIA LYMPHOMA, V44, pS37, DOI 10.1080/10428190310001616944
   Hicke BJ, 2006, J NUCL MED, V47, P668
   HIORT C, 1993, J AM CHEM SOC, V115, P3448, DOI 10.1021/ja00062a007
   Hjelstuen OK, 1999, J LABELLED COMPD RAD, V42, P737, DOI 10.1002/(SICI)1099-1344(199908)42:8<737::AID-JLCR233>3.0.CO;2-Y
   HNATOWICH DJ, 1994, NUCL MED BIOL, V21, P1035, DOI 10.1016/0969-8051(94)90175-9
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   Leroy X, 2006, ANN PATHOL, V26, P257, DOI 10.1016/S0242-6498(06)70718-0
   Limacher JM, 2007, B CANCER, V94, P253
   Mayer G, 2004, BIODRUGS, V18, P351, DOI 10.2165/00063030-200418060-00002
   Moon SJ, 2005, J INORG BIOCHEM, V99, P994, DOI 10.1016/j.jinorgbio.2005.01.003
   Perkins AC, 2007, Q J NUCL MED MOL IM, V51, P292
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Singh R, 2007, CANCER BIOL THER, V6, P481, DOI 10.4161/cbt.6.4.4201
   Tavitian B, 2003, GUT, V52, P40
   Taylor-Papadimitriou J, 2002, J MAMMARY GLAND BIOL, V7, P209, DOI 10.1023/A:1020360121451
   von Mensdorff-Pouilly S, 2000, INT J BIOL MARKER, V15, P343
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Yang E, 2007, HISTOL HISTOPATHOL, V22, P905, DOI 10.14670/HH-22.905
   Zhang YM, 2000, EUR J NUCL MED, V27, P1700, DOI 10.1007/s002590000343
NR 34
TC 89
Z9 90
U1 0
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0969-8051
EI 1872-9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD AUG
PY 2009
VL 36
IS 6
BP 703
EP 710
DI 10.1016/j.nucmedbio.2009.04.004
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 482DW
UT WOS:000268865400015
PM 19647177
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Ragazzon, PA
   Bradshaw, T
   Matthews, C
   Iley, J
   Missailidis, S
AF Ragazzon, Patricia A.
   Bradshaw, Tracey
   Matthews, Charlie
   Iley, Jim
   Missailidis, Sotiris
TI The Characterisation of Flavone-DNA Isoform Interactions as a Basis for
   Anticancer Drug Development
SO ANTICANCER RESEARCH
LA English
DT Article
DE Flavonoids; DNA binding; polynucleotides; triplex DNA; quadruplex DNA;
   cancer cell lines; UV; fluorescence spectroscopy
ID CELL-GROWTH; CANCER; QUERCETIN; ANTIOXIDANT; BAICALEIN; BINDING; ARREST
AB Background: The interactions of small molecules with nucleic acids are of considerable interest for the design of novel anticancer compounds. The physical properties and sequence specificity observed in the interactions between a group of flavonoids with proven antitumour activity and various nucleic acid structures are summarised. Materials and Methods: UV and fluorescence spectroscopy, together with competition dialysis, were used to assess the affinity of the drugs for the nucleic acid structures in the presence or absence of different metal ions. The effect of these compounds on breast and leukaemia cancer cell lines was evaluated using MTS and COMET assays and flow cytometry. Results and Conclusion: The flavonoids studied are weak duplex DNA-binding ligands and the binding of flavonoids to DNA is affected by metal ions. Baicalein and quercetin display stronger affinity for triplex and quadruplex than for double-stranded DNA and offer interesting scaffolds for the design of novel, high order DNA-binding agents.
C1 [Ragazzon, Patricia A.; Iley, Jim; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Bradshaw, Tracey; Matthews, Charlie] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
OI Iley, Jim/0000-0002-2513-8159; Ragazzon, Patricia/0000-0003-0374-4569
CR Antonini I, 2003, BIOORGAN MED CHEM, V11, P399, DOI 10.1016/S0968-0896(02)00442-X
   Asadi M, 2005, J MOL STRUCT, V754, P116, DOI 10.1016/j.molstruc.2005.06.033
   Bayer T, 2001, TOXICOL SCI, V62, P205, DOI 10.1093/toxsci/62.2.205
   Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   CANTERO G, 2006, BIOCHEMISTRY-US, V46, P6097
   Chan HY, 2002, BIOMED PHARMACOTHER, V56, P269, DOI 10.1016/S0753-3322(02)00192-0
   Chao JI, 2007, MOL CANCER THER, V6, P3039, DOI 10.1158/1535-7163.MCT-07-0281
   Cheng MK, 2008, J MED CHEM, V51, P963, DOI 10.1021/jm070587t
   Czyz M, 2005, BIOCHEM PHARMACOL, V70, P1431, DOI 10.1016/j.bcp.2005.08.010
   De Vincenzo R, 2000, CANCER CHEMOTH PHARM, V46, P305, DOI 10.1007/s002800000160
   Dreiseitel A, 2008, BIOCHEM BIOPH RES CO, V372, P57, DOI 10.1016/j.bbrc.2008.04.140
   FULIANG X, 2005, EUR J PHARMACOL, V529, P1
   GANDORI R, 2000, EUR J BIOCHEM, V267, P1168
   Guo Q, 2002, TOXICOLOGY, V179, P171, DOI 10.1016/S0300-483X(02)00241-X
   Haddad AQ, 2006, PROSTATE CANCER P D, V9, P68, DOI 10.1038/sj.pcan.4500845
   Horn V, 2004, BIOCHEMISTRY-US, V43, P11196, DOI 10.1021/bi049287t
   Ikemoto S, 2000, UROLOGY, V55, P951, DOI 10.1016/S0090-4295(00)00467-2
   JENKINS T, 1997, METHOD MOL BIOL, P204
   JENKINS T, 2001, MINI-REV MED CHEM, V1, P31
   Jenkins TC, 2000, CURR MED CHEM, V7, P99, DOI 10.2174/0929867003375551
   La Casa C, 2000, J ETHNOPHARMACOL, V71, P45, DOI 10.1016/S0378-8741(99)00174-9
   Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007
   LI P, 2008, CANCER RES, V686, P4347
   MERGNY J, 2002, NUCLEIC ACIDS RES, V30, P39
   Mills M, 1999, J MOL BIOL, V291, P1035, DOI 10.1006/jmbi.1999.3014
   Mills Martin, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P627, DOI 10.2174/1568011023353877
   Mooren FC, 2005, LIFE SCI, V77, P1211, DOI 10.1016/j.lfs.2004.12.040
   Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793
   Penarrieta JM, 2008, MOL NUTR FOOD RES, V52, P708, DOI 10.1002/mnfr.200700189
   PIERPONT CG, 1994, PROG INORG CHEM, V41, P331, DOI 10.1002/9780470166420.ch5
   Pugazhendhi D, 2008, J ENDOCRINOL, V197, P503, DOI 10.1677/JOE-07-0384
   Ragazzon P, 2007, METHODS, V43, P313, DOI 10.1016/j.ymeth.2007.08.003
   Rossi M, 2001, J NAT PROD, V64, P26, DOI 10.1021/np000068s
   Sepp A, 2005, J MOL BIOL, V354, P212, DOI 10.1016/j.jmb.2005.09.051
   Sun HX, 2006, BIOORG MED CHEM LETT, V16, P3586, DOI 10.1016/j.bmcl.2006.03.087
   Touyz RM, 2003, J CELL PHYSIOL, V197, P326, DOI 10.1002/jcp.10393
   Ujiki MB, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-76
   WANG W, 2001, SCI CHINA, V64, P610
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
   Watanabe S, 2002, BIOMED PHARMACOTHER, V56, P302, DOI 10.1016/S0753-3322(02)00182-8
   Yamashita N, 1999, MUTAT RES-FUND MOL M, V425, P107, DOI 10.1016/S0027-5107(99)00029-9
   Yu ZL, 2006, CANCER LETT, V238, P53, DOI 10.1016/j.canlet.2005.06.022
   Zhang Q, 2008, FOOD CHEM TOXICOL, V46, P2042, DOI 10.1016/j.fct.2008.01.049
   Zhu ZW, 2002, MICROCHEM J, V71, P57, DOI 10.1016/S0026-265X(01)00118-7
NR 44
TC 21
Z9 21
U1 1
U2 12
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2009
VL 29
IS 6
BP 2273
EP 2283
PG 11
WC Oncology
SC Oncology
GA 462WT
UT WOS:000267389500053
PM 19528492
DA 2020-12-17
ER

PT J
AU Ragazzon, PA
   Iley, J
   Missailidis, S
AF Ragazzon, Patricia A.
   Iley, Jim
   Missailidis, Sotiris
TI Structure-activity Studies of the Binding of the Flavonoid Scaffold to
   DNA
SO ANTICANCER RESEARCH
LA English
DT Article
DE Flavonoids; DNA binding; polynucleotides; triplex DNA; quadruplex DNA;
   cancer cell lines; UV; fluorescence spectroscopy; structure-activity
   relationship
ID QUERCETIN; APOPTOSIS; ANTIOXIDANT; INDUCTION; BAICALEIN; AFFINITY
AB Background: Flavonoids have been shown to have a wide variety of biological activities and proven to be good scaffolds for the design of DNA-binding agents as anticancer therapeutics. Materials and Methods: In structure-activity relationship studies, flavonoid derivatives were designed and synthesised through various organic synthesis protocols, resulting in novel or previously described molecules. These were studied by UV-Vis absorbance and fluorescence spectroscopy as well as competition dialysis for their binding to DNA isoforms. Their cytotoxic potential was assessed using MTS assays on MCF-7 breast cancer and CCRFCEM leukaemia cell lines. Results and Conclusion: Introduction of moieties such as chloride, nitrogen, acetoxy and methoxy groups did not help to improve binding affinity, but introduction of tertiary amines improved the binding 1,000-fold due to an improved interaction of the compound with the nucleic acid; replacement of oxygen by sulphur increased the binding 7-fold, possibly because sulphur being less electronegative than oxygen would allow the electrons of the molecule to interact more strongly with the nucleic acid. Inhibition of growth by 50% (IG(50)) values were moderate in breast and leukaemia cancer cell lines possibly due to the flavonoids interacting with other cellular components besides the nucleic acids.
C1 [Ragazzon, Patricia A.; Iley, Jim; Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
OI Iley, Jim/0000-0002-2513-8159; Ragazzon, Patricia/0000-0003-0374-4569
CR ABDOU WM, 1994, TETRAHEDRON, V50, P3595, DOI 10.1016/S0040-4020(01)87036-8
   Anastassopoulou J, 2003, J MOL STRUCT, V651, P19, DOI 10.1016/S0022-2860(02)00625-7
   Antonini I, 2000, J MED CHEM, V43, P4801, DOI 10.1021/jm000131a
   ANTONINI I, 2004, MED CHEM REV, V1, P267
   ARES JJ, 1993, J ORG CHEM, V58, P7903, DOI 10.1021/jo00079a041
   Asadi M, 2005, J MOL STRUCT, V754, P116, DOI 10.1016/j.molstruc.2005.06.033
   Boerner LJK, 2005, CURR OPIN CHEM BIOL, V9, P135, DOI 10.1016/j.cbpa.2005.02.010
   Chan FL, 2000, CANCER LETT, V160, P219, DOI 10.1016/S0304-3835(00)00591-7
   Chan HY, 2002, BIOMED PHARMACOTHER, V56, P269, DOI 10.1016/S0753-3322(02)00192-0
   Cipak L, 2003, LEUKEMIA RES, V27, P65, DOI 10.1016/S0145-2126(02)00063-2
   CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020
   Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5
   JAIN K, 1982, SYNTHESIS-STUTTGART, V3, P221
   Kanakis CD, 2007, CELL BIOCHEM BIOPHYS, V49, P29, DOI 10.1007/s12013-007-0037-2
   KEMP DS, 1981, J ORG CHEM, V46, P1804, DOI 10.1021/jo00322a010
   Lambert JD, 2003, J NUTR, V133, p3262S
   Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007
   Lepore SD, 2003, J ORG CHEM, V68, P8261, DOI 10.1021/jo0345751
   Loke WM, 2008, BIOCHEM PHARMACOL, V75, P1045, DOI 10.1016/j.bcp.2007.11.002
   Lyles MB, 2001, J MED CHEM, V44, P4650, DOI 10.1021/jm9904708
   Marder M, 1997, BIOORG MED CHEM LETT, V7, P2003, DOI 10.1016/S0960-894X(97)00343-0
   Missailidis S, 2002, ONCOL RES, V13, P175
   Mooren FC, 2005, LIFE SCI, V77, P1211, DOI 10.1016/j.lfs.2004.12.040
   Rossi M, 2001, J NAT PROD, V64, P26, DOI 10.1021/np000068s
   Sepp A, 2005, J MOL BIOL, V354, P212, DOI 10.1016/j.jmb.2005.09.051
   Shin JS, 1999, BIOORG MED CHEM LETT, V9, P869, DOI 10.1016/S0960-894X(99)00092-X
   SINGH OV, 1990, TETRAHEDRON LETT, V31, P2747, DOI 10.1016/S0040-4039(00)94689-6
   Touyz RM, 2003, J CELL PHYSIOL, V197, P326, DOI 10.1002/jcp.10393
   Yamashita N, 1999, MUTAT RES-FUND MOL M, V425, P107, DOI 10.1016/S0027-5107(99)00029-9
   Ye B, 2007, ANTI-CANCER DRUG, V18, P1165, DOI 10.1097/CAD.0b013e3280145274
NR 30
TC 13
Z9 13
U1 0
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2009
VL 29
IS 6
BP 2285
EP 2293
PG 9
WC Oncology
SC Oncology
GA 462WT
UT WOS:000267389500054
PM 19528493
DA 2020-12-17
ER

PT J
AU Velasco-Garcia, MN
   Missailidis, S
AF Velasco-Garcia, Maria N.
   Missailidis, Sotiris
TI New trends in aptamer-based electrochemical biosensors
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Aptamer; Biosensor; Aptasensor; Electrochemical detection; SELEX
ID INHIBITING DNA APTAMERS; MUC1 TUMOR-MARKER; LABEL-FREE;
   CAPILLARY-ELECTROPHORESIS; EQUILIBRIUM MIXTURES; GOLD NANOPARTICLES;
   PROTEIN-DETECTION; BLOOD-SERUM; THROMBIN; SENSOR
AB The analytical characteristics of aptamers are comparable with those of antibodies for the development of biosensor technology. However, aptamers offer some crucial advantages over antibodies such as selection capability for a variety of targets, easy synthesis, improved reproducibility and stability, simple modification for immobilization to solid supports and enhanced selectivity. This article reviews aptamer technology as well as aptamer-based assay configurations and goes on to explore reported applications in electrochemical aptasensors.
C1 [Velasco-Garcia, Maria N.; Missailidis, Sotiris] Open Univ, Fac Sci, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Velasco-Garcia, MN (corresponding author), Open Univ, Fac Sci, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM m.n.velasco@open.ac.uk; s.missailidis@open.ac.uk
CR Baker BR, 2006, J AM CHEM SOC, V128, P3138, DOI 10.1021/ja056957p
   Balamurugan S, 2008, ANAL BIOANAL CHEM, V390, P1009, DOI 10.1007/s00216-007-1587-2
   Bang GS, 2005, BIOSENS BIOELECTRON, V21, P863, DOI 10.1016/j.bios.2005.02.002
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Bini A, 2007, ANAL CHEM, V79, P3016, DOI 10.1021/ac070096g
   Centi S, 2008, BIOSENS BIOELECTRON, V23, P1602, DOI 10.1016/j.bios.2008.01.020
   Cho EJ, 2006, ANAL CHIM ACTA, V564, P82, DOI 10.1016/j.aca.2005.12.038
   Cho SY, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni174
   Choi JH, 2006, J AM CHEM SOC, V128, P15584, DOI 10.1021/ja066506k
   de-los-Santos-Alvarez N, 2008, TRAC-TREND ANAL CHEM, V27, P437, DOI 10.1016/j.trac.2008.03.003
   Drabovich A, 2005, J AM CHEM SOC, V127, P11224, DOI 10.1021/ja0530016
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Frauendorf C, 2001, BIOORGAN MED CHEM, V9, P2521, DOI 10.1016/S0968-0896(01)00027-X
   Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473
   Hamula CLA, 2006, TRAC-TREND ANAL CHEM, V25, P681, DOI 10.1016/j.trac.2006.05.007
   Hansen JA, 2006, J AM CHEM SOC, V128, P2228, DOI 10.1021/ja060005h
   HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904
   Hianik T, 2007, BIOELECTROCHEMISTRY, V70, P127, DOI 10.1016/j.bioelechem.2006.03.012
   Ikanovic M, 2007, J FLUORESC, V17, P193, DOI 10.1007/s10895-007-0158-4
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Ikebukuro K, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni108
   Kang Y, 2008, BIOELECTROCHEMISTRY, V73, P76, DOI 10.1016/j.bioelechem.2008.04.024
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   Kim YS, 2007, BIOSENS BIOELECTRON, V22, P2525, DOI 10.1016/j.bios.2006.10.004
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Kusser W, 2000, REV MOL BIOTECHNOL, V74, P27
   Lai RY, 2007, ANAL CHEM, V79, P229, DOI 10.1021/ac061592s
   Levy M, 2005, CHEMBIOCHEM, V6, P2163, DOI 10.1002/cbic.200500218
   Li XX, 2008, ELECTROANAL, V20, P1475, DOI 10.1002/elan.200704193
   Liao W, 2007, BIOSENS BIOELECTRON, V23, P218, DOI 10.1016/j.bios.2007.04.004
   Liu JW, 2007, ANAL CHEM, V79, P4120, DOI 10.1021/ac070055k
   Liu JW, 2004, ANAL CHEM, V76, P1627, DOI 10.1021/ac0351769
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   Lu Y, 2008, ANALYST, V133, P1256, DOI 10.1039/b807913g
   Luzi E, 2003, TRAC-TREND ANAL CHEM, V22, P810, DOI 10.1016/S0165-9936(03)01208-1
   Meng F, 2008, CHEM RES CHINESE U, V24, P138, DOI 10.1016/S1005-9040(08)60029-X
   Min K, 2008, BIOSENS BIOELECTRON, V23, P1819, DOI 10.1016/j.bios.2008.02.021
   Mir M, 2006, ELECTROCHEM COMMUN, V8, P505, DOI 10.1016/j.elecom.2005.12.022
   Mir M, 2008, ELECTROCHEM COMMUN, V10, P1533, DOI 10.1016/j.elecom.2008.04.040
   MISSAILIDIS S, 2008, COMBINATORIAL APPROA
   Ogawa A, 2007, BIOORG MED CHEM LETT, V17, P3156, DOI 10.1016/j.bmcl.2007.03.033
   Ozaki H, 2006, BIOORG MED CHEM LETT, V16, P4381, DOI 10.1016/j.bmcl.2006.05.054
   Papamichael KI, 2007, SENSOR ACTUAT B-CHEM, V121, P178, DOI 10.1016/j.snb.2006.09.024
   PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Potyrailo RA, 1998, ANAL CHEM, V70, P3419, DOI 10.1021/ac9802325
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Stojanovic MN, 2004, J AM CHEM SOC, V126, P9266, DOI 10.1021/ja032013t
   Stojanovic MN, 2001, J AM CHEM SOC, V123, P4928, DOI 10.1021/ja0038171
   Stojanovic MN, 2002, J AM CHEM SOC, V124, P9678, DOI 10.1021/ja0259483
   Suprun E, 2008, BIOSENS BIOELECTRON, V24, P825, DOI 10.1016/j.bios.2008.07.008
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Velasco-Garcia MN, 2003, BIOSYST ENG, V84, P1, DOI 10.1016/S1537-5110(02)00236-2
   Wang J, 2003, ANAL CHIM ACTA, V500, P247, DOI 10.1016/S0003-2670(03)00725-6
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S21
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   Yamana K, 2003, BIOORG MED CHEM LETT, V13, P3429, DOI 10.1016/S0960-894X(03)00799-6
   Yoshida W, 2006, BIOCHEM BIOPH RES CO, V348, P245, DOI 10.1016/j.bbrc.2006.07.069
   Yoshida W, 2006, ANAL CHEM, V78, P3296, DOI 10.1021/ac060254o
   Zheng J, 2007, BIOSENS BIOELECTRON, V23, P341, DOI 10.1016/j.bios.2007.04.015
   Zuo XL, 2007, J AM CHEM SOC, V129, P1042, DOI 10.1021/ja067024b
NR 65
TC 34
Z9 37
U1 0
U2 22
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PD JUN
PY 2009
VL 13
IS 1
BP 1
EP 9
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 470RR
UT WOS:000267997900001
DA 2020-12-17
ER

PT J
AU Hyde, CAC
   Missailidis, S
AF Hyde, C. A. C.
   Missailidis, S.
TI Inhibition of arachidonic acid metabolism and its implication on cell
   proliferation and tumour-angiogenesis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Review
DE Arachidonic acid; COX inhibitors; LOX inhibitors; CYP450; Cancer
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POLYUNSATURATED FATTY-ACIDS;
   LEUKOTRIENE B-4 RECEPTOR; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS;
   CYTOSOLIC PHOSPHOLIPASE A(2); NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION;
   BREAST-CANCER; COLORECTAL-CANCER; COX-2 INHIBITOR
AB Arachidonic acid (AA) and its metabolites have recently generated a heightened interest due to growing evidence of their significant role in cancer biology. Thus, inhibitors of the AA cascade, first and foremost COX inhibitors, which have originally been of interest in the treatment of inflammatory conditions and certain types of cardiovascular disease, are now attracting attention as an arsenal against cancer. An increasing number of investigations support their role in cancer chemoprevention, although the precise molecular mechanisms that link levels of AA, and its metabolites, with cancer progression have still to be elucidated. This article provides an overview of the AA cascade and focuses on the roles of its inhibitors and their implication in cancer treatment. In particular, emphasis is placed on the inhibition of cell proliferation and neo-angiogenesis through inhibition of the enzymes COX-2, 5-LOX and CYP450. Downstream effects of inhibition of AA metabolites are analysed and the molecular mechanisms of action of a selected number of inhibitors of catalytic pathways reviewed. Lastly, the benefits of dietary omega-3 fatty acids and their mechanisms of action leading to reduced cancer risk and impeded cancer cell growth are mentioned. Finally, a proposal is put forward, suggesting a novel and integrated approach in viewing the molecular mechanisms and complex interactions responsible for the involvement of AA metabolites in carcinogenesis and the protective effects of omega-3 fatty acids in inflammation and turnout prevention. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Hyde, C. A. C.; Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK5 7AS, Bucks, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK5 7AS, Bucks, England.
EM s.missailidis@open.ac.uk
FU The Open University; MSc course S807 'Molecules in Medicine'
FX This work was supported by The Open University and the MSc course S807
   'Molecules in Medicine', in particular.
CR Ahmed F, 2007, INT J CANCER, V120, P734, DOI 10.1002/ijc.22383
   Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460-9592.2008.02764.x
   Andersson P, 2004, SCAND J IMMUNOL, V60, P249, DOI 10.1111/j.0300-9475.2004.01469.x
   Anthonsen MW, 2001, J BIOL CHEM, V276, P35344, DOI 10.1074/jbc.M105264200
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912
   Asano TK, 2004, DIS COLON RECTUM, V47, P665, DOI 10.1007/s10350-003-0111-9
   Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje
   Banan A, 1998, AM J PHYSIOL-GASTR L, V274, pG111
   BANG HO, 1976, ACTA MED SCAND, V200, P69
   Barnes N, 2006, BRIT J CANCER, V94, P253, DOI 10.1038/sj.bjc.6602932
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   BLOT WJ, 1975, JNCI-J NATL CANCER I, V55, P547, DOI 10.1093/jnci/55.3.547
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bonizzi G, 1999, MOL CELL BIOL, V19, P1950
   BONVALET JP, 1987, AM J PHYSIOL, V253, pF377
   Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006
   Boudreau MD, 2001, CANCER RES, V61, P1386
   Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148
   Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679
   Brenneis C, 2006, FASEB J, V20, P1352, DOI 10.1096/fj.05-5346com
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Burdge GC, 2005, REPROD NUTR DEV, V45, P581, DOI 10.1051/rnd:2005047
   Cabral GA, 2005, LIFE SCI, V77, P1699, DOI 10.1016/j.lfs.2005.05.013
   Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140-6736(06)69666-9
   CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362
   Capdevila JH, 2000, J LIPID RES, V41, P163
   Carty E, 2000, GUT, V46, P487, DOI 10.1136/gut.46.4.487
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681
   Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699
   Chavarro JE, 2007, CANCER EPIDEM BIOMAR, V16, P1364, DOI 10.1158/1055-9965.EPI-06-1033
   Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001
   Chen P, 2005, AM J PATHOL, V166, P615, DOI 10.1016/S0002-9440(10)62282-1
   Chen XX, 2004, CLIN CANCER RES, V10, P6703, DOI 10.1158/1078-0432.CCR-04-0838
   Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711
   Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101
   Chung YM, 2003, FREE RADICAL BIO MED, V34, P434, DOI 10.1016/S0891-5849(02)01301-1
   Cianchi F, 2006, MOL CANCER THER, V5, P2716, DOI 10.1158/1535-7163.MCT-06-0318
   CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475
   Coffa G, 2004, P NATL ACAD SCI USA, V101, P15579, DOI 10.1073/pnas.0406727101
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202
   Dairam A, 2006, METAB BRAIN DIS, V21, P221, DOI 10.1007/s11011-006-9014-5
   Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371
   de Leval X, 2002, CURR MED CHEM, V9, P941, DOI 10.2174/0929867024606713
   de Souza PM, 2006, CHEM BIOL, V13, P1121, DOI 10.1016/j.chembiol.2006.11.002
   Del Tacca M, 2002, CLIN DRUG INVEST, V22, P799, DOI 10.2165/00044011-200222120-00001
   Denkins Y, 2005, J LIPID RES, V46, P1278, DOI 10.1194/jlr.M400474-JLR200
   Ding J, 2006, J BIOL CHEM, V281, P39022, DOI 10.1074/jbc.M604798200
   Ding Juan, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P202
   Dvory-Sobol H, 2006, INT J CANCER, V118, P11, DOI 10.1002/ijc.21218
   Endo K, 1997, ANTICANCER RES, V17, P2253
   Falgueyret JP, 2000, BBA-MOL CELL BIOL L, V1484, P51, DOI 10.1016/S1388-1981(99)00198-5
   Falkowski M, 2003, ANTICANCER RES, V23, P2303
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3
   Farooqui AA, 2005, REPROD NUTR DEV, V45, P613, DOI 10.1051/rnd:2005049
   Fernandes E, 2003, FREE RADICAL BIO MED, V35, P1008, DOI 10.1016/S0891-5849(03)00437-4
   FILLIATRE LG, 2001, BRIT J PHARMACOL, V132, P1581
   FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.biochem.63.1.383
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4
   Gallo O, 2001, NEOPLASIA, V3, P53, DOI 10.1038/sj.neo.7900127
   Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412
   Genc S, 2007, CLIN EXP MED, V7, P6, DOI 10.1007/s10238-007-0119-x
   Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54
   GRAVEL J, 1993, ARCH BIOCHEM BIOPHYS, V306, P469, DOI 10.1006/abbi.1993.1539
   Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Gupta K, 2004, J MOL BIOL, V335, P503, DOI 10.1016/j.jmb.2003.10.073
   Gustafsson A, 2007, INT J CANCER, V121, P232, DOI 10.1002/ijc.22582
   Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200
   Hammamieh R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-138
   Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0
   Hasegawa K, 2005, INT J ONCOL, V26, P1419
   Hashimoto H, 2002, J MED CHEM, V45, P1511, DOI 10.1021/jm010484p
   Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200
   Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3
   Hetu PO, 2005, BIOCHEM J, V391, P561, DOI 10.1042/BJ20050451
   Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778
   Hirsch FR, 2005, J CLIN ONCOL, V23, P3186, DOI 10.1200/JCO.2005.14.209
   Hong SH, 1999, CANCER RES, V59, P2223
   Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200
   Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140-6736(03)13915-3
   Hunt RH, 2003, AM J GASTROENTEROL, V98, P1725, DOI 10.1016/S0002-9270(03)00449-0
   Inagaki M, 2000, J MED CHEM, V43, P2040, DOI 10.1021/jm9906015
   Inoue T., 2008, Inflammopharmacology, V16, P36, DOI 10.1007/s10787-006-1543-3
   ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2
   Jacobs ER, 2006, AM J PHYSIOL-LUNG C, V291, pL369, DOI 10.1152/ajplung.00265.2004
   Jacobs EJ, 2007, JNCI-J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132
   Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606
   Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196
   Jiang JG, 2005, CANCER RES, V65, P4707, DOI 10.1158/0008-5472.CAN-04-4173
   Jiang JG, 2007, CANCER RES, V67, P6665, DOI 10.1158/0008-5472.CAN-06-3643
   Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009
   Jiang WG, 2003, PROSTAG LEUKOTR ESS, V69, P275, DOI 10.1016/S0952-3278(03)00110-8
   Kabashima K, 2007, LAB INVEST, V87, P49, DOI 10.1038/labinvest.3700491
   Kalgutkar AS, 1998, J MED CHEM, V41, P4800, DOI 10.1021/jm980303s
   Kandil HM, 1999, DIGEST DIS SCI, V44, P2110, DOI 10.1023/A:1026694907238
   Kankuri E, 2003, THROMB RES, V110, P299, DOI 10.1016/S0049-3848(03)00416-X
   Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765
   KENNEDY TJ, 2006, J AM COLL SURGEONS, V199, P78
   Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x
   Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200
   Kobayashi H, 2004, INT J CANCER, V112, P920, DOI 10.1002/ijc.20523
   Krysan K, 2004, CHEST, V125, p140S, DOI 10.1378/chest.125.5_suppl.140S
   Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8
   Kulkarni SK, 2000, METHOD FIND EXP CLIN, V22, P291, DOI 10.1358/mf.2000.22.5.796648
   Kuriki K, 2007, INT J CANCER, V121, P377, DOI 10.1002/ijc.22682
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Larsson SC, 2004, AM J CLIN NUTR, V79, P935
   Lee LM, 2001, ANTICANCER RES, V21, P1291
   LEVENTE J, 2002, P NATL ACAD SCI USA, V99, P13266
   Li QB, 2006, CHINESE MED J-PEKING, V119, P948, DOI 10.1097/00029330-200606010-00012
   LI W, 2008, MED ONCOL
   Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200
   Ljubimov AV, 2005, AM J PATHOL, V166, P341, DOI 10.1016/S0002-9440(10)62257-2
   LOMBARDO D, 1986, J BIOL CHEM, V261, P1663
   LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961
   Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927
   Lush CW, 2003, GASTROENTEROLOGY, V124, P118, DOI 10.1053/gast.2003.50001
   Marjanovic M, 2007, CHEM BIOL DRUG DES, V69, P222, DOI 10.1111/j.1747-0285.2007.00494.x
   Massaro M, 2006, P NATL ACAD SCI USA, V103, P15184, DOI 10.1073/pnas.0510086103
   Matsumoto G, 2004, ONCOL REP, V12, P281
   Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013
   Maxis K, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2092
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   MENARD L, 1990, BRIT J PHARMACOL, V100, P15, DOI 10.1111/j.1476-5381.1990.tb12044.x
   Michaelis UR, 2005, J CELL SCI, V118, P5489, DOI 10.1242/jcs.02674
   Minter HA, 2003, CLIN CANCER RES, V9, P1885
   Moon C, 2005, BRAIN RES, V1035, P206, DOI 10.1016/j.brainres.2004.12.017
   Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1
   Murakami A, 2005, BIOCHEM PHARMACOL, V70, P1330, DOI 10.1016/j.bcp.2005.07.032
   Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435
   Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701
   Nakanishi Y, 2001, EUR J CANCER, V37, P1570, DOI 10.1016/S0959-8049(01)00160-5
   Narayanan BA, 2001, INT J ONCOL, V19, P1255
   Naruse T, 2006, CARCINOGENESIS, V27, P584, DOI 10.1093/carcin/bgi240
   Nie DT, 2003, CLIN EXP METASTAS, V20, P657, DOI 10.1023/A:1027302408187
   Nieves D, 2006, J LIPID RES, V47, P2681, DOI 10.1194/jlr.M600212-JLR200
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011
   Okamoto A, 2008, UROLOGY, V71, P156, DOI 10.1016/j.urology.2007.09.061
   Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014
   Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9
   PALMERINI E, 2005, J CLIN ONCOL 1 2, V23, P1026
   Patrignani P, 2005, BRAIN RES REV, V48, P352, DOI 10.1016/j.brainresrev.2004.12.024
   PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0
   Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262
   Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200
   POULOS TL, 1988, PHARMACEUT RES, V5, P67, DOI 10.1023/A:1015920931701
   Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002
   Psaty BM, 2005, NEW ENGL J MED, V352, P1133, DOI 10.1056/NEJMe058042
   REDFERN JS, 1989, GASTROENTEROLOGY, V96, P596, DOI 10.1016/S0016-5085(89)80055-1
   REEDER MK, 2004, CANC DRUG DISC DEV, P401
   REGINSTER JY, 2002, ANN RHEUM DIS, V61, P116
   REID GK, 1990, J BIOL CHEM, V265, P19818
   Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076
   RIENDEAU D, 1989, BIOCHEM PHARMACOL, V38, P2313, DOI 10.1016/0006-2952(89)90471-1
   Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com
   Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200
   SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360
   Sanchez T, 2002, AM J PHYSIOL-CELL PH, V282, pC280, DOI 10.1152/ajpcell.00128.2001
   SANO H, 1995, CANCER RES, V55, P3785
   Schwab JM, 2003, LANCET, V361, P981, DOI 10.1016/S0140-6736(03)12841-3
   Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s
   Sen CK, 1996, FASEB J, V10, P709
   Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7
   Serhan CN, 2004, HISTOCHEM CELL BIOL, V122, P305, DOI 10.1007/s00418-004-0695-8
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Shaheen NJ, 2002, CANCER-AM CANCER SOC, V94, P950, DOI 10.1002/cncr.10333
   Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6
   Shappell SB, 2001, CANCER RES, V61, P497
   Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6
   Shoji T, 2003, CANCER LETT, V195, P235, DOI 10.1016/S0304-3835(02)00108-8
   Shureiqi I, 2001, CANCER RES, V61, P6307
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Simonsen N, 1998, AM J EPIDEMIOL, V147, P342
   Skelly MM, 2003, INT J CLIN PRACT, V57, P301
   Soh JW, 2003, PROG EXP TUMOR RES, V37, P261
   Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200
   Sugimoto T, 2007, INTERNAL MED, V46, P1055, DOI 10.2169/internalmedicine.46.0094
   Sun WH, 2005, JPN J CLIN ONCOL, V35, P707, DOI 10.1093/jjco/hyi196
   Taccone-Gallucci M, 2006, KIDNEY INT, V69, P1450, DOI 10.1038/sj.ki.5000291
   Tang DW, 2003, J ORAL PATHOL MED, V32, P522, DOI 10.1034/j.1600-0714.2003.00182.x
   Tavares IA, 2000, ALIMENT PHARM THERAP, V14, P795
   Theodoratou E, 2007, AM J EPIDEMIOL, V166, P181, DOI 10.1093/aje/kwm063
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tong WG, 2002, CLIN CANCER RES, V8, P3232
   Touhey S, 2002, EUR J CANCER, V38, P1661, DOI 10.1016/S0959-8049(02)00128-4
   Tries S, 2002, INFLAMM RES, V51, P135, DOI 10.1007/PL00000285
   Uefuji K, 2001, J SURG ONCOL, V76, P26, DOI 10.1002/1096-9098(200101)76:1<26::AID-JSO1005>3.0.CO;2-A
   URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L
   Vural F, 2005, LEUKEMIA LYMPHOMA, V46, P753, DOI 10.1080/10428190400027860
   Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x
   Wang DZ, 2004, P NATL ACAD SCI USA, V101, P415, DOI 10.1073/pnas.0307640100
   Waskewich C, 2002, CANCER RES, V62, P2029
   Werz O, 2006, PHARMACOL THERAPEUT, V112, P701, DOI 10.1016/j.pharmthera.2006.05.009
   Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6
   White William B, 2004, Am J Ther, V11, P244, DOI 10.1097/01.mjt.0000127360.23508.04
   Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621
   Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286
   Williams JL, 2001, CANCER RES, V61, P3285
   Wong DR, 2005, CURR OPIN PHARMACOL, V5, P204, DOI 10.1016/j.coph.2005.02.001
   Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243
   Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307
   Yang K, 2007, PLOS COMPUT BIOL, V3, P523, DOI 10.1371/journal.pcbi.0030055
   Yao M, 2005, CLIN CANCER RES, V11, P1618, DOI 10.1158/1078-0432.CCR-04-1696
   Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421
   Yoshimura R, 2004, INT J MOL MED, V13, P389
   Yoshimura R, 2003, J UROLOGY, V170, P1994, DOI 10.1097/01.ju.0000080296.54262.c8
   Yoshinaga M, 2004, PROSTAG OTH LIPID M, V73, P111, DOI 10.1016/j.prostaglandins.2004.01.001
   Ziboh VA, 2002, ARCH PHARM RES, V25, P747, DOI 10.1007/BF02976988
NR 216
TC 97
Z9 104
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2009
VL 9
IS 6
SI SI
BP 701
EP 715
DI 10.1016/j.intimp.2009.02.003
PG 15
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 452VH
UT WOS:000266568800011
PM 19239926
OA Green Accepted
DA 2020-12-17
ER

PT J
AU Ferreira, CSM
   Cheung, MC
   Missailidis, S
   Bisland, S
   Gariepy, J
AF Ferreira, Catia S. M.
   Cheung, Melissa C.
   Missailidis, Sotiris
   Bisland, Stuart
   Gariepy, Jean
TI Phototoxic aptamers selectively enter and kill epithelial cancer cells
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID PHOTODYNAMIC THERAPY PDT; BREAST-CANCER; MONOCLONAL-ANTIBODIES; MEDIATED
   ENDOCYTOSIS; INTERFERING RNAS; TUMOR-MARKER; DNA APTAMERS; MUC1;
   RECEPTOR; GLYCOSYLATION
AB The majority of cancers arise from malignant epithelial cells. We report the design of synthetic oligonucleotides (aptamers) that are only internalized by epithelial cancer cells and can be precisely activated by light to kill such cells. Specifically, phototoxic DNA aptamers were selected to bind to unique short O-glycan-peptide signatures on the surface of breast, colon, lung, ovarian and pancreatic cancer cells. These surface antigens are not present on normal epithelial cells but are internalized and routed through endosomal and Golgi compartments by cancer cells, thus providing a focused mechanism for their intracellular delivery. When modified at their 5' end with the photodynamic therapy agent chlorin e(6) and delivered to epithelial cancer cells, these aptamers exhibited a remarkable enhancement (> 500-fold increase) in toxicity upon light activation, compared to the drug alone and were not cytotoxic towards cell types lacking such O-glycan-peptide markers. Our findings suggest that these synthetic oligonucleotide aptamers can serve as delivery vehicles in precisely routing cytotoxic cargoes to and into epithelial cancer cells.
C1 [Ferreira, Catia S. M.; Cheung, Melissa C.; Bisland, Stuart; Gariepy, Jean] Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
   [Missailidis, Sotiris] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
RP Gariepy, J (corresponding author), Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
EM gariepy@uhnres.utoronto.ca
CR Ackroyd R, 2003, ENDOSCOPY, V35, P496
   Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819
   BRADLEY JR, 1993, J IMMUNOL, V150, P5544
   Brayman Melissa, 2004, Reprod Biol Endocrinol, V2, P4, DOI 10.1186/1477-7827-2-4
   Breaker RR, 1997, CURR OPIN CHEM BIOL, V1, P26, DOI 10.1016/S1367-5931(97)80105-6
   Brokx RD, 2003, BIOCHEMISTRY-US, V42, P13817, DOI 10.1021/bi0353070
   Burchell JM, 2001, J MAMMARY GLAND BIOL, V6, P355, DOI 10.1023/A:1011331809881
   CALAFAT J, 1988, CANCER RES, V48, P3822
   CERIANI RL, 1992, INT J CANCER, V51, P343, DOI 10.1002/ijc.2910510303
   Cheung KL, 2000, CANCER TREAT REV, V26, P91, DOI 10.1053/ctrv.1999.0151
   Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672
   Cuenca RE, 2004, ANN SURG ONCOL, V11, P322, DOI 10.1245/ASO.2004.03.025
   Du KL, 2006, LASER SURG MED, V38, P427, DOI 10.1002/lsm.20341
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Feigon J, 1996, CHEM BIOL, V3, P611, DOI 10.1016/S1074-5521(96)90127-1
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn SM, 2006, CLIN CANCER RES, V12, P5464, DOI 10.1158/1078-0432.CCR-06-0953
   Henderikx P, 2002, AM J PATHOL, V160, P1597, DOI 10.1016/S0002-9440(10)61107-8
   Ho JJL, 2000, CURR PHARM DESIGN, V6, P1881, DOI 10.2174/1381612003398609
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200
   LINSLEY PS, 1988, CANCER RES, V48, P2138
   LITVINOV SV, 1993, J BIOL CHEM, V268, P21364
   Manimala JC, 2005, CHEMBIOCHEM, V6, P2229, DOI 10.1002/cbic.200500165
   MCCABE PC, 1990, PCR PROTOCOLS GUIDE, P76
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Moghissi K, 2000, EUR J CARDIO-THORAC, V17, P95, DOI 10.1016/S1010-7940(99)00350-4
   Moghissi K, 2007, THORAX, V62, P391, DOI 10.1136/thx.2006.061143
   Plumb LA, 2004, METH MOLEC MED, V88, P165
   Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500
   PRICE MR, 1999, VACCINE, V18, P268
   Ray E, 1996, FEBS LETT, V378, P235, DOI 10.1016/0014-5793(95)01462-4
   Salouti M, 2008, NUCL MED BIOL, V35, P763, DOI 10.1016/j.nucmedbio.2008.07.002
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
NR 37
TC 152
Z9 155
U1 6
U2 65
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB
PY 2009
VL 37
IS 3
BP 866
EP 876
DI 10.1093/nar/gkn967
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 413YP
UT WOS:000263831400030
PM 19103663
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Smith, GR
   Missailidis, S
AF Smith, Gary Robert
   Missailidis, Sotiris
TI Learning from cancer: The adaptive growth, wound and immune responses
SO GENE THERAPY AND MOLECULAR BIOLOGY
LA English
DT Review
DE Cancer; inflammation; immunity; angiotensin; AT1 receptors; AT1
   inhibitors; ACE inhibitors; Oxidative Stress; Hypoxia; Wound; Growth
ID ANGIOTENSIN-CONVERTING ENZYME; TOLL-LIKE-RECEPTORS; II TYPE-1 RECEPTOR;
   LOW-DENSITY-LIPOPROTEIN; ENDOTOXIN-INDUCED UVEITIS; RENAL-CELL
   CARCINOMA; 13-CIS RETINOIC ACID; EPSTEIN-BARR-VIRUS; REGULATORY T-CELLS;
   AT1 RECEPTOR
AB The life cycle of cancer, and solid tumours in particular, can be usefully simplified into two phases of the disease; the earlier phase where change in intracellular processes is required for carcinogenesis and the later phase, malignancy, where the continued development of the cancer relies on the support of extra-cellular processes. From this systems view of cancer and the failure modes of healthy biological processes associated with it, a three-vector portrayal of cellular dynamics is abstracted. This overarching framework for the direction of biosystem responses places the categorisation of disease at the extreme points of these vectors and provides an explanation for their cause. Furthermore, laboratory and clinical evidence suggests that a synergistic systems approach to disease management, based on the manipulation of these vectors, could lead to new paradigms in treatment.
C1 [Smith, Gary Robert] Perses Biosyst Ltd, Res Dept, Coventry CV4 7EZ, W Midlands, England.
   [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Smith, GR (corresponding author), Perses Biosyst Ltd, Res Dept, Univ Warwick Sci Pk, Coventry CV4 7EZ, W Midlands, England.
EM gary.smith@persescomms.com
FU Open University
FX Gary R Smith would like to acknowledge family and friends, who have
   significantly contributed to this hypothesis through their experiences
   and questioning, notably Paul Jaep, a long term ME sufferer, Catherine
   O'Driscoll and especially Gary's wife Alison. He would also like to make
   a special mention of his grandfather Thomas William Flowers to whom he
   would like to dedicate this paper.; Sotiris Missailidis would like to
   acknowledge the Open University for their financial support.
CR Abiko M, 1996, J INVEST SURG, V9, P447, DOI 10.3109/08941939609025862
   Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127
   Anand P, 2008, PHARM RES-DORDR, V25, P2097, DOI 10.1007/s11095-008-9661-9
   Anders HJ, 2004, J AM SOC NEPHROL, V15, P854, DOI 10.1097/01.ASN.0000121781.89599.16
   [Anonymous], 2008, Duke Med Health News, V14, P3
   Arafat HA, 2007, J AM COLL SURGEONS, V204, P996, DOI 10.1016/j.jamcollsurg.2007.01.067
   Arai H, 2006, HISTOL HISTOPATHOL, V21, P673, DOI 10.14670/HH-21.673
   Arganaraz GA, 2008, EPILEPSIA, V49, P1348, DOI 10.1111/j.1528-1167.2008.01581.x
   Arrieta O, 2008, BRIT J CANCER, V99, P160, DOI 10.1038/sj.bjc.6604431
   Athyros VG, 2009, CURR PHARM DESIGN, V15, P479, DOI 10.2174/138161209787315729
   Attoub S, 2008, ANN NY ACAD SCI, V1138, P65, DOI 10.1196/annals.1414.011
   Azad N, 2008, J TOXICOL ENV HEAL B, V11, P1, DOI 10.1080/10937400701436460
   Baum M, 2005, EUR J CANCER, V41, P508, DOI 10.1016/j.ejca.2004.09.031
   Becker Y, 2004, VIRUS GENES, V28, P319, DOI 10.1023/B:VIRU.0000025778.56507.61
   Bedair HS, 2008, AM J SPORT MED, V36, P1548, DOI 10.1177/0363546508315470
   Belino-Studzinska Paulina, 2008, Przegl Epidemiol, V62, P767
   Ben-Haim S, 2009, SEMIN NUCL MED, V39, P103, DOI 10.1053/j.semnuclmed.2008.10.004
   Bento CAM, 2009, AIDS, V23, P9, DOI 10.1097/QAD.0b013e328317461e
   Blackburn SD, 2007, TRENDS MICROBIOL, V15, P143, DOI 10.1016/j.tim.2007.02.006
   Bondy B, 2005, PROG NEURO-PSYCHOPH, V29, P1094, DOI 10.1016/j.pnpbp.2005.03.015
   Boorom KF, 2007, MED HYPOTHESES, V69, P652, DOI 10.1016/j.mehy.2007.01.027
   Breslin JW, 2008, SHOCK, V29, P349, DOI 10.1097/shk.0b013e3181454975
   Brody Jerome S, 2006, Proc Am Thorac Soc, V3, P535, DOI 10.1513/pats.200603-089MS
   Brooke SM, 2000, BIOL PSYCHIAT, V48, P881, DOI 10.1016/S0006-3223(00)00922-7
   Brown ER, 2008, ANN ONCOL, V19, P1340, DOI 10.1093/annonc/mdn054
   Brown MJ, 2006, ANN NY ACAD SCI, V1073, P436, DOI 10.1196/annals.1353.047
   Bullock GR, 2001, HISTOCHEM CELL BIOL, V115, P117, DOI 10.1007/s004180000235
   Busquets Xavier, 2007, Int J Chron Obstruct Pulmon Dis, V2, P329
   Cabezas MC, 1998, NETH J MED, V53, P32, DOI 10.1016/S0300-2977(98)00051-5
   Cairns BA, 2008, J TRAUMA, V64, P1069, DOI 10.1097/TA.0b013e318166b7d9
   Cann SAH, 2003, POSTGRAD MED J, V79, P672
   Carey RM, 2005, CURR OPIN NEPHROL HY, V14, P67, DOI 10.1097/00041552-200501000-00011
   Castellon R, 2007, CURR PHARM DESIGN, V13, P1191, DOI 10.2174/138161207780618902
   Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208
   Chan YC, 2009, J PHARMACOL EXP THER, V329, P450, DOI 10.1124/jpet.108.148353
   Chen FP, 2007, ACTA PHARMACOL SIN, V28, P227, DOI 10.1111/j.1745-7254.2007.00493.x
   Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253
   Chetty A, 2002, MOL GENET METAB, V75, P265, DOI 10.1006/mgme.2002.3295
   Chytil F, 1996, FASEB J, V10, P986
   Congote LF, 2005, CLIN CHIM ACTA, V361, P30, DOI 10.1016/j.cccn.2005.05.001
   Cooke A, 2008, CLIN EXP RHEUMATOL, V26, pS1
   Cuatrecasas P, 2006, J CLIN INVEST, V116, P2837, DOI 10.1172/JCI29999
   D'Arpa N, 2009, BURNS, V35, P513, DOI 10.1016/j.burns.2008.05.027
   D'Ercole AJ, 2008, ENDOCRINOLOGY, V149, P5958, DOI 10.1210/en.2008-0920
   Dalgleish AG, 2006, CANC TREAT, V130, P1
   de Cavanagh EMV, 2007, FRONT BIOSCI-LANDMRK, V12, P1049, DOI 10.2741/2125
   Deans DAC, 2009, BRIT J CANCER, V100, P63, DOI 10.1038/sj.bjc.6604828
   Debernardi-Venon W, 2007, J HEPATOL, V46, P1026, DOI 10.1016/j.jhep.2007.01.017
   Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999
   Dobbs RJ, 2008, HELICOBACTER, V13, P309, DOI 10.1111/j.1523-5378.2008.00622.x
   Dolle L, 2006, CURR CANCER DRUG TAR, V6, P729, DOI 10.2174/156800906779010263
   Drakopanagiotakis F, 2008, EUR RESPIR J, V32, P1631, DOI 10.1183/09031936.00176807
   Dupont J, 2003, HORM METAB RES, V35, P740
   Erlinger TP, 2004, CANCER EPIDEM BIOMAR, V13, P1052
   Esteban V, 2006, J NEPHROL, V19, P725
   Everett M, 2008, J SURG ONCOL, V98, P588, DOI 10.1002/jso.21030
   Ferder LF, 2002, CURR OPIN PHARMACOL, V2, P189, DOI 10.1016/S1471-4892(02)00139-X
   Ferrari V, 2006, CANCER CHEMOTH PHARM, V57, P185, DOI 10.1007/s00280-005-0028-1
   Ferreri AJM, 2006, JNCI-J NATL CANCER I, V98, P1375, DOI 10.1093/jnci/djj373
   Forrest LM, 2004, BRIT J CANCER, V90, P1704, DOI 10.1038/sj.bjc.6601789
   Fowble B, 2001, INT J RADIAT ONCOL, V51, P679, DOI 10.1016/S0360-3016(01)01665-0
   Franscini LMD, 2002, AM J HYPERTENS, V15, P1057, DOI 10.1016/S0895-7061(02)03083-2
   Gao Jinming, 2000, Chinese Medical Sciences Journal, V15, P24
   Garay RP, 2007, EUR J PHARMACOL, V563, P1, DOI 10.1016/j.ejphar.2007.02.018
   Gard PR, 2004, EXPERT OPIN THER TAR, V8, P7, DOI 10.1517/eott.8.1.7.26409
   Gatti CD, 2008, CLIN EXP HYPERTENS, V30, P616, DOI 10.1080/10641960802443183
   Ge JA, 1996, EUR J PHARMACOL, V297, P299, DOI 10.1016/0014-2999(95)00762-8
   Giannitrapani L, 2006, ANN NY ACAD SCI, V1089, P228, DOI 10.1196/annals.1386.044
   Gilliver SC, 2007, CLIMACTERIC, V10, P276, DOI 10.1080/13697130701456630
   Gilliver SC, 2009, J PATHOL, V217, P73, DOI 10.1002/path.2444
   Gilliver SC, 2008, ENDOCRINOLOGY, V149, P5747, DOI 10.1210/en.2008-0355
   Gilman AL, 2009, J CLIN ONCOL, V27, P85, DOI 10.1200/JCO.2006.10.3564
   Giovannini S, 2008, MECH AGEING DEV, V129, P593, DOI 10.1016/j.mad.2008.08.001
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007-0036
   Gnanalingham MG, 2005, J PHYSIOL-LONDON, V565, P159, DOI 10.1113/jphysiol.2005.083246
   Goldman-Johnson DR, 2008, ENDOCRINOLOGY, V149, P5, DOI 10.1210/en.2007-1123
   Grammatopoulos TN, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-1
   Granucci F, 2003, EMBO J, V22, P2546, DOI 10.1093/emboj/cdg261
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136
   Heymes C, 1998, THERAPIE, V53, P213
   Hitomi H, 2006, J HYPERTENS, V24, P1089, DOI 10.1097/01.hjh.0000226199.51805.88
   Hosseini-Khalili Ali Reza, 2008, BMC Pulm Med, V8, P15, DOI 10.1186/1471-2466-8-15
   Hoyer KK, 2008, IMMUNOL REV, V226, P19, DOI 10.1111/j.1600-065X.2008.00697.x
   Hu CP, 2008, HYPERTENSION, V52, P556, DOI 10.1161/HYPERTENSIONAHA.108.115287
   Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004-0536
   Ibragimov AI, 2005, MATH MED BIOL, V22, P305, DOI 10.1093/imammb/dqi011
   Ikura Y, 2005, HEPATOL RES, V32, P107, DOI 10.1016/j.hepres.2005.01.017
   Imai N, 2007, LAB INVEST, V87, P189, DOI 10.1038/labinvest.3700504
   Ingber DE, 2008, SEMIN CANCER BIOL, V18, P356, DOI 10.1016/j.semcancer.2008.03.016
   Ino K, 2006, BRIT J CANCER, V94, P552, DOI 10.1038/sj.bjc.6602961
   Irani RA, 2008, PLACENTA, V29, P763, DOI 10.1016/j.placenta.2008.06.011
   Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357
   Iwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x
   Iwata K, 2008, J GASTROINTEST LIVER, V17, P21
   *J HOPK MED LETT S, 2002, HLTH AFTER 50, V14, P1
   *J HOPK MED LETT S, 2002, HLTH AFTER 50, V14, P7
   Jacobs EJ, 2007, JNCI-J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132
   Janes KA, 2005, SCIENCE, V310, P1646, DOI 10.1126/science.1116598
   Janiak P, 2006, EUR J PHARMACOL, V534, P271, DOI 10.1016/j.ejphar.2006.01.032
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   Joglar B, 2009, J NEUROCHEM, V109, P656, DOI 10.1111/j.1471-4159.2009.05999.x
   Kamer AR, 2008, ALZHEIMERS DEMENT, V4, P242, DOI 10.1016/j.jalz.2007.08.004
   Kara M, 2001, EUR J CARDIO-THORAC, V20, P868, DOI 10.1016/S1010-7940(01)00866-1
   Katagiri D, 2006, INT IMMUNOPHARMACOL, V6, P170, DOI 10.1016/j.intimp.2005.07.017
   Kaufman R P, 1987, Physician Exec, V13, P10
   Kehoe AD, 2009, EUR J NEUROL, V16, P95, DOI 10.1111/j.1468-1331.2008.02355.x
   Khor LY, 2007, LANCET ONCOL, V8, P912, DOI 10.1016/S1470-2045(07)70280-2
   Kikkawa F, 2004, AM J OBSTET GYNECOL, V190, P1258, DOI 10.1016/j.ajog.2003.12.013
   Kim TH, 2008, CLIN EXP ALLERGY, V38, P1727, DOI 10.1111/j.1365-2222.2008.03082.x
   Kitayama H, 2006, AM J HYPERTENS, V19, P718, DOI 10.1016/j.amjhyper.2005.09.022
   Kjaer M, 2006, J ANAT, V208, P445, DOI 10.1111/j.1469-7580.2006.00549.x
   Kluwe J, 2009, J MOL MED, V87, P125, DOI 10.1007/s00109-008-0426-z
   Kobayashi T, 2008, SURGERY, V144, P729, DOI 10.1016/j.surg.2008.08.015
   Kowajiri M, 2008, MULT SCLER J, V14, P557, DOI 10.1177/1352458507085760
   Krick S, 2005, FASEB J, V19, P857, DOI 10.1096/fj.04-2890fje
   Krutzik SR, 2004, SEMIN IMMUNOL, V16, P35, DOI 10.1016/j.smim.2003.10.005
   Kuhn DM, 2003, CLIN MICROBIOL REV, V16, P144, DOI 10.1128/CMR.16.1.144-172.2003
   Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002
   Laesser M, 2004, ACTA ANAESTH SCAND, V48, P198, DOI 10.1111/j.0001-5172.2004.00283.x
   Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X
   Laudanno Oscar Miguel, 2006, Acta Gastroenterologica Latinoamericana, V36, P76
   Lawson JS, 2006, FUTURE MICROBIOL, V1, P33, DOI 10.2217/17460913.1.1.33
   Lee B, 2005, J MOL BIOL, V345, P1083, DOI 10.1016/j.jmb.2004.11.027
   Lee JY, 2006, ALLERGY ASTHMA PROC, V27, P341, DOI 10.2500/aap.2006.27.2908
   Lee JM, 2008, CRIT REV ONCOL HEMAT, V66, P208, DOI 10.1016/j.critrevonc.2008.01.004
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li DY, 1999, CIRC RES, V84, P1043, DOI 10.1161/01.RES.84.9.1043
   Li JY, 1998, MOL CELL ENDOCRINOL, V139, P61
   Liao Yan-Dan, 2007, Zhonghua Zhongliu Zazhi, V29, P360
   Lilenbaum R, 2006, J CLIN ONCOL, V24, P4825, DOI 10.1200/JCO.2006.07.4773
   Lin JJ, 2002, J NEUROL SCI, V199, P25, DOI 10.1016/S0022-510X(02)00081-3
   Lorusso L, 2009, AUTOIMMUN REV, V8, P287, DOI 10.1016/j.autrev.2008.08.003
   Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006
   Maggio M, 2006, AM J CARDIOL, V97, P1525, DOI 10.1016/j.amjcard.2005.11.089
   Mahnke K, 2007, J DERMATOL SCI, V46, P159, DOI 10.1016/j.jdermsci.2007.03.002
   Mann JR, 2005, NAT CLIN PRACT ONCOL, V2, P202, DOI 10.1038/ncponc0140
   Marastoni S, 2008, CONNECT TISSUE RES, V49, P203, DOI 10.1080/03008200802143190
   Martens JWM, 2003, THROMB HAEMOSTASIS, V89, P393
   Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253
   Maruo T, 2004, HUM REPROD UPDATE, V10, P207, DOI 10.1093/humupd/dmh019
   Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925
   Maul B, 2005, FASEB J, V19, P1474, DOI 10.1096/fj.05-3742com
   MAUNG AA, 2005, J LEUKOCYTE BIOL
   Maus U, 2008, Z ORTHOP UNFALLCHIR, V146, P59, DOI 10.1055/s-2007-989436
   Meduri GU, 2002, CRIT CARE, V6, P24, DOI 10.1186/cc1450
   Menaker RJ, 2003, MICROBES INFECT, V5, P1149, DOI [10.1016/j.micinf.2003.08.001, 10.1016/J.MICINF.2003.08.001]
   Mendes JP, 2008, REV PORT PNEUMOL, V14, P647, DOI 10.1016/S0873-2159(15)30275-0
   Menke MN, 2008, GYNECOL ONCOL, V111, pS87, DOI 10.1016/j.ygyno.2008.07.052
   Miller AC, 2007, J TRAUMA, V63, P1407, DOI 10.1097/TA.0b013e31815b839e
   Miyajima A, 2002, CANCER RES, V62, P4176
   Miyazaki A, 2008, GRAEF ARCH CLIN EXP, V246, P747, DOI 10.1007/s00417-007-0730-2
   Mizoue S, 2006, CURR EYE RES, V31, P129, DOI 10.1080/02713680500507200
   Mocellin S, 2004, CYTOKINE GROWTH F R, V15, P61, DOI 10.1016/j.cytogfr.2003.11.001
   Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08
   Moskowitz DW, 2004, CURR TOP MED CHEM, V4, P1433
   MULLER OA, 1992, J STEROID BIOCHEM, V43, P403, DOI 10.1016/0960-0760(92)90076-U
   Munteanu I., 2007, PNEUMOLOGIA, V56, P43
   Munteanu Ioana, 2007, Pneumologia, V56, P43
   Murphy E, 2006, Ernst Schering Found Symp Proc, P13
   Murphy TF, 2006, CURR OPIN INFECT DIS, V19, P225, DOI 10.1097/01.qco.0000224815.89363.15
   Muthu K, 2008, J BURN CARE RES, V29, P12, DOI 10.1097/BCR.0b013e31815fa499
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476
   Nakamura H, 2005, EUR J PHARMACOL, V512, P239, DOI 10.1016/j.ejphar.2005.02.047
   Nakayama M, 2005, BIOCHEM BIOPH RES CO, V332, P927, DOI 10.1016/j.bbrc.2005.05.065
   Neal CP, 2009, EUR J CANCER, V45, P56, DOI 10.1016/j.ejca.2008.08.019
   Nickenig G, 1997, J HYPERTENS, V15, pS27, DOI 10.1097/00004872-199715066-00006
   Nicod LP, 2001, EUR RESPIR J, V17, P133, DOI 10.1183/09031936.01.17101330
   OAKLEY F, 2009, GASTROENTEROLOGY
   Ochoa J, 2008, J TRAUMA, V64, P1077
   Ogarkov O B, 2008, Mol Gen Mikrobiol Virusol, P12
   Owczarek H, 1991, Pol J Occup Med Environ Health, V4, P127
   Ozacmak VH, 2007, NEUROCHEM RES, V32, P1314, DOI 10.1007/s11064-007-9305-1
   Pasare C, 2005, ADV EXP MED BIOL, V560, P11
   Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002
   Paterson HM, 2003, J IMMUNOL, V171, P1473, DOI 10.4049/jimmunol.171.3.1473
   Peebles KA, 2007, EXPERT REV ANTICANC, V7, P1405, DOI 10.1586/14737140.7.10.1405
   Peehl D M, 1995, Urol Oncol, V1, P188, DOI 10.1016/1078-1439(95)00063-1
   Pelaia G, 2006, RESP MED, V100, P775, DOI 10.1016/j.rmed.2005.08.025
   Pelletier G, 2004, HISTOL HISTOPATHOL, V19, P629, DOI 10.14670/HH-19.629
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Pordeus V, 2008, CLIN REV ALLERG IMMU, V34, P283, DOI 10.1007/s12016-007-8048-8
   Rabbani MA, 2008, SAUDI J KIDNEY DIS T, V19, P1009
   Ramachandran V, 2008, J RENIN-ANGIO-ALDO S, V9, P208, DOI 10.1177/1470320308097499
   Recchia F, 2006, J IMMUNOTHER, V29, P87, DOI 10.1097/01.cji.0000186244.85058.1b
   Recchia F, 2005, ANTICANCER RES, V25, P3149
   Recchia F, 2008, ONCOL REP, V20, P1173, DOI 10.3892/or_00000126
   Recchia F, 2007, CANCER IMMUNOL IMMUN, V56, P699, DOI 10.1007/s00262-006-0224-9
   Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112
   Riaz AA, 2004, FASEB J, V18, P881, DOI 10.1096/fj.03-0502fje
   Richmond RS, 2004, J RENIN-ANGIO-ALDO S, V5, P176, DOI 10.3317/jraas.2004.037
   Rocken C, 2007, NEOPLASIA, V9, P716, DOI 10.1593/neo.07418
   Rodriguez-Pallares J, 2008, NEUROBIOL DIS, V31, P58, DOI 10.1016/j.nbd.2008.03.003
   Rocken C, 2007, CANCER EPIDEM BIOMAR, V16, P1206, DOI 10.1158/1055-9965.EPI-05-0934
   Ross JS, 2001, ANN NY ACAD SCI, V947, P271
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Saibeni S, 2007, EUR J GASTROEN HEPAT, V19, P976, DOI 10.1097/MEG.0b013e3282efa3fc
   Sanchez-Lemus E, 2008, ENDOCRINOLOGY, V149, P5177, DOI 10.1210/en.2008-0242
   Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1
   Schneider CP, 2004, BBA-MOL BASIS DIS, V1689, P22, DOI 10.1016/j.bbadis.2004.01.003
   Schulman IH, 2008, CURR HYPERTENS REP, V10, P188, DOI 10.1007/s11906-008-0036-8
   Schwacha MG, 2008, CYTOKINE, V44, P328, DOI 10.1016/j.cyto.2008.09.001
   Seckl JR, 2004, ANN NY ACAD SCI, V1032, P63, DOI 10.1196/annals.1314.006
   Sengupta S, 2004, ANN NY ACAD SCI, V1024, P54, DOI 10.1196/annals.1321.005
   Sethi S, 2006, CHEST, V129, P223, DOI 10.1378/chest.129.2.223
   Shafiq N, 2005, J NEGAT RESULTS BIOM, V4, DOI 10.1186/1477-5751-4-3
   Shankar A, 2006, ARCH INTERN MED, V166, P188, DOI 10.1001/archinte.166.2.188
   Sharma R, 2008, CLIN COLORECTAL CANC, V7, P331, DOI 10.3816/CCC.2008.n.044
   Sharma R, 2008, EUR J CANCER, V44, P251, DOI 10.1016/j.ejca.2007.11.011
   Shen LH, 2009, SHOCK, V31, P500, DOI 10.1097/SHK.0b013e318189017a
   Shibata K, 2005, TUMOR BIOL, V26, P9, DOI 10.1159/000084181
   Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028
   Silverman MN, 2005, VIRAL IMMUNOL, V18, P41, DOI 10.1089/vim.2005.18.41
   Slaviero KA, 2003, LANCET ONCOL, V4, P224, DOI 10.1016/S1470-2045(03)01034-9
   Smith CJ, 2006, INHAL TOXICOL, V18, P667, DOI 10.1080/08958370600742821
   Smith Gary Robert, 2004, J Inflamm (Lond), V1, P3, DOI 10.1186/1476-9255-1-3
   Smith GR, 2008, ANTICANCER THERAPEUTICS, P349, DOI 10.1002/9780470697047.ch19
   Sonnex C, 1998, SEX TRANSM INFECT, V74, P11, DOI 10.1136/sti.74.1.11
   Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007
   Sparks DL, 2009, AM J MED GENET B, V150B, P290, DOI 10.1002/ajmg.b.30793
   Steckelings UM, 2005, BRIT J DERMATOL, V153, P887, DOI 10.1111/j.1365-2133.2005.06806.x
   Steckelings UM, 2004, EXP DERMATOL, V13, P148, DOI 10.1111/j.0906-6705.2004.0139.x
   Sun GL, 2009, J NEUROL SCI, V280, P40, DOI 10.1016/j.jns.2009.01.020
   Sutmuller R, 2007, ANN RHEUM DIS, V66, P91, DOI 10.1136/ard.2007.078535
   Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6
   Tahir M, 2007, SARCOIDOSIS VASC DIF, V24, P106
   Tamari M, 2009, RECENT PATENTS INFLA, V3, P17, DOI 10.2174/187221309787158380
   Tamura M, 1999, EUR J PHARMACOL, V386, P289, DOI 10.1016/S0014-2999(99)00755-4
   Taranova AG, 2008, CANCER RES, V68, P8582, DOI 10.1158/0008-5472.CAN-08-1673
   Tarantini F, 2007, ALLERGY, V62, P605, DOI 10.1111/j.1398-9995.2007.01390.x
   Tatokoro M, 2008, INT J UROL, V15, P848, DOI 10.1111/j.1442-2042.2008.02102.x
   Tauro S, 2008, MICROBES INFECT, V10, P1014, DOI 10.1016/j.micinf.2008.07.037
   Toblli JE, 2008, OBESITY, V16, P770, DOI 10.1038/oby.2007.114
   Todorovic V, 2008, REGUL PEPTIDES, V150, P7, DOI 10.1016/j.regpep.2008.05.006
   Toulon A, 2009, J EXP MED, V206, P743, DOI 10.1084/jem.20081787
   Toussirot E, 2008, BEST PRACT RES CL RH, V22, P883, DOI 10.1016/j.berh.2008.09.007
   Tsang SW, 2004, REGUL PEPTIDES, V119, P213, DOI 10.1016/j.regpep.2004.02.003
   Tsang SW, 2004, INT J BIOCHEM CELL B, V36, P330, DOI 10.1016/S1357-2725(03)00257-7
   Tseng RJ, 2005, BRAIN BEHAV IMMUN, V19, P153, DOI 10.1016/j.bbi.2004.07.001
   Tsung K, 2006, SURG ONCOL, V15, P25, DOI 10.1016/j.suronc.2006.05.002
   Turney MK, 2004, MOL CELL ENDOCRINOL, V219, P105, DOI 10.1016/j.mce.2004.01.005
   Uemura Hiroji, 2005, Int J Clin Oncol, V10, P405, DOI 10.1007/s10147-005-0520-y
   Uppal SS, 2007, J RHEUMATOL, V34, P2395
   Urhan M, 2004, ALLERGY ASTHMA PROC, V25, P243
   US Preventive Services Task Force, 2007, ANN INTERN MED, V146, P361, DOI 10.7326/0003-4819-146-5-200703060-00008
   Vairaktaris E, 2007, ACTA ONCOL, V46, P1097, DOI 10.1080/02841860701373579
   Vaziri ND, 2007, J PHARMACOL EXP THER, V323, P85, DOI 10.1124/jpet.107.123638
   Vigano A, 2009, CLIN CANCER RES, V15, P2442, DOI 10.1158/1078-0432.CCR-08-1720
   Vladutiu GD, 2004, MUSCLE NERVE, V30, P38, DOI 10.1002/mus.20055
   Walton RP, 2008, CURR OPIN ALLERGY CL, V8, P150, DOI 10.1097/ACI.0b013e3282f889df
   Watanabe T, 2001, J HYPERTENS, V19, P1065, DOI 10.1097/00004872-200106000-00011
   Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271
   Whiteside TL, 2006, CANC TREAT, V130, P103
   Willard NR, 2002, CELL MOL LIFE SCI, V59, P1771, DOI 10.1007/PL00012505
   Woetmann A, 2007, BLOOD, V109, P3325, DOI 10.1182/blood-2006-04-017863
   Wolf G, 2008, NUTR REV, V66, P55, DOI 10.1111/j.1753-4887.2007.00006.x
   Wu J, 2009, HEPATOLOGY, V49, P1132, DOI 10.1002/hep.22751
   Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC
   Xia Y, 2007, J IMMUNOL, V179, P3391, DOI 10.4049/jimmunol.179.6.3391
   Yamagata T, 2006, EUR J PHARMACOL, V533, P289, DOI 10.1016/j.ejphar.2005.12.046
   Yang YH, 2008, TOHOKU J EXP MED, V215, P295, DOI 10.1620/tjem.215.295
   Yaren A, 2007, J INVEST MED, V55, P255, DOI 10.2310/6650.2007.00006
   Yasuda N, 2008, N-S ARCH PHARMACOL, V377, P393, DOI 10.1007/s00210-007-0215-1
   Yigit B, 2007, ANTICANCER RES, V27, P933
   Yoshiji Hitoshi, 2009, Nihon Rinsho, V67, P799
   Zhang H, 2006, J SURG RES, V134, P190, DOI 10.1016/j.jss.2006.01.026
   Zhou Jianhua, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P158
   Zuniga MC, 2003, J BIOSCIENCES, V28, P273, DOI 10.1007/BF02970147
NR 269
TC 3
Z9 3
U1 0
U2 3
PU GENE THERAPY PRESS
PI ATHENS
PA GREGORIOU AFXENTIOU 7, ALIMOS, ATHENS, 17455, GREECE
SN 1529-9120
J9 GENE THER MOL BIOL
JI Gene Ther. Mol. Biol.
PY 2009
VL 13A
BP 158
EP 185
PG 28
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 482DU
UT WOS:000268865200008
DA 2020-12-17
ER

PT B
AU Peduto, A
   Filosa, R
   Petronzi, C
   Missailidis, S
   Ragazzon, P
   Smith, S
   Esposito, V
   Virgilio, A
   Galeone, A
AF Peduto, A.
   Filosa, R.
   Petronzi, C.
   Missailidis, S.
   Ragazzon, P.
   Smith, S.
   Esposito, V
   Virgilio, A.
   Galeone, A.
GP MEDIMOND
TI Trisubstituted naphthalimides for DNA Quadruplex Binding Selectivity:
   synthesis, NMR and biophysical studies
SO JOINT MEETING ON MEDICAL CHEMISTRY
LA English
DT Proceedings Paper
CT Joint Meeting on Medical Chemistry
CY JUN 24-27, 2009
CL Budapest, HUNGARY
AB Selectivity for quadruplex DNA binding and stabilization by a it of compounds were explored through two different methods: UV absorption and thermal denaturation. Quadruplex DNA interaction was further characterized through NMR study. Quantification of relative quadruplex and duplex binding affinity constants puts some of these ligands among the most selective quadruplex DNA interactive agents reported to date.
C1 [Peduto, A.; Filosa, R.; Petronzi, C.] Univ Salerno, Dept Pharmaceut Sci, Via Ponte Don Melillo, I-84084 Fisciano, SA, Italy.
   [Missailidis, S.; Ragazzon, P.; Smith, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Esposito, V; Virgilio, A.; Galeone, A.] Univ Federico II, Dept Chem Nat Prod, I-80131 Naples, Italy.
RP Peduto, A (corresponding author), Univ Salerno, Dept Pharmaceut Sci, Via Ponte Don Melillo, I-84084 Fisciano, SA, Italy.
CR De Cian A, 2008, BIOCHIMIE, V90, P131, DOI 10.1016/j.biochi.2007.07.011
   Kelland L, 2007, CLIN CANCER RES, V13, P4960, DOI 10.1158/1078-0432.CCR-07-0422
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Monchaud D, 2008, ORG BIOMOL CHEM, V6, P627, DOI 10.1039/b714772b
   Oganesian L, 2007, BIOESSAYS, V29, P155, DOI 10.1002/bies.20523
NR 5
TC 0
Z9 0
U1 0
U2 3
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 978-88-7587-545-9
PY 2009
BP 45
EP +
PG 2
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA BVP17
UT WOS:000292154800010
DA 2020-12-17
ER

PT J
AU Bernardo, M
   Santos, SD
   da Fonseca, AD
   Carter, K
   Missailidis, S
AF Bernardo-Filho, Mario
   Santos-Filho, Sebastiao David
   da Fonseca, Adenilson de Souza
   Carter, Kevin
   Missailidis, Sotiris
TI Nuclear Medicine Procedures for the Evaluation of Male Sexual Organs: A
   Brief Review
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Review
DE Male sexual organs; PET; SPECT; radiopharmaceutical; sexuality
ID POSITRON-EMISSION-TOMOGRAPHY; RESIDUAL MASSES; PROSTATE; SCANS;
   LYMPHOSCINTIGRAPHY; CANCER
AB Sexuality consists of three aspects that are interrelated and inseparable, biological, physiological and social. The biological aspect considers the individual's capability to give and to receive pleasure. In consequence, it covers the functionality of the sexual organs and the physiology of human sexual response cycle. Diagnostic imaging modalities, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) have been used to evaluate clinical disorders of the male reproductive system. PET and SPECT procedures basically involve the administration of a radiopharmaceutical that has a higher uptake in a specific tumor or tissue. The aim of this brief review is to present some radiopharmaceuticals that have been used in the clinical evaluation of the male sexual organs (testes, prostate, seminal vesicles, penis) related with male sexuality. This information could be useful in better understanding the male sexual response cycle, as well as the sexual disorders, when considering the male sexual organs and the pelvic floor. Moreover, the findings obtained with PET and SPECT imaging could help to evaluate the efficacy of clinical results of therapeutic procedures. In conclusion, the knowledge from these images could aid in better understanding the physiology of the different organs related with sexuality. Furthermore, they could be important tools to evaluate the physiological integrity of the involved organs, to improve clinical strategies and to accompany the patients under treatment.
C1 [Bernardo-Filho, Mario; Santos-Filho, Sebastiao David; da Fonseca, Adenilson de Souza] Univ Estado Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Biofis & Biometria, Lab Radiofarm Expt, BR-20551030 Rio De Janeiro, Brazil.
   [Bernardo-Filho, Mario] Inst Nacl Canc, BR-20230130 Rio De Janeiro, Brazil.
   [Carter, Kevin] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02446 USA.
   [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
RP Bernardo, M (corresponding author), Univ Estado Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Biofis & Biometria, Lab Radiofarm Expt, BR-20551030 Rio De Janeiro, Brazil.
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); UERJ; INCAInstitut National du Cancer (INCA) France;
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX The authors thank CAPES, CNPq, UERJ, INCA and FAPERJ for the financial
   support.
CR Bernardo-Filho Mario, 2005, Braz. arch. biol. technol., V48, P13, DOI 10.1590/S1516-89132005000700003
   Beutel ME, 2006, ANDROLOGIA, V38, P115, DOI 10.1111/j.1439-0272.2006.00730.x
   Bouchelouche K, 2008, J UROLOGY, V179, P34, DOI 10.1016/j.juro.2007.08.176
   Chaffanjon PCJ, 2004, ANN CHIR, V129, P100, DOI 10.1016/j.anchir.2003.12.005
   Choe W, 2003, CLIN NUCL MED, V28, P501, DOI 10.1097/00003072-200306000-00013
   Dennerstein L, 2005, AM J MED, V118, P1407, DOI 10.1016/j.amjmed.2005.10.013
   Fanti S, 2007, Q J NUCL MED MOL IM, V51, P260
   Ganjoo KN, 1999, J CLIN ONCOL, V17, P3457, DOI 10.1200/JCO.1999.17.11.3457
   GERBER G, 1991, UROLOGY, V37, P418, DOI 10.1016/0090-4295(91)80101-C
   Halac M, 2007, HELL J NUCL MED, V10, P113
   Hatzimouratidis K, 2007, J SEX MED, V4, P241, DOI 10.1111/j.1743-6109.2007.00409.x
   Jana S, 2006, SEMIN NUCL MED, V36, P51, DOI 10.1053/j.semnuclmed.2005.09.001
   KIM CK, 1993, SEMIN ROENTGENOL, V28, P31, DOI 10.1016/S0037-198X(05)80111-7
   KOLODNY RC, 1979, TXB SEXUAL MED
   Kotzerke J, 2000, EUR J NUCL MED, V27, P1415, DOI 10.1007/s002590000309
   Kotzerke J, 2002, EUR J NUCL MED MOL I, V29, P1380, DOI 10.1007/s00259-002-0882-6
   Kumar V., 2005, ROBBINS COTRAN PATHO
   Lange PH, 2001, UROLOGY, V57, P402, DOI 10.1016/S0090-4295(00)01109-2
   MASTERS WH, 1970, HUMANLY SEXUAL INADE
   Olmos RAV, 2001, EUR J NUCL MED, V28, P581
   Orhan I, 2008, UROLOGY, V71, P672, DOI 10.1016/j.urology.2007.11.103
   PERKINS A, 1999, NUCL MED PHARM RES
   PERKINS AC, 2007, CANC CLOCK
   Ravizzini GC, 2001, J UROLOGY, V165, P1633, DOI 10.1016/S0022-5347(05)66372-0
   Roivainen A, 2000, EUR J NUCL MED, V27, P25, DOI 10.1007/PL00006658
   Ryu JK, 2003, ASIAN J ANDROL, V5, P179
   SAHA G, 2004, FUNDAMENTALS NUCL PH
   Shen YY, 1998, UROL INT, V61, P27, DOI 10.1159/000030279
   Stelzner F, 2005, CHIRURG, V76, P1168, DOI 10.1007/s00104-005-1117-8
   Sumich AL, 2003, HOSP MED, V64, P28, DOI 10.12968/hosp.2003.64.1.2378
   Timmermans L, 1998, Acta Urol Belg, V66, P13
   Toth G, 2005, J UROLOGY, V173, P66, DOI 10.1097/01.ju.0000148326.71981.44
   WARREN GP, 1995, J CLIN ONCOL, V13, P2784, DOI 10.1200/JCO.1995.13.11.2784
   WILLAN BD, 1987, CLIN NUCL MED, V12, P813, DOI 10.1097/00003072-198710000-00014
   ZUCKIER LS, 1990, NUCL MED COMMUN, V11, P589, DOI 10.1097/00006231-199009000-00002
NR 35
TC 1
Z9 1
U1 0
U2 0
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
EI 1678-4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD DEC
PY 2008
VL 51
SI SI
BP 13
EP 21
DI 10.1590/S1516-89132008000700004
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 416YW
UT WOS:000264042400004
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Perkins, A
   Santos, SD
   da Fonseca, AD
   Bernardo, M
AF Missailidis, Sotiris
   Perkins, Alan
   Santos-Filho, Sebastiao David
   da Fonseca, Adenilson de Souza
   Bernardo-Filho, Mario
TI Aptamer-Based Radiopharmaceuticals for Diagnostic Imaging and Targeted
   Radiotherapy of Epithelial Tumors
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article
DE Aptamer; radiopharmaceutical; diagnostic imaging; radiotherapy;
   epithelial tumor
ID IN-VITRO SELECTION; CAPILLARY-ELECTROPHORESIS; EQUILIBRIUM MIXTURES;
   LIGANDS; DESIGN; MOLECULES; THERAPY; TOOL
AB In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular degeneration, aptamers have found only limited applications or interest in oncology, and even less as radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as radiopharmaceuticals is now available and recent advances in their development can demonstrate that these molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced side effects.
C1 [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK6 7AA, Bucks, England.
   [Perkins, Alan] Univ Nottingham, Dept Med Phys, Nottingham NG7 2RD, England.
   [Santos-Filho, Sebastiao David; da Fonseca, Adenilson de Souza; Bernardo-Filho, Mario] Univ Estado Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Biofis, BR-20551030 Rio De Janeiro, Brazil.
   [da Fonseca, Adenilson de Souza] Ctr Univ Serra Orgaos, Ctr Ciencias Saude, BR-25964004 Teresopolis, RJ, Brazil.
   [Bernardo-Filho, Mario] Inst Nacl Canc, BR-20230130 Rio De Janeiro, Brazil.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem & Analyt Sci, Walton Hall, Milton Keynes MK6 7AA, Bucks, England.
EM s.missailidis@open.ac.uk
RI Fonseca, Adenilson/Y-2700-2019
OI Fonseca, Adenilson/0000-0002-4441-4008; Perkins,
   Alan/0000-0002-1054-8200
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); UERJ; The Open University; Breast
   Cancer Campaign
FX The authors would like to acknowledge the support of CNPq, FAPERJ, UERJ,
   The Open University and the Breast Cancer Campaign.
CR Bacher JM, 1998, DRUG DISCOV TODAY, V3, P265, DOI 10.1016/S1359-6446(97)01166-5
   BELIMEZI M, ANTICANCER THERAPEUT
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Drabovich A, 2005, J AM CHEM SOC, V127, P11224, DOI 10.1021/ja0530016
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2008, ANAL BIOANAL CHEM, V390, P1039, DOI 10.1007/s00216-007-1470-1
   Ferreira CSM, 2007, BRAZ ARCH BIOL TECHN, V50, P63, DOI 10.1590/S1516-89132007000600008
   Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169
   Hamula CLA, 2006, TRAC-TREND ANAL CHEM, V25, P681, DOI 10.1016/j.trac.2006.05.007
   Hesselberth J, 2000, J Biotechnol, V74, P15, DOI 10.1016/S1389-0352(99)00005-7
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jhaveri S, 2000, NAT BIOTECHNOL, V18, P1293, DOI 10.1038/82414
   Khan H, 2008, GENE THER MOL BIOL, V12, P111
   Makwana V., ANTICANCER THERAPEUT
   MISSAILIDIS S, ANTICANCER THERAPEUT
   Missailidis S, 2007, CANCER BIOTHER RADIO, V22, P453, DOI 10.1089/cbr.2007.357
   Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902
   Perkins AC, 2007, Q J NUCL MED MOL IM, V51, P292
   Potyrailo RA, 1998, ANAL CHEM, V70, P3419, DOI 10.1021/ac9802325
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
NR 23
TC 2
Z9 2
U1 0
U2 8
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD DEC
PY 2008
VL 51
BP 77
EP 82
DI 10.1590/S1516-89132008000700013
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 416YW
UT WOS:000264042400013
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Agostinho, RT
   Santos, SD
   da Fonseca, AD
   Missailidis, S
   Bernardo, M
AF Agostinho, Raquel Terra
   Santos-Filho, Sebastiao David
   da Fonseca, Adenilson de Souza
   Missailidis, Sotiris
   Bernardo-Filho, Mario
TI The Effect of an Extract From Ganoderma Lucidum (Reishi) on the Labeling
   of Blood Constituents with Technetium-99m and on the Survival of
   Escherichia Coli
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article
DE blood constituents; Escherichia coli; Ganoderma lucidum; stannous
   chloride; technetium-99m
ID STANNOUS CHLORIDE; ANTIOXIDANT; ANTITUMOR
AB This study evaluated effects of an aqueous extract of Ganoderma lucidum (reishi) on the labeling of blood constituents with technetium-99m (Tc-99m) and on the survival of cultures of Escherichia coli treated with stannous chloride. Blood samples from Wistar rats were treated with reishi extract, radiolabeling procedure was performed, plasma (P), blood cells (BC) and insoluble (IF) and soluble (SF) fractions of P and BC were separated. The radioactivity was counted for the determination of the percentages of radioactivity (%ATI). Cultures of Escherichia coli AB1157 were treated with stannous chloride in the presence and absence of reishi extract. Blood samples and bacterial cultures treated with NaCl 0.9% were used as controls. Data indicated that reishi extract altered significantly (p<0.05) the %ATI of P, BC, IF-P, SF-P, IF-BC and SF-BC, as well as increased the survival of bacterial cultures treated with stannous chloride. Our results suggest that reishi extract could present a redox/chelating action, altering the labeling of blood constituents with Tc-99m and protecting bacterial cultures against oxidative damage induced by stannous chloride.
C1 [Agostinho, Raquel Terra; Santos-Filho, Sebastiao David; da Fonseca, Adenilson de Souza; Bernardo-Filho, Mario] Univ Fed Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Biofis & Biometria, BR-20551030 Rio De Janeiro, Brazil.
   [Agostinho, Raquel Terra] Univ Fed Rio Grande do Norte, BR-59010180 Natal, RN, Brazil.
   [da Fonseca, Adenilson de Souza] Ctr Univ Serra Orgaos, Ctr Ciencias Saude, BR-25964004 Teresopolis, RJ, Brazil.
   [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK6 7AA, Bucks, England.
RP da Fonseca, AD (corresponding author), Univ Fed Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Biofis & Biometria, Av 28 Setembro 87, BR-20551030 Rio De Janeiro, Brazil.
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Universidade do Estado do Rio de Janeiro (UERJ); The
   Open University (OU)
FX This research was supported by Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Universidade do Estado do Rio de
   Janeiro (UERJ) and The Open University (OU).
CR Ajith TA, 2007, J CLIN BIOCHEM NUTR, V40, P157, DOI 10.3164/jcbn.40.157
   Almeida MC, 2007, CELL MOL BIOL, V53, pOL923, DOI 10.1170/105
   Bao XF, 2002, PHYTOCHEMISTRY, V59, P175, DOI 10.1016/S0031-9422(01)00450-2
   Benarroz MO, 2008, APPL RADIAT ISOTOPES, V66, P139, DOI 10.1016/j.apradiso.2007.08.004
   BERNARDOFILHO M, 1983, ARQ BIOL TECNOL, V26, P455
   Cao Li-zhen, 2003, Yaoxue Xuebao, V38, P92
   El-Demerdash FM, 2005, FOOD CHEM TOXICOL, V43, P1743, DOI 10.1016/j.fct.2005.05.017
   Fonseca AS, 2007, ACTA BIOL HUNG, V58, P187, DOI 10.1556/ABiol.58.2007.2.5
   FRYDMAN JNG, 2008, J MED FOOD IN PRESS
   Lima EAC, 2002, FOOD CHEM TOXICOL, V40, P919, DOI 10.1016/S0278-6915(02)00065-0
   Lin ZB, 2005, J PHARMACOL SCI, V99, P144, DOI 10.1254/jphs.CRJ05008X
   Lin ZB, 2004, ACTA PHARMACOL SIN, V25, P1387
   LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226
   Olds GD, 2005, J CLIN GASTROENTEROL, V39, P273, DOI 10.1097/01.mcg.0000155131.04821.f3
   Presta Giuseppe A., 2007, Rev. bras. farmacogn., V17, P331, DOI 10.1590/S0102-695X2007000300005
   SAHA GB, 2004, FUDAMENTALS NUCL PHA
   Verdu J, 2005, CLIN NUCL MED, V30, P25, DOI 10.1097/00003072-200501000-00007
NR 17
TC 2
Z9 2
U1 0
U2 0
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
EI 1678-4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD DEC
PY 2008
VL 51
SI SI
BP 157
EP 162
DI 10.1590/S1516-89132008000700025
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 416YW
UT WOS:000264042400025
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Diniz, CL
   do Carmo, FS
   de Almeida, DS
   Santos, SD
   Missailidis, S
   da Fonseca, AD
   Bernardo, M
AF Diniz, Claudia Leite
   do Carmo, Fernanda Santos
   de Almeida, Danielle Santos
   Santos-Filho, Sebastiao David
   Missailidis, Sotiris
   da Fonseca, Adenilson de Souza
   Bernardo Filho, Mario
TI Effect of an Extract of Centella asiatica on the Biodistribution of
   Sodium Pertechnetate ((NaTcO4)-Tc-99m) and on the Fixation of
   Radioactivity on Blood Constituents
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article
DE Biodistribution; Centella asiatica; Blood; Plasma; Tcchnctium-99m
ID TC-99M; CELLS; RATS
AB This study evaluates the effects of an acute treatment with a Centella asiatica (CA) extract on the biodistribution of the radiopharmaceutical (NaTcO4)-Tc-99m and on the fixation of technetium-99m on blood constituents. Wistar rats were treated with CA extract and, 1 hour after, (NaTcO4)-Tc-99m was administered; organs/tissues were withdrawn and weighted. The radioactivity was counted to calculate the percentage of activity per gram (%ATI/g). Also, blood samples were withdrawn, plasma (P), blood cells (BC), insoluble fraction (IF) and soluble fractions of P and BC were isolated and the radioactivity was counted to calculate the percentage of activity (%ATI). Data indicated that the acute treatment with CA extract changed significantly (p<0.05) the %ATI/g in several organs/tissues (spleen, heart, duodenum, stomach, liver, muscle, kidney, testis and blood) and the %ATI on the blood constituents (P, BC, IF-P and IF-BC). These results indicate that the substances or metabolites of the CA extract would change the biodistribution of (NaTcO4)-Tc-99m and the fixation of the technetium-99m on blood constituents in an acute treatment.
C1 [Diniz, Claudia Leite; do Carmo, Fernanda Santos; de Almeida, Danielle Santos; Santos-Filho, Sebastiao David; da Fonseca, Adenilson de Souza; Bernardo Filho, Mario] Univ Estado Rio de Janeiro, Lab Radiofarm Expt, Dept Biofis & Biometria, Inst Biol Roberto Alcantara Gomes, BR-20551030 Rio De Janeiro, Brazil.
   [da Fonseca, Adenilson de Souza] Ctr Univ Serra Orgaos, Ctr Ciencias Saude, BR-25964004 Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK6 7AA, Bucks, England.
   [Bernardo Filho, Mario] Inst Nacl Canc, BR-20230130 Rio De Janeiro, Brazil.
RP Diniz, CL (corresponding author), Univ Estado Rio de Janeiro, Lab Radiofarm Expt, Dept Biofis & Biometria, Inst Biol Roberto Alcantara Gomes, Av 28 Setembro 87, BR-20551030 Rio De Janeiro, Brazil.
EM claudiadiniz@uerj.br
RI Fonseca, Adenilson/Y-2700-2019
OI Fonseca, Adenilson/0000-0002-4441-4008
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientfico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Universidade do Estado do Rio de Janeiro (UERJ); The
   Open University
FX This research was supported by Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento
   Cientfico e Tecnologico (CNPq), Universidade do Estado do Rio de Janeiro
   (UERJ) and The Open University. We are grateful to Analu Custodio,
   Gabrielle de Souza Rocha, Cristiano Viana and Raphael Sancho Sisley de
   Souza for technical support.
CR Benarroz MO, 2008, APPL RADIAT ISOTOPES, V66, P139, DOI 10.1016/j.apradiso.2007.08.004
   Bernardo-Filho Mario, 2005, Braz. arch. biol. technol., V48, P13, DOI 10.1590/S1516-89132005000700003
   Capriles PVSZ, 2002, CELL MOL BIOL, V48, P771
   Fonseca AS, 2007, ACTA BIOL HUNG, V58, P187, DOI 10.1556/ABiol.58.2007.2.5
   FRYDMAN JNG, 2008, J MED FOOD IN PRESS
   GOEL HC, 1996, INDIAN J EXP BIOL, V34, P194
   Inamdar PK, 1996, J CHROMATOGR A, V742, P127, DOI 10.1016/0021-9673(96)00237-3
   Jayashree G, 2003, FITOTERAPIA, V74, P431, DOI 10.1016/S0367-326X(03)00121-7
   Moreno SRF, 2007, BRAZ J MED BIOL RES, V40, P77, DOI 10.1590/S0100-879X2007000100010
   OWUNWANNE A, 1995, HDB RADIOPHARMACEUTI
   Padma P. R., 1998, Indian Journal of Nutrition and Dietetics, V35, P1
   Rebello BM, 2007, BRAZ ARCH BIOL TECHN, V50, P153, DOI 10.1590/S1516-89132007000600019
   SAHA G, 2004, FUNDAMENTALS NUCL PH
   Sharma J, 2002, PHYTOTHER RES, V16, P785, DOI 10.1002/ptr.1069
   Shobi V, 2001, PHYSIOL BEHAV, V73, P19, DOI 10.1016/S0031-9384(01)00434-6
   SIMOES CMO, 1999, FARMACOGNOSIA PLANTA, P617
NR 16
TC 4
Z9 4
U1 0
U2 2
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD DEC
PY 2008
VL 51
SI SI
BP 215
EP 219
DI 10.1590/S1516-89132008000700035
PG 5
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 416YW
UT WOS:000264042400035
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Bernardo, M
   Missailidis, S
   Palestro, CJ
AF Bernardo-Filho, Mario
   Missailidis, Sotiris
   Palestro, Christopher J.
TI Untitled
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Editorial Material
C1 [Bernardo-Filho, Mario] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil.
   [Bernardo-Filho, Mario] Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Missailidis, Sotiris] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Palestro, Christopher J.] Albert Einstein Coll Med, Bronx, NY 10461 USA.
   [Palestro, Christopher J.] N Shore Long Island Jewish Hlth Syst, New York, NY USA.
RP Bernardo, M (corresponding author), Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD DEC
PY 2008
VL 51
PG 2
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 416YW
UT WOS:000264042400001
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Perkins, A
   Missailidis, S
AF Da Pieve, C.
   Perkins, A.
   Missailidis, S.
TI DEVELOPMENT OF APTAMERS AS TARGETED RADIOPHARMACEUTICALS FOR THE
   DIAGNOSTIC IMAGING AND RADIOTHERAPY OF BREAST CANCER
SO ANTICANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Da Pieve, C.; Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, A.] Univ Nottingham, Sch Med, Dept Med Phys, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 2008
VL 28
IS 5C
MA 134
BP 3251
EP 3251
PG 1
WC Oncology
SC Oncology
GA 367ME
UT WOS:000260555300135
DA 2020-12-17
ER

PT J
AU Khan, H
   Makwana, V
   Courtenay-Luck, N
   Missailidis, S
AF Khan, H.
   Makwana, V.
   Courtenay-Luck, N.
   Missailidis, S.
TI DEVELOPMENT AND CHARACTERISATION OF APTAMERS AS INHIBITORS OF VITAL
   PATHWAYS IN CANCER THERAPY
SO ANTICANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Khan, H.; Makwana, V.; Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Courtenay-Luck, N.] Antisoma Res Ltd, Welwyn Garden City, Herts, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 2008
VL 28
IS 5C
MA 335
BP 3346
EP 3347
PG 2
WC Oncology
SC Oncology
GA 367ME
UT WOS:000260555300336
DA 2020-12-17
ER

PT J
AU Makwana, V
   Khan, H
   Courtenay-Luck, N
   Missailidis, S
AF Makwana, V.
   Khan, H.
   Courtenay-Luck, N.
   Missailidis, S.
TI FUNCTIONALISATION OF APTAMERS FOR THE DEVELOPMENT OF EFFECTIVE CANCER
   THERAPEUTICS
SO ANTICANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Makwana, V.; Khan, H.; Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Courtenay-Luck, N.] Antisoma Res Ltd, Welwyn Garden City, Herts, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 2008
VL 28
IS 5C
MA 433
BP 3394
EP 3395
PG 2
WC Oncology
SC Oncology
GA 367ME
UT WOS:000260555300434
DA 2020-12-17
ER

PT J
AU Missailidis, S
AF Missailidis, S.
TI THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OF APTAMERS IN CANCER
SO ANTICANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK5 7AS, Bucks, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 2008
VL 28
IS 5C
MA 459
BP 3408
EP 3409
PG 2
WC Oncology
SC Oncology
GA 367ME
UT WOS:000260555300460
DA 2020-12-17
ER

PT J
AU Simmons, SC
   Velasco-Garcia, MN
   Brenchley, PEC
   McKenzie, E
   Missailidis, S
AF Simmons, S. C.
   Velasco-Garcia, M. N.
   Brenchley, P. E. C.
   McKenzie, E.
   Missailidis, S.
TI DEVELOPING APTAMERS AS EFFECTIVE ANTICANCER AGENTS OR RECOGNITION UNITS
   IN BIOSENSOR TECHNOLOGIES
SO ANTICANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Simmons, S. C.; Velasco-Garcia, M. N.; Missailidis, S.] Open Univ, Dept Chem & Analyt Sci, Milton Keynes MK7 6AA, Bucks, England.
   [Brenchley, P. E. C.] Manchester Inst Nephrol & Transplantat, Renal Res Labs, Manchester, Lancs, England.
   [McKenzie, E.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
OI Brenchley, Paul/0000-0003-1290-9919
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 2008
VL 28
IS 5C
MA 614
BP 3486
EP 3486
PG 1
WC Oncology
SC Oncology
GA 367ME
UT WOS:000260555300616
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Perkins, A
   Missailidis, S
AF Da Pieve, C.
   Perkins, A.
   Missailidis, S.
TI Development of anti MUC1 DNA aptamers for the imaging of breast cancer
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Association-for-Cancer-Research
CY JUL 05-08, 2008
CL Lyon, FRANCE
SP European Assoc Canc Res
C1 [Da Pieve, C.; Missailidis, S.] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, A.] Univ Nottingham, Med Phys Med Sch, Nottingham NG7 2RD, England.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUL
PY 2008
VL 6
IS 9
BP 30
EP 31
DI 10.1016/S1359-6349(08)71292-8
PG 2
WC Oncology
SC Oncology
GA 330DF
UT WOS:000257919000118
DA 2020-12-17
ER

PT J
AU Khan, H
   Makwana, V
   Courtenay-Luck, N
   Missailidis, S
AF Khan, H.
   Makwana, V.
   Courtenay-Luck, N.
   Missailidis, S.
TI Development and characterisation of aptamers for cancer therapy
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Association-for-Cancer-Research
CY JUL 05-08, 2008
CL Lyon, FRANCE
SP European Assoc Canc Res
C1 [Khan, H.; Makwana, V.; Missailidis, S.] Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   [Courtenay-Luck, N.] Antisoma, Pharmaceut, London, England.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUL
PY 2008
VL 6
IS 9
BP 137
EP 138
DI 10.1016/S1359-6349(08)71702-6
PG 2
WC Oncology
SC Oncology
GA 330DF
UT WOS:000257919000523
DA 2020-12-17
ER

PT J
AU Cheng, MK
   Modi, C
   Cookson, JC
   Hutchinson, I
   Heald, RA
   McCarroll, AJ
   Missailidis, S
   Tanious, F
   Wilson, WD
   Mergny, JL
   Laughton, CA
   Stevens, MFG
AF Cheng, Mai-Kim
   Modi, Chetna
   Cookson, Jennifer C.
   Hutchinson, Ian
   Heald, Robert A.
   McCarroll, Andrew J.
   Missailidis, Sotiris
   Tanious, Farial
   Wilson, W. David
   Mergny, Jean-Louis
   Laughton, Charles A.
   Stevens, Malcolm F. G.
TI Antitumor polycyclic acridines. 20. search for DNA quadruplex binding
   selectivity in a series of 8,13-dimethylquino[4,3,2-kl]acridinium salts:
   Telomere-targeted agents
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID GRAEBE-ULLMANN THERMOLYSIS; SURFACE-PLASMON RESONANCE; HUMAN
   TUMOR-CELLS; PENTACYCLIC ACRIDINES; BIOLOGICAL-PROPERTIES; INTERACTIVE
   AGENTS; SMALL-MOLECULE; LIGAND RHPS4; CANCER-CELLS; G-TETRAPLEX
AB The growth-inhibitory activities of an extensive series of quaternized quino[4,3,2-kl]acridinium salts against tumor cell lines in vitro have been measured and their biological properties interpreted in the light of differential binding to different DNA isoforms. Selectivity for quadruplex DNA binding and stabilization by compounds were explored through an array of methods: UV absorption and fluorescence emission spectroscopy, surface plasmon resonance, and competition dialysis. Quadruplex DNA interaction was further characterized through FRET and DNA polymerase arrest assays. Telomerase inhibition, inferred from the TRAP assay, is attributed to quadruplex stabilization, supported by the strong correlation (R-2 = 0.81) across. the series between quadruplex DNA binding affinity and TRAP inhibition potency. Growth inhibition potency in the NCI60 human tumor cell line panel is more marked in compounds with greater DNA duplex binding affinity (R-2 = 0.82). Quantification of relative quadruplex and duplex binding affinity constants puts some of these ligands among the most selective quadruplex DNA interactive agents reported to date.
C1 [Cheng, Mai-Kim; Modi, Chetna; Cookson, Jennifer C.; Hutchinson, Ian; Heald, Robert A.; McCarroll, Andrew J.; Laughton, Charles A.; Stevens, Malcolm F. G.] Univ Nottingham, Sch Pharm, Canc Res UK Expt Canc Chemotherapy Res Grp, Ctr Biomol Sci, Nottingham NG7 2RD, England.
   [Missailidis, Sotiris] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Tanious, Farial; Wilson, W. David] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
   [Mergny, Jean-Louis] Museum Natl Hist Nat, CNRS, UMR 5153,U565, INSERM, F-75005 Paris, France.
RP Stevens, MFG (corresponding author), Univ Nottingham, Sch Pharm, Canc Res UK Expt Canc Chemotherapy Res Grp, Ctr Biomol Sci, Nottingham NG7 2RD, England.
EM malcolm.stevens@nottingham.ac.uk
RI Laughton, Charles A/E-5667-2010; Mergny, Jean-Louis/E-2860-2013
OI Laughton, Charles A/0000-0003-4090-3960; Mergny,
   Jean-Louis/0000-0003-3043-8401
FU Cancer Research UKCancer Research UK Funding Source: Medline
CR ALBERT A, 1966, ACRIDINES
   Ambrus A, 2006, NUCLEIC ACIDS RES, V34, P2723, DOI 10.1093/nar/gkl348
   BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858
   Biroccio A, 2006, EUR J CANCER, V42, P1881, DOI 10.1016/j.ejca.2006.03.010
   Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500
   Bostock-Smith CE, 1999, BIOCHEMISTRY-US, V38, P6723, DOI 10.1021/bi9825807
   Cookson JC, 2005, J MED CHEM, V48, P7198, DOI 10.1021/jm058031y
   Cookson JC, 2005, MOL PHARMACOL, V68, P1551, DOI 10.1124/mol.105.013300
   Davis TM, 2000, ANAL BIOCHEM, V284, P348, DOI 10.1006/abio.2000.4726
   De Cian A, 2007, METHODS, V42, P183, DOI 10.1016/j.ymeth.2006.10.004
   Ellis MJ, 2001, J CHEM SOC PERK T 1, P3174, DOI 10.1039/b106324n
   Ellis MJ, 2001, J CHEM SOC PERK T 1, P3180, DOI 10.1039/b106327h
   FUGMANN B, 1984, TETRAHEDRON LETT, V25, P3575, DOI 10.1016/S0040-4039(01)91079-2
   Gavathiotis E, 2003, J MOL BIOL, V334, P25, DOI 10.1016/j.jmb.2003.09.018
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P431
   GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x
   Gowan SM, 2001, MOL PHARMACOL, V60, P981
   Hagan DJ, 1997, J CHEM SOC PERK T 1, P2739, DOI 10.1039/a702299i
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   Hahn WC, 1999, NAT MED, V5, P1164
   Haq I, 1999, J AM CHEM SOC, V121, P1768, DOI 10.1021/ja981554t
   Harrison RJ, 1999, BIOORG MED CHEM LETT, V9, P2463, DOI 10.1016/S0960-894X(99)00394-7
   Harrison RJ, 2003, J MED CHEM, V46, P4463, DOI 10.1021/jm0308693
   Heald RA, 2003, ORG BIOMOL CHEM, V1, P3377, DOI 10.1039/b305177n
   Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q
   Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609
   Hutchinson I, 2004, ORG BIOMOL CHEM, V2, P220, DOI 10.1039/b310796p
   Hutchinson I, 2007, ORG BIOMOL CHEM, V5, P114, DOI 10.1039/b613580n
   Incles CM, 2004, MOL CANCER THER, V3, P1201
   Izbicka E, 1999, ANTI-CANCER DRUG DES, V14, P355
   Izbicka E, 1999, CANCER RES, V59, P639
   Jenkins T C, 1997, Methods Mol Biol, V90, P195
   Julino M, 1998, J CHEM SOC PERK T 1, P1677, DOI 10.1039/a800575c
   Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523
   Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Leonetti C, 2004, MOL PHARMACOL, V66, P1138, DOI 10.1124/mol.104.001537
   Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h
   LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2
   Luu KN, 2006, J AM CHEM SOC, V128, P9963, DOI 10.1021/ja062791w
   McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9
   Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839
   Mergny JL, 2001, P NATL ACAD SCI USA, V98, P3062, DOI 10.1073/pnas.051620698
   Missailidis S, 2002, ONCOL RES, V13, P175
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Moore MJB, 2006, J MED CHEM, V49, P582, DOI 10.1021/jm050555a
   MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622
   Muniyappa K, 2000, MOL CELL BIOL, V20, P1361, DOI 10.1128/MCB.20.4.1361-1369.2000
   Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793
   OSZCZAPOWICZ J, 1988, TETRAHEDRON, V44, P6645, DOI 10.1016/S0040-4020(01)90102-4
   Paeschke K, 2005, NAT STRUCT MOL BIOL, V12, P847, DOI 10.1038/nsmb982
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Phan AT, 2006, CURR OPIN STRUC BIOL, V16, P288, DOI 10.1016/j.sbi.2006.05.011
   Pothukuchy A, 2005, BIOCHEMISTRY-US, V44, P2163, DOI 10.1021/bi0485981
   RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X
   Ren JS, 2001, METHOD ENZYMOL, V340, P99
   Rezler EM, 2005, J AM CHEM SOC, V127, P9439, DOI 10.1021/ja0505088
   Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099
   Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461
   Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498
   Schultes CM, 2004, BIOORG MED CHEM LETT, V14, P4347, DOI 10.1016/j.bmcl.2004.05.090
   Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073
   Stanslas J, 2000, J MED CHEM, V43, P1563, DOI 10.1021/jm9909490
   Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198
   Teulade-Fichou MP, 2003, J AM CHEM SOC, V125, P4732, DOI 10.1021/ja021299j
   WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9
   Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343
   Weitzmann MN, 1996, J BIOL CHEM, V271, P20958, DOI 10.1074/jbc.271.34.20958
   White EW, 2007, BIOPHYS CHEM, V126, P140, DOI 10.1016/j.bpc.2006.06.006
   ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0
NR 73
TC 66
Z9 69
U1 1
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 28
PY 2008
VL 51
IS 4
BP 963
EP 975
DI 10.1021/jm070587t
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 265JB
UT WOS:000253353800027
PM 18247546
DA 2020-12-17
ER

PT J
AU Ferreira, CSM
   Papamichael, K
   Guilbault, G
   Schwarzacher, T
   Gariepy, J
   Missailidis, S
AF Ferreira, C. S. M.
   Papamichael, K.
   Guilbault, G.
   Schwarzacher, T.
   Gariepy, J.
   Missailidis, S.
TI DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody
   sandwich ELISA for the early diagnosis of epithelial tumours
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE MUC1; aptamers; ELISA; diagnostic assay; immunoassay
ID IN-VITRO SELECTION; RNA APTAMERS; AFFINITY-CHROMATOGRAPHY; EXPONENTIAL
   ENRICHMENT; ANTI-MUC1 ANTIBODIES; SYSTEMATIC EVOLUTION; BIND; LIGANDS;
   PROTEIN; CANCER
AB Aptamers are functional molecules able to bind tightly and selectively to disease markers, offering great potential for applications in disease diagnosis and therapy. MUC1 is a well-known tumour marker present in epithelial malignancies and is used in immunotherapeutic and diagnostic approaches. We report the selection of DNA aptamers that bind with high affinity and selectivity an MUC1 recombinant protein containing five repeats of the variable tandem repeat region. Aptamers were selected using the SELEX methodology from an initial library containing a 25-base-long variable region for their ability to bind to the unglycosylated form of the MUC1 protein. After ten rounds of in vitro selection and amplification, more than 90% of the pool of sequences consisted of target-binding molecules, which were cloned, sequenced and found to share no sequence consensus. The binding properties of these aptamers were quantified using ELISA and surface plasmon resonance. The lead aptamer sequence was subsequently used in the design of an aptamer-antibody hybrid sandwich ELISA for the identification and quantification of MUC1 in buffered solutions. Following optimisation of the operating conditions, the resulting enzyme immunoassay displayed an EC50 value of 25 mu g/ml, a detection limit of 1 mu g/ml and a linear range between 8 and 100 mu g/ml for the MUC1 five tandem repeat analyte. In addition, recovery studies performed in buffer conditions resulted in averaged recoveries between 98.2 and 101.7% for all spiked samples, demonstrating the usability of the aptamer as a receptor in microtitre-based assays. Our results aim towards the formation of new diagnostic assays against this tumour marker for the early diagnosis of primary or metastatic disease in breast, bladder and other epithelial tumours.
C1 [Ferreira, C. S. M.; Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Papamichael, K.; Guilbault, G.] Natl Univ Ireland Univ Coll Cork, Dept Chem, Cork, Ireland.
   [Schwarzacher, T.] Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England.
   [Gariepy, J.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
   [Papamichael, K.] Tyndall Natl Inst, Cork, Ireland.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
OI Schwarzacher, Trude/0000-0001-8310-5489
FU Breast Cancer Now [2005MAY11] Funding Source: Medline
CR Akhtar S, 2002, BIOCHEM PHARMACOL, V63, P2187, DOI 10.1016/S0006-2952(02)00985-1
   Apostolopoulos V, 1999, VACCINE, V18, P268, DOI 10.1016/S0264-410X(99)00197-8
   Bacher JM, 1998, DRUG DISCOV TODAY, V3, P265, DOI 10.1016/S1359-6446(97)01166-5
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bianchini M, 2001, J IMMUNOL METHODS, V252, P191, DOI 10.1016/S0022-1759(01)00350-7
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Brokx RD, 2003, BIOCHEMISTRY-US, V42, P13817, DOI 10.1021/bi0353070
   BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
   Fujino T, 2003, J STEROID BIOCHEM, V87, P247, DOI 10.1016/j.jsbmb.2003.09.008
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   German I, 1998, ANAL CHEM, V70, P4540, DOI 10.1021/ac980638h
   Gewirtz AM, 1999, CURR OPIN MOL THER, V1, P297
   GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z
   Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439
   HELENE C, 1996, DEV EUR J CANC, V32, P3
   Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Jarrard JA, 1998, CANCER RES, V58, P5582
   Karanikas V, 1998, TUMOR BIOL, V19, P71, DOI 10.1159/000056507
   Kawakami J, 1998, ANAL CHIM ACTA, V365, P95, DOI 10.1016/S0003-2670(97)00579-5
   Kimoto M, 2002, EUR J BIOCHEM, V269, P697, DOI 10.1046/j.0014-2956.2001.02703.x
   LAUHON CT, 1994, J AM CHEM SOC, V14, P5798
   LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016
   Lupold SE, 2002, CANCER RES, V62, P4029
   MCGUCKIN MA, 1995, TUMORDIAGN THER, V16, P1
   Missailidis S, 2005, J IMMUNOL METHODS, V296, P45, DOI 10.1016/j.jim.2004.10.011
   Murray A, 1998, J PEPT RES, V52, P375
   Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Romig TS, 1999, J CHROMATOGR B, V731, P275, DOI 10.1016/S0378-4347(99)00243-1
   Rye PD, 2001, TUMOR BIOL, V22, P269, DOI 10.1159/000050626
   Smith RG, 2002, J CHROMATOGR B, V766, P13, DOI 10.1016/S0378-4347(01)00422-4
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uhrbom L, 2000, INT J CANCER, V85, P398, DOI 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L
   Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200
   Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Xu W, 1996, P NATL ACAD SCI USA, V93, P7475, DOI 10.1073/pnas.93.15.7475
   Yan AC, 2005, FRONT BIOSCI-LANDMRK, V10, P1802, DOI 10.2741/1663
NR 47
TC 123
Z9 131
U1 3
U2 145
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD FEB
PY 2008
VL 390
IS 4
BP 1039
EP 1050
DI 10.1007/s00216-007-1470-1
PG 12
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 259DA
UT WOS:000252918100006
PM 17694298
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Iley, JN
   Perkins, A
   Missailidis, S
AF Da Pieve, C.
   Iley, J. N.
   Perkins, A.
   Missailidis, S.
TI Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy
   of breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Meeting Abstract
CT Breast Cancer Research Meeting
CY MAY 13, 2008
CL London, ENGLAND
SP Royal Soc
C1 [Da Pieve, C.; Iley, J. N.; Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, A.] Univ Nottingham, Dept Med Phys, Sch Med, Nottingham NG7 2RD, England.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
SU 2
MA P62
BP S31
EP S32
AR P62
DI 10.1186/bcr1946
PG 2
WC Oncology
SC Oncology
GA 302BI
UT WOS:000255940900067
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Perkins, AC
   Missailidis, S
AF Perkins, A. C.
   Missailidis, S.
TI Radiolabelled aptamers for tumour imaging and therapy
SO QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article; Proceedings Paper
CT 18th International Congress of the
   International-Research-Group-in-Immuno-Scintigraphy-and-Therapy (IRIST)
CY JUL, 2006
CL London, ENGLAND
SP Int Res Grp Immuno Scintig & Therapy
DE aptamers; peptides; radiopharmaceuticals; neoplasms
ID RNA MOLECULES; DNA APTAMERS; LIGANDS; SELECTION; CELLS; BIND;
   POLYMERASE; DELIVERY; PEPTIDE; PROTEIN
AB Advances in biotechnology have led to new techniques for the design, selection and production of ligands suitable for molecular targeting. One promising approach is the production of specific receptor binding molecules based on defined nucleic acid sequences that are capable of recognising a wide array of target molecules. These oligonuclide ligands are known as aptamers. The technology that allows production of aptamer molecules is known as systematic evolution of ligands by exponential enrichment (SELEX). Using these techniques, aptamers can now be produced rapidly, inexpensively, and with high homogeneity. Furthermore, they are stable over long term storage at ambient room temperatures. A monomeric aptamer is small in size, with a molecular weight as low as 5 to 10 kDa. However, the aptamer molecule may be used as building block for custom designed targeting agents, offering several advantages. These molecules penetrate tumour readily, reach peak levels quickly and clear from the body rapidly, thus having properties of low toxicity and immunoreactivity. Previous work with radiolabelled aptamers is limited and is currently restricted to preclinical studies, but the body of evidence is steadily growing and aptamers are emerging as valuable clinical products for diagnostic imaging and therapy. We have shown that aptamers directed against the mucin 1 (MUC1) antigen, a tumour marker previously extensively used in tumour imaging and therapy, demonstrated high specificity and uniform penetration in tumour xenografts. The future strategy will be to manipulate the molecular weight of the molecules to achieve an optimum balance between the low immunogenicity and excellent tumour penetration for diagnostic imaging and targeted therapy. In this way, a balance can be achieved between the rapid renal clearance and adequate tumour uptake required for diagnostic imaging and targeted therapy.
C1 [Perkins, A. C.] Univ Nottingham Hosp, Queens Med Ctr, Acad Med Phys, Nottingham NG7 2UH, England.
   [Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
RP Perkins, AC (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Acad Med Phys, Nottingham NG7 2UH, England.
EM alan.perkins@nottingham.ac.uk
OI Perkins, Alan/0000-0002-1054-8200
FU Breast Cancer Now [2005MAY11] Funding Source: Medline
CR Biroccio A, 2002, J VIROL, V76, P3688, DOI 10.1128/JVI.76.8.3688-3696.2002
   Butz K, 2001, ONCOGENE, V20, P6579, DOI 10.1038/sj.onc.1204805
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Di Giusto DA, 2004, J BIOL CHEM, V279, P46483, DOI 10.1074/jbc.M408037200
   Dougan H, 2003, NUCL MED BIOL, V30, P61, DOI 10.1016/S0969-8051(02)00378-5
   Eaton BE, 1997, BIOORGAN MED CHEM, V5, P1087, DOI 10.1016/S0968-0896(97)00044-8
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hilger CS, 1998, TETRAHEDRON LETT, V39, P9403, DOI 10.1016/S0040-4039(98)02193-5
   Hughes ODM, 2000, J CLIN ONCOL, V18, P363, DOI 10.1200/JCO.2000.18.2.363
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Lee JF, 2004, NUCLEIC ACIDS RES, V32, pD95, DOI 10.1093/nar/gkh094
   Lupold SE, 2002, CANCER RES, V62, P4029
   PERKINS AC, 1993, NUCL MED COMMUN, V14, P578, DOI 10.1097/00006231-199307000-00011
   PERKINS AC, 1993, NUCL MED COMMUN, V20, P1
   TAVITIAN B, 2003, GUT, V52
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wagner S, 1997, NUCLEOS NUCLEOT, V16, P1789, DOI 10.1080/07328319708006279
   Winnard P, 1997, NUCL MED BIOL, V24, P425, DOI 10.1016/S0969-8051(97)00027-9
   Yamamoto R, 1995, Nucleic Acids Symp Ser, P145
   Ylera F, 2002, BIOCHEM BIOPH RES CO, V290, P1583, DOI 10.1006/bbrc.2002.6354
NR 26
TC 39
Z9 44
U1 1
U2 13
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 1824-4785
J9 Q J NUCL MED MOL IM
JI Q. J. Nucl. Med. Mol. Imag.
PD DEC
PY 2007
VL 51
IS 4
BP 292
EP 296
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 252SW
UT WOS:000252467900003
PM 17464274
DA 2020-12-17
ER

PT J
AU Ferreira, CSM
   Missailidis, S
AF Ferreira, Catia S. M.
   Missailidis, Sotiris
TI Aptamer-based therapeutics and their potential in radiopharmaceutical
   design
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article
DE aptamers; radiopharmaceuticals; SELEX; radiolabeling; medical imaging
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-VEGF APTAMER; RNA APTAMERS; DNA
   APTAMERS; MONOCLONAL-ANTIBODY; FUNCTIONAL-CHARACTERIZATION;
   REVERSE-TRANSCRIPTASE; SYSTEMATIC EVOLUTION; THROMBIN APTAMER; EMERGING
   CLASS
AB Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications. These range from inhibition of receptors and enzymes to the identification of small molecules in sensor applications, and from the development of targeted therapeutic to the design of novel diagnostic and imaging agents. Furthermore, aptamers have been designed for targets that cover a wide range of diseases, from HIV to tropical diseases, cancer and inflammation. Their easy development and flexibility of use and manipulation, offers further potential. In this paper we review their selection and consider some of the recent applications of aptamers in the design of radiopharmaceuticals for the targeted radiotherapy and medical imaging of disease.
C1 [Ferreira, Catia S. M.; Missailidis, Sotiris] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Ferreira, Catia S. M.] Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 1J6, Canada.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Berens C, 2001, BIOORGAN MED CHEM, V9, P2549, DOI 10.1016/S0968-0896(01)00063-3
   Berkower I, 1996, CURR OPIN BIOTECH, V7, P622, DOI 10.1016/S0958-1669(96)80073-5
   Bernardo-Filho Mario, 2005, Braz. arch. biol. technol., V48, P13, DOI 10.1590/S1516-89132005000700003
   Biroccio A, 2002, J VIROL, V76, P3688, DOI 10.1128/JVI.76.8.3688-3696.2002
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   BORBAS KE, 2007, IN PRESS BIOCONGUGAT
   Breaker RR, 1997, CURR OPIN CHEM BIOL, V1, P26, DOI 10.1016/S1367-5931(97)80105-6
   Britz-Cunningham SH, 2003, J NUCL MED, V44, P1945
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Burgstaller P, 1996, BIOORG MED CHEM LETT, V6, P1157, DOI 10.1016/0960-894X(96)00189-8
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cerchia L, 2002, FEBS LETT, V528, P12, DOI 10.1016/S0014-5793(02)03275-1
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   Deng Q, 2001, ANAL CHEM, V73, P5415, DOI 10.1021/ac0105437
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Dieckmann T, 1997, J MOL BIOL, V273, P467, DOI 10.1006/jmbi.1997.1329
   Dieckmann T, 1996, RNA, V2, P628
   Dougan H, 2003, NUCL MED BIOL, V30, P61, DOI 10.1016/S0969-8051(02)00378-5
   Duzgunes N, 2001, EXPERT OPIN BIOL TH, V1, P949
   Eaton BE, 1997, BIOORGAN MED CHEM, V5, P1087, DOI 10.1016/S0968-0896(97)00044-8
   Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825
   Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9
   Fan P, 1996, J MOL BIOL, V258, P480, DOI 10.1006/jmbi.1996.0263
   Feigon J, 1996, CHEM BIOL, V3, P611, DOI 10.1016/S1074-5521(96)90127-1
   FitzGerald K, 2000, DRUG DISCOV TODAY, V5, P253, DOI 10.1016/S1359-6446(00)01501-4
   Gewirtz AM, 1999, CURR OPIN MOL THER, V1, P297
   Glickman MH, 2005, FEBS LETT, V579, P3214, DOI 10.1016/j.febslet.2005.04.048
   GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z
   Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930
   Hale SP, 1996, P NATL ACAD SCI USA, V93, P2755, DOI 10.1073/pnas.93.7.2755
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hilger CS, 1998, TETRAHEDRON LETT, V39, P9403, DOI 10.1016/S0040-4039(98)02193-5
   Holland CA, 2000, FEBS LETT, V484, P87, DOI 10.1016/S0014-5793(00)02131-1
   Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006
   Homann M, 2001, BIOORGAN MED CHEM, V9, P2571, DOI 10.1016/S0968-0896(01)00032-3
   HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466
   Hwang J, 2000, BIOCHEM BIOPH RES CO, V279, P557, DOI 10.1006/bbrc.2000.4007
   Hwang WYK, 2005, METHODS, V36, P3, DOI 10.1016/j.ymeth.2005.01.001
   Hyland S, 2003, ONCOGENE, V22, P1557, DOI 10.1038/sj.onc.1206299
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Kankia BI, 2001, J AM CHEM SOC, V123, P10799, DOI 10.1021/ja010008o
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Knight R, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng030
   Kosmas C, 1993, J DRUG TARGET, V1, P81, DOI 10.3109/10611869308996064
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   LATHAM JA, 1994, NUCLEIC ACIDS RES, V22, P2817, DOI 10.1093/nar/22.14.2817
   Le Tinevez R, 1998, NUCLEIC ACIDS RES, V26, P2273, DOI 10.1093/nar/26.10.2273
   Lin CH, 1996, NAT STRUCT BIOL, V3, P1046, DOI 10.1038/nsb1296-1046
   Lupold SE, 2002, CANCER RES, V62, P4029
   MACAYA RF, 1995, BIOCHEMISTRY-US, V34, P4478, DOI 10.1021/bi00013a041
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Patel D J, 2000, J Biotechnol, V74, P39, DOI 10.1016/S1389-0352(99)00003-3
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Patel DJ, 1997, CURR OPIN CHEM BIOL, V1, P32, DOI 10.1016/S1367-5931(97)80106-8
   Pavski V, 2001, ANAL CHEM, V73, P6070, DOI 10.1021/ac0107305
   Pendergrast P Shannon, 2005, J Biomol Tech, V16, P224
   PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0
   Pileur F, 2003, NUCLEIC ACIDS RES, V31, P5776, DOI 10.1093/nar/gkg748
   Potyrailo RA, 1998, ANAL CHEM, V70, P3419, DOI 10.1021/ac9802325
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   Robertson SA, 2000, BIOCHEMISTRY-US, V39, P946, DOI 10.1021/bi9915061
   Santulli-Marotto S, 2003, CANCER RES, V63, P7483
   Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200
   Schlosser K, 2006, NUCLEIC ACIDS RES, V34, P2445, DOI 10.1093/nar/gkl276
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Sooter LJ, 2002, CHEM BIOL, V9, P857, DOI 10.1016/S1074-5521(02)00190-4
   TOR Y, 1993, J AM CHEM SOC, V115, P4461, DOI 10.1021/ja00064a007
   TSIANG M, 1995, J BIOL CHEM, V270, P19370, DOI 10.1074/jbc.270.33.19370
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Tungpradabkul S, 2005, MOL IMMUNOL, V42, P713, DOI 10.1016/j.molimm.2004.09.023
   Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200
   Urbain JL, 1999, J NUCL MED, V40, P498
   Vo NV, 2003, VIROLOGY, V307, P301, DOI 10.1016/S0042-6822(02)00095-8
   Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997
   White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100
   WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415
   Ye XM, 1999, CHEM BIOL, V6, P657, DOI 10.1016/S1074-5521(99)80117-3
NR 86
TC 15
Z9 15
U1 1
U2 15
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
EI 1678-4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD SEP
PY 2007
VL 50
SI SI
BP 63
EP 76
DI 10.1590/S1516-89132007000600008
PG 14
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 279WW
UT WOS:000254386900008
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Perkins, A
AF Missailidis, Sotiris
   Perkins, Alan
TI Aptamers as novel radiopharmaceuticals: Their applications and future
   prospects in diagnosis and therapy
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE aptamers; radiopharmaceuticals; diagnostics; therapeutics
ID IN-VITRO SELECTION; INTRACORONARY RADIATION-THERAPY; RECEPTOR IMAGING
   AGENT; GROWTH-FACTOR; RNA APTAMERS; PEPTIDE APTAMERS; TUMOR-CELLS;
   ALZHEIMERS-DISEASE; CANCER-CELLS; PROTEIN
AB The production of biomaterials with the capacity to bind tightly and specifically to cell surface receptors of malignant cells can greatly benefit cancer diagnosis and treatment. Whereas antibodies have the ability to specifically recognize some tumor cell makers, their large size and immunogenecity markedly limit their value. The development of nuclease-resistant oligonucleotide agents, termed aptamers, offers an alternative to antibodies as targeting, diagnostic, and delivery agents. Using the systematic evolution of ligands by exponential enrichment (SELEX) methodology or other variations, one can select specific sequences that have appropriate binding affinities and specificities against clinically relevant markers from large libraries of oligonucleotide ligands. Aptamers have beenfound to bind their targets with high specificity and with dissociation constants in the subnanomolar or picomolar range. However, the possibility for the selected aptamers to be developed as targeting agents for diagnostic imaging or targeted radiotherapy purposes has yet to be realized. Peptide-coupling reactions between amino and carboxylic groups offer the possibility of labeling the aptamers with a number of chelators that, coupled with appropriate radionuclides, would generate novel targeted radiopharmaceuticals for the diagnosis and therapy of disease. The unparalleled combinatorial chemical diversity, small size, and modification ability of aptamers is expected to meet the criteria for robust, generic drug discovery technology and open new horizons for the development offuture radiopharmaceuticals.
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Acad Med Phys, Queens Med Ctr, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
RI Sanguansri, Luz/B-6630-2011
OI Sanguansri, Luz/0000-0003-1908-7604; Perkins, Alan/0000-0002-1054-8200
CR Akhtar S, 2002, BIOCHEM PHARMACOL, V63, P2187, DOI 10.1016/S0006-2952(02)00985-1
   Aldaz-Carroll L, 2002, BIOCHEMISTRY-US, V41, P5883, DOI 10.1021/bi0121508
   Balasubramaniam V, 2003, AM J PHYSIOL-LUNG C, V284, pL826, DOI 10.1152/ajplung.00199.2002
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369
   Behr TM, 1999, CANCER RES, V59, P2635
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x
   Bianchini M, 2001, J IMMUNOL METHODS, V252, P191, DOI 10.1016/S0022-1759(01)00350-7
   Biroccio A, 2002, J VIROL, V76, P3688, DOI 10.1128/JVI.76.8.3688-3696.2002
   Bless NM, 1997, CURR BIOL, V7, P877, DOI 10.1016/S0960-9822(06)00376-9
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J
   Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897
   Butz K, 2001, ONCOGENE, V20, P6579, DOI 10.1038/sj.onc.1204805
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   CHO JE, 2006, ANALYTI CHIM ACTA, V564, P82
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   CHUMPRADIT S, 1989, J MED CHEM, V32, P1431, DOI 10.1021/jm00127a005
   Collett JR, 2005, METHODS, V37, P4, DOI 10.1016/j.ymeth.2005.05.009
   Coussement PK, 2002, CATHETER CARDIO INTE, V55, P28, DOI 10.1002/ccd.10043
   Crocker I, 2002, SEMIN RADIAT ONCOL, V12, P3, DOI 10.1053/S1053-4296(02)80021-2
   Dougan H, 2003, NUCL MED BIOL, V30, P61, DOI 10.1016/S0969-8051(02)00378-5
   Eaton BE, 1997, BIOORGAN MED CHEM, V5, P1087, DOI 10.1016/S0968-0896(97)00044-8
   EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9
   Frankle WG, 2002, ANN NUCL MED, V16, P437, DOI 10.1007/BF02988639
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guhlke S, 2003, EUR J NUCL MED MOL I, V30, P1441, DOI 10.1007/s00259-003-1346-3
   Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169
   HELENE C, 1996, EUR J CANCER, V32, P3
   Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hilger CS, 1998, TETRAHEDRON LETT, V39, P9403, DOI 10.1016/S0040-4039(98)02193-5
   Hjelstuen OK, 1998, NUCL MED BIOL, V25, P651, DOI 10.1016/S0969-8051(98)00040-7
   Holland CA, 2000, FEBS LETT, V484, P87, DOI 10.1016/S0014-5793(00)02131-1
   Homann M, 2001, BIOORGAN MED CHEM, V9, P2571, DOI 10.1016/S0968-0896(01)00032-3
   Hoppe-Seyler F, 2000, J MOL MED, V78, P426, DOI 10.1007/s001090000140
   ISRAEL BM, 1997, ELECTROEN CLIN NEURO, V103, P83
   JACOBONI MI, 1999, CLIN NEUROPHYSIOL, V110, P2
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jeong S, 2001, BIOCHEM BIOPH RES CO, V281, P237, DOI 10.1006/bbrc.2001.4327
   Katsifis A, 2003, NUCL MED BIOL, V30, P191, DOI 10.1016/S0969-8051(02)00394-3
   Kim KU, 2002, INT CONGR SER, V1247, P185, DOI 10.1016/S0531-5131(02)01054-3
   Kimoto M, 2002, EUR J BIOCHEM, V269, P697, DOI 10.1046/j.0014-2956.2001.02703.x
   Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X
   KROLICK KA, 1980, P NATL ACAD SCI-BIOL, V77, P5419, DOI 10.1073/pnas.77.9.5419
   Kumar N, 2002, INT J PARASITOL, V32, P1537, DOI 10.1016/S0020-7519(02)00180-7
   KUNG HF, 1988, NUCL MED BIOL, V15, P187
   Laruelle M, 1997, SCHIZOPHR RES, V24, P179, DOI 10.1016/S0920-9964(97)82515-7
   LEMOAL M, 1997, EUR NEUORPSYCHOPHARM, V7, pS80
   Lin Y, 1997, J MOL BIOL, V271, P100, DOI 10.1006/jmbi.1997.1165
   Lupold SE, 2002, CANCER RES, V62, P4029
   McLaughlin P, 2001, CRIT REV ONCOL HEMAT, V40, P3, DOI 10.1016/S1040-8428(01)00130-5
   Metzdorff MT, 2001, NEW ENGL J MED, V344, P1796
   Moore AH, 2002, ADV DRUG DELIVER REV, V54, P1627, DOI 10.1016/S0169-409X(02)00162-X
   Moore SA, 2002, LANCET INFECT DIS, V2, P737, DOI 10.1016/S1473-3099(02)00451-6
   Olsson H, 2001, NEUROIMAGE, V14, P936, DOI 10.1006/nimg.2001.0879
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   PAULIS DT, 2003, CURR PHARM DESIGN, V9, P673
   Petach H, 2002, CURR OPIN BIOTECH, V13, P309, DOI 10.1016/S0958-1669(02)00329-4
   Pietras K, 2001, CANCER RES, V61, P2929
   Pike VW, 2000, NUCL MED BIOL, V27, P449, DOI 10.1016/S0969-8051(00)00110-4
   Reiser M, 2002, EUR J CANCER, V38, P1167, DOI 10.1016/S0959-8049(02)00087-4
   REITHINGER R, 2002, TRENDS PARASITOL, V18, P202
   Remme JHF, 2002, TRENDS MICROBIOL, V10, P435, DOI 10.1016/S0966-842X(02)02431-9
   Ruddon RW, 1995, CANC BIOL
   Sabate M, 2000, CIRCULATION, V101, P2467, DOI 10.1161/01.CIR.101.21.2467
   Salame MY, 2001, EUR HEART J, V22, P629, DOI 10.1053/euhj.2000.2338
   Seabra-Gomes R, 2001, EUR HEART J, V22, P621, DOI 10.1053/euhj.2000.2512
   Spencer T, 1997, ULTRASOUND MED BIOL, V23, P191, DOI 10.1016/S0301-5629(96)00199-8
   STEPHENSON JA, 1988, EUR J PHARMACOL, V153, P271, DOI 10.1016/0014-2999(88)90615-2
   Tang J, 1997, RNA, V3, P914
   Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6
   Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uhrbom L, 2000, INT J CANCER, V85, P398, DOI 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L
   Urbain JL, 1999, J NUCL MED, V40, P498
   Vo NV, 2003, VIROLOGY, V307, P301, DOI 10.1016/S0042-6822(02)00095-8
   Wagner S, 1997, NUCLEOS NUCLEOT, V16, P1789, DOI 10.1080/07328319708006279
   Waksman R, 2001, Cardiovasc Radiat Med, V2, P61, DOI 10.1016/S1522-1865(00)00087-1
   Waksman R, 2001, Cardiovasc Radiat Med, V2, P63, DOI 10.1016/S1522-1865(00)00086-X
   Wilairatana P, 2002, ARCH MED RES, V33, P416, DOI 10.1016/S0188-4409(02)00371-5
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Winnard P, 1997, NUCL MED BIOL, V24, P425, DOI 10.1016/S0969-8051(97)00027-9
   YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5
   Yamamoto R, 1995, Nucleic Acids Symp Ser, P145
   Ylera F, 2002, BIOCHEM BIOPH RES CO, V290, P1583, DOI 10.1006/bbrc.2002.6354
   Zanardi A, 2002, TOXICOL LETT, V127, P207, DOI 10.1016/S0378-4274(01)00502-1
   2006, MED SANS FRONTIERES
NR 93
TC 28
Z9 28
U1 1
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084-9785
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD AUG
PY 2007
VL 22
IS 4
BP 453
EP 468
DI 10.1089/cbr.2007.357
PG 16
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA 208LM
UT WOS:000249320800001
PM 17803440
DA 2020-12-17
ER

PT J
AU Borbas, KE
   Ferreira, CSM
   Perkins, A
   Bruce, JI
   Missailidis, S
AF Borbas, K. Eszter
   Ferreira, Catia S. M.
   Perkins, Alan
   Bruce, James I.
   Missailidis, Sotiris
TI Design and synthesis of mono- and multimeric targeted
   radiopharmaceuticals based on novel cyclen ligands coupled to Anti-MUC1
   aptamers for the diagnostic imaging and targeted radiotherapy of cancer
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID MONOCLONAL-ANTIBODY C595; BREAST-CANCER; BLADDER-CANCER; TUMOR-MARKER;
   MUCIN; RADIOIMMUNOTHERAPY; IMMUNOSCINTIGRAPHY; AUTORADIOGRAPHY;
   SPIEGELMERS; EXPRESSION
AB Targeted radiopharmaceuticals offer the possibility of improved tumor imaging and radiotherapy, with reduced side effects. A variety of monoclonal antibodies and antibody fragments have previously been successfully radiolabeled and used in diagnostic imaging and targeted radiotherapy of cancer. Many such antibodies have been shown to recognize the well-characterized MUC1 tumor marker and have recently been in clinical trials. Furthermore, a number of chelators have been synthesized and are currently used as radiopharmaceuticals for imaging and therapy. We now report the synthesis of a novel, cyclen-based ligand with a sulfur-containing arm that offers increased stability of the ligand-metal complex. We have coupled this ligand with previously selected aptamers to the MUC1 tumor marker to generate a novel targeted radiopharmaceutical with improved properties. We have tested the complex against known, commercially available chelators such as MAG3 in model breast cancer systems. To improve the pharmacokinetic properties of the aptamer-based targeted radiopharmaceutical, we have generated multi-aptamer complexes around a central chelator. Such multi-aptamer complexes have increased retention of the complex in circulation, without affecting the lack of immunogenicity of the complex or altering its superior tumor penetration properties.
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Dept Med Phys, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM J.I.Bruce@open.ac.uk; s.missailidis@open.ac.uk
OI Perkins, Alan/0000-0002-1054-8200
CR Apostolopoulos V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1505
   Bodanszky M., 1984, PRINCIPLES PEPTIDE S, P10
   Bon GG, 1999, EUR J OBSTET GYN R B, V83, P67, DOI 10.1016/S0301-2115(98)00302-9
   BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605
   CAZIN JL, 1992, ANTICANCER RES, V12, P719
   DEANDA A, 1994, ANN THORAC SURG, V58, P344, DOI 10.1016/0003-4975(94)92206-3
   Dent GA, 1999, AM J CLIN PATHOL, V111, P741
   DEVINE PL, 1994, TUMOR BIOL, V15, P337, DOI 10.1159/000217910
   Dilworth JR, 1998, CHEM SOC REV, V27, P43
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   GOKEL GW, 1992, CHEM SOC REV, V21, P39, DOI 10.1039/cs9922100039
   Gold DV, 2003, CLIN CANCER RES, V9, p3929S
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hilger CS, 1998, TETRAHEDRON LETT, V39, P9403, DOI 10.1016/S0040-4039(98)02193-5
   Hughes ODM, 1997, EUR J NUCL MED, V24, P439, DOI 10.1007/BF00881818
   Hughes ODM, 2000, J CLIN ONCOL, V18, P363, DOI 10.1200/JCO.2000.18.2.363
   Hughes ODM, 2001, BJU INT, V87, P39, DOI 10.1046/j.1464-410x.2001.00985.x
   Kasina S, 1998, BIOCONJUGATE CHEM, V9, P108, DOI 10.1021/bc970047i
   Kuhnast B, 2003, J LABELLED COMPD RAD, V46, P1205, DOI 10.1002/jlcr.781
   KUNG HF, 1985, J MED CHEM, V28, P1280, DOI 10.1021/jm00147a028
   KUNKLER RB, 1995, BRIT J UROL, V76, P81, DOI 10.1111/j.1464-410X.1995.tb07837.x
   Kuralay F, 2000, CLIN CHIM ACTA, V300, P43, DOI 10.1016/S0009-8981(00)00302-8
   Kusser W, 2000, REV MOL BIOTECHNOL, V74, P27
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Lees JE, 1997, NUCL INSTRUM METH A, V392, P349, DOI 10.1016/S0168-9002(97)00219-2
   Lees JE, 2002, IEEE T NUCL SCI, V49, P153, DOI 10.1109/TNS.2002.998743
   Lees JE, 1999, ELECTROPHORESIS, V20, P2139, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2139::AID-ELPS2139>3.0.CO;2-R
   Lindoy L. F., 1990, CHEM MACROCYCLIC LIG
   Murray A, 2001, J NUCL MED, V42, P726
   Nicolini A, 2003, BIOMED PHARMACOTHER, V57, P452, DOI 10.1016/j.biopha.2003.09.004
   Packer LM, 2004, INT J ONCOL, V25, P1119
   Pestourie C, 2005, BIOCHIMIE, V87, P921, DOI 10.1016/j.biochi.2005.04.013
   Richman CM, 2001, CRIT REV ONCOL HEMAT, V38, P25, DOI 10.1016/S1040-8428(00)00136-0
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   Schuhmacher J, 2001, CANCER RES, V61, P3712
   SCHWARTZ MJ, 1984, AM J GASTROENTEROL, V79, P611
   Simms MS, 2001, UROL RES, V29, P13, DOI 10.1007/s002400000147
   Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040-4020(98)00015-5
   Tavitian B, 2003, GUT, V52, P40
   TOMLINSON IPM, 1995, EUR J CANCER, V31A, P899, DOI 10.1016/0959-8049(94)00447-1
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   von Mensdorff-Pouilly S, 2000, INT J BIOL MARKER, V15, P343
   ZOTTER S, 1988, Cancer Reviews, V11-12, P55
NR 44
TC 81
Z9 81
U1 1
U2 42
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL-AUG
PY 2007
VL 18
IS 4
BP 1205
EP 1212
DI 10.1021/bc0700741
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 190UI
UT WOS:000248085700024
PM 17583928
DA 2020-12-17
ER

PT J
AU Alcaro, S
   Artese, A
   Iley, JN
   Maccari, R
   Missailidis, S
   Ortuso, F
   Ottana, R
   Ragazzon, P
   Vigorita, MG
AF Alcaro, Stefano
   Artese, Anna
   Iley, James N.
   Maccari, Rosanna
   Missailidis, Sotiris
   Ortuso, Francesco
   Ottana, Rosario
   Ragazzon, Patricia
   Vigorita, Maria Gabriella
TI Tetraplex DNA specific ligands based on the fluorenone-carboxamide
   scaffold
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE fluorenone-carboxamides; DNA binding; thermal denaturation; UV
   spectroscopy; competition dialysis; fluorescence spectroscopy; molecular
   modeling
ID ANTITUMOR POLYCYCLIC ACRIDINES; TILORONE HYDROCHLORIDE;
   AROMATIC-COMPOUNDS; ANTIVIRAL AGENTS; TELOMERASE; DERIVATIVES;
   INHIBITION; BINDING; TARGET
AB A series of fluorenone-carboxamide compounds was analyzed with regard to DNA binding properties by UV spectroscopy and competition dialysis methods. The morpholino derivative 10 provided interesting results in terms of affinity and specificity toward the DNA G-tetraplex structures. Interactions against this target were evaluated by a comparative molecular modeling study in agreement with the experimental data, proposing a model for the rational design of new agents with potent and selective DNA tetraplex binding properties. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Magna Graecia Univ Catanzaro, Dipartimento Sci Farmacobiol, I-88021 Roccelletta di Borgia, CZ, Italy.
   Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Messina, Fac Farm, Dipartimento Farmacochim, I-98168 Messina, Italy.
RP Alcaro, S (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Sci Farmacobiol, Complesso Nini Barbieri, I-88021 Roccelletta di Borgia, CZ, Italy.
EM alcaro@unicz.it
OI Iley, Jim/0000-0002-2513-8159; Ragazzon, Patricia/0000-0003-0374-4569;
   ORTUSO, Francesco/0000-0001-6235-8161; ALCARO,
   Stefano/0000-0002-0437-358X
CR ALBRECHT WL, 1974, J MED CHEM, V17, P886, DOI 10.1021/jm00254a021
   Alcaro S, 2004, ARKIVOC, P334, DOI 10.3998/ark.5550190.0005.529
   Alcaro S, 2000, J COMPUT CHEM, V21, P515, DOI 10.1002/(SICI)1096-987X(200005)21:7<515::AID-JCC2>3.0.CO;2-5
   ANDREWS ER, 1974, J MED CHEM, V17, P882, DOI 10.1021/jm00254a020
   Arcamone F., 1981, DOXORUBICIN ANTICANC
   Chandra P, 1977, Top Curr Chem, V72, P125
   Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n
   Gowan SM, 2001, MOL PHARMACOL, V60, P981
   Han FXG, 1999, J AM CHEM SOC, V121, P3561, DOI 10.1021/ja984153m
   Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q
   Kelland LR, 2000, ANTI-CANCER DRUG, V11, P503, DOI 10.1097/00001813-200008000-00001
   Koeppel F, 2001, NUCLEIC ACIDS RES, V29, P1087, DOI 10.1093/nar/29.5.1087
   KRUEGER RF, 1970, SCIENCE, V169, P1213, DOI 10.1126/science.169.3951.1213
   Missailidis S, 2005, ONCOL RES, V15, P95, DOI 10.3727/096504005775082002
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547
   Neidle S, 1999, ANTI-CANCER DRUG DES, V14, P341
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q
   PLUM GE, 1995, ANNU REV BIOPH BIOM, V24, P319
   Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598
   Ren JS, 2001, METHOD ENZYMOL, V340, P99
   RIOU JF, 2000, P AM ASSOC CANC RES, V41, P4496
   SOEHNER RL, 1974, P SOC EXP BIOL MED, V145, P1114
   Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z
NR 25
TC 20
Z9 21
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2007
VL 17
IS 9
BP 2509
EP 2514
DI 10.1016/j.bmcl.2007.02.022
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 162LD
UT WOS:000246087900023
PM 17317164
DA 2020-12-17
ER

PT J
AU Strat, D
   Missailidis, S
   Drake, AF
AF Strat, Daniela
   Missailidis, Sotiris
   Drake, Alex F.
TI A novel methodological approach for the analysis of host-ligand
   interactions
SO CHEMPHYSCHEM
LA English
DT Article
DE circular dichroism; host-guest systems; linear dichroism; nucleic acids;
   mathematical model
ID DNA; SPECTROSCOPY
AB Traditional analysis of drug binding data relies upon the Scatch and formalism. These methods rely upon fitting of a linear equation providing intercept and gradient data that relate to physical properties, such as the binding constant, cooperativity coefficients and number of binding sites. However, the existence of different binding modes with different binding constants makes the implementation of these models difficult. This article describes a novel approach to the binding model of host-ligand interactions by using a derived analytical function describing the observed signal. The benefit of this method is that physically significant parameters, that is, binding constants and number of binding sites, are automatically derived by the use of a minimisation routine. This methodology was utilised to analyse the interactions between a noval antitumour agent and DNA. An optical spectroscopy study confirms that the pentacycil acridine derivative (DH208) binds to nucleic acids. Two binding modes can be identified. A stronger one that involves intercalation and a weaker one that involves oriented outer-sphere binding. In both cases the plane of the bound acridine ring is parallel to the nucleic acid bases, orthogonal to the phosphate backbone. Ultraviolet (UV) and circular dichroism (CD) data were fitting using the proposed model. The binding constants and the number of binding sites derived from the model remained consistent across the different techniques used. The different wavelengths at which the measurements were made maintained the coherence of the results.
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Dage Precis Ind Ltd, Colchester CO1 2XL, Essex, England.
   Kings Coll London, Dept Pharm, London SE1 9NN, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
CR Becker HC, 1997, J AM CHEM SOC, V119, P5798, DOI 10.1021/ja963919k
   BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030
   Bostock-Smith CE, 1999, BIOCHEMISTRY-US, V38, P6723, DOI 10.1021/bi9825807
   Eadie GS, 1942, J BIOL CHEM, V146, P85
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P431
   Hagan DJ, 1997, J CHEM SOC PERK T 1, P2739, DOI 10.1039/a702299i
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036
   MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X
   MISSAILIDIS S, 2004, METHOD MOL BIOL, V51, P547
   NORDEN B, 1982, BIOPOLYMERS, V21, P1713, DOI 10.1002/bip.360210904
   NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SCOTT RL, 1956, RECL TRAV CHIM PAY B, V75, P787, DOI 10.1002/recl.19560750711
   Wyman J., 1990, BINDING LINKAGE FUNC
NR 15
TC 6
Z9 6
U1 0
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4235
EI 1439-7641
J9 CHEMPHYSCHEM
JI ChemPhysChem
PD FEB 2
PY 2007
VL 8
IS 2
BP 270
EP 278
DI 10.1002/cphc.200600442
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 136KI
UT WOS:000244220600014
PM 17183524
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Bactyari, A
   Perkins, A
   Missailidis, S
   Iley, J
AF Da Pieve, C.
   Bactyari, A.
   Perkins, A.
   Missailidis, S.
   Iley, J.
TI Design of an anti MUC1 DNA aptamer as novel radiopharmaceutical for the
   diagnostic imaging and targeted radiotherapy of tumours
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
C1 Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD NOV
PY 2006
VL 4
IS 12
MA 211
BP 65
EP 66
DI 10.1016/S1359-6349(06)70216-6
PG 2
WC Oncology
SC Oncology
GA 114TM
UT WOS:000242688500209
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Arash, B
   Perkins, AC
   Missailidis, S
AF Da Pieve, C.
   Arash, B.
   Perkins, A. C.
   Missailidis, S.
TI DNA aptamers as novel radiopharmaceuticals for imaging and targeted
   radiotherapy of epithelial tumours
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
C1 Open Univ, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD SEP
PY 2006
VL 33
SU 2
BP S104
EP S105
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V43XI
UT WOS:000202967400110
DA 2020-12-17
ER

PT J
AU Da Pieve, C
   Iley, JN
   Perkins, A
   Missailidis, S
AF Da Pieve, C.
   Iley, J. N.
   Perkins, A.
   Missailidis, S.
TI Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy
   of breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Meeting Abstract
CT Meeting on Breast Cancer Research - The Past and the Future
CY NOV   01, 2006
CL London, ENGLAND
SP Royal Soc
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Dept Phys Med, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2006
VL 8
SU 2
BP S15
EP S16
DI 10.1186/bcr1587
PG 2
WC Oncology
SC Oncology
GA 101UQ
UT WOS:000241766700043
OA DOAJ Gold, Green Accepted
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Perkins, AC
AF Missailidis, S.
   Perkins, A. C.
TI DNA aptamers for in vivo molecular targeted imaging and therapy
SO TUMOR BIOLOGY
LA English
DT Meeting Abstract
C1 [Missailidis, S.] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   [Perkins, A. C.] Univ Nottingham Hosp, Sch Med, Nottingham NG7 2UH, England.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1010-4283
J9 TUMOR BIOL
JI Tumor Biol.
PY 2006
VL 27
SU 1
BP 22
EP 22
PG 1
WC Oncology
SC Oncology
GA V50KU
UT WOS:000203408000043
DA 2020-12-17
ER

PT J
AU Ferreira, CSM
   Matthews, CS
   Missailidis, S
AF Ferreira, C. S. M.
   Matthews, C. S.
   Missailidis, S.
TI DNA aptamers that bind to MUC1 tumour marker: Design and
   characterization of MUC1-binding single-stranded DNA aptamers
SO TUMOR BIOLOGY
LA English
DT Article
DE aptamers; enzyme-linked immunosorbent assay; fluorescent microscopy;
   MUC1; surface plasmon resonance; tumour targeting
ID IN-VITRO SELECTION; AFFINITY-CHROMATOGRAPHY; SYSTEMATIC EVOLUTION; RNA
   APTAMERS; EXPONENTIAL ENRICHMENT; MONOCLONAL-ANTIBODIES; ANTI-MUC1
   ANTIBODIES; BREAST-CANCER; PROTEIN; LIGANDS
AB Agents able to bind tightly and selectively to disease markers can greatly benefit disease diagnosis and therapy. Aptamers are functional molecules, usually DNA or RNA oligonucleotides, with the appropriate sequence and structure to form a complex with a target molecule. MUC1 is a well-known tumour marker present in a variety of malignant tumours and it has been a target of interest for many years. In this work we report the selection of DNA aptamers that bind with high affinity and selectivity to the MUC1 peptides. Combinatorial chemistry techniques based on the SELEX methodology were used for the identification of the specific aptamers. These were selected from an initial library containing a 25-base-long variable region, resulting in 4 25 random sequences of single-stranded DNA molecules, for their ability to bind to synthetic forms of MUC1. Ten rounds of in vitro selection were performed enriching for MUC1 binding. By round ten more than 90% of the pool of sequences consisted of MUC1-binding molecules. Selected aptamer families were cloned, sequenced and found to be unique, sharing no sequence consensus. The binding properties of these aptamers were quantitated by enzyme-linked immunosorbent assay and surface plasmon resonance, whereas their specificity for MUC1-expressing cancer cells has been validated using fluorescent microscopy. Aptamers offer significant advantages over existing antibody-based recognition procedures in that they offer higher binding affinity (higher retention/reduced dissociation) and specificity to the target (ability to determine variations on the protein target down to single amino acid changes), higher selectivity against mutated protein epitopes and potentially reduced immunogenicity and increased tumour penetration associated with their size. Copyright (c) 2006 S. Karger AG, Basel
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England.
RP Ferreira, CSM (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
FU Breast Cancer Now [2005MAY11] Funding Source: Medline
CR Akhtar S, 2002, BIOCHEM PHARMACOL, V63, P2187, DOI 10.1016/S0006-2952(02)00985-1
   Apostolopoulos V, 1999, VACCINE, V18, P268, DOI 10.1016/S0264-410X(99)00197-8
   Bacher JM, 1998, DRUG DISCOV TODAY, V3, P265, DOI 10.1016/S1359-6446(97)01166-5
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bianchini M, 2001, J IMMUNOL METHODS, V252, P191, DOI 10.1016/S0022-1759(01)00350-7
   Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Brokx RD, 2003, BIOCHEMISTRY-US, V42, P13817, DOI 10.1021/bi0353070
   BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
   Fujino T, 2003, J STEROID BIOCHEM, V87, P247, DOI 10.1016/j.jsbmb.2003.09.008
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   GERMAN I, 1998, ANAL CHEM, V45, P40
   Gewirtz AM, 1999, CURR OPIN MOL THER, V1, P297
   Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169
   Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439
   HELENE C, 1996, EUR J CANCER, V32, P3
   Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Jarrard JA, 1998, CANCER RES, V58, P5582
   Kawakami J, 1998, ANAL CHIM ACTA, V365, P95, DOI 10.1016/S0003-2670(97)00579-5
   Kimoto M, 2002, EUR J BIOCHEM, V269, P697, DOI 10.1046/j.0014-2956.2001.02703.x
   LAUHON CT, 1994, J AM CHEM SOC, V14, P5798
   Li JWJ, 2002, BIOCHEM BIOPH RES CO, V292, P31, DOI 10.1006/bbrc.2002.6581
   LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016
   Lupold SE, 2002, CANCER RES, V62, P4029
   MCGUCKIN MA, 1995, TUMORDIAGN THER, V16, P1
   Missailidis S, 2005, J IMMUNOL METHODS, V296, P45, DOI 10.1016/j.jim.2004.10.011
   Murray A, 1998, J PEPT RES, V52, P375
   Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Patel DJ, 1997, CURR OPIN CHEM BIOL, V1, P32, DOI 10.1016/S1367-5931(97)80106-8
   Pavski V, 2003, CURR OPIN BIOTECH, V14, P65, DOI 10.1016/S0958-1669(02)00016-2
   Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500
   Reddish MA, 1998, INT J CANCER, V76, P817, DOI 10.1002/(SICI)1097-0215(19980610)76:6<817::AID-IJC9>3.0.CO;2-0
   Romig TS, 1999, J CHROMATOGR B, V731, P275, DOI 10.1016/S0378-4347(99)00243-1
   Rye PD, 2001, TUMOR BIOL, V22, P269, DOI 10.1159/000050626
   Smith RG, 2002, J CHROMATOGR B, V766, P13, DOI 10.1016/S0378-4347(01)00422-4
   Spencer DIR, 1999, BIOSPECTROSCOPY, V5, P79, DOI 10.1002/(SICI)1520-6343(1999)5:2<79::AID-BSPY2>3.0.CO;2-#
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uhrbom L, 2000, INT J CANCER, V85, P398, DOI 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L
   Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Xu W, 1996, P NATL ACAD SCI USA, V93, P7475, DOI 10.1073/pnas.93.15.7475
NR 50
TC 244
Z9 252
U1 12
U2 173
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PY 2006
VL 27
IS 6
BP 289
EP 301
DI 10.1159/000096085
PG 13
WC Oncology
SC Oncology
GA 101FU
UT WOS:000241725800002
PM 17033199
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Thomaidou, D
   Borbas, KE
   Price, MR
AF Missailidis, S
   Thomaidou, D
   Borbas, KE
   Price, MR
TI Selection of aptamers with high affinity and high specificity against
   C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE aptamers; anti-idiotypic targeting; SELEX; antibodies; C595;
   fluorescence; FRET
ID B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; IDIOTYPE VACCINES; VARIABLE
   REGIONS; IMMUNE-RESPONSES; DENDRITIC CELLS; MUC1 MUCIN; VACCINATION;
   BINDING; IMMUNOTHERAPY
AB Targeting of antibodies has found a number of applications in assays, anti-idiotypic therapies and vaccine design with a number of anti-idiotypic Abs generated and used in clinical applications, and some currently in clinical trials. Meanwhile., aptamers are a novel and particularly interesting targeting modality, with a unique ability to bind to a variety of targets. Aptamers offer unique benefits compared to other targeting agents, due to their high affinity and selectivity, relatively small size and in vitro synthesis, making them attractive alternatives to Abs and peptides. Aptamers have already been selected against a number of Abs for various applications. We now present a novel methodology for the selection of aptamers against Abs, which minimises the number of steps used and results in molecules that bind to the target Ab with high affinity and specificity. We have used the well-characterised anti-MUC1 monoclonal Ab C595 as an exemplar for raising aptamers against Abs. The methodology is based on the adsorption of the Ab to the surface of a PCR tube and the performance of SELEX selections in the PCR tube, based on elution steps resulting from the denaturation of the Ab on the first PCR amplification cycle. After 10 rounds of selection and amplification, selected aptamers have been characterised using a number of techniques, including fluorescence quenching, ELISA and competition ELISA procedures and a FRET type assay. Aptamers were found to bind their target Ab with a higher affinity than its natural antigenic peptide, as observed in fluorescent quenching and FRET experiments. Furthermore, they were able to displace the antigens from the antibody binding pocket in competition assays. This methodology offers the possibility of rapidly selecting aptamers for antibody targeting that could be used as diagnostic, imaging or therapeutic agents, or as recognition units in immunoassays, and can be potentially useful in raising aptamers against other protein targets. (C) 2004 Elsevier B.V. All rights reserved.
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
CR Bacher JM, 1998, DRUG DISCOV TODAY, V3, P265, DOI 10.1016/S1359-6446(97)01166-5
   Bianchi A, 1997, MOL MED TODAY, V3, P435, DOI 10.1016/S1357-4310(97)89745-6
   Bohlen H, 1996, CYTOKINES MOL THER, V2, P231
   Caspar CB, 1997, BLOOD, V90, P3699, DOI 10.1182/blood.V90.9.3699
   Ciesiolka J, 1996, METHOD ENZYMOL, V267, P315
   Connolly L, 2002, J IMMUNOL METHODS, V264, P45, DOI 10.1016/S0022-1759(02)00040-6
   Conrad RC, 1996, METHOD ENZYMOL, V267, P336
   Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190
   De Jonge J, 1998, J IMMUNOL, V161, P1454
   Deitiker P, 2000, HUM IMMUNOL, V61, P255, DOI 10.1016/S0198-8859(99)00117-2
   DeJonge J, 1997, CANCER IMMUNOL IMMUN, V45, P162, DOI 10.1007/s002620050423
   DeNardo SJ, 1998, CANCER BIOTHER RADIO, V13, P1, DOI 10.1089/cbr.1998.13.1
   Haimovich J, 1999, CANCER IMMUNOL IMMUN, V47, P330, DOI 10.1007/s002620050538
   Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169
   Hansen HJ, 1996, BIOCHEM J, V320, P293, DOI 10.1042/bj3200293
   Hefty PS, 1999, INFECT DIS CLIN N AM, V13, P27, DOI 10.1016/S0891-5520(05)70041-6
   Hesselberth J, 2000, J Biotechnol, V74, P15, DOI 10.1016/S1389-0352(99)00005-7
   Hilger CS, 1998, TETRAHEDRON LETT, V39, P9403, DOI 10.1016/S0040-4039(98)02193-5
   Honeychurch J, 1997, CANCER IMMUNOL IMMUN, V45, P171, DOI 10.1007/s002620050425
   Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129
   Hwang B, 2002, BIOCHEM BIOPH RES CO, V290, P656, DOI 10.1006/bbrc.2001.6252
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Kohler S, 1998, GEBURTSH FRAUENHEILK, V58, P180, DOI 10.1055/s-2007-1022146
   Kumar N, 2004, BIOCHEM BIOPH RES CO, V319, P759, DOI 10.1016/j.bbrc.2004.05.052
   Link BK, 1998, LEUKEMIA LYMPHOMA, V31, P237, DOI 10.3109/10428199809059217
   Liu SJ, 1998, BLOOD, V92, P2103, DOI 10.1182/blood.V92.6.2103.418a01_2103_2112
   MACAYA RF, 1995, BIOCHEMISTRY-US, V34, P4478, DOI 10.1021/bi00013a041
   Maloney DG, 1998, ONCOLOGY-NY, V12, P63
   Marshall KA, 1997, STRUCTURE, V5, P729, DOI 10.1016/S0969-2126(97)00227-X
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Murray A, 1998, J PEPT RES, V52, P375
   Murray A, 2002, J CHROMATOGR SCI, V40, P343, DOI 10.1093/chromsci/40.6.343
   OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922
   Okada CY, 1997, J IMMUNOL, V159, P5516
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Penichet ML, 1998, J INTERF CYTOK RES, V18, P597, DOI 10.1089/jir.1998.18.597
   PRICE MR, 1990, BRIT J CANCER, V61, P681, DOI 10.1038/bjc.1990.154
   Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500
   PRICE MR, 1991, J IMMUNOL METHODS, V139, P83, DOI 10.1016/0022-1759(91)90354-I
   Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419
   Reinartz S, 1999, HYBRIDOMA, V18, P41, DOI 10.1089/hyb.1999.18.41
   Schultze JL, 1997, HEMATOL ONCOL, V15, P129, DOI 10.1002/(SICI)1099-1069(199708)15:3<129::AID-HON607>3.0.CO;2-N
   Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d
   Smith RG, 2002, J CHROMATOGR B, V766, P13, DOI 10.1016/S0378-4347(01)00422-4
   Spencer DIR, 1999, BIOSPECTROSCOPY, V5, P79, DOI 10.1002/(SICI)1520-6343(1999)5:2<79::AID-BSPY2>3.0.CO;2-#
   Terness P, 1997, HUM IMMUNOL, V56, P17, DOI 10.1016/S0198-8859(97)00145-6
   Thurin M, 2002, HYBRIDOMA HYBRIDOM, V21, P111, DOI 10.1089/153685902317401708
   Tseng YL, 1999, INT J CANCER, V80, P723, DOI 10.1002/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   Wurflein D, 1998, CANCER RES, V58, P3051
   ZUKER M, 1999, NATO ASI SERIES
NR 53
TC 27
Z9 30
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JAN
PY 2005
VL 296
IS 1-2
BP 45
EP 62
DI 10.1016/j.jim.2004.10.011
PG 18
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 898ZW
UT WOS:000227115700006
PM 15680150
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Modi, C
   Trapani, V
   Laughton, CA
   Stevens, MFG
AF Missailidis, S
   Modi, C
   Trapani, V
   Laughton, CA
   Stevens, MFG
TI Antitumor polycyclic acridines. Part 16. Triplex DNA as a target for
   DNA-binding polycyclic acridine derivatives
SO ONCOLOGY RESEARCH
LA English
DT Article
DE polycyclic acridine derivatives; DNA binding; triplex DNA;
   spectrophotometric analysis; UV; fluorescence; circular dichroism;
   thermal denaturation
ID GRAEBE-ULLMANN THERMOLYSIS; HELIX FORMATION; PENTACYCLIC ACRIDINES;
   BIOLOGICAL-PROPERTIES; SEQUENCE SPECIFICITY; INTERCALATING AGENTS;
   CIRCULAR-DICHROISM; PROMOTER REGION; OLIGONUCLEOTIDES; INHIBITION
AB Triple-stranded DNA structures have been implicated in a number of major biological processes, including the transcription and translation of a number of genes, as well as in the interaction of DNA with a number of proteins. Furthermore, antigene therapies under development are based on the recognition and binding of a single oligonucleotide strand to a double-stranded sequence, thus forming a triple helix. Triplex DNA formation is a relatively weak and temporary phenomenon; therefore, molecules that selectively bind to and stabilize triple helices may show a variety of novel biological effects. The biophysical and biological characterization of a series of antitumor polycyclic acridines that bind to triplex DNA is reported. These compounds, whose synthesis has been previously reported, have been tested for their interaction with both purine and pyrimidine type triple helices and compared with the relevant double-stranded DNA. As a pyrimidine triplex model we have used the T*AT sequence, which we have compared with the AT duplex, whereas the purine triplex oligonucleotide d[G(3)A(4)G(3)]*d[G(3)A(4)G(3)].d[C3T4C3] has been compared with the duplex d[G(3)A(4)G(3)].d[C3T4C3]. The compounds demonstrate various degrees of preferential binding to triplex DNA over normal duplex DNA, as measured by UV, fluorescence, circular dichroism, and thermal denaturation. Tri-substituted acridine derivatives demonstrated the highest affinity and ability to stabilize triplex DNA structures. Furthermore, structure/affinity analysis gives insights into the structural features that optimize affinity and selectivity for triplex DNA, and may play a role in their profile of antitumor activity.
C1 Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
   Univ Nottingham, Sch Pharm, Canc Res UK Expt Canc Chemotherapy Res Grp, Ctr Biomol Sci, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
EM s.missailidis@open.ac.uk
RI Laughton, Charles A/E-5667-2010
OI Laughton, Charles A/0000-0003-4090-3960; Trapani,
   Valentina/0000-0002-0259-6624
CR ALBERT A, 1966, ACRIDINES
   ARLIN ZA, 1989, CANCER INVEST, V7, P607, DOI 10.3109/07357908909017537
   BAILLY C, 1992, BIOCHEMISTRY-US, V31, P3514, DOI 10.1021/bi00128a028
   BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689
   BLUME SW, 1992, NUCLEIC ACIDS RES, V20, P1777
   Bostock-Smith CE, 1999, BIOCHEMISTRY-US, V38, P6723, DOI 10.1021/bi9825807
   Brown PM, 1996, BIOCHEM J, V314, P427, DOI 10.1042/bj3140427
   Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P2396, DOI 10.1093/nar/gkh527
   Cassidy SA, 1996, NUCLEIC ACIDS RES, V24, P4133, DOI 10.1093/nar/24.21.4133
   CASSIDY SA, 1994, BIOCHEMISTRY-US, V33, P15338, DOI 10.1021/bi00255a015
   CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005
   CHANDLER SP, 1995, BIOCHEMISTRY-US, V34, P7234, DOI 10.1021/bi00021a039
   COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213
   DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406
   DENNY WA, 1992, SEARCH NEW ANTICANCE, P19
   DENNY WA, 1994, MOL ASPECTS ANTICANC, P270
   DOUGHERTY G, 1984, INT J BIOCHEM, V16, P1179, DOI 10.1016/0020-711X(84)90215-5
   DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017
   Escude C, 1996, BIOCHEMISTRY-US, V35, P5735, DOI 10.1021/bi960120c
   FOX KR, 1995, FEBS LETT, V357, P312, DOI 10.1016/0014-5793(94)01387-G
   FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011
   FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433
   GEE JE, 1994, GENE, V149, P109, DOI 10.1016/0378-1119(94)90418-9
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P431
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P125
   Gondeau C, 1998, NUCLEIC ACIDS RES, V26, P4996, DOI 10.1093/nar/26.21.4996
   Gowan SM, 2001, MOL PHARMACOL, V60, P981
   Hagan DJ, 1997, J CHEM SOC PERK T 1, P2739, DOI 10.1039/a702299i
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   HARVEY VJ, 1991, EUR J CANCER, V27, P1617, DOI 10.1016/0277-5379(91)90427-F
   Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q
   JONES GB, 1990, ANTI-CANCER DRUG DES, V5, P249
   Julino M, 1998, J CHEM SOC PERK T 1, P1677, DOI 10.1039/a800575c
   Keppler MD, 2001, NUCLEIC ACIDS RES, V29, P1935, DOI 10.1093/nar/29.9.1935
   LATIMER LJP, 1995, BIOCHEM CELL BIOL, V73, P11, DOI 10.1139/o95-002
   MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631
   MAYFIELD C, 1994, J BIOL CHEM, V269, P18232
   MCDONALD LA, 1994, J MED CHEM, V37, P3819, DOI 10.1021/jm00048a017
   MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681
   Missailidis S, 2002, ONCOL RES, V13, P175
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435
   PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001
   PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   PLUM GE, 1995, ANNU REV BIOPH BIOM, V24, P319
   POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227
   Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598
   Ren JS, 2000, J AM CHEM SOC, V122, P424, DOI 10.1021/ja9934955
   Silver GC, 1997, BIOCONJUGATE CHEM, V8, P15, DOI 10.1021/bc9600675
   Stanslas J, 2000, J MED CHEM, V43, P1563, DOI 10.1021/jm9909490
   SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198
   Turner C, 2003, CELL DEATH DIFFER, V10, P302, DOI 10.1038/sj.cdd.4401170
   Willard HH, 1988, INSTRUMENTAL METHODS
   WILSON WD, 1990, NUCLEIC ACIDS CHEM B, P297
NR 55
TC 7
Z9 7
U1 0
U2 1
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2005
VL 15
IS 2
BP 95
EP 105
DI 10.3727/096504005775082002
PG 11
WC Oncology
SC Oncology
GA 932CN
UT WOS:000229531900005
PM 16119007
DA 2020-12-17
ER

PT J
AU Murray, A
   Missailidis, S
   Price, MR
AF Murray, A
   Missailidis, S
   Price, MR
TI Epitope affinity chromatography and biophysical studies of monoclonal
   antibodies and recombinant antibody fragments
SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
LA English
DT Article
ID BLADDER-CANCER; MUCIN; C595; PURIFICATION; CORE
C1 Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Neurosci Res Grp, Nottingham NG7 2UH, England.
   Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
   Open Univ, Chem Dept, Milton Keynes MK7 6AA, Bucks, England.
RP Murray, A (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Neurosci Res Grp, Nottingham NG7 2UH, England.
CR BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423
   Denton G, 1999, CANCER IMMUNOL IMMUN, V48, P29, DOI 10.1007/s002620050545
   Hughes ODM, 2000, J CLIN ONCOL, V18, P363, DOI 10.1200/JCO.2000.18.2.363
   KUNKLER RB, 1995, BRIT J UROL, V76, P81, DOI 10.1111/j.1464-410X.1995.tb07837.x
   LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6
   MATHER SJ, 1990, J NUCL MED, V31, P692
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Murray A, 1998, J PEPT RES, V52, P375
   Murray A, 1997, J CHROMATOGR A, V782, P49, DOI 10.1016/S0021-9673(97)00674-2
   PERKINS AC, 1993, NUCL MED COMMUN, V14, P578, DOI 10.1097/00006231-199307000-00011
   PRICE MR, 1990, BRIT J CANCER, V61, P681, DOI 10.1038/bjc.1990.154
   Price PW, 1991, BIOL CONTROL, V1, P83, DOI 10.1016/1049-9644(91)90107-B
   SAMBROOK J, 1989, MOL DLONING LAB MANU
   Spencer DIR, 1999, BIOSPECTROSCOPY, V5, P79, DOI 10.1002/(SICI)1520-6343(1999)5:2<79::AID-BSPY2>3.0.CO;2-#
NR 14
TC 3
Z9 3
U1 0
U2 1
PU PRESTON PUBLICATIONS INC
PI NILES
PA 7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA
SN 0021-9665
J9 J CHROMATOGR SCI
JI J. Chromatogr. Sci.
PD JUL
PY 2002
VL 40
IS 6
BP 343
EP 349
DI 10.1093/chromsci/40.6.343
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 573EF
UT WOS:000176815800007
PM 12137207
OA Bronze
DA 2020-12-17
ER

PT J
AU Smith, RG
   Missailidis, S
   Price, MR
AF Smith, RG
   Missailidis, S
   Price, MR
TI Purification of anti-MUC1 antibodies by peptide mimotope affinity
   chromatography using peptides derived from a polyvalent phage display
   library
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE affinity purification; polyvalent phage display library; anti-MUC1
   antibodies; peptides
ID MONOCLONAL-ANTIBODY; BLADDER-CANCER; PROTEIN CORE; MUC1 MUCIN; EPITOPE;
   RECOGNITION; LIGANDS; DOMAINS; C595
AB A polyvalent, lytic phage display system (T7Select415-lb) displaying a random peptide library has been investigated for its ability to discover novel mimotopes reactive with the therapeutic monoclonal antibody C595. Sequence analysis of enriched phage lead to the identification of a predominant sequence RNREAPRGKICS, and two other consensus sequences RXXP and RXP. The novel synthetic peptide RNREAPRGKICS was linked to beaded agarose and the performance as a mimotope affinity chromatography matrix evaluated. Antibody purified using the novel matrix was found to be of higher specific reactivity than antibody purified using the conventional epitope matrix (peptide APDTRPAPG). The RNREAPRGKICS peptide binding to C595 demonstrated a higher equilibrium association constant (K-A=0.75 x 10(6)) than the epitope peptide (K-A=0.16 x 10(6)). Circular dichroism showed that the novel peptide had a more highly ordered structure at 4 degreesC and room temperature, than the epitope peptide. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
   Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England.
RP Smith, RG (corresponding author), Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
EM rgsmith@dstl.gov.uk
RI Smith, Richard/B-2194-2009
CR BADLEY RA, 1999, Patent No. 005989926
   BAILON P, 2000, METHODS MOL BIOL AFF, P209
   BAUMBACH GA, 1992, BIOPHARM         MAY, P24
   BRIGGS S, 1993, EUR J CANCER, V29A, P230, DOI 10.1016/0959-8049(93)90181-E
   CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531
   Dalcol I, 1996, J ORG CHEM, V61, P6775, DOI 10.1021/jo960987g
   de Haard H, 1998, ADV DRUG DELIVER REV, V31, P5, DOI 10.1016/S0169-409X(97)00091-4
   DeNardo SJ, 1999, CURR OPIN IMMUNOL, V11, P563, DOI 10.1016/S0952-7915(99)00017-5
   Denton G, 1997, BRIT J CANCER, V76, P614, DOI 10.1038/bjc.1997.434
   FERREIRA MU, 1995, J IMMUNOL METHODS, V187, P297, DOI 10.1016/0022-1759(95)00186-4
   GENDLER S, 1988, J BIOL CHEM, V263, P12820
   Hammond DJ, 1998, CHROMATOGRAPHIA, V47, P475, DOI 10.1007/BF02466484
   Hudson PJ, 1999, CURR OPIN IMMUNOL, V11, P548, DOI 10.1016/S0952-7915(99)00013-8
   Hughes ODM, 2000, J CLIN ONCOL, V18, P363, DOI 10.1200/JCO.2000.18.2.363
   Hughes ODM, 2001, BJU INT, V87, P39, DOI 10.1046/j.1464-410x.2001.00985.x
   Kay Brian K., 1996, P21, DOI 10.1016/B978-012402380-2/50004-6
   MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2
   MCCONNELL SJ, 1994, GENE, V151, P115, DOI 10.1016/0378-1119(94)90640-8
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Murray A, 1998, J PEPT RES, V52, P375
   Murray A, 1997, J CHROMATOGR A, V782, P49, DOI 10.1016/S0021-9673(97)00674-2
   Murray A, 2001, ANAL BIOCHEM, V296, P9, DOI 10.1006/abio.2001.5235
   Murray A, 2001, J NUCL MED, V42, P726
   Narhi LO, 1997, ANAL BIOCHEM, V253, P246, DOI 10.1006/abio.1997.2376
   PRICE MR, 1990, BRIT J CANCER, V61, P681, DOI 10.1038/bjc.1990.154
   PRICE MR, 1990, MOL IMMUNOL, V27, P795, DOI 10.1016/0161-5890(90)90089-I
   PRICE MR, 1991, J IMMUNOL METHODS, V139, P83, DOI 10.1016/0022-1759(91)90354-I
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   Rosenbrock H, 1996, J PROCESS CONTR, V6, P1, DOI 10.1016/0959-1524(96)81787-2
   Sambrook J., 1989, MOL CLONING LAB MANU
   SILIGARDI G, 1995, BIOPOLYMERS, V37, P281, DOI 10.1002/bip.360370406
   Simms MS, 1999, BJU INT, V84, P350
   Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540
   Spencer DIR, 1999, BIOSPECTROSCOPY, V5, P79, DOI 10.1002/(SICI)1520-6343(1999)5:2<79::AID-BSPY2>3.0.CO;2-#
NR 34
TC 16
Z9 16
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD JAN 5
PY 2002
VL 766
IS 1
BP 13
EP 26
DI 10.1016/S0378-4347(01)00422-4
PG 14
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 508NC
UT WOS:000173094500003
PM 11820288
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Stanslas, J
   Modi, C
   Ellis, MJ
   Robins, RA
   Laughton, CA
   Stevens, MFG
AF Missailidis, S
   Stanslas, J
   Modi, C
   Ellis, MJ
   Robins, RA
   Laughton, CA
   Stevens, MFG
TI Antitumor polycyclic acridines. part 12. Physical and biological
   properties of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: A
   lead compound in anticancer drug design
SO ONCOLOGY RESEARCH
LA English
DT Article
DE polycyclic acridine derivatives; DNA binding; spectrophotometric
   analysis; UV; fluorescence; circular dichroism
ID TRIPLE-HELIX FORMATION; TOPOISOMERASE-II INHIBITORS; LIGAND-DNA SYSTEMS;
   ANTI-TUMOR AGENTS; CANCER CELL-LINES; CIRCULAR-DICHROISM; BINDING
   LIGAND; PENTACYCLIC ACRIDINES; TELOMERASE INHIBITORS; INTERCALATING
   AGENTS
AB The biophysical and biological characterization of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide (6) is reported. The compound binds to DNA, as measured by UV, fluorescence, and circular dichroism studies, and stabilizes the double helix and higher order DNA structures (DNA triplexes and quadruplexes) against thermal denaturation. Unlike many DNA ligands, (6) shows no specificity for binding to specific base pair combinations and does not inhibit topoisomerase I (topo 1) or topo II activity. Furthermore, the biological fingerprint elicited by (6) in in vitro evaluations does not compare with clinical agents of the topo H inhibition class. The compound provokes cell cycle arrest in response to DNA damage and the biological sequelae are dependent on the p53 status of the cell line. DNA damage by (6) upregulates p53 and p2l(CIP/) WAR proteins. The unusual structure of (6) and its ease of synthesis in a "one-pot" reaction are features that are being exploited in the design and development of a new series of G-quadruplex stabilizing telomerase inhibitors. However, although the second-generation compounds that resulted from (6) present strong telomerase inhibition, (6) in itself presents yet a different mode of action, with a strong preference for triplex DNA, sequences often found in a number of genes.
C1 Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
   Univ Nottingham, Sch Clin Lab Sci, Div Immunol, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Open Univ, Dept Chem, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.
RI Robins, Richard Adrian/A-2234-2009; Laughton, Charles A/E-5667-2010;
   Stanslas, Johnson/E-8266-2011
OI Laughton, Charles A/0000-0003-4090-3960; Stanslas,
   Johnson/0000-0002-6938-954X
CR ALBERT A, 1966, ACRIDINES
   ARLIN ZA, 1989, CANCER INVEST, V7, P607, DOI 10.3109/07357908909017537
   BAGULEY BC, 1981, J MED CHEM, V24, P170, DOI 10.1021/jm00134a009
   BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507
   BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689
   Bostock-Smith CE, 1999, BIOCHEMISTRY-US, V38, P6723, DOI 10.1021/bi9825807
   BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   Brown PM, 1996, BIOCHEM J, V314, P427, DOI 10.1042/bj3140427
   Cassidy SA, 1996, NUCLEIC ACIDS RES, V24, P4133, DOI 10.1093/nar/24.21.4133
   CASSIDY SA, 1994, BIOCHEMISTRY-US, V33, P15338, DOI 10.1021/bi00255a015
   CHANDLER SP, 1995, BIOCHEMISTRY-US, V34, P7234, DOI 10.1021/bi00021a039
   CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157
   COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213
   DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406
   DENNY WA, 1983, J MED CHEM, V26, P1625, DOI 10.1021/jm00365a014
   DENNY WA, 1992, SEARCH NEW ANTICANCE, P19
   DENNY WA, 1994, MOL ASPECTS ANTICANC, P270
   DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42
   Finlay GJ, 1996, EUR J CANCER, V32A, P708, DOI 10.1016/0959-8049(95)00604-4
   FOX KR, 1995, FEBS LETT, V357, P312, DOI 10.1016/0014-5793(94)01387-G
   FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011
   FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P431
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P125
   Gowan SM, 2001, MOL PHARMACOL, V60, P981
   HACHIYA M, 1994, ANTICANCER RES, V14, P1853
   Hagan DJ, 1997, J CHEM SOC PERK T 1, P2739, DOI 10.1039/a702299i
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   Hahn WC, 1999, NAT MED, V5, P1164
   HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305
   HARVEY VJ, 1991, EUR J CANCER, V27, P1617, DOI 10.1016/0277-5379(91)90427-F
   Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q
   HERNANDEZ L, 1995, CANCER RES, V55, P2338
   Houlbrook S, 1996, ANTICANCER RES, V16, P1603
   HOULBROOK S, 1995, BRIT J CANCER, V72, P1454, DOI 10.1038/bjc.1995.529
   JONES GB, 1990, ANTI-CANCER DRUG DES, V5, P249
   Julino M, 1998, J CHEM SOC PERK T 1, P1677, DOI 10.1039/a800575c
   Kelland LR, 2000, ANTI-CANCER DRUG, V11, P503, DOI 10.1097/00001813-200008000-00001
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kohn KW, 1996, CANCER RES, V56, P5533
   LATIMER LJP, 1995, BIOCHEM CELL BIOL, V73, P11, DOI 10.1139/o95-002
   LYNG R, 1992, BIOPOLYMERS, V32, P1201, DOI 10.1002/bip.360320910
   LYNG R, 1991, BIOPOLYMERS, V31, P1709
   MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631
   MCDONALD LA, 1994, J MED CHEM, V37, P3819, DOI 10.1021/jm00048a017
   MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681
   MEZCES LM, 1997, CANCER CHEMOTH PHARM, V39, P367
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   Neidle S, 1999, ANTI-CANCER DRUG DES, V14, P341
   NORDEN B, 1982, BIOPOLYMERS, V21, P1713, DOI 10.1002/bip.360210904
   NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728
   OSZCZAPOWICZ J, 1988, TETRAHEDRON, V44, P6645, DOI 10.1016/S0040-4020(01)90102-4
   Piche A, 1998, CANCER RES, V58, P2134
   Pitts AE, 1999, DRUG DISCOV TODAY, V4, P155, DOI 10.1016/S1359-6446(99)01322-7
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   PLUM GE, 1995, ANNU REV BIOPH BIOM, V24, P319
   Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598
   Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s
   SAKURA C, 1996, INT J CANCER, V67, P101
   SCHIPPER PE, 1979, CHEM PHYS LETT, V67, P99, DOI 10.1016/0009-2614(79)87114-6
   Silver GC, 1997, BIOCONJUGATE CHEM, V8, P15, DOI 10.1021/bc9600675
   Stanslas J, 2000, J MED CHEM, V43, P1563, DOI 10.1021/jm9909490
   SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198
   TEIXEIRA C, 1995, CANCER RES, V55, P3902
   TURNER C, 2001, THESIS U NOTTINGHAM
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343
   WILSON WR, 1981, MOL PHARMACOL, V20, P404
   WIRTH M, 1988, J AM CHEM SOC, V110, P932, DOI 10.1021/ja00211a038
NR 69
TC 20
Z9 20
U1 1
U2 6
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0965-0407
J9 ONCOL RES
JI Oncol. Res.
PY 2002
VL 13
IS 3
BP 175
EP 189
PG 15
WC Oncology
SC Oncology
GA 634AA
UT WOS:000180316600006
PM 12549627
DA 2020-12-17
ER

PT J
AU Arrowsmith, J
   Missailidis, S
   Stevens, MFG
AF Arrowsmith, J
   Missailidis, S
   Stevens, MFG
TI Antitumour imidazotetrazines. Part 37. Conjugation of the DNA
   major-groove alkylating imidazotetrazine mitozolomide to peptide motifs
   recognizing the minor groove
SO ANTI-CANCER DRUG DESIGN
LA English
DT Article
DE antitumour imidazotetrazines; circular dichroism; fluorescence
   quenching; SPKK motif; Taq polymerase; thermal denaturation
ID ACID-BINDING UNIT; PHASE-I TRIAL; DRUG TEMOZOLOMIDE;
   BIOLOGICAL-ACTIVITY; AGENTS; SPKK; DISTAMYCIN; ALKYLTRANSFERASE;
   SEQUENCES; BASE
AB Methods have been developed to conjugate the antitumour imidazotetrazines mitozolomide and temozolomide to DNA minor and major groove-binding peptidic motifs by solid phase peptide synthesis. Side chain deprotection and resin cleavage steps were accomplished under acidic conditions to maintain the structural integrity of the imidazotetrazine nucleus. When mitozolomide was conjugated to the DNA minor groove-binding peptide (SPKK)(2)-NH2 (3) a strong preference for binding with [dA-dT](2) sequences was observed by circular dichroism studies, consistent with the construct making non-covalent interactions within the minor groove. This conjugate showed a >100-fold DNA alkylating activity compared with the free imidazotetrazine as measured by a Taq polymerase assay. Unexpectedly, alkylation patterns of all conjugates were nearly identical to those elicited by the major groove interactive agents cisplatin and the unconjugated imidazotetrazines temozolomide and mitozolomide, indicating that covalent modification was restricted to guanine sites in the major groove of DNA irrespective of the targeting property of the peptidic ligand. The electrophilic reactive chloroethyldiazonium ion intermediate formed in the breakdown of the imidazotetrazine ring of mitozolomide (methyldiazonium ion from temozolomide) must be liberated from the DNA-bound conjugate prior to the alkylation event, and must diffuse to and react with more nucleophilic sites in the major groove.
C1 Univ Nottingham, Canc Res Labs, Sch Pharmaceut Sci, Nottingham NG7 2RD, England.
RP Stevens, MFG (corresponding author), Univ Nottingham, Canc Res Labs, Sch Pharmaceut Sci, Univ Pk, Nottingham NG7 2RD, England.
CR ARROWSMITH J, 1997, THESIS U NOTTINGHAM
   BAGULEY BC, 1981, J MED CHEM, V24, P170, DOI 10.1021/jm00134a009
   BAILLY F, 1992, BIOCHEM BIOPH RES CO, V184, P930, DOI 10.1016/0006-291X(92)90680-J
   BAILLY F, 1993, FEBS LETT, V324, P181, DOI 10.1016/0014-5793(93)81389-H
   BAILLY F, 1992, ANTI-CANCER DRUG DES, V7, P83
   BRENNAN RG, 1989, J BIOL CHEM, V264, P1903
   Brock CS, 1998, CANCER RES, V58, P4363
   BROGGINI M, 1995, NUCLEIC ACIDS RES, V23, P81, DOI 10.1093/nar/23.1.81
   CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077
   CLARK AS, 1995, J MED CHEM, V38, P1493, DOI 10.1021/jm00009a010
   DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045, DOI 10.1021/bi00197a003
   FRIEDMAN HS, 1995, CANCER RES, V55, P2853
   GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043
   HARTLEY JA, 1992, NUCLEIC ACIDS RES, V20, P3175, DOI 10.1093/nar/20.12.3175
   HORSPOOL KR, 1990, J MED CHEM, V33, P1393, DOI 10.1021/jm00167a018
   KAFUKU Y, 1993, CHEM PHARM BULL, V41, P231
   LEE M, 1993, J MED CHEM, V36, P863, DOI 10.1021/jm00059a011
   Liu LL, 1996, CANCER RES, V56, P5375
   MCCONNAUGHIE AW, 1995, J MED CHEM, V38, P3488, DOI 10.1021/jm00018a009
   MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547
   Newlands ES, 1996, EUR J CANCER, V32A, P2236, DOI 10.1016/S0959-8049(96)00258-4
   NEWLANDS ES, 1992, BRIT J CANCER, V65, P287, DOI 10.1038/bjc.1992.57
   NEWLANDS ES, 1985, CANCER TREAT REP, V69, P801
   PONTI M, 1991, NUCLEIC ACIDS RES, V19, P2929, DOI 10.1093/nar/19.11.2929
   STEVENS MFG, 1984, J MED CHEM, V27, P196, DOI 10.1021/jm00368a016
   SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x
   TAKEUCHI H, 1995, BIOPOLYMERS, V35, P359, DOI 10.1002/bip.360350403
   Wang YF, 1997, J ORG CHEM, V62, P7288, DOI 10.1021/jo970802l
   Wang YF, 1998, J CHEM SOC PERK T 1, P1669, DOI 10.1039/a800572i
   Wedge SR, 1996, BRIT J CANCER, V73, P1049, DOI 10.1038/bjc.1996.203
   WYATT MD, 1994, ANTI-CANCER DRUG DES, V9, P511
NR 31
TC 6
Z9 6
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0266-9536
J9 ANTI-CANCER DRUG DES
JI Anti-Cancer Drug Des.
PD JUN
PY 1999
VL 14
IS 3
BP 205
EP 217
PG 13
WC Biochemistry & Molecular Biology; Oncology; Chemistry, Medicinal;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy
GA 240KZ
UT WOS:000082826300003
PM 10500496
DA 2020-12-17
ER

PT J
AU Bostock-Smith, CE
   Gimenez-Arnau, E
   Missailidis, S
   Laughton, CA
   Stevens, MFG
   Searle, MS
AF Bostock-Smith, CE
   Gimenez-Arnau, E
   Missailidis, S
   Laughton, CA
   Stevens, MFG
   Searle, MS
TI Molecular recognition between a new pentacyclic acridinium salt and DNA
   sequences investigated by optical spectroscopic techniques, proton
   nuclear magnetic resonance spectroscopy, and molecular modeling
SO BIOCHEMISTRY
LA English
DT Article
ID ANTITUMOR POLYCYCLIC ACRIDINES; TOPOISOMERASE-II INHIBITORS;
   DEOXYRIBONUCLEIC-ACID; BIOLOGICAL-ACTIVITY; BINDING; DERIVATIVES;
   DYNAMICS; INTERCALATION; AGENTS; ANALOG
AB A pentacyclic acridine, 1H-2,3-dihydroindolizino[7,6,5-kl]acridinium chloride (1), related in structure to tetra- and pentacyclic marine natural products, has previously been shown to induce apoptosis in breast and non-small-cell lung tumor cell lines and shows significant differences in biological potency and antitumor profile from other intercalating agents based on the acridine framework. We report on the molecular recognition of the acridinium salt with DNA, quantified by optical spectroscopic methods, and have compared these results with the clinical agent amsacrine (m-AMSA). The results point to an intercalative association between 1 and G-C-rich sequences of DNA. We have synthesized a hexamer duplex d(ACGCGT)(2), presenting two potential 5'-GpG recipient sites, and have investigated in detail by NMR and molecular modeling methods the orientational preferences of 1, particularly with regard to the pyrrolidine ring system. On the basis of the intermolecular nuclear Overhauser effect (NOE) data, four possible intercalation models were considered; no single model produced a significantly better fit than any of the others. The best fit to the experimental data was obtained by considering a dynamic equilibrium between the different intercalated orientations with the drug maximizing ct-overlap with the G-C base pairs at the intercalation site. We found little evidence for any degree of groove specificity imparted by the pyrrolidine ring. If these simulations have biological relevance they suggest that, at most, the agent induces only a transitory hot spot in the DNA which, evidently, is sufficient to be sensed by damage-recognition mechanisms of the cell.
C1 Univ Nottingham, Sch Pharmaceut Sci, Dept Chem, Nottingham NG7 2RD, England.
   Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
RP Stevens, MFG (corresponding author), Univ Nottingham, Sch Pharmaceut Sci, Dept Chem, Nottingham NG7 2RD, England.
EM malcolm.stevens@nottingham.ac.uk; mark.searle@nottingham.ac.uk
RI Laughton, Charles A/E-5667-2010
OI Laughton, Charles A/0000-0003-4090-3960; Wilkes,
   Clare/0000-0002-9423-0987; Searle, Mark/0000-0001-8387-9978
CR ALBERT A, 1966, ACRIDINES
   ARMSTRONG RW, 1970, J AM CHEM SOC, V92, P3174, DOI 10.1021/ja00713a041
   BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1
   BAILLY C, 1989, J PHARM SCI, V78, P910, DOI 10.1002/jps.2600781106
   BAILLY C, 1992, BIOCHEMISTRY-US, V31, P3514, DOI 10.1021/bi00128a028
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Blagbrough IS, 1998, CHEM COMMUN, P929, DOI 10.1039/a709193a
   BLAKE A, 1968, BIOPOLYMERS, V6, P1225, DOI 10.1002/bip.1968.360060902
   Bostock-Smith CE, 1998, NUCLEIC ACIDS RES, V26, P1660, DOI 10.1093/nar/26.7.1660
   DENNY WA, 1983, J MED CHEM, V26, P1625, DOI 10.1021/jm00365a014
   DENNY WA, 1994, MOL ASPECTS ANTICANC, P270
   GAUGAIN B, 1981, BIOCHEMISTRY-US, V20, P3035, DOI 10.1021/bi00514a008
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P431
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P125
   GORMLEY PE, 1978, CANCER RES, V38, P1300
   Hagan DJ, 1997, J CHEM SOC PERK T 1, P2739, DOI 10.1039/a702299i
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442
   HOULBROOK S, 1995, BRIT J CANCER, V72, P1454, DOI 10.1038/bjc.1995.529
   Julino M, 1998, J CHEM SOC PERK T 1, P1677, DOI 10.1039/a800575c
   Kohn KW, 1996, CANCER RES, V56, P5533
   MCCONNAUGHIE AW, 1995, J MED CHEM, V38, P3488, DOI 10.1021/jm00018a009
   MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X
   MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547
   Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8
   PEACOCKE AR, 1956, T FARADAY SOC, V52, P261, DOI 10.1039/tf9565200261
   PEARLMAN DA, 1995, AMBER 4 1
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sartorius J, 1997, J CHEM SOC PERK T 2, P2319, DOI 10.1039/a702628e
   Stanslas J, 1998, BRIT J CANCER, V78, P32
   STEWART JPP, MOPAC 6 0 QCPE
   TAN JD, 1994, INORG CHEM, V33, P4295, DOI 10.1021/ic00097a017
   VOET D, 1995, BIOCHEMISTRY-US, P35
   Woo RA, 1998, NATURE, V394, P700
NR 35
TC 21
Z9 21
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 25
PY 1999
VL 38
IS 21
BP 6723
EP 6731
DI 10.1021/bi9825807
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 201KL
UT WOS:000080593900002
PM 10346892
DA 2020-12-17
ER

PT J
AU Spencer, DIR
   Missailidis, S
   Denton, G
   Murray, A
   Brady, K
   Matteis, CID
   Searle, MS
   Tendler, SJB
   Price, MR
AF Spencer, DIR
   Missailidis, S
   Denton, G
   Murray, A
   Brady, K
   Matteis, CID
   Searle, MS
   Tendler, SJB
   Price, MR
TI Structure activity studies of the anti-MUC1 monoclonal antibody C595 and
   synthetic MUC1 mucin-core-related peptides and glycopeptides
SO BIOSPECTROSCOPY
LA English
DT Article
DE circular dichroism; fluorescence; antibody; glycopeptide; MUC1 mucin;
   nuclear magnetic resonance spectroscopy
ID CIRCULAR-DICHROISM SPECTRA; SECONDARY STRUCTURE; II CONFORMATION; TANDEM
   REPEATS; GLYCOSYLATION; RECOGNITION; EXPRESSION; BINDING; TN; CARCINOMAS
AB MUC1 mucin is a large complex glycoprotein expressed on normal epithelial cells in humans and overexpressed and under or aberrantly glycosylated on many malignant cancer cells which consequently allows recognition of the protein core by antibodies. In order to understand how glycosylation may modulate or regulate antibody binding of mucin protein core epitopes, we have analyzed the antibody C595 (epitope RPAP) for its structure, stability, and its binding to a series of synthetic peptides and glycopeptides by a number of spectroscopic methods. Thermal and pH denaturation studies followed by changes in the CD spectrum of the antibody indicate critical involvement of specific residues to the stability of the antibody. Fluorescence binding studies indicate that alpha-N-acetylgalactosamine (GalNAc) glycosylation of a MUC1 mucin synthetic peptide TAPPAHGVT(9)SAPDTRPAPGS(20)T(21)APPA at threonine residues 9 and 21 and serine residue 20 enhanced the binding of antibody. The structural effects of GalNAc glycosylation on the conformation of the MUC1 peptide were studied. CD of the peptides and glycopeptides in a cryogenic mixture cooled to approximately -97 degrees C revealed that a left-handed polyproline II helix (PPII) is adopted by the peptides in solution, which appears to be further stabilized by addition of the GalNAc residues. Consistent with the PPII helical structure, which has no intra-amide hydrogen bonds, high-field NMR spectroscopy of the glycopeptide revealed no sequential d(NN), medium-range, or long-range nuclear Overhauser effect (NOE) connectivities. These studies indicate that stabilization of the PPII helix by GalNAc glycosylation present the epitope of C595 antibody with a favorable conformation for binding. Furthermore, they illustrate that glycosylation of the MUC1 tumor marker protein with a simple O-linked saccharide expressed in many cancers, can enhance the binding of the clinically relevant C595 antibody. (C) 1999 John Wiley & Sons, Inc.
C1 Univ Nottingham, Canc Res Labs, Nottingham NG7 2RD, England.
   Univ Nottingham, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
   Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England.
   Univ Nottingham, Dept Chem, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Univ Nottingham, Canc Res Labs, Nottingham NG7 2RD, England.
RI Maffeis, Claudio/AAG-5347-2020
OI Searle, Mark/0000-0001-8387-9978
CR BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x
   COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1
   Dalcol I, 1996, J ORG CHEM, V61, P6775, DOI 10.1021/jo960987g
   DRAKE AF, 1988, BIOPHYS CHEM, V31, P143, DOI 10.1016/0301-4622(88)80019-X
   FONTENOT JD, 1995, J BIOMOL STRUCT DYN, V13, P245, DOI 10.1080/07391102.1995.10508837
   FONTENOT JD, 1993, J CANC RES, V53, P5586
   GENDLER S, 1988, J BIOL CHEM, V263, P12820
   GENDLER SJ, 1991, J ANN REV RESP DIS, V144, pS42
   Greenstein JP, 1931, J BIOL CHEM, V93, P479
   GREENSTEIN JP, 1979, CRC HDB CHEM PHYSICS, P757
   HELBECQUE N, 1982, INT J PEPT PROT RES, V19, P94
   HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007
   HUDECZ F, 1992, J IMMUNOL METHODS, V147, P201, DOI 10.1016/S0022-1759(12)80009-3
   HULL SR, 1988, FASEB J, V2, P2380
   ITZKOWITZ SH, 1989, CANCER RES, V49, P197
   JENSENIUS JC, 1974, EUR J IMMUNOL, V4, P91, DOI 10.1002/eji.1830040207
   MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7
   MEINJOHANNS E, 1995, J CHEM SOC P1, V17, P2165
   MIMURA Y, 1989, INT J PEPT PROT RES, V34, P363
   MIMURA Y, 1992, INT J BIOL MACROMOL, V14, P242, DOI 10.1016/S0141-8130(05)80036-4
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509
   OTVOS L, 1991, INT J PEPT PROT RES, V38, P476
   Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3
   PRICE MR, 1993, INT J CANCER, V55, P753, DOI 10.1002/ijc.2910550510
   PRICE MR, 1990, BRIT J CANCER, V61, P681, DOI 10.1038/bjc.1990.154
   SILIGARDI G, 1995, BIOPOLYMERS, V37, P281, DOI 10.1002/bip.360370406
   SIMMS JS, 1928, J GEN PHYSIOL, V11, P629
   SIMMS JS, 1979, CRC HDB CHEM PHYSI C, P757
   SIMMS JS, 1928, J GEN PHYSIOL, V12, P231
   Spencer DIR, 1996, CANCER LETT, V100, P11, DOI 10.1016/0304-3835(95)04055-2
   SPRINGER GF, 1995, CRIT REV ONCOGENESIS, V6, P57, DOI 10.1615/CritRevOncog.v6.i1.50
   STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x
   TASHIRO Y, 1994, HUM PATHOL, V25, P364, DOI 10.1016/0046-8177(94)90144-9
   Terada T, 1996, AM J CLIN PATHOL, V105, P613
   Tetin SY, 1996, BIOCHEMISTRY-US, V35, P1258, DOI 10.1021/bi951576h
   TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010
   URGE L, 1992, BIOCHEM BIOPH RES CO, V184, P1125, DOI 10.1016/0006-291X(92)90709-T
   VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023
   Winnek PS, 1935, J GEN PHYSIOL, V18, P889, DOI 10.1085/jgp.18.6.889
   WINNEK PS, 1979, CRC HDB CHEM PHYSICS, P757
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
NR 42
TC 22
Z9 22
U1 0
U2 5
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 1075-4261
J9 BIOSPECTROSCOPY
JI Biospectroscopy
PY 1999
VL 5
IS 2
BP 79
EP 91
DI 10.1002/(SICI)1520-6343(1999)5:2<79::AID-BSPY2>3.0.CO;2-#
PG 13
WC Biochemical Research Methods; Biophysics; Spectroscopy
SC Biochemistry & Molecular Biology; Biophysics; Spectroscopy
GA 206UZ
UT WOS:000080898800002
PM 10217327
DA 2020-12-17
ER

PT J
AU Murray, A
   Spencer, DIR
   Missailidis, S
   Denton, G
   Price, MR
AF Murray, A
   Spencer, DIR
   Missailidis, S
   Denton, G
   Price, MR
TI Design of ligands for the purification of anti-MUC1 antibodies by
   peptide epitope affinity chromatography
SO JOURNAL OF PEPTIDE RESEARCH
LA English
DT Article
DE circular dichroism; epitope affinity chromatography; fluorescence
   quenching; monoclonal antibody; MUC1 mucin; replacement net analysis
ID POLYMORPHIC EPITHELIAL MUCIN; ADVANCED BREAST-CANCER; PROTEIN CORE;
   MONOCLONAL-ANTIBODIES; TANDEM REPEAT; CARCINOEMBRYONIC ANTIGEN;
   THERAPEUTIC RESPONSE; II CONFORMATION; BLADDER-CANCER; CARCINOMAS
AB The fine specificity of epitope recognition of the anti-MUC1 mucin monoclonal antibody, C595 has been studied using solid-phase replacement net (RNET) analysis. Two peptides (RAAP and RPPP) showed increased reactivity with C595 antibody compared with the native epitope (RPAP). These were synthesized as integral motifs within MUC1 immunodominant peptides and analyzed by fluorescence quenching (FQ) and circular dichroism (CD). They were also tested as ligands for the purification of C595 antibody using epitope affinity chromatography. Affinity matrices were compared with respect to capacity, affinity, and quality of the purified product.
   In FQ tests the native epitope peptide (APDTRPAPG) and the alanine substituted peptide had similar association constants when reacting with C595 antibody, whereas the proline substituted peptide (APDTRPPPG) had a higher association constant. This order of affinity for C595 was confirmed in chromatography experiments in which antibody was eluted from the former two peptide matrices at approximately the same point on the NaSCN elution gradient, whereas antibody was desorbed from APDTRPPPG at a higher NaSCN concentration. Circular dichroism analysis showed that the thermodynamically preferred conformation of these peptides in aqueous solution is the P-II extended helix, the conformation preferred for an extended bound form of the peptide held by interactions with the peptide amides. The stronger binding peptide (APDTRPPPG) has the higher population of the P-II helix in solution.
   In conclusion, RNET analysis is useful in the rational design of peptide ligands so that the performance of affinity matrices may be regulated.
C1 Univ Nottingham, Canc Res Lab, Sch Pharmaceut Sci, Nottingham NG7 2RD, England.
RP Murray, A (corresponding author), Univ Nottingham, Canc Res Lab, Sch Pharmaceut Sci, Univ Pk, Nottingham NG7 2RD, England.
CR BRIGGS S, 1993, EUR J CANCER, V29A, P230, DOI 10.1016/0959-8049(93)90181-E
   BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423
   BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605
   CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531
   CORCORAN D, 1990, J PATHOL, V161, P161, DOI 10.1002/path.1711610211
   Dalcol I, 1996, J ORG CHEM, V61, P6775, DOI 10.1021/jo960987g
   Denton G, 1997, BRIT J CANCER, V76, P614, DOI 10.1038/bjc.1997.434
   DEPRESBRUMMER P, 1995, J CANCER RES CLIN, V121, P419, DOI 10.1007/BF01212949
   DIXON AR, 1993, BRIT J CANCER, V68, P947, DOI 10.1038/bjc.1993.459
   DOMENECH N, 1995, J IMMUNOL, V155, P4766
   DRAKE AF, 1988, BIOPHYS CHEM, V31, P143, DOI 10.1016/0301-4622(88)80019-X
   EISEN H N, 1964, Methods Med Res, V10, P115
   GENDLER S, 1988, J BIOL CHEM, V263, P12820
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8
   HAYES DF, 1986, J CLIN ONCOL, V4, P1542, DOI 10.1200/JCO.1986.4.10.1542
   HUANG PY, 1995, BIOTECHNOL BIOENG, V47, P288, DOI 10.1002/bit.260470303
   Huang PY, 1996, BIOORGAN MED CHEM, V4, P699, DOI 10.1016/0968-0896(96)00066-1
   Hughes ODM, 1997, EUR J NUCL MED, V24, P439, DOI 10.1007/BF00881818
   JEROME KR, 1991, CANCER RES, V51, P2908
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KOTERA Y, 1994, CANCER RES, V54, P2856
   KUNKLER RB, 1995, BRIT J UROL, V76, P81, DOI 10.1111/j.1464-410X.1995.tb07837.x
   MACLENNAN J, 1995, BIO-TECHNOL, V13, P1180, DOI 10.1038/nbt1195-1180
   Murray A, 1997, J CHROMATOGR A, V782, P49, DOI 10.1016/S0021-9673(97)00674-2
   OSULLIVAN C, 1990, BRIT J CANCER, V61, P801, DOI 10.1038/bjc.1990.181
   PERKINS AC, 1993, NUCL MED COMMUN, V14, P578, DOI 10.1097/00006231-199307000-00011
   Price MR, 1997, ONCOL REP, V4, P337
   PRICE MR, 1990, BRIT J CANCER, V61, P681, DOI 10.1038/bjc.1990.154
   PRICE MR, 1990, MOL IMMUNOL, V27, P795, DOI 10.1016/0161-5890(90)90089-I
   PRICE MR, 1991, J IMMUNOL METHODS, V139, P83, DOI 10.1016/0022-1759(91)90354-I
   ROBERTSON JFR, 1991, BRIT J CANCER, V64, P757, DOI 10.1038/bjc.1991.394
   RUGHETTI A, 1993, CANCER RES, V53, P2457
   SILIGARDI G, 1995, BIOPOLYMERS, V37, P281, DOI 10.1002/bip.360370406
   SLOANE JP, 1981, CANCER, V47, P1786, DOI 10.1002/1097-0142(19810401)47:7<1786::AID-CNCR2820470711>3.0.CO;2-8
   VENGOPAL MG, 1994, BIOCHEM, V33, P7984
   WOODY RW, 1995, METHOD ENZYMOL, V246, P34
NR 36
TC 16
Z9 17
U1 0
U2 1
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-002X
J9 J PEPT RES
JI J. Pept. Res.
PD NOV
PY 1998
VL 52
IS 5
BP 375
EP 383
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 147UC
UT WOS:000077515000007
PM 9894842
DA 2020-12-17
ER

PT J
AU Gimenez-Arnau, E
   Missailidis, S
   Stevens, MFG
AF Gimenez-Arnau, E
   Missailidis, S
   Stevens, MFG
TI Antitumour polycyclic acridines. Part 4. Physico-chemical studies on the
   interactions between DNA and novel tetracyclic acridine derivatives
SO ANTI-CANCER DRUG DESIGN
LA English
DT Article
DE circular dichroism; DNA binding; fluorescence quenching; linear
   dichroism; polycyclic acridine derivatives; spectrophotometric analysis;
   thermal denaturation; topoisomerase II
ID TOPOISOMERASE-II; DICHROISM SPECTROSCOPY; ETHIDIUM FLUORESCENCE;
   BIOLOGICAL-ACTIVITY; CIRCULAR-DICHROISM; B-DNA; AMSACRINE; BINDING;
   CANCER; SYSTEMS
AB The non-covalent interactions between a series of new tetracyclic acridine derivatives (5-11) and DNA have been studied by spectrophotometric analysis, fluorescence quenching, thermal denaturation, and circular and linear dichroism. In order to compare the extent of the DNA binding by compounds 5-11 in their neutral and cationic forms, all experiments were conducted at pH 7.4 (physiological pH) and 5.0. The results indicated that compounds 5-11 are strong DNA-binding ligands with DNA affinities comparable to that of m-AMSA (1) or even higher. They showed a stronger DNA binding activity at pH 5.0 as a result of the N-protonation of the pyridoacridine aromatic chromophore. Ethidium-DNA fluorescence assays showed an A-T base pair preference of the binding distinguishing these novel compounds from simple acridines which show a slight G-C base pair preference. Circular and linear dichroism studies indicated that the drugs bind to DNA by undergoing intercalation inside the duplex macromolecule at high DNA:drug ratios and revealed alternative binding modes at low DNA:drug ratios.
C1 Univ Nottingham, Sch Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
RP Gimenez-Arnau, E (corresponding author), CHU Strasbourg, Lab Dermatochim, Dermatol Clin, F-67091 Strasbourg, France.
CR ALBERT A, 1973, ACRIDINES THEIR PREP, P159
   ALBERT A, 1966, ACRIDINES
   ARLIN ZA, 1989, CANCER INVEST, V7, P607, DOI 10.3109/07357908909017537
   BAGULEY BC, 1984, BIOCHEMISTRY-US, V23, P937, DOI 10.1021/bi00300a022
   BAILEY ML, 1973, ACRIDINES, P631
   BAILLY C, 1989, J PHARM SCI, V78, P910, DOI 10.1002/jps.2600781106
   Becker HC, 1997, J AM CHEM SOC, V119, P5798, DOI 10.1021/ja963919k
   BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   DENNY WA, 1983, J MED CHEM, V26, P1625, DOI 10.1021/jm00365a014
   DENNY WA, 1992, SEARCH NEW ANTICANCE, P19
   DENNY WA, 1994, MOL ASPECTS ANTICANC, P270
   DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029
   Finlay GJ, 1996, EUR J CANCER, V32A, P708, DOI 10.1016/0959-8049(95)00604-4
   Gimenez-Arnau E, 1998, ANTI-CANCER DRUG DES, V13, P125
   Hagan DJ, 1998, J CHEM SOC PERK T 1, P915, DOI 10.1039/a707343g
   HAGAN DJ, 1997, J CHEM SOC P1, V18, P2739
   HARVEY VJ, 1991, EUR J CANCER, V27, P1617, DOI 10.1016/0277-5379(91)90427-F
   JONES GB, 1990, ANTI-CANCER DRUG DES, V5, P249
   Kohn KW, 1996, CANCER RES, V56, P5533
   LYNG R, 1992, BIOPOLYMERS, V32, P1201, DOI 10.1002/bip.360320910
   LYNG R, 1991, BIOPOLYMERS, V31, P1709
   MCCONNAUGHIE AW, 1995, J MED CHEM, V38, P3488, DOI 10.1021/jm00018a009
   MCDONALD LA, 1994, J MED CHEM, V37, P3819, DOI 10.1021/jm00048a017
   Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x
   MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547
   NORDEN B, 1982, BIOPOLYMERS, V21, P1713, DOI 10.1002/bip.360210904
   NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   Sandri MI, 1996, BRIT J CANCER, V73, P1518, DOI 10.1038/bjc.1996.286
   SCHIPPER PE, 1979, CHEM PHYS LETT, V67, P99, DOI 10.1016/0009-2614(79)87114-6
   VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19
   WADA A, 1964, J POLYM SCI PART A, V2, P853, DOI 10.1002/pol.1964.100020222
   WADA A, 1964, BIOPOLYMERS, V2, P361, DOI 10.1002/bip.1964.360020407
   WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
   Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223
   Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343
   Wilson MA., 1981, FINTAS, V4, P9
   WIRTH M, 1988, J AM CHEM SOC, V110, P932, DOI 10.1021/ja00211a038
NR 38
TC 47
Z9 47
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0266-9536
J9 ANTI-CANCER DRUG DES
JI Anti-Cancer Drug Des.
PD JUL
PY 1998
VL 13
IS 5
BP 431
EP 451
PG 21
WC Biochemistry & Molecular Biology; Oncology; Chemistry, Medicinal;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy
GA 106GG
UT WOS:000075121100005
PM 9702209
DA 2020-12-17
ER

PT J
AU Gimenez-Arnau, E
   Missailidis, S
   Stevens, MFG
AF Gimenez-Arnau, E
   Missailidis, S
   Stevens, MFG
TI Antitumour polycyclic acridines. Part 2. Physicochemical studies on the
   interactions between DNA and novel polycyclic acridine derivatives
SO ANTI-CANCER DRUG DESIGN
LA English
DT Article
DE circular dichroism; DNA binding; fluorescence quenching; linear
   dichroism; polycyclic acridine derivatives; spectrophotometric analysis;
   thermal denaturation; topoisomerase II
ID BIOLOGICAL-ACTIVITY; TOPOISOMERASE-II; DICHROISM SPECTROSCOPY;
   NUCLEIC-ACIDS; B-DNA; BINDING; LIGANDS; CD; EXPRESSION; ABSORPTION
AB The noncovalent interactions between a series of new polycyclic acridine derivatives (1-5) and salmon testes DNA have been studied using several physicochemical techniques. These include spectrophotometric analysis, fluorescence quenching, thermal denaturation, and circular and linear dichroism. In order to compare the extent of the DNA binding by compounds 1-5 in their neutral and cationic forms, all experiments have been conducted at pH 7.4 and at pH 5.0. Other polynucleotides, including [Poly(dA-dT)](2) and [Poly(dG-dC)](2), were used in order to study the DNA base-pair binding specificity of these novel annelated acridine derivatives The results indicate that the new polycyclic acridines display the following properties: (i) they are strong DNA-binding ligands with affinities 10- to 400-fold greater than that of acridine, 3- to 100-fold greater than that of m-AMSA (6) and I-to 23-fold greater than that of proflavine at physiological pH (7.4); (ii) they have stronger DNA-binding activity at pH 5.0 as a result of the N-protonation of the aromatic chromophore; (iii) they bind more selectively to [Poly(dA-dT)](2) polynucleotide than to [Poly(dG-dC)](2) polynucleotide; (iv) within the series compound 3 binds to DNA less than compounds 1, 2, 4 and 5 at both pH values studied; and (v) the polycyclic acridines form a molecular complex with DNA undergoing intercalation inside the duplex macromolecule, as shown by linear and circular dichroism. Nevertheless, circular dichroism studies reveal alternative binding modes at low DNA:drug ratios.
C1 Univ Nottingham, Dept Pharmaceut Sci, Canc Res Labs, Nottingham NG7 2RD, England.
RP Gimenez-Arnau, E (corresponding author), Univ Nottingham, Dept Pharmaceut Sci, Canc Res Labs, Univ Pk, Nottingham NG7 2RD, England.
CR ACHESON RM, 1973, ACRIDINES, P723
   ALBERT A, 1985, SELECTIVE TOXICITY, P379
   ALBERT A, 1973, ACRIDINES THEIR PREP, P159
   ALBERT A, 1966, ACRIDINES
   ARMSTRONG RW, 1970, J AM CHEM SOC, V92, P3174, DOI 10.1021/ja00713a041
   BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1
   BAILLY C, 1989, J PHARM SCI, V78, P910, DOI 10.1002/jps.2600781106
   BAILLY F, 1992, ANTI-CANCER DRUG DES, V7, P83
   Becker HC, 1997, J AM CHEM SOC, V119, P5798, DOI 10.1021/ja963919k
   BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   DENNY WA, 1983, J MED CHEM, V26, P1625, DOI 10.1021/jm00365a014
   DENNY WA, 1992, SEARCH NEW ANTICANCE, P19
   DENNY WA, 1994, MOL ASPECTS ANTICANC, P270
   DOUGHERTY G, 1982, CRC CR REV BIOCH MOL, V12, P103, DOI 10.3109/10409238209108704
   DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029
   Finlay GJ, 1996, EUR J CANCER, V32A, P708, DOI 10.1016/0959-8049(95)00604-4
   HAGAN DJ, 1997, J CHEM SOC P1, V18, P2739
   Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442
   HOULBROOK S, 1995, BRIT J CANCER, V72, P1454, DOI 10.1038/bjc.1995.529
   HUDDART RA, 1995, EUR J CANCER, V31A, P739, DOI 10.1016/0959-8049(95)00047-M
   JONES GB, 1990, ANTI-CANCER DRUG DES, V5, P249
   Kim HK, 1996, BIOCHEMISTRY-US, V35, P1187, DOI 10.1021/bi951913m
   Kohn KW, 1996, CANCER RES, V56, P5533
   LYNG R, 1992, BIOPOLYMERS, V32, P1201, DOI 10.1002/bip.360320910
   LYNG R, 1991, BIOPOLYMERS, V31, P1709
   MCCONNAUGHIE AW, 1995, J MED CHEM, V38, P3488, DOI 10.1021/jm00018a009
   MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X
   MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P547, DOI 10.1093/nar/7.3.547
   NORDEN B, 1982, BIOPOLYMERS, V21, P1713, DOI 10.1002/bip.360210904
   NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728
   PEACOCKE AR, 1956, T FARADAY SOC, V52, P261, DOI 10.1039/tf9565200261
   PEACOCKE AR, 1973, ACRIDINES, P723
   PILCH DS, 1993, J AM CHEM SOC, V115, P9942, DOI 10.1021/ja00075a010
   PRATT WB, 1994, ANTI-CANCER DRUG, P183
   Sandri MI, 1996, BRIT J CANCER, V73, P1518, DOI 10.1038/bjc.1996.286
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x
   SELISKAR CJ, 1971, J AM CHEM SOC, V93, P5414, DOI 10.1021/ja00750a017
   VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19
   WADA A, 1964, J POLYM SCI PART A, V2, P853, DOI 10.1002/pol.1964.100020222
   WADA A, 1964, BIOPOLYMERS, V2, P361, DOI 10.1002/bip.1964.360020407
   WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
   Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343
   WILSON WR, 1981, MOL PHARMACOL, V20, P404
NR 43
TC 12
Z9 12
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0266-9536
J9 ANTI-CANCER DRUG DES
JI Anti-Cancer Drug Des.
PD MAR
PY 1998
VL 13
IS 2
BP 125
EP 143
PG 19
WC Biochemistry & Molecular Biology; Oncology; Chemistry, Medicinal;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Oncology; Pharmacology & Pharmacy
GA ZB196
UT WOS:000072446000003
PM 9524555
DA 2020-12-17
ER

PT J
AU Hagan, DJ
   Stanslas, J
   Ellis, ME
   Missailidis, S
   Arnau, EG
   Double, JA
   Stevens, MFG
AF Hagan, DJ
   Stanslas, J
   Ellis, ME
   Missailidis, S
   Arnau, EG
   Double, JA
   Stevens, MFG
TI New DNA interactive aza-polycyclic compounds: Physical and biological
   properties
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England.
   Univ Nottingham, Canc Res Labs, Nottingham NG7 2RD, England.
RI Stanslas, Johnson/E-8266-2011
OI Stanslas, Johnson/0000-0002-6938-954X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PY 1998
VL 9
SU 2
MA 135
BP 35
EP 35
PG 1
WC Oncology
SC Oncology
GA ZZ632
UT WOS:000074749600107
DA 2020-12-17
ER

PT J
AU Missailidis, S
   Cannon, WV
   Drake, A
   Wang, XY
   Buck, M
AF Missailidis, S
   Cannon, WV
   Drake, A
   Wang, XY
   Buck, M
TI Analysis of the architecture of the transcription factor sigma(N)
   (sigma(54)) and its domains by circular dichroism
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID PROTEIN SECONDARY STRUCTURE; CLOSED PROMOTER COMPLEXES; CORE
   RNA-POLYMERASE; FACTOR SIGMA-54; ESCHERICHIA-COLI; ATPASE ACTIVITY; DNA;
   BINDING; ACTIVATOR; IDENTIFICATION
AB Enhancer-dependent transcription in bacteria requires the alternative transcription factor sigma(N) (sigma(54)), which forms an RNA polymerase holoenzyme that binds promoters as a transcriptionally inactive complex. We have examined the structure of sigma(N) by circular dichroism (CD) analysis. The sigma(N) protein and its domains are well structured in the absence of the core RNA polymerase subunits or promoter DNA. Denaturation of sigma(N) by temperature as followed by changes in CD shows a concomitant loss of secondary and tertiary structures with a melting temperature of 38 degrees C. The secondary structure displays a two-state melting curve with a second Tm of 85 degrees C. The amino-terminal Region I activation domain together with the acidic Region II does not contribute to the two-state melting. In marked contrast, the integrity of the C-terminal DNA-binding domain is required for the two-state melting. Measurements of pKb also demonstrated that a C-terminal part of sigma(N), but not regions I or I+II, is required for the structural integrity of sigma(N) at high pH. Measurements of pKa suggested that alpha-helical structures are important in sigma(N) for the establishment of tertiary structural elements. The tertiary structure near ultraviolet CD signals of sigma(N) do not require regions I or I+II but were strongly diminished by C-terminal truncation of sigma(N). Promoter DNA binding resulted in a conformational change in sigma(N), permitting the determination of a binding constant. A typical B-DNA conformation was adopted by the promoter DNA. Implications for the modular domain organization of sigma(N), the function of C-terminal sequences, and domain communication and its role in activation of transcription are discussed.
C1 UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,LONDON SW7 2BB,ENGLAND.
   UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.
   UNIV LONDON BIRKBECK COLL,DEPT CHEM,LONDON WC1H 0AJ,ENGLAND.
   INST PLANT PHYSIOL,SHANGHAI,PEOPLES R CHINA.
CR AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x
   BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0
   BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0
   CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x
   CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351
   CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260
   CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x
   CANNON W, 1997, IN PRESS P NATL ACAD
   DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699
   Drake A F, 1994, Methods Mol Biol, V22, P173
   DRAKE AF, 1988, CHIROPTICAL SPECTR B, V3, P1
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   GREENSTEIN JP, 1979, CRC HDB CHEM PHYSICS, P757
   Gross C.A., 1992, TRANSCRIPTIONAL REGU, P129
   HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007
   JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302
   KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989
   LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702
   Luidens MK, 1996, BIOPOLYMERS, V39, P367, DOI 10.1002/(SICI)1097-0282(199609)39:3<367::AID-BIP8>3.3.CO;2-C
   Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X
   MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992
   MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x
   MORRIS L, 1994, J BIOL CHEM, V269, P11563
   POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595
   REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2
   ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413
   ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558
   SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K
   Taylor M, 1996, MOL MICROBIOL, V22, P1045, DOI 10.1046/j.1365-2958.1996.01547.x
   TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120
   WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992
   WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N
   WINNEK PS, 1979, CRC HDB CHEM PHYSICS, P757
   WONG C, 1992, J BIOL CHEM, V276, P24762
   WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120
   WOODY RW, 1995, METHOD ENZYMOL, V246, P34
NR 36
TC 19
Z9 19
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD MAY
PY 1997
VL 24
IS 3
BP 653
EP 664
DI 10.1046/j.1365-2958.1997.3691738.x
PG 12
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA XA651
UT WOS:A1997XA65100019
PM 9179857
OA Bronze
DA 2020-12-17
ER

PT B
AU Spencer, DIR
   Missailidis, S
   De Matteis, C
   Searle, MS
   Price, MR
   Tendler, SJB
AF Spencer, DIR
   Missailidis, S
   De Matteis, C
   Searle, MS
   Price, MR
   Tendler, SJB
BE Carmona, P
   Navarro, R
   Hernanz, A
TI A polyproline II motif is determined in MUC1 mucin synthetic
   (glyco)peptides using CD and NMR
SO SPECTROSCOPY OF BIOLOGICAL MOLECULES: MODERN TRENDS
LA English
DT Proceedings Paper
CT 1997 European Conference on Spectroscopy of Biological Molecules (ECSBM)
CY 1997
CL MADRID, SPAIN
SP Univ Nacl Educ Distancia, Consejo Super Invest Cient, Spanish Minist Educ, Complutense Univ Madrid, Univ S Pable CEU, Reg Community Madrid, Embassy France, Spain, British Council, Deutsch Forsch Gemeinsch, Caja Ahorros Madrid
C1 Univ Nottingham, Canc Res Campaign Labs, Dept Pharmaceut Sci, Nottingham NG7 2RD, England.
RP Spencer, DIR (corresponding author), Univ Nottingham, Canc Res Campaign Labs, Dept Pharmaceut Sci, Nottingham NG7 2RD, England.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-4685-8
PY 1997
BP 35
EP 36
PG 2
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Chemistry, Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Spectroscopy
GA BK55N
UT WOS:000072556800016
DA 2020-12-17
ER

PT B
AU Missailidis, S
   Gimenez-Arnau, E
   Hagan, DJ
   Drake, AF
   Stevens, MFG
AF Missailidis, S
   Gimenez-Arnau, E
   Hagan, DJ
   Drake, AF
   Stevens, MFG
BE Carmona, P
   Navarro, R
   Hernanz, A
TI Spectroscopic studies of the interactions between DNA and novel
   polycyclic acridine derivatives
SO SPECTROSCOPY OF BIOLOGICAL MOLECULES: MODERN TRENDS
LA English
DT Proceedings Paper
CT 1997 European Conference on Spectroscopy of Biological Molecules (ECSBM)
CY 1997
CL MADRID, SPAIN
SP Univ Nacl Educ Distancia, Consejo Super Invest Cient, Spanish Minist Educ, Complutense Univ Madrid, Univ S Pable CEU, Reg Community Madrid, Embassy France, Spain, British Council, Deutsch Forsch Gemeinsch, Caja Ahorros Madrid
C1 Univ Nottingham, Canc Res Labs, Nottingham NG7 2RD, England.
RP Missailidis, S (corresponding author), Univ Nottingham, Canc Res Labs, Univ Pk, Nottingham NG7 2RD, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-4685-8
PY 1997
BP 391
EP 392
PG 2
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Chemistry, Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Spectroscopy
GA BK55N
UT WOS:000072556800175
DA 2020-12-17
ER

PT J
AU Cannon, W
   Missailidis, S
   Austin, S
   Moore, M
   Drake, A
   Buck, M
AF Cannon, W
   Missailidis, S
   Austin, S
   Moore, M
   Drake, A
   Buck, M
TI Purification and activities of the Rhodobacter capsulatus RpoN
   (sigma(N)) protein
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID TRANSCRIPTION FACTOR SIGMA(54); CLOSED PROMOTER COMPLEXES;
   RNA-POLYMERASE; FACTOR SIGMA-54; REPEAT REGION; DNA; EXPRESSION;
   BINDING; GENES; IDENTIFICATION
AB The rpoN-encoded sigma factors (sigma(N)) are a distinct class of bacterial sigma factors, with no obvious homology to the major sigma(70) class. The sigma(N)-containing RNA polymerase holoenzyme functions in enhancer-dependent transcription to allow expression of positively controlled genes, We have purified the Rhodobacter capsulatus sigma(N) protein, which is distinctive in lacking an acidic region implicated in the melting of promoter DNA by the Escherichia coli sigma(N) holoenzyme, and may represent a minor subclass of sigma(N) proteins. Assays of promoter recognition and holoenzyme formation and function showed that the purified R. capsulatus sigma(N) protein is distinct in activity compared to the enteric proteins, but retains the broad functions described for these proteins. As first described for the Klebsiella pneumoniae protein, promoter recognition in the absence of core RNA polymerase was detected, but contact of certain promoter bases by the R. capsulatus sigma(N) protein and its response to core RNA polymerase was clearly different from that determined for the K. pneumoniae and E. coli proteins. Results are discussed in the context of a requirement to modulate the activity of the DNA-binding surfaces of sigma(N) to regulate sigma(N) function, Circular dichroism was used to evaluate the structure of the R. capsulatus protein and revealed differences in the tertiary signals as compared to the K. pneumoniae protein, some of which are attributable to the DNA-binding domain of sigma(N).
C1 UNIV SUSSEX,AFRC,INST PLANT SCI RES,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND.
   UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.
   UNIV LONDON BIRKBECK COLL,DEPT CHEM,LONDON WC1H 0AJ,ENGLAND.
CR AUSTIN S, 1987, MOL MICROBIOL, V1, P92, DOI 10.1111/j.1365-2958.1987.tb00532.x
   BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0
   BUCK M, 1994, NUCLEIC ACIDS RES, V22, P1119, DOI 10.1093/nar/22.6.1119
   CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x
   CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351
   CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6
   CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x
   CANNON W, 1992, MOL MICROBIOL, V6, P1625
   CANNON W, 1995, J MOL BIOL, V249, P781
   CULLEN PJ, 1994, MOL MICROBIOL, V11, P51, DOI 10.1111/j.1365-2958.1994.tb00289.x
   GROSS CA, 1992, TRANSCRIPTIONAL REGU
   HSIEH ML, 1994, J BIOL CHEM, V269, P373
   JONES R, 1989, MOL GEN GENET, V215, P507, DOI 10.1007/BF00427050
   KARLS RK, 1993, J BACTERIOL, V175, P7629, DOI 10.1128/JB.175.23.7629-7638.1993
   KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989
   MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992
   MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992
   MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x
   MORRIS L, 1994, J BIOL CHEM, V269, P11563
   PREKER P, 1992, MOL MICROBIOL, V6, P1035, DOI 10.1111/j.1365-2958.1992.tb02169.x
   SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107
   SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K
   STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2
   TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120
   WONG CN, 1992, J BIOL CHEM, V267, P24762
   WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120
NR 26
TC 6
Z9 6
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD JUL
PY 1996
VL 21
IS 2
BP 233
EP 245
DI 10.1046/j.1365-2958.1996.6181334.x
PG 13
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA VA416
UT WOS:A1996VA41600004
PM 8858579
DA 2020-12-17
ER

PT B
AU Missailidis, S
   Anastassopoulou, J
   Theophanides, T
AF Missailidis, S
   Anastassopoulou, J
   Theophanides, T
BE Collery, P
   Corbella, J
   Domingo, JL
   Etienne, JC
   Llobet, JM
TI FT-IR spectra of oligonucleotide-Mg++ complexes
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 4
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 4th International Symposium on Metal Ions in Biology and Medicine
CY MAY 19-22, 1996
CL BARCELONA, SPAIN
SP Natl Ctr Toxicol Res, Food & Drug Adm, NCI, Assoc Reg Enseignement & Rech Sci Champagne Ardenne, Int Res Inst Metal Ions, Univ Rovira Virgili, Univ Barcelona, Escola Profess Med Treball, Direcc Gen Investigac Cient & Tecn, Commiss Univ Rec CIRIT Generalitat Catalunya
RP Missailidis, S (corresponding author), NATL TECH UNIV ATHENS,DEPT CHEM ENGN,ZOGRAFOU CAMPUS,ZOGRAFOS 15780,ATHENS,GREECE.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
BN 2-7420-0130-1
J9 MET ION BIO
PY 1996
VL 4
BP 39
EP 41
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BH13A
UT WOS:A1996BH13A00012
DA 2020-12-17
ER

PT B
AU Anastassopoulou, J
   Sarros, G
   Fotopoulos, N
   Missailidis, S
   Nastou, H
   Sarrou, V
   Nastos, A
AF Anastassopoulou, J
   Sarros, G
   Fotopoulos, N
   Missailidis, S
   Nastou, H
   Sarrou, V
   Nastos, A
BE Collery, P
   Corbella, J
   Domingo, JL
   Etienne, JC
   Llobet, JM
TI Zinc ions and nucleotide interactions
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 4
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 4th International Symposium on Metal Ions in Biology and Medicine
CY MAY 19-22, 1996
CL BARCELONA, SPAIN
SP Natl Ctr Toxicol Res, Food & Drug Adm, NCI, Assoc Reg Enseignement & Rech Sci Champagne Ardenne, Int Res Inst Metal Ions, Univ Rovira Virgili, Univ Barcelona, Escola Profess Med Treball, Direcc Gen Investigac Cient & Tecn, Commiss Univ Rec CIRIT Generalitat Catalunya
RP Anastassopoulou, J (corresponding author), NATL TECH UNIV ATHENS,DEPT CHEM ENGN,ZOGRAFOU CAMPUS,ZOGRAFOS 15780,ATHENS,GREECE.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
BN 2-7420-0130-1
J9 MET ION BIO
PY 1996
VL 4
BP 45
EP 47
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BH13A
UT WOS:A1996BH13A00014
DA 2020-12-17
ER

PT J
AU CANNON, W
   MISSAILIDIS, S
   SMITH, C
   COTTIER, A
   AUSTIN, S
   MOORE, M
   BUCK, M
AF CANNON, W
   MISSAILIDIS, S
   SMITH, C
   COTTIER, A
   AUSTIN, S
   MOORE, M
   BUCK, M
TI CORE RNA-POLYMERASE AND PROMOTER DNA INTERACTIONS OF PURIFIED DOMAINS OF
   SIGMA(N) - BIPARTITE FUNCTIONS
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE SIGMA FACTOR; DOMAINS; PROMOTER BINDING; CORE BINDING; ALLOSTERIC
   EFFECTOR
ID TRANSCRIPTION FACTOR SIGMA(54); BINDING-PROTEIN NTRC; TURN-HELIX MOTIF;
   KLEBSIELLA-PNEUMONIAE; FACTOR SIGMA-54; NUCLEOTIDE-SEQUENCE; ATPASE
   ACTIVITY; GENE NTRA; ACTIVATION; GLNA
AB The sigma(N) class of sigma factors confer upon RNA polymerase the requirement for enhancer-binding activator proteins. The sigma-N (sigma(N)) protein of Klebsiella pneumoniae was analysed by the assay of purified peptides comprising domains or regions of sigma(N) defined by proteolysis or by homology alignment, respectively The NH2-terminal Region I is required for the correct interaction of holoenzyme with the promoter, and promoter complexes forming with a truncated sigma(N) lacking Region I are not activatable. The complexes lack the DNA structure believed to represent nucleated strand separation but still make close contacts with this promoter part. Determinants of specific DNA recognition by sigma(N) were shown to reside in a C-terminal 16 kDa peptide, and core RNA polymerase binding determinants in an adjacent peptide. The latter contacts and appears to pack against the DNA-binding domain. Thus the DNA-binding and core-binding domains are bipartite in function, consistent with core functioning as an allosteric effector of the sigma DNA-binding activity The DNA-binding and core-binding domains together include Region III of sigma(N). Although not the primary determinant of core or DNA recognition, the acidic Region II of sigma(N) influenced both activities. Regions I and II in combination with core RNA polymerase thus appear to control the activity of C-terminal DNA contacting surfaces to allow formation of a closed promoter complex that is susceptible to activation.
C1 UNIV SUSSEX, NITROGEN FIXAT LAB, BRIGHTON BN1 9RQ, E SUSSEX, ENGLAND.
   UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND.
CR AUSTIN S, 1987, MOL MICROBIOL, V1, P92, DOI 10.1111/j.1365-2958.1987.tb00532.x
   AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x
   AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994
   BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0
   BUCK M, 1994, NUCLEIC ACIDS RES, V22, P1119, DOI 10.1093/nar/22.6.1119
   BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x
   CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x
   CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351
   CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x
   CHAMBERS S, 1993, NEW HORIZONS NITROGE, P451
   COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x
   CULLEN PJ, 1994, MOL MICROBIOL, V11, P51, DOI 10.1111/j.1365-2958.1994.tb00289.x
   DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446
   DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B
   Gross C.A., 1992, TRANSCRIPTIONAL REGU, P129
   HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525
   HSIEH ML, 1994, J MOL BIOL, V239, P15, DOI 10.1006/jmbi.1994.1347
   HSIEH ML, 1994, J BIOL CHEM, V269, P373
   HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453
   JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958
   JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102
   KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991
   KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989
   LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700
   LEE HS, 1993, J BACTERIOL, V175, P2479, DOI 10.1128/JB.175.8.2479-2482.1993
   LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992
   MERRICK M, 1987, MOL GEN GENET, V210, P323, DOI 10.1007/BF00325701
   MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992
   MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x
   MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607
   MORRIS L, 1994, J BIOL CHEM, V269, P11563
   PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355
   POPHAM D, 1991, J BIOL CHEM, V266, P19510
   RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994
   SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074
   SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K
   TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120
   WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N
   WONG CN, 1992, J BIOL CHEM, V267, P24762
   WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120
NR 40
TC 62
Z9 62
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAY 12
PY 1995
VL 248
IS 4
BP 781
EP 803
DI 10.1006/jmbi.1995.0260
PG 23
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA QX872
UT WOS:A1995QX87200007
PM 7752240
DA 2020-12-17
ER

PT J
AU MISSAILIDIS, S
   HESTER, RE
AF MISSAILIDIS, S
   HESTER, RE
TI FTIR SPECTRA OF DEOXYOLIGONUCLEOTIDE-NOGALAMYCIN COMPLEXES
SO BIOSPECTROSCOPY
LA English
DT Article
ID ANTITUMOR DRUG NOGALAMYCIN; RESONANCE RAMAN-SPECTRA;
   MOLECULAR-STRUCTURE; DNA COMPLEX; ANTIBIOTIC NOGALAMYCIN; DUPLEX
   D(5'-GCATGC)2; BINDING; ADRIAMYCIN; NMR; DAUNOMYCIN
AB FTIR spectroscopy has been used to study the three self-complementary oligonucleotides TGATCA, CGATCG, and TGTACA in the form of complexes with the anthracycline drug nogalamycin. These complexes were prepared under conditions that enabled the bulky nogalamycin to intercalate into the double helixes of the oligonucleotide duplexes. Changes in the FTIR spectra on complexation are indicative of strong perturbation of the AT base pairs, in contrast with the effect of the structurally related drugs adriamycin and daunamycin, which show affinity for GC base pairs. These differences are attributed to binding interactions with the functional groups attached to the aglycone chromophore rather than to the specific site of drug intercalation in the double helix. (C) 1995 John Wiley & Sons, Inc.
C1 UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.
CR ARORA SK, 1983, J AM CHEM SOC, V105, P1328, DOI 10.1021/ja00343a042
   BHUYAN BK, 1970, CANCER RES, V30, P984
   BRADBURY EM, 1961, J MOL BIOL, V3, P301, DOI 10.1016/S0022-2836(61)80071-5
   DIMARCO A, 1977, CHEM-BIOL INTERACT, V19, P291, DOI 10.1016/0009-2797(77)90052-7
   DUVERNAY VH, 1979, BIOCHEMISTRY-US, V18, P4024, DOI 10.1021/bi00585a028
   EGLI M, 1991, BIOCHEMISTRY-US, V30, P1364, DOI 10.1021/bi00219a029
   ENNIS HL, 1981, ANTIMICROB AGENTS CH, V19, P657, DOI 10.1128/AAC.19.4.657
   FALK M, 1963, J AM CHEM SOC, V85, P391, DOI 10.1021/ja00887a005
   FALK M, 1963, J AM CHEM SOC, V85, P387, DOI 10.1021/ja00887a004
   FOX KR, 1986, BIOCHEMISTRY-US, V25, P4349, DOI 10.1021/bi00363a026
   FOX KR, 1984, BIOCHIM BIOPHYS ACTA, V802, P162, DOI 10.1016/0304-4165(84)90157-0
   GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004
   HARTMAN KA, 1973, PHYSICO CHEMICAL PRO, V2, P1
   HARTMAN KA, 1973, PHYSICOCHEMICAL PROP, V2, P92
   KRUEGER WC, 1981, CHEM-BIOL INTERACT, V36, P1, DOI 10.1016/0009-2797(81)90025-9
   LIAW YC, 1989, BIOCHEMISTRY-US, V28, P9913, DOI 10.1021/bi00452a006
   MANFAIT M, 1983, BIOCHEM BIOPH RES CO, V116, P321, DOI 10.1016/0006-291X(83)90417-5
   MANFAIT M, 1981, J RAMAN SPECTROSC, V11, P68, DOI 10.1002/jrs.1250110205
   MANFAIT M, 1984, SPECTROSCOPY BIOL MO, P113
   MISSAILIDIS S, 1993, THESIS U YORK
   OKAMOTO K, 1987, INORG CHIM A-BIOINOR, V135, P207, DOI 10.1016/S0020-1693(00)81300-6
   PARKER FS, 1983, APPLICATIONS INFRARE, P353
   POHLE W, 1985, SPECTROSCOPY BIOL MO, P254
   QUIGLEY GJ, 1980, P NATL ACAD SCI-BIOL, V77, P7204, DOI 10.1073/pnas.77.12.7204
   ROBINSON H, 1990, NUCLEIC ACIDS RES, V18, P4851, DOI 10.1093/nar/18.16.4851
   SEARLE MS, 1988, BIOCHEMISTRY-US, V27, P4340, DOI 10.1021/bi00412a022
   SEARLE MS, 1990, BIOCHEM J, V269, P341, DOI 10.1042/bj2690341
   SEARLE MS, 1991, NUCLEIC ACIDS RES, V19, P2897, DOI 10.1093/nar/19.11.2897
   SEARLE MS, 1992, FEBS LETT, V297, P292
   SMITH CK, UNPUB BIOCHEMISTRY
   SMULEVICH G, 1986, J PHYS CHEM-US, V90, P6388, DOI 10.1021/j100281a064
   SUTHERLAND GBBM, 1957, PROC R SOC LON SER-A, V239, P446, DOI 10.1098/rspa.1957.0054
   TAILLANDIER E, 1985, ADV INFRARED RAMAN S, P65
   TSUBOI M, 1968, B CHEM SOC JPN, V41, P1821, DOI 10.1246/bcsj.41.1821
   TSUBOI M, 1957, J AM CHEM SOC, V79, P1351, DOI 10.1021/ja01563a026
   Tsuboi M., 1973, PHYSICO CHEMICAL PRO, V2, P91
   WARD DC, 1965, SCIENCE, V149, P1259, DOI 10.1126/science.149.3689.1259
   WILEY PF, 1968, TETRAHEDRON LETT, V6, P663
   WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225
   ZHANG XL, 1990, BIOCHEMISTRY-US, V29, P9451, DOI 10.1021/bi00492a020
   ZUNINO F, 1977, BIOCHIM BIOPHYS ACTA, V476, P38, DOI 10.1016/0005-2787(77)90283-0
   ZUNINO F, 1974, CHEM-BIOL INTERACT, V9, P25, DOI 10.1016/0009-2797(74)90064-7
   ZUNINO F, 1976, BIOCHEM BIOPH RES CO, V69, P744, DOI 10.1016/0006-291X(76)90938-4
NR 43
TC 4
Z9 4
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 1075-4261
J9 BIOSPECTROSCOPY
JI Biospectroscopy
PY 1995
VL 1
IS 2
BP 91
EP 99
DI 10.1002/bspy.350010202
PG 9
WC Biochemical Research Methods; Biophysics; Spectroscopy
SC Biochemistry & Molecular Biology; Biophysics; Spectroscopy
GA TG389
UT WOS:A1995TG38900001
DA 2020-12-17
ER

PT B
AU Malsbury, JA
   Missailidis, S
AF Malsbury, JA
   Missailidis, S
BE Miley, GH
   Elliot, C
TI What you don't know can hurt! Reducing hazardous waste liability through
   the prudent use of audits
SO SOFE '95 - 16TH IEEE/NPSS SYMPOSIUM ON FUSION ENGINEERING, VOLS 1 AND 2:
   SEEKING A NEW ENERGY ERA
LA English
DT Proceedings Paper
CT 16th IEEE/NPSS Symposium on Fusion Engineering - Seeking a New Energy
   Era (SOFE 95)
CY OCT 01-05, 1995
CL CHAMPAIGN, IL
SP IEEE/NPSS Standing Comm, Univ Illinois
C1 PRINCETON PLASMA PHYS LAB,PRINCETON,NJ 08543.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-2970-8
PY 1995
BP 634
EP 637
PG 4
WC Nuclear Science & Technology
SC Nuclear Science & Technology
GA BF98R
UT WOS:A1995BF98R00143
DA 2020-12-17
ER

PT B
AU MISSAILIDIS, S
   HESTER, RE
AF MISSAILIDIS, S
   HESTER, RE
BE Theophanides, T
   Anastassopoulou, J
   Fotopoulos, N
TI FTIR STUDIES OF NOGALAMYCIN - OLIGONUCLEOTIDE INTERACTIONS
SO FIFTH INTERNATIONAL CONFERENCE ON THE SPECTROSCOPY OF BIOLOGICAL
   MOLECULES
LA English
DT Proceedings Paper
CT 5TH EUROPEAN CONF ON THE SPECTROSCOPY OF BIOLOGY MOLECULES ( ECSBM )
CY SEP 05-10, 1993
CL LOUTRAKI, GREECE
SP GREEK CHEM SOC, INT UNION PURE & APPL CHEM, INT UNION PURE & APPL BIOCHEM, COMMISS EUROPEAN COMMUNITIES, GREEK SECRETARIAT RES & TECHNOL, NATL TECH UNIV ATHENS, FOURTH EUROPEAN CONF SPECTROSCOPY BIOL MOLEC YORK
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA DORDRECHT
BN 0-7923-2534-6
PY 1993
BP 67
EP 68
PG 2
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA BZ34Q
UT WOS:A1993BZ34Q00020
DA 2020-12-17
ER

PT B
AU MISSAILIDIS, S
   ANASTASSOPOULOU, J
   POLISSIOU, M
   TARANTILIS, P
   THEOPHANIDES, T
AF MISSAILIDIS, S
   ANASTASSOPOULOU, J
   POLISSIOU, M
   TARANTILIS, P
   THEOPHANIDES, T
BE Anastassopoulou, J
   Collery, P
   Etienne, JC
   Theophanides, T
TI MAGNESIUM AND DRINKING-WATER FOR HEALTH
SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 2
SE METAL IONS IN BIOLOGY AND MEDICINE
LA English
DT Proceedings Paper
CT 2ND INTERNATIONAL SYMP ON METAL IONS IN BIOLOGY AND MEDICINE
CY MAY 18-22, 1992
CL LOUTRAKI, GREECE
SP AMER COLL NUTR, ANTICANC RES, US FDA, INT SOC TRACE ELEMENTS RES HUMAN, SOC FRANCOPHONE ETUDE & RECH ELEMENTS TRACE ESSENTIELS, SOC INT DEV RECH MAGNESIUM
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA MONTROUGE
BN 0-86196-340-7
J9 METAL IONS BIOL MED
PY 1992
VL 2
BP 351
EP 353
PG 3
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA BW15K
UT WOS:A1992BW15K00097
DA 2020-12-17
ER

EF